Anhang 4-G

Separate Darstellung zu Subgruppenanalysen

Angiotensin-II-Acetat (GIAPREZA®)

PAION Deutschland GmbH

Modul 4A Anhang 4-G

Behandlung der refraktären Hypotonie bei Erwachsenen mit einem septischen oder anderen distributiven Schock

Stand: 15.07.2021

Table 14.2.9.1.1
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Age (years)						
< 65	54	11 (20.4%)	62	43 (69.4%)	8.85 (3.76 - 20.8)	<.0001
>=65	61	15 (24.6%)	52	33 (63.5%)	5.33 (2.37 - 12.0)	<.0001
Within Treatment Arm [b]	1.27 (0.53 - 3.08), 0.5893		0.77 (0.35 - 1.68), 0.5062			
Across Treatment Arm [c]	6.83 (3.80 - 12.3), <.0001					
Treatment Interaction [d]	0.60 (0.19 - 1.96), 0.3987					
Gender						
Female	39	9 (23.1%)	49	28 (57.1%)	4.44 (1.74 - 11.3)	0.0013
Male	76	17 (22.4%)	65	48 (73.8%)	9.80 (4.52 - 21.2)	<.0001
Within Treatment Arm [b]	0.96 (0.38 - 2.41), 0.9315		2.12 (0.96 - 4.67), 0.0611			
Across Treatment Arm [c]	7.25 (3.99 - 13.2), <.0001					
Treatment Interaction [d]	2.20 (0.66 - 7.42), 0.2015					
Race						
Other	29	4 (13.8%)	17	11 (64.7%)	11.5 (2.69 - 48.9)	0.0004
White	86	22 (25.6%)	97	65 (67.0%)	5.91 (3.11 - 11.2)	<.0001
Within Treatment Arm [b]	2.15 (0.67 - 6.86), 0.1894		1.11 (0.38 - 3.27), 0.8525			
Across Treatment Arm [c]	6.64 (3.69 - 11.9), <.0001					
Treatment Interaction [d]	0.52 (0.11 - 2.52), 0.4137					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	17 (28.3%)	60	41 (68.3%)	5.46 (2.50 - 11.9)	<.0001
>=30 kg/m2	54	9 (16.7%)	52	34 (65.4%)	9.44 (3.78 - 23.6)	<.0001
Within Treatment Arm [b]	0.51 (0.20 - 1.26), 0.1383		0.88 (0.40 - 1.93), 0.7407			
Across Treatment Arm [c]	6.94 (3.84 - 12.5), <.0001					
Treatment Interaction [d]	1.73 (0.52 - 5.77), 0.3722					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	14 (29.8%)	27	23 (85.2%)	13.6 (3.95 - 46.5)	<.0001
< 2.5 g/dL	67	11 (16.4%)	82	50 (61.0%)	7.95 (3.63 - 17.4)	<.0001
Within Treatment Arm [b]	0.46 (0.19 - 1.14), 0.0895		0.27 (0.09 - 0.86), 0.0203			
Across Treatment Arm [c]	9.38 (4.85 - 18.1), <.0001					
Treatment Interaction [d]	0.59 (0.14 - 2.53), 0.4746					
Geographic Region						
Rest of World	17	3 (17.6%)	17	9 (52.9%)	5.25 (1.09 - 25.2)	0.0313
US/Canada	98	23 (23.5%)	97	67 (69.1%)	7.28 (3.86 - 13.7)	<.0001
Within Treatment Arm [b]	1.43 (0.38 - 5.42), 0.5963		1.99 (0.70 - 5.65), 0.1931			
Across Treatment Arm [c]	6.97 (3.86 - 12.6), <.0001					
Treatment Interaction [d]	1.39 (0.26 - 7.54), 0.7047					
Baseline MAP						
>=65 mmHg	70	17 (24.3%)	74	56 (75.7%)	9.70 (4.53 - 20.8)	<.0001
< 65 mmHg	45	9 (20.0%)	40	20 (50.0%)	4.00 (1.53 - 10.4)	0.0036
Within Treatment Arm [b]	0.78 (0.31 - 1.94), 0.5918		0.32 (0.14 - 0.73), 0.0055			
Across Treatment Arm [c]	7.03 (3.87 - 12.8), <.0001					
Treatment Interaction [d]	0.41 (0.12 - 1.40), 0.1561					
Baseline APACHE II Score						
<=30	63	12 (19.0%)	74	51 (68.9%)	9.42 (4.24 - 20.9)	<.0001
> 30	52	14 (26.9%)	40	25 (62.5%)	4.52 (1.86 - 11.0)	0.0006
Within Treatment Arm [b]	1.57 (0.65 - 3.77), 0.3150		0.75 (0.34 - 1.69), 0.4878			
Across Treatment Arm [c]	6.89 (3.82 - 12.4), <.0001					
Treatment Interaction [d]	0.48 (0.15 - 1.58), 0.2279					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Exposure to ACEi						
No	102	21 (20.6%)	106	69 (65.1%)	7.19 (3.85 - 13.4)	<.0001
Yes	13	5 (38.5%)	8	7 (87.5%)	11.2 (1.04 - 120)	0.0274
Within Treatment Arm [b]	2.41 (0.71 - 8.13), 0.1468		3.75 (0.44 - 31.7), 0.1949			
Across Treatment Arm [c]	7.42 (4.06 - 13.6), <.0001					
Treatment Interaction [d]	1.56 (0.13 - 18.1), 0.7243					
Exposure to ARBs						
No	108	26 (24.1%)	106	74 (69.8%)	7.29 (3.98 - 13.4)	<.0001
Yes	7	0 (0.0%)	8	2 (25.0%)		0.1553
Within Treatment Arm [b]	, 0.1400		0.14 (0.03 - 0.75), 0.0095			
Across Treatment Arm [c]	7.47 (4.10 - 13.6), <.0001					
Treatment Interaction [d]	69E3 (0.00 - I), 0.9808					
Medical History of ARDS						
No	85	18 (21.2%)	95	65 (68.4%)	8.06 (4.10 - 15.9)	<.0001
Yes	30	8 (26.7%)	19	11 (57.9%)	3.78 (1.12 - 12.8)	0.0288
Within Treatment Arm [b]	1.35 (0.52 - 3.54), 0.5365		0.63 (0.23 - 1.74), 0.3743			
Across Treatment Arm [c]	6.81 (3.78 - 12.3), <.0001					
Treatment Interaction [d]	0.47 (0.12 - 1.89), 0.2867					
Chest X-ray Finding of ARDS						
No	72	11 (15.3%)	88	62 (70.5%)	13.2 (6.01 - 29.1)	<.0001
Yes	43	15 (34.9%)	25	14 (56.0%)	2.38 (0.87 - 6.51)	0.0896
Within Treatment Arm [b]	2.97 (1.21 - 7.29), 0.0150		0.53 (0.21 - 1.33), 0.1741			
Across Treatment Arm [c]	7.39 (4.04 - 13.5), <.0001					
Treatment Interaction [d]	0.18 (0.05 - 0.65), 0.0086					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
History of Sepsis						
No	15	0 (0.0%)	17	12 (70.6%)		<.0001
Yes	100	26 (26.0%)	97	64 (66.0%)	5.52 (2.99 - 10.2)	<.0001
Within Treatment Arm [b]	, 0.0248		0.81 (0.26 - 2.49), 0.7100			
Across Treatment Arm [c]	7.00 (3.88 - 12.6), <.0001					
Treatment Interaction [d]	0.00 (0.00 - 7.66E157), 0.9485					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	20 (26.0%)	81	63 (77.8%)	9.98 (4.80 - 20.7)	<.0001
>=0.5 ug/kg/min	38	6 (15.8%)	33	13 (39.4%)	3.47 (1.13 - 10.6)	0.0250
Within Treatment Arm [b]	0.53 (0.19 - 1.47), 0.2194		0.19 (0.08 - 0.44), <.0001			
Across Treatment Arm [c]	7.49 (4.05 - 13.8), <.0001					
Treatment Interaction [d]	0.35 (0.09 - 1.32), 0.1206					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	73	62 (84.9%)		0.0221
>=20 ng/kg/min	114	26 (22.8%)	41	14 (34.1%)	1.75 (0.80 - 3.83)	0.1547
Within Treatment Arm [b]	, 0.5872		0.09 (0.04 - 0.23), <.0001			
Across Treatment Arm [c]	1.97 (0.92 - 4.23), 0.0827					
Treatment Interaction [d]	0.00 (0.00 - 1.4E136), 0.9452					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	3 (13.0%)	27	24 (88.9%)	53.3 (9.68 - 294)	<.0001
72.3 - <253 pg/mL	26	7 (26.9%)	22	12 (54.5%)	3.26 (0.97 - 10.9)	0.0512
253 - <676 pg/mL	25	10 (40.0%)	27	18 (66.7%)	3.00 (0.97 - 9.30)	0.0539
>=676 pg/mL	27	3 (11.1%)	26	15 (57.7%)	10.9 (2.61 - 45.6)	0.0003
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	13 (25.0%)	53	33 (62.3%)	4.95 (2.14 - 11.4)	0.0001
<253 pg/mL	49	10 (20.4%)	49	36 (73.5%)	10.8 (4.22 - 27.7)	<.0001
Within Treatment Arm [b]	0.77 (0.30 - 1.96), 0.5823		1.68 (0.72 - 3.90), 0.2268			
Across Treatment Arm [c]	7.12 (3.81 - 13.3), <.0001					
Treatment Interaction [d]	2.18 (0.62 - 7.69), 0.2249					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	6 (20.7%)	28	23 (82.1%)	17.6 (4.71 - 66.0)	<.0001
23.85 - <83.75 pg/mL	28	8 (28.6%)	25	17 (68.0%)	5.31 (1.64 - 17.2)	0.0041
83.75 - <299.5 pg/mL	12	2 (16.7%)	28	18 (64.3%)	9.00 (1.64 - 49.4)	0.0058
>=299.5 pg/mL	31	7 (22.6%)	20	10 (50.0%)	3.43 (1.02 - 11.6)	0.0426
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	9 (20.9%)	48	28 (58.3%)	5.29 (2.08 - 13.4)	0.0003
<83.75 pg/mL	57	14 (24.6%)	53	40 (75.5%)	9.45 (3.96 - 22.5)	<.0001
Within Treatment Arm [b]	1.23 (0.48 - 3.18), 0.6692		2.20 (0.94 - 5.14), 0.0667			
Across Treatment Arm [c]	7.29 (3.86 - 13.8), <.0001					
Treatment Interaction [d]	1.79 (0.50 - 6.39), 0.3720					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	12 (23.1%)	53	34 (64.2%)	5.96 (2.54 - 14.0)	<.0001
< 1.63	47	10 (21.3%)	46	32 (69.6%)	8.46 (3.31 - 21.6)	<.0001
Within Treatment Arm [b]	0.90 (0.35 - 2.33), 0.8296		1.28 (0.55 - 2.97), 0.5687			
Across Treatment Arm [c]	7.01 (3.73 - 13.2), <.0001					
Treatment Interaction [d]	1.42 (0.40 - 5.05), 0.5901					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1a
Mean Arterial Pressure at Hour 3: Univariate Analyses of Vasopressor Count (mITT Population)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Number of Vasopressors						
1	43	11 (25.6%)	49	38 (77.6%)	10.0 (3.85 - 26.2)	<.0001
>=2	115	26 (22.6%)	114	76 (66.7%)	6.85 (3.81 - 12.3)	<.0001
Within Treatment Arm [b]	0.85 (0.38 - 1.92), 0.6945		0.58 (0.27 - 1.26), 0.1646			
Across Treatment Arm [c]	7.63 (4.63 - 12.6), <.0001					
Treatment Interaction [d]	0.68 (0.22 - 2.10), 0.5031					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.2
Mean Arterial Pressure at Hour 3: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Age (years)						
< 65	50	11 (22.0%)	57	39 (68.4%)	7.68 (3.21 - 18.4)	<.0001
>=65	60	14 (23.3%)	47	30 (63.8%)	5.80 (2.49 - 13.5)	<.0001
Within Treatment Arm [b]	1.08 (0.44 - 2.65), 0.8680		0.81 (0.36 - 1.84), 0.6219			
Across Treatment Arm [c]	6.66 (3.63 - 12.2), <.0001					
Treatment Interaction [d]	0.75 (0.22 - 2.54), 0.6495					
Gender						
Female	37	9 (24.3%)	46	26 (56.5%)	4.04 (1.56 - 10.5)	0.0032
Male	73	16 (21.9%)	58	43 (74.1%)	10.2 (4.55 - 22.9)	<.0001
Within Treatment Arm [b]	0.87 (0.34 - 2.22), 0.7760		2.21 (0.96 - 5.05), 0.0590			
Across Treatment Arm [c]	7.10 (3.83 - 13.2), <.0001					
Treatment Interaction [d]	2.53 (0.73 - 8.79), 0.1457					
Race						
Other	27	3 (11.1%)	16	11 (68.8%)	17.6 (3.56 - 87.1)	<.0001
White	83	22 (26.5%)	88	58 (65.9%)	5.36 (2.78 - 10.3)	<.0001
Within Treatment Arm [b]	2.89 (0.79 - 10.5), 0.0973		0.88 (0.28 - 2.76), 0.8249			
Across Treatment Arm [c]	6.53 (3.56 - 12.0), <.0001					
Treatment Interaction [d]	0.30 (0.05 - 1.72), 0.1778					
Body Mass Index (kg/m^2)						
< 30 kg/m2	58	16 (27.6%)	57	40 (70.2%)	6.18 (2.75 - 13.9)	<.0001
>=30 kg/m2	51	9 (17.6%)	45	28 (62.2%)	7.69 (3.01 - 19.7)	<.0001
Within Treatment Arm [b]	0.56 (0.22 - 1.41), 0.2181		0.70 (0.31 - 1.60), 0.3975			
Across Treatment Arm [c]	6.79 (3.68 - 12.5), <.0001					
Treatment Interaction [d]	1.24 (0.36 - 4.30), 0.7295					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.2
Mean Arterial Pressure at Hour 3: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	45	14 (31.1%)	23	20 (87.0%)	14.8 (3.76 - 58.0)	<.0001
< 2.5 g/dL	64	10 (15.6%)	76	46 (60.5%)	8.28 (3.66 - 18.7)	<.0001
Within Treatment Arm [b]	0.41 (0.16 - 1.03), 0.0547		0.23 (0.06 - 0.84), 0.0185			
Across Treatment Arm [c]	9.77 (4.86 - 19.6), <.0001					
Treatment Interaction [d]	0.56 (0.11 - 2.76), 0.4768					
Geographic Region						
Rest of World	17	3 (17.6%)	17	9 (52.9%)	5.25 (1.09 - 25.2)	0.0313
US/Canada	93	22 (23.7%)	87	60 (69.0%)	7.17 (3.71 - 13.9)	<.0001
Within Treatment Arm [b]	1.45 (0.38 - 5.50), 0.5867		1.98 (0.69 - 5.67), 0.2009			
Across Treatment Arm [c]	6.85 (3.73 - 12.6), <.0001					
Treatment Interaction [d]	1.37 (0.25 - 7.49), 0.7194					
Baseline MAP						
>=65 mmHg	69	17 (24.6%)	66	50 (75.8%)	9.56 (4.36 - 21.0)	<.0001
< 65 mmHg	41	8 (19.5%)	38	19 (50.0%)	4.13 (1.52 - 11.2)	0.0043
Within Treatment Arm [b]	0.74 (0.29 - 1.91), 0.5351		0.32 (0.14 - 0.75), 0.0074			
Across Treatment Arm [c]	7.08 (3.81 - 13.1), <.0001					
Treatment Interaction [d]	0.43 (0.12 - 1.54), 0.1953					
Baseline APACHE II Score						
<=30	62	12 (19.4%)	67	47 (70.1%)	9.79 (4.32 - 22.2)	<.0001
> 30	48	13 (27.1%)	37	22 (59.5%)	3.95 (1.58 - 9.85)	0.0026
Within Treatment Arm [b]	1.55 (0.63 - 3.79), 0.3374		0.62 (0.27 - 1.44), 0.2694			
Across Treatment Arm [c]	6.68 (3.65 - 12.2), <.0001					
Treatment Interaction [d]	0.40 (0.12 - 1.38), 0.1471					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.2
Mean Arterial Pressure at Hour 3: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Exposure to ACEi						
No	97	20 (20.6%)	97	63 (64.9%)	7.13 (3.74 - 13.6)	<.0001
Yes	13	5 (38.5%)	7	6 (85.7%)	9.60 (0.88 - 105)	0.0428
Within Treatment Arm [b]	2.41 (0.71 - 8.16), 0.1494		3.24 (0.37 - 28.0), 0.2615			
Across Treatment Arm [c]	7.29 (3.91 - 13.6), <.0001					
Treatment Interaction [d]	1.35 (0.11 - 16.0), 0.8146					
Exposure to ARBs						
No	103	25 (24.3%)	97	67 (69.1%)	6.97 (3.74 - 13.0)	<.0001
Yes	7	0 (0.0%)	7	2 (28.6%)		0.1266
Within Treatment Arm [b]	, 0.1381		0.18 (0.03 - 0.98), 0.0285			
Across Treatment Arm [c]	7.18 (3.87 - 13.3), <.0001					
Treatment Interaction [d]	86E3 (0.00 - I), 0.9804					
Medical History of ARDS						
No	81	17 (21.0%)	86	59 (68.6%)	8.23 (4.08 - 16.6)	<.0001
Yes	29	8 (27.6%)	18	10 (55.6%)	3.28 (0.95 - 11.3)	0.0552
Within Treatment Arm [b]	1.43 (0.54 - 3.80), 0.4668		0.57 (0.20 - 1.61), 0.2867			
Across Treatment Arm [c]	6.66 (3.63 - 12.2), <.0001					
Treatment Interaction [d]	0.40 (0.10 - 1.65), 0.2051					
Chest X-ray Finding of ARDS						
No	70	11 (15.7%)	79	55 (69.6%)	12.3 (5.51 - 27.4)	<.0001
Yes	40	14 (35.0%)	24	14 (58.3%)	2.60 (0.92 - 7.35)	0.0685
Within Treatment Arm [b]	2.89 (1.16 - 7.21), 0.0202		0.61 (0.24 - 1.57), 0.3031			
Across Treatment Arm [c]	7.28 (3.91 - 13.6), <.0001					
Treatment Interaction [d]	0.21 (0.06 - 0.79), 0.0205					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.2
Mean Arterial Pressure at Hour 3: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
History of Sepsis						
No	15	0 (0.0%)	14	10 (71.4%)		<.0001
Yes	95	25 (26.3%)	90	59 (65.6%)	5.33 (2.84 - 10.0)	<.0001
Within Treatment Arm [b]	, 0.0238		0.76 (0.22 - 2.63), 0.6653			
Across Treatment Arm [c]	6.80 (3.70 - 12.5), <.0001					
Treatment Interaction [d]	0.00 (0.00 - 1.56E158), 0.9483					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	74	19 (25.7%)	72	57 (79.2%)	11.0 (5.08 - 23.8)	<.0001
>=0.5 ug/kg/min	36	6 (16.7%)	32	12 (37.5%)	3.00 (0.97 - 9.30)	0.0519
Within Treatment Arm [b]	0.58 (0.21 - 1.61), 0.2901		0.16 (0.06 - 0.39), <.0001			
Across Treatment Arm [c]	7.62 (4.02 - 14.5), <.0001					
Treatment Interaction [d]	0.27 (0.07 - 1.07), 0.0630					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	65	55 (84.6%)		0.0242
>=20 ng/kg/min	109	25 (22.9%)	39	14 (35.9%)	1.88 (0.85 - 4.15)	0.1148
Within Treatment Arm [b]	, 0.5859		0.10 (0.04 - 0.26), <.0001			
Across Treatment Arm [c]	2.11 (0.97 - 4.59), 0.0594					
Treatment Interaction [d]	0.00 (0.00 - 3.02E136), 0.9458					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.2
Mean Arterial Pressure at Hour 3: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	22	3 (13.6%)	26	23 (88.5%)	48.6 (8.77 - 269)	<.0001
72.3 - <253 pg/mL	26	7 (26.9%)	20	12 (60.0%)	4.07 (1.17 - 14.1)	0.0239
253 - <676 pg/mL	22	9 (40.9%)	26	17 (65.4%)	2.73 (0.84 - 8.81)	0.0899
>=676 pg/mL	27	3 (11.1%)	21	11 (52.4%)	8.80 (2.01 - 38.4)	0.0018
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	49	12 (24.5%)	47	28 (59.6%)	4.54 (1.90 - 10.9)	0.0005
<253 pg/mL	48	10 (20.8%)	46	35 (76.1%)	12.1 (4.58 - 31.9)	<.0001
Within Treatment Arm [b]	0.81 (0.31 - 2.11), 0.6672		2.16 (0.88 - 5.28), 0.0885			
Across Treatment Arm [c]	7.24 (3.79 - 13.8), <.0001					
Treatment Interaction [d]	2.66 (0.72 - 9.83), 0.1421					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	27	6 (22.2%)	27	22 (81.5%)	15.4 (4.08 - 58.2)	<.0001
23.85 - <83.75 pg/mL	28	8 (28.6%)	24	17 (70.8%)	6.07 (1.82 - 20.2)	0.0024
83.75 - <299.5 pg/mL	11	1 (9.1%)	23	14 (60.9%)	15.6 (1.69 - 143)	0.0044
>=299.5 pg/mL	30	7 (23.3%)	18	9 (50.0%)	3.29 (0.94 - 11.5)	0.0578
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	41	8 (19.5%)	41	23 (56.1%)	5.27 (1.96 - 14.2)	0.0006
<83.75 pg/mL	55	14 (25.5%)	51	39 (76.5%)	9.52 (3.92 - 23.1)	<.0001
Within Treatment Arm [b]	1.41 (0.53 - 3.76), 0.4932		2.54 (1.04 - 6.22), 0.0383			
Across Treatment Arm [c]	7.39 (3.82 - 14.3), <.0001					
Treatment Interaction [d]	1.81 (0.48 - 6.81), 0.3831					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.2
Mean Arterial Pressure at Hour 3: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	49	11 (22.4%)	47	30 (63.8%)	6.10 (2.49 - 14.9)	<.0001
< 1.63	46	10 (21.7%)	43	30 (69.8%)	8.31 (3.19 - 21.6)	<.0001
Within Treatment Arm [b]	0.96 (0.36 - 2.53), 0.9336		1.31 (0.54 - 3.16), 0.5506			
Across Treatment Arm [c]	7.07 (3.67 - 13.6), <.0001					
Treatment Interaction [d]	1.36 (0.37 - 5.06), 0.6436					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.2a
Mean Arterial Pressure at Hour 3: Univariate Analyses of Vasopressor Count (PP Population)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Number of Vasopressors						
1	39	10 (25.6%)	46	35 (76.1%)	9.23 (3.44 - 24.8)	<.0001
>=2	110	25 (22.7%)	104	69 (66.3%)	6.70 (3.67 - 12.3)	<.0001
Within Treatment Arm [b]	0.85 (0.37 - 1.99), 0.7123		0.62 (0.28 - 1.37), 0.2329			
Across Treatment Arm [c]	7.33 (4.38 - 12.3), <.0001					
Treatment Interaction [d]	0.73 (0.23 - 2.31), 0.5884					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.3
Mean Arterial Pressure at Hour 3: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Age (years)						
< 65	66	15 (22.7%)	64	43 (67.2%)	6.96 (3.20 - 15.1)	<.0001
>=65	62	15 (24.2%)	54	34 (63.0%)	5.33 (2.39 - 11.9)	<.0001
Within Treatment Arm [b]	1.09 (0.48 - 2.46), 0.8448		0.83 (0.39 - 1.77), 0.6311			
Across Treatment Arm [c]	6.13 (3.51 - 10.7), <.0001					
Treatment Interaction [d]	0.77 (0.25 - 2.34), 0.6384					
Gender						
Female	43	11 (25.6%)	52	29 (55.8%)	3.67 (1.53 - 8.81)	0.0030
Male	85	19 (22.4%)	66	48 (72.7%)	9.26 (4.40 - 19.5)	<.0001
Within Treatment Arm [b]	0.84 (0.36 - 1.97), 0.6838		2.11 (0.98 - 4.57), 0.0548			
Across Treatment Arm [c]	6.44 (3.65 - 11.4), <.0001					
Treatment Interaction [d]	2.53 (0.80 - 7.98), 0.1144					
Race						
Other	32	4 (12.5%)	20	12 (60.0%)	10.5 (2.65 - 41.6)	0.0003
White	96	26 (27.1%)	98	65 (66.3%)	5.30 (2.87 - 9.81)	<.0001
Within Treatment Arm [b]	2.60 (0.83 - 8.13), 0.0917		1.31 (0.49 - 3.53), 0.5882			
Across Treatment Arm [c]	5.99 (3.42 - 10.5), <.0001					
Treatment Interaction [d]	0.51 (0.11 - 2.28), 0.3748					
Body Mass Index (kg/m^2)						
< 30 kg/m2	69	19 (27.5%)	62	42 (67.7%)	5.53 (2.61 - 11.7)	<.0001
>=30 kg/m2	58	11 (19.0%)	54	34 (63.0%)	7.26 (3.08 - 17.1)	<.0001
Within Treatment Arm [b]	0.62 (0.27 - 1.43), 0.2573		0.81 (0.38 - 1.74), 0.5891			
Across Treatment Arm [c]	6.23 (3.55 - 11.0), <.0001					
Treatment Interaction [d]	1.31 (0.42 - 4.11), 0.6383					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.3
Mean Arterial Pressure at Hour 3: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	48	15 (31.3%)	26	22 (84.6%)	12.1 (3.54 - 41.3)	<.0001
< 2.5 g/dL	67	11 (16.4%)	82	50 (61.0%)	7.95 (3.63 - 17.4)	<.0001
Within Treatment Arm [b]	0.43 (0.18 - 1.05), 0.0608		0.28 (0.09 - 0.90), 0.0259			
Across Treatment Arm [c]	9.04 (4.68 - 17.5), <.0001					
Treatment Interaction [d]	0.66 (0.15 - 2.82), 0.5726					
Geographic Region						
Rest of World	20	5 (25.0%)	18	10 (55.6%)	3.75 (0.95 - 14.8)	0.0543
US/Canada	108	25 (23.1%)	100	67 (67.0%)	6.74 (3.66 - 12.4)	<.0001
Within Treatment Arm [b]	0.90 (0.30 - 2.73), 0.8575		1.62 (0.59 - 4.50), 0.3479			
Across Treatment Arm [c]	6.15 (3.52 - 10.7), <.0001					
Treatment Interaction [d]	1.80 (0.40 - 8.09), 0.4448					
Baseline MAP						
>=65 mmHg	78	19 (24.4%)	77	57 (74.0%)	8.85 (4.28 - 18.3)	<.0001
< 65 mmHg	50	11 (22.0%)	41	20 (48.8%)	3.38 (1.36 - 8.36)	0.0073
Within Treatment Arm [b]	0.88 (0.38 - 2.04), 0.7585		0.33 (0.15 - 0.74), 0.0061			
Across Treatment Arm [c]	6.21 (3.53 - 10.9), <.0001					
Treatment Interaction [d]	0.38 (0.12 - 1.22), 0.1040					
Baseline APACHE II Score						
<=30	72	16 (22.2%)	75	50 (66.7%)	7.00 (3.36 - 14.6)	<.0001
> 30	56	14 (25.0%)	43	27 (62.8%)	5.06 (2.13 - 12.0)	0.0002
Within Treatment Arm [b]	1.17 (0.51 - 2.65), 0.7128		0.84 (0.39 - 1.85), 0.6704			
Across Treatment Arm [c]	6.13 (3.50 - 10.7), <.0001					
Treatment Interaction [d]	0.72 (0.23 - 2.25), 0.5756					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.3
Mean Arterial Pressure at Hour 3: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Exposure to ACEi						
No	103	22 (21.4%)	105	68 (64.8%)	6.77 (3.65 - 12.6)	<.0001
Yes	13	5 (38.5%)	8	7 (87.5%)	11.2 (1.04 - 120)	0.0274
Within Treatment Arm [b]	2.30 (0.68 - 7.74), 0.1691		3.81 (0.45 - 32.2), 0.1894			
Across Treatment Arm [c]	7.01 (3.86 - 12.7), <.0001					
Treatment Interaction [d]	1.65 (0.14 - 19.2), 0.6879					
Exposure to ARBs						
No	109	27 (24.8%)	105	73 (69.5%)	6.93 (3.80 - 12.6)	<.0001
Yes	7	0 (0.0%)	8	2 (25.0%)		0.1553
Within Treatment Arm [b]	, 0.1328		0.15 (0.03 - 0.76), 0.0102			
Across Treatment Arm [c]	7.10 (3.91 - 12.9), <.0001					
Treatment Interaction [d]	72E3 (0.00 - I), 0.9807					
Medical History of ARDS						
No	86	19 (22.1%)	94	64 (68.1%)	7.52 (3.85 - 14.7)	<.0001
Yes	30	8 (26.7%)	19	11 (57.9%)	3.78 (1.12 - 12.8)	0.0288
Within Treatment Arm [b]	1.28 (0.49 - 3.34), 0.6098		0.64 (0.24 - 1.77), 0.3912			
Across Treatment Arm [c]	6.46 (3.60 - 11.6), <.0001					
Treatment Interaction [d]	0.50 (0.13 - 2.02), 0.3320					
Chest X-ray Finding of ARDS						
No	74	12 (16.2%)	87	61 (70.1%)	12.1 (5.61 - 26.2)	<.0001
Yes	43	15 (34.9%)	25	14 (56.0%)	2.38 (0.87 - 6.51)	0.0896
Within Treatment Arm [b]	2.77 (1.15 - 6.68), 0.0209		0.54 (0.22 - 1.35), 0.1860			
Across Treatment Arm [c]	7.06 (3.88 - 12.8), <.0001					
Treatment Interaction [d]	0.20 (0.06 - 0.70), 0.0118					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.3
Mean Arterial Pressure at Hour 3: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
History of Sepsis						
No	16	1 (6.3%)	16	11 (68.8%)	33.0 (3.36 - 324)	0.0003
Yes	100	26 (26.0%)	97	64 (66.0%)	5.52 (2.99 - 10.2)	<.0001
Within Treatment Arm [b]	5.27 (0.66 - 41.9), 0.0826		0.88 (0.28 - 2.75), 0.8279			
Across Treatment Arm [c]	6.58 (3.67 - 11.8), <.0001					
Treatment Interaction [d]	0.17 (0.02 - 1.78), 0.1383					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	87	24 (27.6%)	82	63 (76.8%)	8.70 (4.34 - 17.5)	<.0001
>=0.5 ug/kg/min	41	6 (14.6%)	36	14 (38.9%)	3.71 (1.24 - 11.1)	0.0154
Within Treatment Arm [b]	0.45 (0.17 - 1.21), 0.1065		0.19 (0.08 - 0.45), <.0001			
Across Treatment Arm [c]	6.95 (3.85 - 12.5), <.0001					
Treatment Interaction [d]	0.43 (0.12 - 1.56), 0.1977					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	2	1 (50.0%)	72	61 (84.7%)	5.55 (0.32 - 95.4)	0.1888
>=20 ng/kg/min	114	26 (22.8%)	41	14 (34.1%)	1.75 (0.80 - 3.83)	0.1547
Within Treatment Arm [b]	0.30 (0.02 - 4.89), 0.3670		0.09 (0.04 - 0.23), <.0001			
Across Treatment Arm [c]	1.89 (0.89 - 4.02), 0.0984					
Treatment Interaction [d]	0.32 (0.02 - 6.05), 0.4448					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.3
Mean Arterial Pressure at Hour 3: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	3 (13.0%)	27	24 (88.9%)	53.3 (9.68 - 294)	<.0001
72.3 - <253 pg/mL	26	7 (26.9%)	22	12 (54.5%)	3.26 (0.97 - 10.9)	0.0512
253 - <676 pg/mL	25	10 (40.0%)	27	18 (66.7%)	3.00 (0.97 - 9.30)	0.0539
>=676 pg/mL	28	4 (14.3%)	25	14 (56.0%)	7.64 (2.04 - 28.6)	0.0014
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	53	14 (26.4%)	52	32 (61.5%)	4.46 (1.95 - 10.2)	0.0003
<253 pg/mL	49	10 (20.4%)	49	36 (73.5%)	10.8 (4.22 - 27.7)	<.0001
Within Treatment Arm [b]	0.71 (0.28 - 1.80), 0.4749		1.73 (0.74 - 4.03), 0.2014			
Across Treatment Arm [c]	6.71 (3.61 - 12.5), <.0001					
Treatment Interaction [d]	2.42 (0.69 - 8.48), 0.1662					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	30	7 (23.3%)	27	22 (81.5%)	14.5 (3.99 - 52.4)	<.0001
23.85 - <83.75 pg/mL	28	8 (28.6%)	25	17 (68.0%)	5.31 (1.64 - 17.2)	0.0041
83.75 - <299.5 pg/mL	12	2 (16.7%)	28	18 (64.3%)	9.00 (1.64 - 49.4)	0.0058
>=299.5 pg/mL	31	7 (22.6%)	20	10 (50.0%)	3.43 (1.02 - 11.6)	0.0426
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	9 (20.9%)	48	28 (58.3%)	5.29 (2.08 - 13.4)	0.0003
<83.75 pg/mL	58	15 (25.9%)	52	39 (75.0%)	8.60 (3.64 - 20.3)	<.0001
Within Treatment Arm [b]	1.32 (0.51 - 3.38), 0.5648		2.14 (0.92 - 5.02), 0.0766			
Across Treatment Arm [c]	6.93 (3.68 - 13.1), <.0001					
Treatment Interaction [d]	1.63 (0.46 - 5.78), 0.4525					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.3
Mean Arterial Pressure at Hour 3: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	53	13 (24.5%)	52	33 (63.5%)	5.34 (2.30 - 12.4)	<.0001
< 1.63	47	10 (21.3%)	46	32 (69.6%)	8.46 (3.31 - 21.6)	<.0001
Within Treatment Arm [b]	0.83 (0.33 - 2.12), 0.6998		1.32 (0.57 - 3.06), 0.5234			
Across Treatment Arm [c]	6.60 (3.53 - 12.3), <.0001					
Treatment Interaction [d]	1.58 (0.45 - 5.59), 0.4759					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.3a
Mean Arterial Pressure at Hour 3: Univariate Analyses of Vasopressor Count (ITT Population)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Number of Vasopressors						
1	44	11 (25.0%)	53	39 (73.6%)	8.36 (3.34 - 20.9)	<.0001
>=2	128	30 (23.4%)	118	77 (65.3%)	6.13 (3.51 - 10.7)	<.0001
Within Treatment Arm [b]	0.92 (0.41 - 2.03), 0.8338		0.67 (0.33 - 1.38), 0.2808			
Across Treatment Arm [c]	6.68 (4.15 - 10.8), <.0001					
Treatment Interaction [d]	0.73 (0.25 - 2.14), 0.5720					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	54	40.7 (29.0 - 55.0)	62	27.4 (18.0 - 40.3)	0.63 (0.33- 1.19), 0.1500
>=65	61	41.0 (29.9 - 54.3)	52	40.4 (28.5 - 54.9)	0.90 (0.50- 1.61), 0.7205
Hazard Ratio (95%CI), P-value [b]		1.03 (0.58- 1.83), 0.9192		1.48 (0.78- 2.81), 0.2264	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.50- 1.17), 0.2177			
Hazard Ratio (95%CI), P-value [d]		1.43 (0.61- 3.39), 0.4099			
Gender					
Female	39	43.6 (29.8 - 60.4)	49	38.8 (26.8 - 53.8)	0.84 (0.44- 1.62), 0.6046
Male	76	39.5 (29.5 - 51.4)	65	29.2 (19.8 - 41.9)	0.67 (0.38- 1.18), 0.1635
Hazard Ratio (95%CI), P-value [b]		0.90 (0.49- 1.63), 0.7216		0.70 (0.37- 1.33), 0.2727	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.48- 1.13), 0.1642			
Hazard Ratio (95%CI), P-value [d]		0.79 (0.33- 1.88), 0.5928			
Race					
Other	29	41.4 (26.0 - 61.2)	17	41.2 (22.2 - 67.5)	0.97 (0.38- 2.46), 0.9481
White	86	40.7 (31.2 - 51.8)	97	32.0 (23.7 - 42.2)	0.71 (0.44- 1.16), 0.1711
Hazard Ratio (95%CI), P-value [b]		0.98 (0.51- 1.88), 0.9474		0.71 (0.31- 1.61), 0.4060	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.49- 1.17), 0.2152			
Hazard Ratio (95%CI), P-value [d]		0.73 (0.26- 2.09), 0.5564			
Body Mass Index (kg/m^2)					
< 30 kg/m2	60	33.3 (23.0 - 46.8)	60	31.7 (21.5 - 45.0)	0.88 (0.47- 1.65), 0.6972
>=30 kg/m2	54	50.0 (37.6 - 63.9)	52	32.7 (21.8 - 47.2)	0.59 (0.32- 1.08), 0.0850
Hazard Ratio (95%CI), P-value [b]		1.69 (0.95- 3.02), 0.0718		1.12 (0.58- 2.15), 0.7342	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.46- 1.10), 0.1302			
Hazard Ratio (95%CI), P-value [d]		0.66 (0.27- 1.58), 0.3468			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	47	27.7 (17.1 - 42.8)	27	18.5 (8.2 - 38.9)	0.59 (0.21- 1.65), 0.3076
< 2.5 g/dL	67	49.3 (38.1 - 61.7)	82	37.8 (28.3 - 49.2)	0.70 (0.43- 1.14), 0.1468
Hazard Ratio (95%CI), P-value [b]		2.00 (1.05- 3.80), 0.0308		2.40 (0.93- 6.16), 0.0615	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.43- 1.05), 0.0804			
Hazard Ratio (95%CI), P-value [d]		1.18 (0.38- 3.69), 0.7801			
Geographic Region					
Rest of World	17	23.5 (9.6 - 51.2)	17	23.5 (9.6 - 51.2)	0.90 (0.23- 3.62), 0.8876
US/Canada	98	43.9 (34.7 - 54.3)	97	35.1 (26.5 - 45.4)	0.73 (0.47- 1.15), 0.1718
Hazard Ratio (95%CI), P-value [b]		1.91 (0.69- 5.33), 0.2073		1.56 (0.55- 4.40), 0.3951	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.49- 1.15), 0.1810			
Hazard Ratio (95%CI), P-value [d]		0.80 (0.19- 3.44), 0.7646			
Baseline MAP					
>=65 mmHg	70	32.9 (23.2 - 45.2)	74	25.7 (17.2 - 37.2)	0.72 (0.39- 1.32), 0.2813
< 65 mmHg	45	53.3 (39.7 - 68.3)	40	47.5 (33.5 - 63.9)	0.83 (0.46- 1.52), 0.5558
Hazard Ratio (95%CI), P-value [b]		1.95 (1.10- 3.46), 0.0197		2.28 (1.21- 4.32), 0.0089	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.50- 1.19), 0.2409			
Hazard Ratio (95%CI), P-value [d]		1.15 (0.49- 2.70), 0.7487			
Baseline APACHE II Score					
<=30	63	33.3 (23.2 - 46.4)	74	29.7 (20.7 - 41.6)	0.85 (0.47- 1.55), 0.6006
> 30	52	50.0 (37.4 - 64.2)	40	40.0 (26.7 - 56.8)	0.72 (0.39- 1.34), 0.2952
Hazard Ratio (95%CI), P-value [b]		1.77 (0.99- 3.14), 0.0496		1.49 (0.78- 2.84), 0.2197	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.51- 1.21), 0.2688			
Hazard Ratio (95%CI), P-value [d]		0.83 (0.35- 1.98), 0.6794			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	102	41.2 (32.3 - 51.4)	106	34.0 (25.8 - 43.8)	0.76 (0.49- 1.18), 0.2212
Yes	13	38.5 (18.2 - 69.2)	8	25.0 (6.9 - 68.5)	0.60 (0.12- 3.09), 0.5338
Hazard Ratio (95%CI), P-value [b]		0.88 (0.35- 2.23), 0.7938		0.69 (0.17- 2.88), 0.6136	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.49- 1.14), 0.1793			
Hazard Ratio (95%CI), P-value [d]		0.79 (0.14- 4.30), 0.7810			
Exposure to ARBs					
No	108	42.6 (33.9 - 52.5)	106	32.1 (24.1 - 41.9)	0.67 (0.43- 1.05), 0.0774
Yes	7	14.3 (2.1 - 66.6)	8	50.0 (22.5 - 84.8)	4.49 (0.50-40.35), 0.1420
Hazard Ratio (95%CI), P-value [b]		0.27 (0.04- 1.96), 0.1651		1.93 (0.68- 5.43), 0.2073	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.49- 1.14), 0.1763			
Hazard Ratio (95%CI), P-value [d]		7.20 (0.77-67.37), 0.0835			
Medical History of ARDS					
No	85	40.0 (30.5 - 51.2)	95	29.5 (21.4 - 39.8)	0.66 (0.40- 1.09), 0.1005
Yes	30	43.3 (27.9 - 62.7)	19	52.6 (32.7 - 75.6)	1.30 (0.57- 2.97), 0.5296
Hazard Ratio (95%CI), P-value [b]		1.03 (0.54- 1.95), 0.9361		2.06 (1.00- 4.24), 0.0453	
Hazard Ratio (95%CI), P-value [c]		0.79 (0.51- 1.21), 0.2756			
Hazard Ratio (95%CI), P-value [d]		1.97 (0.75- 5.18), 0.1671			
Chest X-ray Finding of ARDS					
No	72	34.7 (25.0 - 46.9)	88	26.1 (18.2 - 36.7)	0.69 (0.39- 1.22), 0.2010
Yes	43	51.2 (37.4 - 66.7)	25	60.0 (41.9 - 78.7)	1.18 (0.61- 2.28), 0.6207
Hazard Ratio (95%CI), P-value [b]		1.59 (0.89- 2.82), 0.1109		2.82 (1.47- 5.41), 0.0011	
Hazard Ratio (95%CI), P-value [c]		0.87 (0.56- 1.34), 0.5155			
Hazard Ratio (95%CI), P-value [d]		1.72 (0.72- 4.09), 0.2213			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	15	53.3 (31.3 - 78.8)	17	17.6 (6.1 - 45.3)	0.24 (0.06- 0.90), 0.0221
Yes	100	39.0 (30.2 - 49.3)	97	36.1 (27.4 - 46.5)	0.89 (0.56- 1.40), 0.6160
Hazard Ratio (95%CI), P-value [b]		0.59 (0.28- 1.26), 0.1695		2.34 (0.72- 7.60), 0.1457	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.49- 1.16), 0.2045			
Hazard Ratio (95%CI), P-value [d]		3.95 (0.97-16.07), 0.0551			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	77	33.8 (24.4 - 45.5)	81	23.5 (15.7 - 34.3)	0.66 (0.36- 1.19), 0.1594
>=0.5 ug/kg/min	38	55.3 (40.5 - 71.3)	33	57.6 (41.7 - 74.4)	0.91 (0.49- 1.69), 0.7650
Hazard Ratio (95%CI), P-value [b]		2.34 (1.31- 4.16), 0.0030		3.27 (1.73- 6.18), 0.0001	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.50- 1.17), 0.2206			
Hazard Ratio (95%CI), P-value [d]		1.36 (0.58- 3.20), 0.4835			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	1	0.0 (0.0 - 0.0)	73	23.3 (15.2 - 34.8)	45E4 (0.00-), 0.6080
>=20 ng/kg/min	114	41.2 (32.8 - 50.8)	41	51.2 (37.1 - 67.1)	1.32 (0.79- 2.21), 0.2838
Hazard Ratio (95%CI), P-value [b]		45E4 (0.00-), 0.4673		2.80 (1.48- 5.31), 0.0010	
Hazard Ratio (95%CI), P-value [c]		1.34 (0.81- 2.23), 0.2586			
Hazard Ratio (95%CI), P-value [d]		0.00 (0.00-), 0.9854			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	23	26.1 (12.7 - 49.1)	27	14.8 (5.8 - 34.8)	0.51 (0.14- 1.82), 0.2920
72.3 - <253 pg/mL	26	42.3 (26.1 - 63.2)	22	45.5 (27.6 - 67.9)	1.03 (0.44- 2.42), 0.9506
253 - <676 pg/mL	25	48.0 (30.8 - 68.8)	27	37.0 (21.9 - 57.9)	0.70 (0.30- 1.62), 0.4025
>=676 pg/mL	27	44.4 (28.2 - 64.8)	26	34.6 (19.7 - 56.0)	0.75 (0.32- 1.79), 0.5196
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	52	46.2 (33.8 - 60.5)	53	35.8 (24.6 - 50.3)	0.73 (0.40- 1.33), 0.2985
< 253 pg/mL	49	34.7 (23.2 - 49.7)	49	28.6 (18.0 - 43.4)	0.76 (0.37- 1.54), 0.4428
Hazard Ratio (95%CI), P-value [b]		0.75 (0.40- 1.39), 0.3524		0.76 (0.38- 1.51), 0.4277	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.47- 1.17), 0.1995			
Hazard Ratio (95%CI), P-value [d]		1.03 (0.41- 2.60), 0.9564			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	29	37.9 (23.1 - 57.9)	28	14.3 (5.6 - 33.7)	0.32 (0.10- 1.02), 0.0416
23.85 - <83.75 pg/mL	28	42.9 (27.1 - 62.9)	25	32.0 (17.5 - 53.9)	0.65 (0.27- 1.60), 0.3503
83.75 - <299.5 pg/mL	12	33.3 (14.0 - 66.3)	28	50.0 (33.4 - 69.4)	1.81 (0.60- 5.51), 0.2870
>=299.5 pg/mL	31	41.9 (26.9 - 61.0)	20	30.0 (14.7 - 54.9)	0.71 (0.27- 1.86), 0.4821
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	43	39.5 (26.7 - 55.7)	48	41.7 (29.2 - 56.8)	1.11 (0.58- 2.11), 0.7567
< 83.75 pg/mL	57	40.4 (29.0 - 54.2)	53	22.6 (13.5 - 36.4)	0.48 (0.24- 0.96), 0.0345
Hazard Ratio (95%CI), P-value [b]		1.17 (0.62- 2.18), 0.6321		0.49 (0.24- 1.00), 0.0454	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.47- 1.18), 0.2127			
Hazard Ratio (95%CI), P-value [d]		0.42 (0.16- 1.09), 0.0755			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	52	50.0 (37.4 - 64.2)	53	32.1 (21.3 - 46.4)	0.53 (0.29- 0.98), 0.0410
< 1.63	47	29.8 (18.9 - 45.0)	46	32.6 (21.1 - 48.1)	1.13 (0.55- 2.35), 0.7347
Hazard Ratio (95%CI), P-value [b]		0.48 (0.25- 0.92), 0.0240		1.03 (0.51- 2.05), 0.9436	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.45- 1.16), 0.1760			
Hazard Ratio (95%CI), P-value [d]		2.15 (0.83- 5.56), 0.1156			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1a
Mortality at Day 7: Univariate Analyses of Vasopressor Count (mITT Population)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Number of Vasopressors					
1	43	18.6 (9.8 - 33.8)	49	18.4 (10.0 - 32.3)	1.01 (0.39- 2.61), 0.9868
>=2	115	40.9 (32.5 - 50.4)	114	33.3 (25.5 - 42.8)	0.75 (0.49- 1.15), 0.1864
Hazard Ratio (95%CI), P-value [b]		2.71 (1.28- 5.75), 0.0066		2.02 (0.98- 4.18), 0.0524	
Hazard Ratio (95%CI), P-value [c]		0.79 (0.53- 1.16), 0.2314			
Hazard Ratio (95%CI), P-value [d]		0.74 (0.26- 2.10), 0.5708			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.2
Mortality at Day 7: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	50	38.0 (26.2 - 52.9)	57	28.1 (18.2 - 41.7)	0.70 (0.36- 1.37), 0.2986
>=65	60	40.0 (28.9 - 53.5)	47	38.3 (26.1 - 53.7)	0.85 (0.46- 1.56), 0.5888
Hazard Ratio (95%CI), P-value [b]		1.10 (0.60- 2.01), 0.7591		1.33 (0.68- 2.61), 0.4030	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.49- 1.22), 0.2728			
Hazard Ratio (95%CI), P-value [d]		1.21 (0.49- 2.98), 0.6845			
Gender					
Female	37	40.5 (26.8 - 58.0)	46	37.0 (24.8 - 52.5)	0.86 (0.43- 1.72), 0.6635
Male	73	38.4 (28.3 - 50.5)	58	29.3 (19.4 - 42.8)	0.68 (0.37- 1.24), 0.2093
Hazard Ratio (95%CI), P-value [b]		0.94 (0.50- 1.76), 0.8532		0.74 (0.38- 1.45), 0.3780	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.48- 1.18), 0.2157			
Hazard Ratio (95%CI), P-value [d]		0.79 (0.32- 1.99), 0.6203			
Race					
Other	27	37.0 (21.9 - 57.9)	16	37.5 (18.9 - 65.1)	0.94 (0.34- 2.59), 0.9060
White	83	39.8 (30.2 - 51.1)	88	31.8 (23.2 - 42.6)	0.73 (0.44- 1.20), 0.2109
Hazard Ratio (95%CI), P-value [b]		1.08 (0.53- 2.19), 0.8348		0.81 (0.33- 1.95), 0.6332	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.49- 1.20), 0.2428			
Hazard Ratio (95%CI), P-value [d]		0.76 (0.24- 2.35), 0.6305			
Body Mass Index (kg/m^2)					
< 30 kg/m2	58	31.0 (20.8 - 44.6)	57	31.6 (21.2 - 45.3)	0.95 (0.49- 1.82), 0.8715
>=30 kg/m2	51	49.0 (36.4 - 63.4)	45	31.1 (19.8 - 46.8)	0.56 (0.29- 1.09), 0.0824
Hazard Ratio (95%CI), P-value [b]		1.80 (0.98- 3.30), 0.0540		1.06 (0.53- 2.13), 0.8766	
Hazard Ratio (95%CI), P-value [c]		0.73 (0.46- 1.15), 0.1743			
Hazard Ratio (95%CI), P-value [d]		0.58 (0.23- 1.47), 0.2520			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.2
Mortality at Day 7: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	45	26.7 (16.1 - 42.2)	23	21.7 (9.7 - 44.6)	0.73 (0.26- 2.07), 0.5527
< 2.5 g/dL	64	46.9 (35.6 - 59.8)	76	35.5 (25.9 - 47.4)	0.67 (0.40- 1.13), 0.1344
Hazard Ratio (95%CI), P-value [b]		1.98 (1.02- 3.88), 0.0408		1.85 (0.71- 4.81), 0.1992	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.43- 1.09), 0.1118			
Hazard Ratio (95%CI), P-value [d]		0.91 (0.28- 2.93), 0.8774			
Geographic Region					
Rest of World	17	23.5 (9.6 - 51.2)	17	23.5 (9.6 - 51.2)	0.90 (0.23- 3.62), 0.8876
US/Canada	93	41.9 (32.7 - 52.6)	87	34.5 (25.5 - 45.5)	0.75 (0.46- 1.20), 0.2257
Hazard Ratio (95%CI), P-value [b]		1.80 (0.64- 5.04), 0.2559		1.52 (0.53- 4.31), 0.4295	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.49- 1.19), 0.2345			
Hazard Ratio (95%CI), P-value [d]		0.82 (0.19- 3.54), 0.7864			
Baseline MAP					
>=65 mmHg	69	33.3 (23.6 - 45.8)	66	24.2 (15.6 - 36.5)	0.65 (0.34- 1.23), 0.1825
< 65 mmHg	41	48.8 (34.8 - 64.9)	38	47.4 (33.0 - 64.2)	0.92 (0.49- 1.74), 0.7963
Hazard Ratio (95%CI), P-value [b]		1.73 (0.95- 3.15), 0.0706		2.45 (1.25- 4.80), 0.0072	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.49- 1.21), 0.2599			
Hazard Ratio (95%CI), P-value [d]		1.39 (0.56- 3.42), 0.4770			
Baseline APACHE II Score					
<=30	62	32.3 (22.2 - 45.4)	67	29.9 (20.4 - 42.4)	0.88 (0.47- 1.64), 0.6923
> 30	48	47.9 (35.0 - 62.8)	37	37.8 (24.4 - 55.4)	0.70 (0.36- 1.35), 0.2824
Hazard Ratio (95%CI), P-value [b]		1.78 (0.98- 3.24), 0.0566		1.41 (0.71- 2.78), 0.3260	
Hazard Ratio (95%CI), P-value [c]		0.79 (0.50- 1.24), 0.3041			
Hazard Ratio (95%CI), P-value [d]		0.78 (0.31- 1.92), 0.5831			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.2
Mortality at Day 7: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	97	39.2 (30.3 - 49.6)	97	33.0 (24.6 - 43.3)	0.77 (0.48- 1.23), 0.2664
Yes	13	38.5 (18.2 - 69.2)	7	28.6 (8.0 - 74.2)	0.69 (0.13- 3.59), 0.6618
Hazard Ratio (95%CI), P-value [b]		0.93 (0.37- 2.37), 0.8863		0.84 (0.20- 3.51), 0.8115	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.48- 1.20), 0.2353			
Hazard Ratio (95%CI), P-value [d]		0.90 (0.16- 4.98), 0.9082			
Exposure to ARBs					
No	103	40.8 (32.0 - 50.9)	97	32.0 (23.7 - 42.2)	0.70 (0.44- 1.11), 0.1288
Yes	7	14.3 (2.1 - 66.6)	7	42.9 (16.3 - 82.8)	3.56 (0.37-34.35), 0.2406
Hazard Ratio (95%CI), P-value [b]		0.29 (0.04- 2.07), 0.1859		1.48 (0.45- 4.84), 0.5141	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.48- 1.19), 0.2267			
Hazard Ratio (95%CI), P-value [d]		5.31 (0.53-53.50), 0.1568			
Medical History of ARDS					
No	81	38.3 (28.7 - 49.8)	86	29.1 (20.7 - 39.9)	0.67 (0.40- 1.14), 0.1385
Yes	29	41.4 (26.0 - 61.2)	18	50.0 (29.9 - 74.1)	1.27 (0.53- 3.01), 0.5891
Hazard Ratio (95%CI), P-value [b]		1.00 (0.51- 1.95), 0.9993		1.93 (0.90- 4.14), 0.0846	
Hazard Ratio (95%CI), P-value [c]		0.79 (0.50- 1.25), 0.3195			
Hazard Ratio (95%CI), P-value [d]		1.89 (0.69- 5.21), 0.2171			
Chest X-ray Finding of ARDS					
No	70	34.3 (24.5 - 46.6)	79	25.3 (17.1 - 36.4)	0.68 (0.37- 1.23), 0.1965
Yes	40	47.5 (33.5 - 63.9)	24	58.3 (39.9 - 77.8)	1.19 (0.60- 2.38), 0.6184
Hazard Ratio (95%CI), P-value [b]		1.50 (0.82- 2.74), 0.1851		2.78 (1.40- 5.52), 0.0022	
Hazard Ratio (95%CI), P-value [c]		0.86 (0.54- 1.35), 0.5067			
Hazard Ratio (95%CI), P-value [d]		1.77 (0.71- 4.41), 0.2176			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.2
Mortality at Day 7: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	15	53.3 (31.3 - 78.8)	14	21.4 (7.5 - 52.8)	0.29 (0.08- 1.11), 0.0549
Yes	95	36.8 (28.0 - 47.4)	90	34.4 (25.6 - 45.2)	0.89 (0.55- 1.44), 0.6310
Hazard Ratio (95%CI), P-value [b]		0.55 (0.26- 1.20), 0.1269		1.77 (0.54- 5.80), 0.3367	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.49- 1.20), 0.2457			
Hazard Ratio (95%CI), P-value [d]		3.21 (0.78-13.18), 0.1056			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	74	32.4 (23.1 - 44.4)	72	22.2 (14.3 - 33.7)	0.63 (0.34- 1.19), 0.1511
>=0.5 ug/kg/min	36	52.8 (37.7 - 69.5)	32	56.3 (40.2 - 73.5)	0.94 (0.49- 1.80), 0.8578
Hazard Ratio (95%CI), P-value [b]		2.23 (1.22- 4.09), 0.0074		3.38 (1.72- 6.65), 0.0002	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.49- 1.20), 0.2479			
Hazard Ratio (95%CI), P-value [d]		1.46 (0.59- 3.60), 0.4136			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	1	0.0 (0.0 - 0.0)	65	23.1 (14.6 - 35.3)	45E4 (0.00-), 0.6101
>=20 ng/kg/min	109	39.4 (31.0 - 49.3)	39	48.7 (34.5 - 65.2)	1.27 (0.74- 2.18), 0.3807
Hazard Ratio (95%CI), P-value [b]		45E4 (0.00-), 0.4801		2.61 (1.32- 5.13), 0.0040	
Hazard Ratio (95%CI), P-value [c]		1.29 (0.76- 2.20), 0.3479			
Hazard Ratio (95%CI), P-value [d]		0.00 (0.00-), 0.9856			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.2
Mortality at Day 7: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	22	27.3 (13.3 - 50.9)	26	15.4 (6.1 - 36.0)	0.51 (0.14- 1.80), 0.2828
72.3 - <253 pg/mL	26	42.3 (26.1 - 63.2)	20	45.0 (26.5 - 68.7)	0.98 (0.41- 2.38), 0.9713
253 - <676 pg/mL	22	40.9 (23.8 - 63.9)	26	38.5 (22.9 - 59.7)	0.88 (0.36- 2.18), 0.7886
>=676 pg/mL	27	44.4 (28.2 - 64.8)	21	28.6 (14.0 - 52.8)	0.59 (0.22- 1.57), 0.2827
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	49	42.9 (30.4 - 57.8)	47	34.0 (22.4 - 49.4)	0.73 (0.38- 1.40), 0.3471
< 253 pg/mL	48	35.4 (23.7 - 50.6)	46	28.3 (17.5 - 43.6)	0.72 (0.35- 1.49), 0.3735
Hazard Ratio (95%CI), P-value [b]		0.83 (0.44- 1.58), 0.5695		0.79 (0.38- 1.65), 0.5358	
Hazard Ratio (95%CI), P-value [c]		0.73 (0.45- 1.18), 0.1975			
Hazard Ratio (95%CI), P-value [d]		0.97 (0.37- 2.56), 0.9514			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	27	37.0 (21.9 - 57.9)	27	14.8 (5.8 - 34.8)	0.35 (0.11- 1.10), 0.0603
23.85 - <83.75 pg/mL	28	42.9 (27.1 - 62.9)	24	33.3 (18.3 - 55.7)	0.69 (0.28- 1.68), 0.4076
83.75 - <299.5 pg/mL	11	27.3 (9.7 - 62.9)	23	47.8 (30.0 - 69.5)	2.02 (0.56- 7.23), 0.2720
>=299.5 pg/mL	30	40.0 (25.0 - 59.5)	18	27.8 (12.6 - 54.4)	0.66 (0.23- 1.88), 0.4343
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	41	36.6 (23.9 - 53.2)	41	39.0 (26.0 - 55.6)	1.06 (0.52- 2.14), 0.8726
< 83.75 pg/mL	55	40.0 (28.5 - 54.1)	51	23.5 (14.1 - 37.7)	0.51 (0.25- 1.02), 0.0533
Hazard Ratio (95%CI), P-value [b]		1.23 (0.64- 2.38), 0.5299		0.57 (0.27- 1.20), 0.1318	
Hazard Ratio (95%CI), P-value [c]		0.73 (0.44- 1.19), 0.2004			
Hazard Ratio (95%CI), P-value [d]		0.46 (0.17- 1.26), 0.1316			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.2
Mortality at Day 7: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	49	49.0 (36.1 - 63.6)	47	29.8 (18.9 - 45.0)	0.49 (0.25- 0.95), 0.0315
< 1.63	46	28.3 (17.5 - 43.6)	43	32.6 (20.7 - 48.7)	1.18 (0.55- 2.51), 0.6668
Hazard Ratio (95%CI), P-value [b]		0.47 (0.24- 0.92), 0.0245		1.12 (0.54- 2.36), 0.7592	
Hazard Ratio (95%CI), P-value [c]		0.71 (0.43- 1.16), 0.1746			
Hazard Ratio (95%CI), P-value [d]		2.42 (0.89- 6.60), 0.0836			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.2a
Mortality at Day 7: Univariate Analyses of Vasopressor Count (PP Population)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Number of Vasopressors					
1	39	17.9 (9.0 - 34.0)	46	19.6 (10.7 - 34.2)	1.13 (0.42- 3.04), 0.8033
>=2	110	39.1 (30.7 - 48.9)	104	32.7 (24.6 - 42.6)	0.76 (0.49- 1.20), 0.2384
Hazard Ratio (95%CI), P-value [b]		2.69 (1.21- 5.98), 0.0116		1.83 (0.88- 3.82), 0.1007	
Hazard Ratio (95%CI), P-value [c]		0.82 (0.54- 1.23), 0.3333			
Hazard Ratio (95%CI), P-value [d]		0.67 (0.23- 1.99), 0.4732			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.3
Mortality at Day 7: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	66	38.9 (28.2 - 52.0)	64	28.6 (19.1 - 41.4)	0.69 (0.38- 1.27), 0.2360
>=65	62	40.3 (29.3 - 53.6)	54	38.9 (27.4 - 53.2)	0.90 (0.50- 1.60), 0.7109
Hazard Ratio (95%CI), P-value [b]		1.07 (0.61- 1.85), 0.8228		1.37 (0.73- 2.57), 0.3272	
Hazard Ratio (95%CI), P-value [c]		0.79 (0.52- 1.20), 0.2767			
Hazard Ratio (95%CI), P-value [d]		1.29 (0.56- 2.98), 0.5534			
Gender					
Female	43	40.3 (27.3 - 56.6)	52	39.2 (27.4 - 53.9)	0.94 (0.49- 1.80), 0.8626
Male	85	39.3 (29.8 - 50.5)	66	28.8 (19.4 - 41.3)	0.67 (0.38- 1.18), 0.1653
Hazard Ratio (95%CI), P-value [b]		0.99 (0.55- 1.78), 0.9741		0.69 (0.37- 1.30), 0.2514	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.51- 1.18), 0.2419			
Hazard Ratio (95%CI), P-value [d]		0.71 (0.30- 1.66), 0.4256			
Race					
Other	32	45.2 (29.7 - 64.0)	20	42.1 (23.7 - 66.8)	0.90 (0.38- 2.15), 0.8168
White	96	37.8 (28.9 - 48.3)	98	31.6 (23.4 - 41.8)	0.78 (0.48- 1.26), 0.3140
Hazard Ratio (95%CI), P-value [b]		0.81 (0.44- 1.51), 0.5089		0.69 (0.32- 1.51), 0.3524	
Hazard Ratio (95%CI), P-value [c]		0.81 (0.53- 1.23), 0.3221			
Hazard Ratio (95%CI), P-value [d]		0.86 (0.32- 2.32), 0.7667			
Body Mass Index (kg/m^2)					
< 30 kg/m2	69	33.8 (23.9 - 46.4)	62	30.6 (20.8 - 43.7)	0.85 (0.46- 1.56), 0.6042
>=30 kg/m2	58	47.2 (35.3 - 60.9)	54	34.0 (22.9 - 48.4)	0.67 (0.37- 1.21), 0.1789
Hazard Ratio (95%CI), P-value [b]		1.53 (0.87- 2.66), 0.1337		1.20 (0.63- 2.28), 0.5869	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.49- 1.15), 0.1861			
Hazard Ratio (95%CI), P-value [d]		0.78 (0.33- 1.82), 0.5622			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.3
Mortality at Day 7: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	48	27.1 (16.7 - 42.0)	26	19.2 (8.5 - 40.2)	0.63 (0.22- 1.76), 0.3717
< 2.5 g/dL	67	49.3 (38.1 - 61.7)	82	36.6 (27.2 - 48.0)	0.67 (0.41- 1.11), 0.1164
Hazard Ratio (95%CI), P-value [b]		2.06 (1.08- 3.92), 0.0240		2.22 (0.86- 5.72), 0.0901	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.43- 1.04), 0.0728			
Hazard Ratio (95%CI), P-value [d]		1.06 (0.34- 3.34), 0.9151			
Geographic Region					
Rest of World	20	20.0 (8.0 - 44.9)	18	22.2 (9.0 - 48.9)	1.04 (0.26- 4.17), 0.9532
US/Canada	108	43.3 (34.5 - 53.3)	100	35.4 (26.8 - 45.6)	0.76 (0.49- 1.18), 0.2233
Hazard Ratio (95%CI), P-value [b]		2.32 (0.83- 6.44), 0.0973		1.69 (0.60- 4.77), 0.3121	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.52- 1.19), 0.2537			
Hazard Ratio (95%CI), P-value [d]		0.73 (0.17- 3.10), 0.6648			
Baseline MAP					
>=65 mmHg	78	31.5 (22.3 - 43.2)	77	26.3 (17.9 - 37.8)	0.78 (0.43- 1.40), 0.3992
< 65 mmHg	50	52.0 (39.1 - 66.3)	41	46.3 (32.6 - 62.6)	0.87 (0.48- 1.57), 0.6481
Hazard Ratio (95%CI), P-value [b]		1.95 (1.12- 3.39), 0.0165		2.21 (1.18- 4.14), 0.0114	
Hazard Ratio (95%CI), P-value [c]		0.82 (0.54- 1.25), 0.3595			
Hazard Ratio (95%CI), P-value [d]		1.12 (0.48- 2.58), 0.7984			
Baseline APACHE II Score					
<=30	72	31.4 (21.9 - 43.6)	75	29.7 (20.7 - 41.6)	0.93 (0.52- 1.69), 0.8237
> 30	56	50.0 (37.8 - 63.6)	43	39.5 (26.7 - 55.7)	0.71 (0.39- 1.30), 0.2632
Hazard Ratio (95%CI), P-value [b]		1.95 (1.11- 3.40), 0.0175		1.47 (0.78- 2.77), 0.2314	
Hazard Ratio (95%CI), P-value [c]		0.82 (0.54- 1.24), 0.3423			
Hazard Ratio (95%CI), P-value [d]		0.75 (0.32- 1.74), 0.5015			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.3
Mortality at Day 7: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	103	40.8 (32.0 - 50.9)	105	33.3 (25.2 - 43.2)	0.75 (0.48- 1.18), 0.2175
Yes	13	38.5 (18.2 - 69.2)	8	25.0 (6.9 - 68.5)	0.60 (0.12- 3.09), 0.5338
Hazard Ratio (95%CI), P-value [b]		0.90 (0.36- 2.27), 0.8212		0.71 (0.17- 2.94), 0.6318	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.48- 1.14), 0.1758			
Hazard Ratio (95%CI), P-value [d]		0.79 (0.14- 4.32), 0.7852			
Exposure to ARBs					
No	109	42.2 (33.6 - 52.0)	105	32.4 (24.3 - 42.2)	0.69 (0.44- 1.07), 0.0955
Yes	7	14.3 (2.1 - 66.6)	8	37.5 (13.9 - 77.1)	3.31 (0.34-31.99), 0.2741
Hazard Ratio (95%CI), P-value [b]		0.27 (0.04- 1.99), 0.1698		1.43 (0.44- 4.67), 0.5485	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.48- 1.14), 0.1664			
Hazard Ratio (95%CI), P-value [d]		5.31 (0.53-53.26), 0.1562			
Medical History of ARDS					
No	86	39.5 (30.1 - 50.7)	94	29.8 (21.6 - 40.1)	0.68 (0.41- 1.12), 0.1243
Yes	30	43.3 (27.9 - 62.7)	19	47.4 (28.1 - 71.3)	1.17 (0.50- 2.74), 0.7152
Hazard Ratio (95%CI), P-value [b]		1.04 (0.55- 1.97), 0.9020		1.82 (0.86- 3.87), 0.1119	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.50- 1.20), 0.2522			
Hazard Ratio (95%CI), P-value [d]		1.73 (0.65- 4.64), 0.2760			
Chest X-ray Finding of ARDS					
No	74	35.1 (25.5 - 47.1)	87	26.4 (18.4 - 37.0)	0.69 (0.39- 1.20), 0.1851
Yes	43	51.2 (37.4 - 66.7)	25	56.0 (38.1 - 75.5)	1.10 (0.56- 2.15), 0.7788
Hazard Ratio (95%CI), P-value [b]		1.55 (0.88- 2.73), 0.1289		2.57 (1.32- 5.01), 0.0039	
Hazard Ratio (95%CI), P-value [c]		0.83 (0.54- 1.28), 0.4022			
Hazard Ratio (95%CI), P-value [d]		1.62 (0.68- 3.88), 0.2797			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.3
Mortality at Day 7: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	16	50.0 (29.0 - 75.5)	16	18.8 (6.5 - 47.5)	0.28 (0.07- 1.06), 0.0453
Yes	100	39.0 (30.2 - 49.3)	97	35.1 (26.5 - 45.4)	0.87 (0.55- 1.37), 0.5382
Hazard Ratio (95%CI), P-value [b]		0.65 (0.30- 1.39), 0.2585		2.12 (0.65- 6.91), 0.2011	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.49- 1.16), 0.1982			
Hazard Ratio (95%CI), P-value [d]		3.28 (0.80-13.34), 0.0978			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	87	32.5 (23.7 - 43.5)	82	23.5 (15.7 - 34.3)	0.69 (0.38- 1.23), 0.2037
>=0.5 ug/kg/min	41	55.0 (40.5 - 70.7)	36	55.6 (40.4 - 72.0)	0.89 (0.49- 1.64), 0.7135
Hazard Ratio (95%CI), P-value [b]		2.40 (1.37- 4.20), 0.0016		3.18 (1.70- 5.98), 0.0001	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.51- 1.18), 0.2407			
Hazard Ratio (95%CI), P-value [d]		1.29 (0.56- 2.99), 0.5534			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	2	0.0 (0.0 - 0.0)	72	23.6 (15.4 - 35.2)	13E5 (0.00-), 0.4648
>=20 ng/kg/min	114	41.2 (32.8 - 50.8)	41	48.8 (34.8 - 64.9)	1.26 (0.75- 2.13), 0.3865
Hazard Ratio (95%CI), P-value [b]		12E5 (0.00-), 0.3040		2.62 (1.37- 5.00), 0.0025	
Hazard Ratio (95%CI), P-value [c]		1.30 (0.78- 2.17), 0.3222			
Hazard Ratio (95%CI), P-value [d]		0.00 (0.00-), 0.9864			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.3
Mortality at Day 7: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	23	26.1 (12.7 - 49.1)	27	14.8 (5.8 - 34.8)	0.51 (0.14- 1.82), 0.2920
72.3 - <253 pg/mL	26	42.3 (26.1 - 63.2)	22	45.5 (27.6 - 67.9)	1.03 (0.44- 2.43), 0.9432
253 - <676 pg/mL	25	48.0 (30.8 - 68.8)	27	37.0 (21.9 - 57.9)	0.70 (0.30- 1.62), 0.4025
>=676 pg/mL	28	42.9 (27.1 - 62.9)	25	36.0 (20.6 - 57.8)	0.82 (0.35- 1.96), 0.6617
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	53	45.3 (33.1 - 59.6)	52	36.5 (25.1 - 51.1)	0.76 (0.42- 1.39), 0.3754
< 253 pg/mL	49	34.7 (23.2 - 49.7)	49	28.6 (18.0 - 43.4)	0.76 (0.37- 1.54), 0.4464
Hazard Ratio (95%CI), P-value [b]		0.76 (0.41- 1.41), 0.3848		0.74 (0.37- 1.47), 0.3894	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.48- 1.20), 0.2441			
Hazard Ratio (95%CI), P-value [d]		0.98 (0.39- 2.49), 0.9712			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	30	36.7 (22.2 - 56.4)	27	14.8 (5.8 - 34.8)	0.35 (0.11- 1.10), 0.0605
23.85 - <83.75 pg/mL	28	42.9 (27.1 - 62.9)	25	32.0 (17.5 - 53.9)	0.65 (0.27- 1.60), 0.3482
83.75 - <299.5 pg/mL	12	33.3 (14.0 - 66.3)	28	50.0 (33.4 - 69.4)	1.81 (0.60- 5.51), 0.2870
>=299.5 pg/mL	31	41.9 (26.9 - 61.0)	20	30.0 (14.7 - 54.9)	0.71 (0.27- 1.86), 0.4821
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	43	39.5 (26.7 - 55.7)	48	41.7 (29.2 - 56.8)	1.10 (0.58- 2.11), 0.7642
< 83.75 pg/mL	58	39.7 (28.4 - 53.4)	52	23.1 (13.8 - 37.0)	0.50 (0.25- 1.01), 0.0471
Hazard Ratio (95%CI), P-value [b]		1.13 (0.60- 2.12), 0.6972		0.50 (0.24- 1.02), 0.0526	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.48- 1.21), 0.2441			
Hazard Ratio (95%CI), P-value [d]		0.44 (0.17- 1.15), 0.0939			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.3
Mortality at Day 7: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	53	49.1 (36.6 - 63.1)	52	32.7 (21.8 - 47.2)	0.56 (0.30- 1.03), 0.0587
< 1.63	47	29.8 (18.9 - 45.0)	46	32.6 (21.1 - 48.1)	1.13 (0.55- 2.35), 0.7383
Hazard Ratio (95%CI), P-value [b]		0.50 (0.26- 0.95), 0.0310		1.00 (0.50- 2.01), 0.9951	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.47- 1.19), 0.2142			
Hazard Ratio (95%CI), P-value [d]		2.04 (0.79- 5.28), 0.1416			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.3a
Mortality at Day 7: Univariate Analyses of Vasopressor Count (ITT Population)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Number of Vasopressors					
1	44	18.2 (9.5 - 33.1)	53	17.3 (9.4 - 30.6)	0.97 (0.37- 2.51), 0.9463
>=2	128	39.6 (31.7 - 48.7)	118	33.3 (25.6 - 42.7)	0.79 (0.52- 1.20), 0.2662
Hazard Ratio (95%CI), P-value [b]		2.66 (1.26- 5.62), 0.0074		2.17 (1.05- 4.49), 0.0313	
Hazard Ratio (95%CI), P-value [c]		0.82 (0.56- 1.20), 0.2963			
Hazard Ratio (95%CI), P-value [d]		0.81 (0.29- 2.29), 0.6912			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	54	59.6 (46.8 - 72.7)	62	38.7 (27.9 - 52.0)	0.57 (0.33- 0.96), 0.0327
>=65	61	62.3 (50.4 - 74.3)	52	59.8 (46.9 - 73.1)	0.88 (0.55- 1.42), 0.6041
Hazard Ratio (95%CI), P-value [b]		1.09 (0.68- 1.74), 0.7253		1.71 (1.00- 2.92), 0.0468	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.51- 1.03), 0.0719			
Hazard Ratio (95%CI), P-value [d]		1.57 (0.77- 3.21), 0.2110			
Gender					
Female	39	56.4 (41.7 - 72.1)	49	53.1 (40.0 - 67.5)	0.88 (0.50- 1.55), 0.6563
Male	76	63.4 (52.7 - 74.1)	65	44.6 (33.5 - 57.5)	0.59 (0.37- 0.93), 0.0231
Hazard Ratio (95%CI), P-value [b]		1.12 (0.68- 1.86), 0.6548		0.76 (0.45- 1.29), 0.3047	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.48- 0.98), 0.0401			
Hazard Ratio (95%CI), P-value [d]		0.68 (0.33- 1.41), 0.2954			
Race					
Other	29	66.7 (49.5 - 83.0)	17	58.8 (37.4 - 81.4)	0.88 (0.41- 1.89), 0.7391
White	86	59.3 (49.2 - 69.7)	97	46.5 (37.1 - 56.9)	0.68 (0.46- 1.02), 0.0579
Hazard Ratio (95%CI), P-value [b]		0.90 (0.53- 1.53), 0.7066		0.70 (0.35- 1.38), 0.2963	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.50- 1.03), 0.0690			
Hazard Ratio (95%CI), P-value [d]		0.77 (0.33- 1.84), 0.5614			
Body Mass Index (kg/m^2)					
< 30 kg/m2	60	56.9 (44.9 - 69.6)	60	43.4 (32.0 - 56.8)	0.70 (0.42- 1.16), 0.1630
>=30 kg/m2	54	64.8 (52.2 - 77.2)	52	51.9 (39.2 - 65.9)	0.67 (0.41- 1.11), 0.1192
Hazard Ratio (95%CI), P-value [b]		1.34 (0.83- 2.14), 0.2276		1.28 (0.75- 2.19), 0.3678	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.48- 0.98), 0.0380			
Hazard Ratio (95%CI), P-value [d]		0.95 (0.47- 1.95), 0.8972			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	47	47.1 (34.0 - 62.3)	27	40.7 (25.0 - 61.4)	0.77 (0.37- 1.58), 0.4682
< 2.5 g/dL	67	70.1 (59.0 - 80.6)	82	51.3 (41.0 - 62.5)	0.61 (0.40- 0.93), 0.0201
Hazard Ratio (95%CI), P-value [b]		1.94 (1.16- 3.22), 0.0096		1.52 (0.78- 2.94), 0.2163	
Hazard Ratio (95%CI), P-value [c]		0.65 (0.45- 0.93), 0.0189			
Hazard Ratio (95%CI), P-value [d]		0.78 (0.34- 1.81), 0.5681			
Geographic Region					
Rest of World	17	47.7 (27.3 - 73.2)	17	29.4 (13.4 - 56.9)	0.57 (0.19- 1.76), 0.3245
US/Canada	98	63.3 (53.8 - 72.7)	97	51.6 (42.1 - 61.9)	0.71 (0.49- 1.03), 0.0714
Hazard Ratio (95%CI), P-value [b]		1.52 (0.73- 3.18), 0.2630		1.94 (0.77- 4.87), 0.1496	
Hazard Ratio (95%CI), P-value [c]		0.70 (0.49- 0.99), 0.0441			
Hazard Ratio (95%CI), P-value [d]		1.27 (0.39- 4.13), 0.6906			
Baseline MAP					
>=65 mmHg	70	51.4 (40.4 - 63.5)	74	43.2 (32.9 - 55.3)	0.75 (0.47- 1.21), 0.2403
< 65 mmHg	45	76.1 (62.8 - 87.3)	40	57.6 (43.1 - 73.0)	0.66 (0.39- 1.13), 0.1286
Hazard Ratio (95%CI), P-value [b]		1.97 (1.23- 3.16), 0.0040		1.71 (1.00- 2.93), 0.0464	
Hazard Ratio (95%CI), P-value [c]		0.71 (0.50- 1.01), 0.0596			
Hazard Ratio (95%CI), P-value [d]		0.86 (0.42- 1.76), 0.6838			
Baseline APACHE II Score					
<=30	63	47.8 (36.3 - 60.8)	74	46.0 (35.5 - 58.0)	0.92 (0.56- 1.50), 0.7318
> 30	52	76.9 (64.8 - 87.2)	40	52.5 (38.2 - 68.4)	0.55 (0.32- 0.94), 0.0252
Hazard Ratio (95%CI), P-value [b]		2.14 (1.33- 3.44), 0.0013		1.28 (0.74- 2.20), 0.3775	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.51- 1.03), 0.0716			
Hazard Ratio (95%CI), P-value [d]		0.60 (0.29- 1.23), 0.1598			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	102	62.9 (53.6 - 72.2)	106	50.1 (41.0 - 59.9)	0.70 (0.48- 1.00), 0.0517
Yes	13	46.2 (24.0 - 75.2)	8	25.0 (6.9 - 68.5)	0.49 (0.10- 2.44), 0.3731
Hazard Ratio (95%CI), P-value [b]		0.67 (0.29- 1.55), 0.3451		0.44 (0.11- 1.81), 0.2432	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.48- 0.98), 0.0361			
Hazard Ratio (95%CI), P-value [d]		0.66 (0.13- 3.40), 0.6189			
Exposure to ARBs					
No	108	62.2 (53.1 - 71.3)	106	47.2 (38.2 - 57.1)	0.64 (0.45- 0.93), 0.0178
Yes	7	42.9 (16.3 - 82.8)	8	62.5 (32.6 - 91.3)	2.07 (0.49- 8.70), 0.3123
Hazard Ratio (95%CI), P-value [b]		0.51 (0.16- 1.64), 0.2522		1.74 (0.69- 4.37), 0.2318	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.49- 0.99), 0.0424			
Hazard Ratio (95%CI), P-value [d]		3.36 (0.77-14.71), 0.1084			
Medical History of ARDS					
No	85	58.9 (48.7 - 69.4)	95	46.4 (37.0 - 56.9)	0.67 (0.44- 1.00), 0.0486
Yes	30	66.7 (50.0 - 82.5)	19	57.9 (37.5 - 79.6)	0.93 (0.45- 1.95), 0.8534
Hazard Ratio (95%CI), P-value [b]		1.09 (0.65- 1.83), 0.7441		1.55 (0.80- 3.00), 0.1917	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.50- 1.03), 0.0716			
Hazard Ratio (95%CI), P-value [d]		1.41 (0.61- 3.27), 0.4226			
Chest X-ray Finding of ARDS					
No	72	55.7 (44.7 - 67.4)	88	43.3 (33.7 - 54.3)	0.67 (0.43- 1.04), 0.0752
Yes	43	69.8 (55.9 - 82.6)	25	68.0 (49.8 - 84.8)	1.02 (0.56- 1.85), 0.9444
Hazard Ratio (95%CI), P-value [b]		1.43 (0.89- 2.29), 0.1381		2.23 (1.25- 3.97), 0.0051	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.54- 1.11), 0.1691			
Hazard Ratio (95%CI), P-value [d]		1.55 (0.74- 3.25), 0.2500			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	15	53.3 (31.3 - 78.8)	17	23.5 (9.6 - 51.2)	0.31 (0.09- 1.04), 0.0457
Yes	100	62.2 (52.8 - 71.6)	97	52.7 (43.1 - 62.9)	0.78 (0.54- 1.13), 0.1896
Hazard Ratio (95%CI), P-value [b]		1.00 (0.48- 2.08), 0.9897		2.73 (0.99- 7.56), 0.0438	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.50- 1.02), 0.0651			
Hazard Ratio (95%CI), P-value [d]		2.74 (0.78- 9.62), 0.1159			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	77	57.3 (46.6 - 68.5)	81	42.1 (32.2 - 53.6)	0.64 (0.41- 1.01), 0.0516
>=0.5 ug/kg/min	38	68.4 (53.6 - 82.3)	33	63.6 (47.7 - 79.4)	0.82 (0.46- 1.45), 0.4931
Hazard Ratio (95%CI), P-value [b]		1.75 (1.07- 2.84), 0.0229		2.16 (1.25- 3.73), 0.0046	
Hazard Ratio (95%CI), P-value [c]		0.70 (0.49- 1.00), 0.0517			
Hazard Ratio (95%CI), P-value [d]		1.23 (0.59- 2.55), 0.5809			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	1	100.0 (. - .)	73	43.8 (33.4 - 55.9)	0.34 (0.05- 2.52), 0.2680
>=20 ng/kg/min	114	60.7 (51.8 - 69.6)	41	56.1 (41.8 - 71.4)	0.98 (0.61- 1.57), 0.9283
Hazard Ratio (95%CI), P-value [b]		0.64 (0.09- 4.65), 0.6584		1.69 (0.99- 2.90), 0.0518	
Hazard Ratio (95%CI), P-value [c]		0.94 (0.59- 1.51), 0.8078			
Hazard Ratio (95%CI), P-value [d]		2.59 (0.33-20.11), 0.3615			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	23	52.2 (33.9 - 73.2)	27	48.1 (31.5 - 68.1)	0.82 (0.37- 1.79), 0.6136
72.3 - <253 pg/mL	26	65.4 (47.5 - 82.5)	22	50.0 (31.6 - 71.8)	0.73 (0.34- 1.56), 0.4120
253 - <676 pg/mL	25	60.0 (41.9 - 78.7)	27	48.6 (31.8 - 68.7)	0.70 (0.33- 1.47), 0.3432
>=676 pg/mL	27	70.4 (53.0 - 85.9)	26	50.0 (32.8 - 70.1)	0.63 (0.31- 1.27), 0.1927
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	52	65.4 (52.6 - 77.9)	53	49.2 (36.7 - 63.3)	0.66 (0.39- 1.09), 0.1042
< 253 pg/mL	49	59.5 (46.2 - 73.2)	49	49.0 (36.1 - 63.6)	0.73 (0.43- 1.26), 0.2555
Hazard Ratio (95%CI), P-value [b]		0.86 (0.52- 1.41), 0.5496		0.95 (0.55- 1.66), 0.8611	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.48- 1.00), 0.0510			
Hazard Ratio (95%CI), P-value [d]		1.12 (0.53- 2.35), 0.7736			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	29	58.6 (41.7 - 76.3)	28	46.4 (30.2 - 66.2)	0.63 (0.31- 1.31), 0.2128
23.85 - <83.75 pg/mL	28	64.3 (47.0 - 81.1)	25	44.0 (27.3 - 65.2)	0.56 (0.27- 1.20), 0.1303
83.75 - <299.5 pg/mL	12	41.7 (19.9 - 73.0)	28	57.4 (40.2 - 75.8)	1.67 (0.61- 4.57), 0.3104
>=299.5 pg/mL	31	72.0 (55.6 - 86.5)	20	45.0 (26.5 - 68.7)	0.52 (0.24- 1.13), 0.0919
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	43	63.3 (49.1 - 77.4)	48	52.3 (39.0 - 66.9)	0.82 (0.48- 1.42), 0.4802
< 83.75 pg/mL	57	61.4 (49.1 - 73.9)	53	45.3 (33.1 - 59.6)	0.59 (0.35- 0.99), 0.0435
Hazard Ratio (95%CI), P-value [b]		1.06 (0.64- 1.75), 0.8159		0.76 (0.43- 1.33), 0.3301	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.47- 1.00), 0.0517			
Hazard Ratio (95%CI), P-value [d]		0.71 (0.34- 1.52), 0.3811			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	52	71.2 (58.6 - 82.7)	53	50.9 (38.4 - 64.9)	0.55 (0.34- 0.91), 0.0174
< 1.63	47	53.5 (40.1 - 68.2)	46	48.0 (34.8 - 63.3)	0.89 (0.50- 1.58), 0.6865
Hazard Ratio (95%CI), P-value [b]		0.57 (0.34- 0.94), 0.0270		0.93 (0.53- 1.63), 0.7936	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.46- 0.98), 0.0405			
Hazard Ratio (95%CI), P-value [d]		1.63 (0.77- 3.49), 0.2048			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

LJPC-501
LJ501-CRH01

Table 14.2.9.5.1a
Mortality at Day 28: Univariate Analyses of Vasopressor Count (mITT Population)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Number of Vasopressors					
1	43	34.9 (22.7 - 51.0)	49	40.9 (28.6 - 55.9)	1.20 (0.62- 2.35), 0.5888
>=2	115	61.0 (52.2 - 69.9)	114	48.3 (39.6 - 57.8)	0.70 (0.49- 0.99), 0.0441
Hazard Ratio (95%CI), P-value [b]		2.33 (1.33- 4.07), 0.0023		1.34 (0.81- 2.24), 0.2558	
Hazard Ratio (95%CI), P-value [c]		0.79 (0.58- 1.07), 0.1279			
Hazard Ratio (95%CI), P-value [d]		0.57 (0.27- 1.23), 0.1515			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.2
Mortality at Day 28: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	50	58.3 (45.2 - 72.1)	57	36.8 (25.8 - 50.7)	0.56 (0.32- 0.99), 0.0431
>=65	60	61.7 (49.6 - 73.8)	47	57.6 (44.0 - 71.8)	0.84 (0.51- 1.38), 0.4876
Hazard Ratio (95%CI), P-value [b]		1.12 (0.69- 1.83), 0.6380		1.67 (0.94- 2.96), 0.0753	
Hazard Ratio (95%CI), P-value [c]		0.70 (0.48- 1.02), 0.0648			
Hazard Ratio (95%CI), P-value [d]		1.50 (0.71- 3.18), 0.2890			
Gender					
Female	37	54.1 (39.1 - 70.4)	46	50.0 (36.7 - 65.1)	0.87 (0.48- 1.58), 0.6373
Male	73	63.3 (52.3 - 74.2)	58	43.1 (31.6 - 56.8)	0.57 (0.35- 0.93), 0.0221
Hazard Ratio (95%CI), P-value [b]		1.19 (0.70- 2.01), 0.5163		0.79 (0.45- 1.38), 0.4021	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.46- 0.98), 0.0370			
Hazard Ratio (95%CI), P-value [d]		0.66 (0.31- 1.44), 0.2986			
Race					
Other	27	64.3 (46.4 - 81.7)	16	56.3 (34.4 - 80.2)	0.85 (0.38- 1.91), 0.6982
White	83	59.0 (48.7 - 69.6)	88	44.4 (34.7 - 55.3)	0.65 (0.43- 1.00), 0.0462
Hazard Ratio (95%CI), P-value [b]		0.96 (0.55- 1.67), 0.8926		0.73 (0.35- 1.50), 0.3911	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.47- 1.01), 0.0533			
Hazard Ratio (95%CI), P-value [d]		0.76 (0.31- 1.89), 0.5548			
Body Mass Index (kg/m^2)					
< 30 kg/m2	58	55.5 (43.2 - 68.5)	57	42.2 (30.6 - 56.0)	0.70 (0.41- 1.19), 0.1859
>=30 kg/m2	51	64.7 (51.8 - 77.4)	45	48.9 (35.5 - 64.2)	0.63 (0.37- 1.08), 0.0888
Hazard Ratio (95%CI), P-value [b]		1.39 (0.86- 2.27), 0.1805		1.23 (0.69- 2.20), 0.4805	
Hazard Ratio (95%CI), P-value [c]		0.66 (0.45- 0.97), 0.0338			
Hazard Ratio (95%CI), P-value [d]		0.88 (0.41- 1.88), 0.7412			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.2
Mortality at Day 28: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	45	47.0 (33.7 - 62.5)	23	39.1 (22.6 - 61.7)	0.76 (0.35- 1.66), 0.4887
< 2.5 g/dL	64	68.8 (57.3 - 79.6)	76	48.7 (38.2 - 60.4)	0.59 (0.38- 0.91), 0.0155
Hazard Ratio (95%CI), P-value [b]		1.90 (1.13- 3.20), 0.0144		1.44 (0.69- 2.98), 0.3272	
Hazard Ratio (95%CI), P-value [c]		0.62 (0.42- 0.91), 0.0158			
Hazard Ratio (95%CI), P-value [d]		0.76 (0.31- 1.85), 0.5426			
Geographic Region					
Rest of World	17	47.7 (27.3 - 73.2)	17	29.4 (13.4 - 56.9)	0.57 (0.19- 1.76), 0.3245
US/Canada	93	62.4 (52.7 - 72.1)	87	49.5 (39.5 - 60.4)	0.69 (0.47- 1.03), 0.0659
Hazard Ratio (95%CI), P-value [b]		1.47 (0.70- 3.09), 0.3005		1.83 (0.72- 4.61), 0.1961	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.47- 0.98), 0.0403			
Hazard Ratio (95%CI), P-value [d]		1.23 (0.38- 4.03), 0.7306			
Baseline MAP					
>=65 mmHg	69	52.2 (41.0 - 64.3)	66	40.9 (30.2 - 53.7)	0.69 (0.42- 1.13), 0.1370
< 65 mmHg	41	73.7 (59.6 - 86.1)	38	55.4 (40.6 - 71.5)	0.67 (0.38- 1.18), 0.1618
Hazard Ratio (95%CI), P-value [b]		1.81 (1.11- 2.94), 0.0158		1.74 (0.98- 3.08), 0.0545	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.47- 0.99), 0.0425			
Hazard Ratio (95%CI), P-value [d]		0.96 (0.45- 2.03), 0.9122			
Baseline APACHE II Score					
<=30	62	47.0 (35.4 - 60.1)	67	44.9 (33.9 - 57.5)	0.91 (0.55- 1.52), 0.7296
> 30	48	77.1 (64.5 - 87.7)	37	48.6 (34.1 - 65.6)	0.50 (0.29- 0.88), 0.0148
Hazard Ratio (95%CI), P-value [b]		2.21 (1.36- 3.61), 0.0011		1.21 (0.67- 2.16), 0.5290	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.48- 1.01), 0.0538			
Hazard Ratio (95%CI), P-value [d]		0.54 (0.25- 1.16), 0.1164			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.2
Mortality at Day 28: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	97	62.0 (52.5 - 71.7)	97	47.5 (38.1 - 57.8)	0.67 (0.46- 0.99), 0.0405
Yes	13	46.2 (24.0 - 75.2)	7	28.6 (8.0 - 74.2)	0.57 (0.12- 2.84), 0.4894
Hazard Ratio (95%CI), P-value [b]		0.69 (0.30- 1.59), 0.3795		0.56 (0.14- 2.30), 0.4143	
Hazard Ratio (95%CI), P-value [c]		0.66 (0.46- 0.97), 0.0321			
Hazard Ratio (95%CI), P-value [d]		0.81 (0.16- 4.19), 0.7993			
Exposure to ARBs					
No	103	61.3 (52.0 - 70.7)	97	45.4 (36.1 - 55.8)	0.63 (0.43- 0.93), 0.0195
Yes	7	42.9 (16.3 - 82.8)	7	57.1 (26.6 - 90.2)	1.73 (0.39- 7.77), 0.4687
Hazard Ratio (95%CI), P-value [b]		0.53 (0.17- 1.68), 0.2728		1.46 (0.52- 4.05), 0.4696	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.46- 0.98), 0.0381			
Hazard Ratio (95%CI), P-value [d]		2.76 (0.59-12.95), 0.1977			
Medical History of ARDS					
No	81	58.1 (47.7 - 69.0)	86	44.2 (34.5 - 55.4)	0.64 (0.42- 0.99), 0.0429
Yes	29	65.5 (48.6 - 81.8)	18	55.6 (34.9 - 78.4)	0.89 (0.41- 1.92), 0.7709
Hazard Ratio (95%CI), P-value [b]		1.07 (0.63- 1.82), 0.8141		1.51 (0.75- 3.03), 0.2439	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.48- 1.01), 0.0581			
Hazard Ratio (95%CI), P-value [d]		1.41 (0.59- 3.39), 0.4437			
Chest X-ray Finding of ARDS					
No	70	55.9 (44.7 - 67.7)	79	40.6 (30.7 - 52.2)	0.62 (0.39- 1.00), 0.0465
Yes	40	67.5 (53.0 - 81.2)	24	66.7 (48.1 - 84.1)	1.02 (0.55- 1.89), 0.9573
Hazard Ratio (95%CI), P-value [b]		1.35 (0.83- 2.21), 0.2259		2.28 (1.25- 4.17), 0.0060	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.51- 1.08), 0.1212			
Hazard Ratio (95%CI), P-value [d]		1.66 (0.77- 3.62), 0.1986			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.2
Mortality at Day 28: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	15	53.3 (31.3 - 78.8)	14	21.4 (7.5 - 52.8)	0.29 (0.08- 1.11), 0.0549
Yes	95	61.2 (51.6 - 71.0)	90	50.0 (40.3 - 60.8)	0.75 (0.51- 1.11), 0.1494
Hazard Ratio (95%CI), P-value [b]		0.97 (0.46- 2.03), 0.9329		2.75 (0.85- 8.84), 0.0772	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.48- 1.00), 0.0510			
Hazard Ratio (95%CI), P-value [d]		2.88 (0.72-11.47), 0.1342			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	74	57.0 (46.1 - 68.4)	72	39.0 (28.8 - 51.2)	0.59 (0.37- 0.96), 0.0306
>=0.5 ug/kg/min	36	66.7 (51.4 - 81.2)	32	62.5 (46.3 - 78.7)	0.84 (0.46- 1.52), 0.5569
Hazard Ratio (95%CI), P-value [b]		1.65 (1.00- 2.73), 0.0485		2.28 (1.28- 4.06), 0.0038	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.47- 0.98), 0.0408			
Hazard Ratio (95%CI), P-value [d]		1.37 (0.64- 2.93), 0.4229			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	1	100.0 (. - .)	65	41.5 (30.7 - 54.4)	0.35 (0.05- 2.58), 0.2785
>=20 ng/kg/min	109	59.8 (50.7 - 69.0)	39	53.8 (39.3 - 69.8)	0.92 (0.56- 1.51), 0.7525
Hazard Ratio (95%CI), P-value [b]		0.61 (0.08- 4.45), 0.6261		1.65 (0.93- 2.93), 0.0811	
Hazard Ratio (95%CI), P-value [c]		0.89 (0.54- 1.45), 0.6396			
Hazard Ratio (95%CI), P-value [d]		2.57 (0.33-20.13), 0.3685			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.2
Mortality at Day 28: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	22	54.5 (35.7 - 75.6)	26	46.2 (29.4 - 66.7)	0.75 (0.33- 1.66), 0.4713
72.3 - <253 pg/mL	26	65.4 (47.5 - 82.5)	20	50.0 (30.8 - 72.9)	0.71 (0.33- 1.55), 0.3891
253 - <676 pg/mL	22	54.5 (35.7 - 75.6)	26	46.4 (29.6 - 67.1)	0.78 (0.35- 1.74), 0.5489
>=676 pg/mL	27	70.4 (53.0 - 85.9)	21	42.9 (25.1 - 66.2)	0.49 (0.22- 1.10), 0.0770
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	49	63.3 (50.0 - 76.4)	47	44.8 (31.9 - 60.0)	0.61 (0.35- 1.07), 0.0820
< 253 pg/mL	48	60.7 (47.3 - 74.4)	46	47.8 (34.6 - 63.0)	0.69 (0.40- 1.20), 0.1878
Hazard Ratio (95%CI), P-value [b]		0.94 (0.57- 1.56), 0.8113		1.04 (0.57- 1.89), 0.8989	
Hazard Ratio (95%CI), P-value [c]		0.65 (0.44- 0.96), 0.0319			
Hazard Ratio (95%CI), P-value [d]		1.12 (0.51- 2.46), 0.7723			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	27	59.3 (41.8 - 77.5)	27	44.4 (28.2 - 64.8)	0.60 (0.28- 1.26), 0.1732
23.85 - <83.75 pg/mL	28	64.3 (47.0 - 81.1)	24	45.8 (28.6 - 67.3)	0.60 (0.28- 1.26), 0.1707
83.75 - <299.5 pg/mL	11	36.4 (15.5 - 70.3)	23	52.2 (33.9 - 73.2)	1.68 (0.54- 5.20), 0.3658
>=299.5 pg/mL	30	71.1 (54.3 - 86.0)	18	38.9 (20.8 - 64.7)	0.45 (0.19- 1.06), 0.0608
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	41	61.5 (46.9 - 76.2)	41	46.3 (32.6 - 62.6)	0.73 (0.40- 1.33), 0.3014
< 83.75 pg/mL	55	61.8 (49.3 - 74.5)	51	45.1 (32.7 - 59.7)	0.59 (0.34- 0.99), 0.0451
Hazard Ratio (95%CI), P-value [b]		1.11 (0.66- 1.86), 0.6937		0.88 (0.48- 1.62), 0.6876	
Hazard Ratio (95%CI), P-value [c]		0.64 (0.43- 0.96), 0.0301			
Hazard Ratio (95%CI), P-value [d]		0.80 (0.36- 1.77), 0.5817			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.2
Mortality at Day 28: Univariate Analyses (PP Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	49	71.4 (58.5 - 83.2)	47	48.9 (35.8 - 63.9)	0.51 (0.30- 0.86), 0.0109
< 1.63	46	52.5 (39.0 - 67.5)	43	44.2 (30.9 - 60.2)	0.85 (0.46- 1.54), 0.5855
Hazard Ratio (95%CI), P-value [b]		0.55 (0.33- 0.93), 0.0236		0.92 (0.50- 1.68), 0.7803	
Hazard Ratio (95%CI), P-value [c]		0.63 (0.42- 0.94), 0.0238			
Hazard Ratio (95%CI), P-value [d]		1.66 (0.75- 3.70), 0.2131			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.2a
Mortality at Day 28: Univariate Analyses of Vasopressor Count (PP Population)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Number of Vasopressors					
1	39	35.9 (23.1 - 53.0)	46	41.4 (28.7 - 56.9)	1.20 (0.60- 2.39), 0.6105
>=2	110	60.1 (51.1 - 69.3)	104	46.2 (37.2 - 56.2)	0.68 (0.47- 0.98), 0.0388
Hazard Ratio (95%CI), P-value [b]		2.21 (1.24- 3.94), 0.0057		1.25 (0.74- 2.13), 0.4059	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.56- 1.07), 0.1154			
Hazard Ratio (95%CI), P-value [d]		0.56 (0.26- 1.23), 0.1506			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.3
Mortality at Day 28: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	66	56.4 (44.7 - 68.7)	64	38.1 (27.4 - 51.2)	0.60 (0.36- 1.01), 0.0518
>=65	62	61.3 (49.5 - 73.3)	54	59.4 (46.7 - 72.5)	0.91 (0.57- 1.45), 0.6868
Hazard Ratio (95%CI), P-value [b]		1.14 (0.72- 1.80), 0.5643		1.72 (1.01- 2.92), 0.0431	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.53- 1.06), 0.1073			
Hazard Ratio (95%CI), P-value [d]		1.52 (0.75- 3.05), 0.2440			
Gender					
Female	43	52.3 (38.2 - 67.8)	52	53.0 (40.1 - 67.1)	0.98 (0.56- 1.73), 0.9561
Male	85	62.1 (51.9 - 72.5)	66	43.9 (33.0 - 56.7)	0.60 (0.38- 0.95), 0.0285
Hazard Ratio (95%CI), P-value [b]		1.23 (0.75- 2.03), 0.4138		0.76 (0.45- 1.28), 0.2961	
Hazard Ratio (95%CI), P-value [c]		0.73 (0.52- 1.04), 0.0787			
Hazard Ratio (95%CI), P-value [d]		0.62 (0.30- 1.27), 0.1889			
Race					
Other	32	68.9 (52.3 - 84.2)	20	57.9 (37.5 - 79.6)	0.81 (0.39- 1.69), 0.5774
White	96	55.7 (46.1 - 65.9)	98	46.0 (36.7 - 56.4)	0.75 (0.50- 1.11), 0.1453
Hazard Ratio (95%CI), P-value [b]		0.77 (0.47- 1.28), 0.3192		0.70 (0.36- 1.36), 0.2956	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.54- 1.08), 0.1240			
Hazard Ratio (95%CI), P-value [d]		0.91 (0.40- 2.10), 0.8339			
Body Mass Index (kg/m^2)					
< 30 kg/m2	69	56.1 (44.8 - 68.1)	62	42.0 (30.8 - 55.2)	0.69 (0.42- 1.13), 0.1399
>=30 kg/m2	58	61.3 (49.0 - 73.8)	54	52.8 (40.2 - 66.6)	0.76 (0.46- 1.25), 0.2722
Hazard Ratio (95%CI), P-value [b]		1.23 (0.78- 1.95), 0.3792		1.35 (0.79- 2.31), 0.2630	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.51- 1.03), 0.0698			
Hazard Ratio (95%CI), P-value [d]		1.10 (0.54- 2.22), 0.7974			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.3
Mortality at Day 28: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	48	48.3 (35.2 - 63.2)	26	38.5 (22.9 - 59.7)	0.70 (0.33- 1.46), 0.3381
< 2.5 g/dL	67	70.1 (59.0 - 80.6)	82	51.3 (41.0 - 62.5)	0.61 (0.40- 0.93), 0.0197
Hazard Ratio (95%CI), P-value [b]		1.90 (1.15- 3.14), 0.0106		1.61 (0.81- 3.22), 0.1704	
Hazard Ratio (95%CI), P-value [c]		0.63 (0.44- 0.91), 0.0135			
Hazard Ratio (95%CI), P-value [d]		0.85 (0.36- 2.00), 0.7161			
Geographic Region					
Rest of World	20	40.4 (22.6 - 64.9)	18	27.8 (12.6 - 54.4)	0.66 (0.22- 2.03), 0.4710
US/Canada	108	62.2 (53.1 - 71.4)	100	51.6 (42.2 - 61.7)	0.74 (0.51- 1.07), 0.1035
Hazard Ratio (95%CI), P-value [b]		1.85 (0.89- 3.86), 0.0952		2.10 (0.84- 5.25), 0.1064	
Hazard Ratio (95%CI), P-value [c]		0.73 (0.52- 1.04), 0.0775			
Hazard Ratio (95%CI), P-value [d]		1.13 (0.35- 3.67), 0.8349			
Baseline MAP					
>=65 mmHg	78	48.6 (38.1 - 60.3)	77	43.4 (33.2 - 55.3)	0.82 (0.51- 1.31), 0.4019
< 65 mmHg	50	74.4 (61.7 - 85.5)	41	56.2 (41.9 - 71.6)	0.69 (0.41- 1.16), 0.1618
Hazard Ratio (95%CI), P-value [b]		2.01 (1.27- 3.18), 0.0023		1.67 (0.98- 2.85), 0.0567	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.54- 1.07), 0.1188			
Hazard Ratio (95%CI), P-value [d]		0.83 (0.41- 1.67), 0.5927			
Baseline APACHE II Score					
<=30	72	45.8 (35.0 - 58.2)	75	46.0 (35.5 - 58.0)	0.99 (0.61- 1.60), 0.9684
> 30	56	75.0 (63.2 - 85.4)	43	51.2 (37.4 - 66.7)	0.56 (0.33- 0.93), 0.0242
Hazard Ratio (95%CI), P-value [b]		2.22 (1.40- 3.53), 0.0005		1.23 (0.72- 2.11), 0.4436	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.53- 1.07), 0.1092			
Hazard Ratio (95%CI), P-value [d]		0.55 (0.27- 1.12), 0.1021			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.3
Mortality at Day 28: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	103	63.3 (54.0 - 72.5)	105	49.6 (40.5 - 59.5)	0.69 (0.48- 0.99), 0.0431
Yes	13	46.2 (24.0 - 75.2)	8	25.0 (6.9 - 68.5)	0.49 (0.10- 2.44), 0.3731
Hazard Ratio (95%CI), P-value [b]		0.67 (0.29- 1.54), 0.3423		0.45 (0.11- 1.83), 0.2503	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.47- 0.96), 0.0304			
Hazard Ratio (95%CI), P-value [d]		0.67 (0.13- 3.45), 0.6304			
Exposure to ARBs					
No	109	62.5 (53.5 - 71.6)	105	46.7 (37.7 - 56.6)	0.63 (0.44- 0.92), 0.0143
Yes	7	42.9 (16.3 - 82.8)	8	62.5 (32.6 - 91.3)	2.07 (0.49- 8.70), 0.3123
Hazard Ratio (95%CI), P-value [b]		0.51 (0.16- 1.63), 0.2479		1.76 (0.70- 4.42), 0.2227	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.48- 0.97), 0.0353			
Hazard Ratio (95%CI), P-value [d]		3.42 (0.78-15.01), 0.1029			
Medical History of ARDS					
No	86	59.4 (49.3 - 69.8)	94	45.8 (36.4 - 56.4)	0.65 (0.44- 0.98), 0.0387
Yes	30	66.7 (50.0 - 82.5)	19	57.9 (37.5 - 79.6)	0.93 (0.45- 1.95), 0.8534
Hazard Ratio (95%CI), P-value [b]		1.08 (0.65- 1.82), 0.7630		1.56 (0.80- 3.03), 0.1840	
Hazard Ratio (95%CI), P-value [c]		0.71 (0.49- 1.01), 0.0593			
Hazard Ratio (95%CI), P-value [d]		1.44 (0.62- 3.33), 0.3969			
Chest X-ray Finding of ARDS					
No	74	56.9 (46.0 - 68.3)	87	42.6 (33.0 - 53.7)	0.64 (0.41- 0.99), 0.0440
Yes	43	69.8 (55.9 - 82.6)	25	68.0 (49.8 - 84.8)	1.02 (0.56- 1.86), 0.9400
Hazard Ratio (95%CI), P-value [b]		1.38 (0.86- 2.21), 0.1758		2.25 (1.26- 4.01), 0.0048	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.52- 1.08), 0.1181			
Hazard Ratio (95%CI), P-value [d]		1.63 (0.77- 3.41), 0.1992			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.3
Mortality at Day 28: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	16	56.3 (34.4 - 80.2)	16	18.8 (6.5 - 47.5)	0.24 (0.07- 0.91), 0.0225
Yes	100	62.2 (52.8 - 71.7)	97	52.7 (43.1 - 62.9)	0.78 (0.54- 1.13), 0.1905
Hazard Ratio (95%CI), P-value [b]		0.96 (0.48- 1.93), 0.9055		3.46 (1.08-11.09), 0.0261	
Hazard Ratio (95%CI), P-value [c]		0.70 (0.49- 1.00), 0.0530			
Hazard Ratio (95%CI), P-value [d]		3.62 (0.93-14.07), 0.0636			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	87	54.8 (44.7 - 65.5)	82	40.8 (31.0 - 52.4)	0.66 (0.43- 1.04), 0.0695
>=0.5 ug/kg/min	41	67.5 (53.0 - 81.2)	36	63.9 (48.6 - 79.0)	0.85 (0.49- 1.48), 0.5583
Hazard Ratio (95%CI), P-value [b]		1.80 (1.12- 2.89), 0.0140		2.27 (1.33- 3.87), 0.0020	
Hazard Ratio (95%CI), P-value [c]		0.73 (0.52- 1.03), 0.0751			
Hazard Ratio (95%CI), P-value [d]		1.25 (0.61- 2.55), 0.5416			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	2	100.0 (. - .)	72	43.1 (32.6 - 55.3)	0.36 (0.08- 1.53), 0.1477
>=20 ng/kg/min	114	60.7 (51.8 - 69.6)	41	56.1 (41.8 - 71.4)	0.98 (0.61- 1.57), 0.9279
Hazard Ratio (95%CI), P-value [b]		0.66 (0.16- 2.69), 0.5546		1.72 (1.00- 2.96), 0.0457	
Hazard Ratio (95%CI), P-value [c]		0.91 (0.57- 1.46), 0.7041			
Hazard Ratio (95%CI), P-value [d]		2.56 (0.57-11.55), 0.2226			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.3
Mortality at Day 28: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	23	52.2 (33.9 - 73.2)	27	48.1 (31.5 - 68.1)	0.82 (0.37- 1.79), 0.6136
72.3 - <253 pg/mL	26	65.8 (47.8 - 83.0)	22	50.0 (31.6 - 71.8)	0.73 (0.34- 1.56), 0.4108
253 - <676 pg/mL	25	60.0 (41.9 - 78.7)	27	48.6 (31.8 - 68.7)	0.70 (0.33- 1.47), 0.3432
>=676 pg/mL	28	71.4 (54.4 - 86.5)	25	48.0 (30.8 - 68.8)	0.60 (0.29- 1.23), 0.1567
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	53	66.0 (53.4 - 78.3)	52	48.2 (35.7 - 62.5)	0.64 (0.38- 1.07), 0.0851
< 253 pg/mL	49	59.5 (46.2 - 73.3)	49	49.0 (36.1 - 63.6)	0.73 (0.43- 1.26), 0.2562
Hazard Ratio (95%CI), P-value [b]		0.85 (0.52- 1.39), 0.5213		0.97 (0.55- 1.70), 0.9168	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.47- 0.99), 0.0434			
Hazard Ratio (95%CI), P-value [d]		1.15 (0.54- 2.42), 0.7165			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	30	60.0 (43.3 - 77.2)	27	44.4 (28.2 - 64.8)	0.59 (0.28- 1.22), 0.1489
23.85 - <83.75 pg/mL	28	64.3 (47.0 - 81.1)	25	44.0 (27.3 - 65.2)	0.56 (0.27- 1.19), 0.1294
83.75 - <299.5 pg/mL	12	41.7 (19.9 - 73.0)	28	57.4 (40.2 - 75.8)	1.67 (0.61- 4.57), 0.3104
>=299.5 pg/mL	31	72.0 (55.6 - 86.5)	20	45.0 (26.5 - 68.7)	0.52 (0.24- 1.13), 0.0919
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	43	63.3 (49.1 - 77.4)	48	52.3 (39.0 - 66.9)	0.82 (0.48- 1.41), 0.4751
< 83.75 pg/mL	58	62.1 (49.9 - 74.4)	52	44.2 (32.0 - 58.7)	0.57 (0.34- 0.96), 0.0321
Hazard Ratio (95%CI), P-value [b]		1.06 (0.65- 1.75), 0.8055		0.74 (0.42- 1.30), 0.2952	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.46- 0.99), 0.0415			
Hazard Ratio (95%CI), P-value [d]		0.69 (0.33- 1.47), 0.3411			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.3
Mortality at Day 28: Univariate Analyses (ITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	53	71.7 (59.3 - 83.0)	52	50.0 (37.4 - 64.2)	0.54 (0.33- 0.89), 0.0140
< 1.63	47	53.5 (40.1 - 68.2)	46	48.0 (34.8 - 63.3)	0.89 (0.50- 1.58), 0.6838
Hazard Ratio (95%CI), P-value [b]		0.57 (0.34- 0.94), 0.0260		0.95 (0.54- 1.67), 0.8478	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.46- 0.97), 0.0348			
Hazard Ratio (95%CI), P-value [d]		1.67 (0.78- 3.56), 0.1879			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.3a
Mortality at Day 28: Univariate Analyses of Vasopressor Count (ITT Population)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Number of Vasopressors					
1	44	34.1 (22.2 - 50.0)	53	38.5 (26.8 - 53.1)	1.15 (0.59- 2.24), 0.6862
>=2	128	58.8 (50.4 - 67.5)	118	47.9 (39.3 - 57.3)	0.74 (0.52- 1.04), 0.0832
Hazard Ratio (95%CI), P-value [b]		2.25 (1.29- 3.93), 0.0032		1.44 (0.86- 2.40), 0.1608	
Hazard Ratio (95%CI), P-value [c]		0.81 (0.60- 1.10), 0.1774			
Hazard Ratio (95%CI), P-value [d]		0.64 (0.30- 1.35), 0.2390			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1b
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Age (years)						
< 65	54	11 (20.4%)	62	43 (69.4%)	8.85 (3.76 - 20.8)	<.0001
>=65	61	15 (24.6%)	52	33 (63.5%)	5.33 (2.37 - 12.0)	<.0001
Within Treatment Arm [b]	1.27 (0.53 - 3.08), 0.5893		0.77 (0.35 - 1.68), 0.5062			
Across Treatment Arm [c]	6.83 (3.80 - 12.3), <.0001					
Treatment Interaction [d]	0.60 (0.19 - 1.96), 0.3987					
Gender						
Female	39	9 (23.1%)	49	28 (57.1%)	4.44 (1.74 - 11.3)	0.0013
Male	76	17 (22.4%)	65	48 (73.8%)	9.80 (4.52 - 21.2)	<.0001
Within Treatment Arm [b]	0.96 (0.38 - 2.41), 0.9315		2.12 (0.96 - 4.67), 0.0611			
Across Treatment Arm [c]	7.25 (3.99 - 13.2), <.0001					
Treatment Interaction [d]	2.20 (0.66 - 7.42), 0.2015					
Race						
Other	29	4 (13.8%)	17	11 (64.7%)	11.5 (2.69 - 48.9)	0.0004
White	86	22 (25.6%)	97	65 (67.0%)	5.91 (3.11 - 11.2)	<.0001
Within Treatment Arm [b]	2.15 (0.67 - 6.86), 0.1894		1.11 (0.38 - 3.27), 0.8525			
Across Treatment Arm [c]	6.64 (3.69 - 11.9), <.0001					
Treatment Interaction [d]	0.52 (0.11 - 2.52), 0.4137					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	17 (28.3%)	60	41 (68.3%)	5.46 (2.50 - 11.9)	<.0001
>=30 kg/m2	54	9 (16.7%)	52	34 (65.4%)	9.44 (3.78 - 23.6)	<.0001
Within Treatment Arm [b]	0.51 (0.20 - 1.26), 0.1383		0.88 (0.40 - 1.93), 0.7407			
Across Treatment Arm [c]	6.94 (3.84 - 12.5), <.0001					
Treatment Interaction [d]	1.73 (0.52 - 5.77), 0.3722					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1b
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	14 (29.8%)	27	23 (85.2%)	13.6 (3.95 - 46.5)	<.0001
< 2.5 g/dL	67	11 (16.4%)	82	50 (61.0%)	7.95 (3.63 - 17.4)	<.0001
Within Treatment Arm [b]	0.46 (0.19 - 1.14), 0.0895		0.27 (0.09 - 0.86), 0.0203			
Across Treatment Arm [c]	9.38 (4.85 - 18.1), <.0001					
Treatment Interaction [d]	0.59 (0.14 - 2.53), 0.4746					
Geographic Region						
Rest of World	17	3 (17.6%)	17	9 (52.9%)	5.25 (1.09 - 25.2)	0.0313
US/Canada	98	23 (23.5%)	97	67 (69.1%)	7.28 (3.86 - 13.7)	<.0001
Within Treatment Arm [b]	1.43 (0.38 - 5.42), 0.5963		1.99 (0.70 - 5.65), 0.1931			
Across Treatment Arm [c]	6.97 (3.86 - 12.6), <.0001					
Treatment Interaction [d]	1.39 (0.26 - 7.54), 0.7047					
Baseline MAP						
>=65 mmHg	70	17 (24.3%)	74	56 (75.7%)	9.70 (4.53 - 20.8)	<.0001
< 65 mmHg	45	9 (20.0%)	40	20 (50.0%)	4.00 (1.53 - 10.4)	0.0036
Within Treatment Arm [b]	0.78 (0.31 - 1.94), 0.5918		0.32 (0.14 - 0.73), 0.0055			
Across Treatment Arm [c]	7.03 (3.87 - 12.8), <.0001					
Treatment Interaction [d]	0.41 (0.12 - 1.40), 0.1561					
Baseline APACHE II Score						
<=30	63	12 (19.0%)	74	51 (68.9%)	9.42 (4.24 - 20.9)	<.0001
> 30	52	14 (26.9%)	40	25 (62.5%)	4.52 (1.86 - 11.0)	0.0006
Within Treatment Arm [b]	1.57 (0.65 - 3.77), 0.3150		0.75 (0.34 - 1.69), 0.4878			
Across Treatment Arm [c]	6.89 (3.82 - 12.4), <.0001					
Treatment Interaction [d]	0.48 (0.15 - 1.58), 0.2279					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1b
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Exposure to ACEi						
No	102	21 (20.6%)	106	69 (65.1%)	7.19 (3.85 - 13.4)	<.0001
Yes	13	5 (38.5%)	8	7 (87.5%)	11.2 (1.04 - 120)	0.0274
Within Treatment Arm [b]	2.41 (0.71 - 8.13), 0.1468		3.75 (0.44 - 31.7), 0.1949			
Across Treatment Arm [c]	7.42 (4.06 - 13.6), <.0001					
Treatment Interaction [d]	1.56 (0.13 - 18.1), 0.7243					
Exposure to ARBs						
No	108	26 (24.1%)	106	74 (69.8%)	7.29 (3.98 - 13.4)	<.0001
Yes	7	0 (0.0%)	8	2 (25.0%)		0.1553
Within Treatment Arm [b]	, 0.1400		0.14 (0.03 - 0.75), 0.0095			
Across Treatment Arm [c]	7.47 (4.10 - 13.6), <.0001					
Treatment Interaction [d]	69E3 (0.00 - I), 0.9808					
Medical History of ARDS						
No	85	18 (21.2%)	95	65 (68.4%)	8.06 (4.10 - 15.9)	<.0001
Yes	30	8 (26.7%)	19	11 (57.9%)	3.78 (1.12 - 12.8)	0.0288
Within Treatment Arm [b]	1.35 (0.52 - 3.54), 0.5365		0.63 (0.23 - 1.74), 0.3743			
Across Treatment Arm [c]	6.81 (3.78 - 12.3), <.0001					
Treatment Interaction [d]	0.47 (0.12 - 1.89), 0.2867					
Chest X-ray Finding of ARDS						
No	72	11 (15.3%)	88	62 (70.5%)	13.2 (6.01 - 29.1)	<.0001
Yes	43	15 (34.9%)	25	14 (56.0%)	2.38 (0.87 - 6.51)	0.0896
Within Treatment Arm [b]	2.97 (1.21 - 7.29), 0.0150		0.53 (0.21 - 1.33), 0.1741			
Across Treatment Arm [c]	7.39 (4.04 - 13.5), <.0001					
Treatment Interaction [d]	0.18 (0.05 - 0.65), 0.0086					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1b
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
History of Sepsis						
No	15	0 (0.0%)	17	12 (70.6%)		<.0001
Yes	100	26 (26.0%)	97	64 (66.0%)	5.52 (2.99 - 10.2)	<.0001
Within Treatment Arm [b]	, 0.0248		0.81 (0.26 - 2.49), 0.7100			
Across Treatment Arm [c]	7.00 (3.88 - 12.6), <.0001					
Treatment Interaction [d]	0.00 (0.00 - 7.66E157), 0.9485					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	20 (26.0%)	81	63 (77.8%)	9.98 (4.80 - 20.7)	<.0001
>=0.5 ug/kg/min	38	6 (15.8%)	33	13 (39.4%)	3.47 (1.13 - 10.6)	0.0250
Within Treatment Arm [b]	0.53 (0.19 - 1.47), 0.2194		0.19 (0.08 - 0.44), <.0001			
Across Treatment Arm [c]	7.49 (4.05 - 13.8), <.0001					
Treatment Interaction [d]	0.35 (0.09 - 1.32), 0.1206					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	73	62 (84.9%)		0.0221
>=20 ng/kg/min	114	26 (22.8%)	41	14 (34.1%)	1.75 (0.80 - 3.83)	0.1547
Within Treatment Arm [b]	, 0.5872		0.09 (0.04 - 0.23), <.0001			
Across Treatment Arm [c]	1.97 (0.92 - 4.23), 0.0827					
Treatment Interaction [d]	0.00 (0.00 - 1.4E136), 0.9452					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1b
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	3 (13.0%)	27	24 (88.9%)	53.3 (9.68 - 294)	<.0001
72.3 - <253 pg/mL	26	7 (26.9%)	22	12 (54.5%)	3.26 (0.97 - 10.9)	0.0512
253 - <676 pg/mL	25	10 (40.0%)	27	18 (66.7%)	3.00 (0.97 - 9.30)	0.0539
>=676 pg/mL	27	3 (11.1%)	26	15 (57.7%)	10.9 (2.61 - 45.6)	0.0003
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	13 (25.0%)	53	33 (62.3%)	4.95 (2.14 - 11.4)	0.0001
<253 pg/mL	49	10 (20.4%)	49	36 (73.5%)	10.8 (4.22 - 27.7)	<.0001
Within Treatment Arm [b]	0.77 (0.30 - 1.96), 0.5823		1.68 (0.72 - 3.90), 0.2268			
Across Treatment Arm [c]	7.12 (3.81 - 13.3), <.0001					
Treatment Interaction [d]	2.18 (0.62 - 7.69), 0.2249					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	6 (20.7%)	28	23 (82.1%)	17.6 (4.71 - 66.0)	<.0001
23.85 - <83.75 pg/mL	28	8 (28.6%)	25	17 (68.0%)	5.31 (1.64 - 17.2)	0.0041
83.75 - <299.5 pg/mL	12	2 (16.7%)	28	18 (64.3%)	9.00 (1.64 - 49.4)	0.0058
>=299.5 pg/mL	31	7 (22.6%)	20	10 (50.0%)	3.43 (1.02 - 11.6)	0.0426
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	9 (20.9%)	48	28 (58.3%)	5.29 (2.08 - 13.4)	0.0003
<83.75 pg/mL	57	14 (24.6%)	53	40 (75.5%)	9.45 (3.96 - 22.5)	<.0001
Within Treatment Arm [b]	1.23 (0.48 - 3.18), 0.6692		2.20 (0.94 - 5.14), 0.0667			
Across Treatment Arm [c]	7.29 (3.86 - 13.8), <.0001					
Treatment Interaction [d]	1.79 (0.50 - 6.39), 0.3720					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.1.1b
Mean Arterial Pressure at Hour 3: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number of Responders (%)	Number of Patients	Number of Responders (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	12 (23.1%)	53	34 (64.2%)	5.96 (2.54 - 14.0)	<.0001
< 1.63	47	10 (21.3%)	46	32 (69.6%)	8.46 (3.31 - 21.6)	<.0001
Within Treatment Arm [b]	0.90 (0.35 - 2.33), 0.8296		1.28 (0.55 - 2.97), 0.5687			
Across Treatment Arm [c]	7.01 (3.73 - 13.2), <.0001					
Treatment Interaction [d]	1.42 (0.40 - 5.05), 0.5901					
Vasopressin Use at Baseline						
No	11	0 (0.0%)	6	3 (50.0%)		0.0098
Yes	104	26 (25.0%)	108	73 (67.6%)	6.26 (3.44 - 11.4)	<.0001
Within Treatment Arm [b]	, 0.0594		2.09 (0.40 - 10.9), 0.3736			
Across Treatment Arm [c]	6.77 (3.75 - 12.2), <.0001					
Treatment Interaction [d]	0.00 (0.00 - 5.09E185), 0.9595					
Baseline AKI (Acute Kidney Injury)						
No	63	15 (23.8%)	82	59 (72.0%)	8.21 (3.86 - 17.4)	<.0001
Yes	52	11 (21.2%)	32	17 (53.1%)	4.22 (1.61 - 11.1)	0.0025
Within Treatment Arm [b]	0.86 (0.36 - 2.08), 0.7347		0.44 (0.19 - 1.03), 0.0554			
Across Treatment Arm [c]	6.44 (3.57 - 11.6), <.0001					
Treatment Interaction [d]	0.51 (0.15 - 1.75), 0.2866					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1b
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	54	40.7 (29.0 - 55.0)	62	27.4 (18.0 - 40.3)	0.63 (0.33- 1.19), 0.1500
>=65	61	41.0 (29.9 - 54.3)	52	40.4 (28.5 - 54.9)	0.90 (0.50- 1.61), 0.7205
Hazard Ratio (95%CI), P-value [b]		1.03 (0.58- 1.83), 0.9192		1.48 (0.78- 2.81), 0.2264	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.50- 1.17), 0.2177			
Hazard Ratio (95%CI), P-value [d]		1.43 (0.61- 3.39), 0.4099			
Gender					
Female	39	43.6 (29.8 - 60.4)	49	38.8 (26.8 - 53.8)	0.84 (0.44- 1.62), 0.6046
Male	76	39.5 (29.5 - 51.4)	65	29.2 (19.8 - 41.9)	0.67 (0.38- 1.18), 0.1635
Hazard Ratio (95%CI), P-value [b]		0.90 (0.49- 1.63), 0.7216		0.70 (0.37- 1.33), 0.2727	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.48- 1.13), 0.1642			
Hazard Ratio (95%CI), P-value [d]		0.79 (0.33- 1.88), 0.5928			
Race					
Other	29	41.4 (26.0 - 61.2)	17	41.2 (22.2 - 67.5)	0.97 (0.38- 2.46), 0.9481
White	86	40.7 (31.2 - 51.8)	97	32.0 (23.7 - 42.2)	0.71 (0.44- 1.16), 0.1711
Hazard Ratio (95%CI), P-value [b]		0.98 (0.51- 1.88), 0.9474		0.71 (0.31- 1.61), 0.4060	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.49- 1.17), 0.2152			
Hazard Ratio (95%CI), P-value [d]		0.73 (0.26- 2.09), 0.5564			
Body Mass Index (kg/m^2)					
< 30 kg/m2	60	33.3 (23.0 - 46.8)	60	31.7 (21.5 - 45.0)	0.88 (0.47- 1.65), 0.6972
>=30 kg/m2	54	50.0 (37.6 - 63.9)	52	32.7 (21.8 - 47.2)	0.59 (0.32- 1.08), 0.0850
Hazard Ratio (95%CI), P-value [b]		1.69 (0.95- 3.02), 0.0718		1.12 (0.58- 2.15), 0.7342	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.46- 1.10), 0.1302			
Hazard Ratio (95%CI), P-value [d]		0.66 (0.27- 1.58), 0.3468			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1b
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	47	27.7 (17.1 - 42.8)	27	18.5 (8.2 - 38.9)	0.59 (0.21- 1.65), 0.3076
< 2.5 g/dL	67	49.3 (38.1 - 61.7)	82	37.8 (28.3 - 49.2)	0.70 (0.43- 1.14), 0.1468
Hazard Ratio (95%CI), P-value [b]		2.00 (1.05- 3.80), 0.0308		2.40 (0.93- 6.16), 0.0615	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.43- 1.05), 0.0804			
Hazard Ratio (95%CI), P-value [d]		1.18 (0.38- 3.69), 0.7801			
Geographic Region					
Rest of World	17	23.5 (9.6 - 51.2)	17	23.5 (9.6 - 51.2)	0.90 (0.23- 3.62), 0.8876
US/Canada	98	43.9 (34.7 - 54.3)	97	35.1 (26.5 - 45.4)	0.73 (0.47- 1.15), 0.1718
Hazard Ratio (95%CI), P-value [b]		1.91 (0.69- 5.33), 0.2073		1.56 (0.55- 4.40), 0.3951	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.49- 1.15), 0.1810			
Hazard Ratio (95%CI), P-value [d]		0.80 (0.19- 3.44), 0.7646			
Baseline MAP					
>=65 mmHg	70	32.9 (23.2 - 45.2)	74	25.7 (17.2 - 37.2)	0.72 (0.39- 1.32), 0.2813
< 65 mmHg	45	53.3 (39.7 - 68.3)	40	47.5 (33.5 - 63.9)	0.83 (0.46- 1.52), 0.5558
Hazard Ratio (95%CI), P-value [b]		1.95 (1.10- 3.46), 0.0197		2.28 (1.21- 4.32), 0.0089	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.50- 1.19), 0.2409			
Hazard Ratio (95%CI), P-value [d]		1.15 (0.49- 2.70), 0.7487			
Baseline APACHE II Score					
<=30	63	33.3 (23.2 - 46.4)	74	29.7 (20.7 - 41.6)	0.85 (0.47- 1.55), 0.6006
> 30	52	50.0 (37.4 - 64.2)	40	40.0 (26.7 - 56.8)	0.72 (0.39- 1.34), 0.2952
Hazard Ratio (95%CI), P-value [b]		1.77 (0.99- 3.14), 0.0496		1.49 (0.78- 2.84), 0.2197	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.51- 1.21), 0.2688			
Hazard Ratio (95%CI), P-value [d]		0.83 (0.35- 1.98), 0.6794			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1b
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	102	41.2 (32.3 - 51.4)	106	34.0 (25.8 - 43.8)	0.76 (0.49- 1.18), 0.2212
Yes	13	38.5 (18.2 - 69.2)	8	25.0 (6.9 - 68.5)	0.60 (0.12- 3.09), 0.5338
Hazard Ratio (95%CI), P-value [b]		0.88 (0.35- 2.23), 0.7938		0.69 (0.17- 2.88), 0.6136	
Hazard Ratio (95%CI), P-value [c]		0.75 (0.49- 1.14), 0.1793			
Hazard Ratio (95%CI), P-value [d]		0.79 (0.14- 4.30), 0.7810			
Exposure to ARBs					
No	108	42.6 (33.9 - 52.5)	106	32.1 (24.1 - 41.9)	0.67 (0.43- 1.05), 0.0774
Yes	7	14.3 (2.1 - 66.6)	8	50.0 (22.5 - 84.8)	4.49 (0.50-40.35), 0.1420
Hazard Ratio (95%CI), P-value [b]		0.27 (0.04- 1.96), 0.1651		1.93 (0.68- 5.43), 0.2073	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.49- 1.14), 0.1763			
Hazard Ratio (95%CI), P-value [d]		7.20 (0.77-67.37), 0.0835			
Medical History of ARDS					
No	85	40.0 (30.5 - 51.2)	95	29.5 (21.4 - 39.8)	0.66 (0.40- 1.09), 0.1005
Yes	30	43.3 (27.9 - 62.7)	19	52.6 (32.7 - 75.6)	1.30 (0.57- 2.97), 0.5296
Hazard Ratio (95%CI), P-value [b]		1.03 (0.54- 1.95), 0.9361		2.06 (1.00- 4.24), 0.0453	
Hazard Ratio (95%CI), P-value [c]		0.79 (0.51- 1.21), 0.2756			
Hazard Ratio (95%CI), P-value [d]		1.97 (0.75- 5.18), 0.1671			
Chest X-ray Finding of ARDS					
No	72	34.7 (25.0 - 46.9)	88	26.1 (18.2 - 36.7)	0.69 (0.39- 1.22), 0.2010
Yes	43	51.2 (37.4 - 66.7)	25	60.0 (41.9 - 78.7)	1.18 (0.61- 2.28), 0.6207
Hazard Ratio (95%CI), P-value [b]		1.59 (0.89- 2.82), 0.1109		2.82 (1.47- 5.41), 0.0011	
Hazard Ratio (95%CI), P-value [c]		0.87 (0.56- 1.34), 0.5155			
Hazard Ratio (95%CI), P-value [d]		1.72 (0.72- 4.09), 0.2213			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1b
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	15	53.3 (31.3 - 78.8)	17	17.6 (6.1 - 45.3)	0.24 (0.06- 0.90), 0.0221
Yes	100	39.0 (30.2 - 49.3)	97	36.1 (27.4 - 46.5)	0.89 (0.56- 1.40), 0.6160
Hazard Ratio (95%CI), P-value [b]		0.59 (0.28- 1.26), 0.1695		2.34 (0.72- 7.60), 0.1457	
Hazard Ratio (95%CI), P-value [c]		0.76 (0.49- 1.16), 0.2045			
Hazard Ratio (95%CI), P-value [d]		3.95 (0.97-16.07), 0.0551			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	77	33.8 (24.4 - 45.5)	81	23.5 (15.7 - 34.3)	0.66 (0.36- 1.19), 0.1594
>=0.5 ug/kg/min	38	55.3 (40.5 - 71.3)	33	57.6 (41.7 - 74.4)	0.91 (0.49- 1.69), 0.7650
Hazard Ratio (95%CI), P-value [b]		2.34 (1.31- 4.16), 0.0030		3.27 (1.73- 6.18), 0.0001	
Hazard Ratio (95%CI), P-value [c]		0.77 (0.50- 1.17), 0.2206			
Hazard Ratio (95%CI), P-value [d]		1.36 (0.58- 3.20), 0.4835			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	1	0.0 (0.0 - 0.0)	73	23.3 (15.2 - 34.8)	45E4 (0.00-), 0.6080
>=20 ng/kg/min	114	41.2 (32.8 - 50.8)	41	51.2 (37.1 - 67.1)	1.32 (0.79- 2.21), 0.2838
Hazard Ratio (95%CI), P-value [b]		45E4 (0.00-), 0.4673		2.80 (1.48- 5.31), 0.0010	
Hazard Ratio (95%CI), P-value [c]		1.34 (0.81- 2.23), 0.2586			
Hazard Ratio (95%CI), P-value [d]		0.00 (0.00-), 0.9854			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1b
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	23	26.1 (12.7 - 49.1)	27	14.8 (5.8 - 34.8)	0.51 (0.14- 1.82), 0.2920
72.3 - <253 pg/mL	26	42.3 (26.1 - 63.2)	22	45.5 (27.6 - 67.9)	1.03 (0.44- 2.42), 0.9506
253 - <676 pg/mL	25	48.0 (30.8 - 68.8)	27	37.0 (21.9 - 57.9)	0.70 (0.30- 1.62), 0.4025
>=676 pg/mL	27	44.4 (28.2 - 64.8)	26	34.6 (19.7 - 56.0)	0.75 (0.32- 1.79), 0.5196
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	52	46.2 (33.8 - 60.5)	53	35.8 (24.6 - 50.3)	0.73 (0.40- 1.33), 0.2985
< 253 pg/mL	49	34.7 (23.2 - 49.7)	49	28.6 (18.0 - 43.4)	0.76 (0.37- 1.54), 0.4428
Hazard Ratio (95%CI), P-value [b]		0.75 (0.40- 1.39), 0.3524		0.76 (0.38- 1.51), 0.4277	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.47- 1.17), 0.1995			
Hazard Ratio (95%CI), P-value [d]		1.03 (0.41- 2.60), 0.9564			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	29	37.9 (23.1 - 57.9)	28	14.3 (5.6 - 33.7)	0.32 (0.10- 1.02), 0.0416
23.85 - <83.75 pg/mL	28	42.9 (27.1 - 62.9)	25	32.0 (17.5 - 53.9)	0.65 (0.27- 1.60), 0.3503
83.75 - <299.5 pg/mL	12	33.3 (14.0 - 66.3)	28	50.0 (33.4 - 69.4)	1.81 (0.60- 5.51), 0.2870
>=299.5 pg/mL	31	41.9 (26.9 - 61.0)	20	30.0 (14.7 - 54.9)	0.71 (0.27- 1.86), 0.4821
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	43	39.5 (26.7 - 55.7)	48	41.7 (29.2 - 56.8)	1.11 (0.58- 2.11), 0.7567
< 83.75 pg/mL	57	40.4 (29.0 - 54.2)	53	22.6 (13.5 - 36.4)	0.48 (0.24- 0.96), 0.0345
Hazard Ratio (95%CI), P-value [b]		1.17 (0.62- 2.18), 0.6321		0.49 (0.24- 1.00), 0.0454	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.47- 1.18), 0.2127			
Hazard Ratio (95%CI), P-value [d]		0.42 (0.16- 1.09), 0.0755			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.3.1b
Mortality at Day 7: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 7 Mortality	LJPC-501 N	LJPC-501 Day 7 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	52	50.0 (37.4 - 64.2)	53	32.1 (21.3 - 46.4)	0.53 (0.29- 0.98), 0.0410
< 1.63	47	29.8 (18.9 - 45.0)	46	32.6 (21.1 - 48.1)	1.13 (0.55- 2.35), 0.7347
Hazard Ratio (95%CI), P-value [b]		0.48 (0.25- 0.92), 0.0240		1.03 (0.51- 2.05), 0.9436	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.45- 1.16), 0.1760			
Hazard Ratio (95%CI), P-value [d]		2.15 (0.83- 5.56), 0.1156			
Vasopressin Use at Baseline					
No	11	27.3 (9.7 - 62.9)	6	16.7 (2.5 - 72.7)	0.56 (0.06- 5.43), 0.6154
Yes	104	42.3 (33.5 - 52.4)	108	34.3 (26.2 - 44.0)	0.74 (0.48- 1.15), 0.1785
Hazard Ratio (95%CI), P-value [b]		1.72 (0.53- 5.52), 0.3600		2.32 (0.32-16.89), 0.3928	
Hazard Ratio (95%CI), P-value [c]		0.73 (0.48- 1.13), 0.1571			
Hazard Ratio (95%CI), P-value [d]		1.33 (0.13-13.35), 0.8071			
Baseline AKI (Acute Kidney Injury)					
No	63	27.0 (17.7 - 39.8)	82	34.1 (25.0 - 45.5)	1.28 (0.70- 2.33), 0.4263
Yes	52	57.7 (44.8 - 71.2)	32	31.3 (18.2 - 50.3)	0.46 (0.23- 0.95), 0.0313
Hazard Ratio (95%CI), P-value [b]		2.73 (1.50- 4.95), 0.0006		0.98 (0.47- 2.01), 0.9500	
Hazard Ratio (95%CI), P-value [c]		0.82 (0.53- 1.27), 0.3739			
Hazard Ratio (95%CI), P-value [d]		0.35 (0.14- 0.90), 0.0296			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1d
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Age (years)					
< 65	54	59.6 (46.8 - 72.7)	62	38.7 (27.9 - 52.0)	0.57 (0.33- 0.96), 0.0327
>=65	61	62.3 (50.4 - 74.3)	52	59.8 (46.9 - 73.1)	0.88 (0.55- 1.42), 0.6041
Hazard Ratio (95%CI), P-value [b]		1.09 (0.68- 1.74), 0.7253		1.71 (1.00- 2.92), 0.0468	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.51- 1.03), 0.0719			
Hazard Ratio (95%CI), P-value [d]		1.57 (0.77- 3.21), 0.2110			
Gender					
Female	39	56.4 (41.7 - 72.1)	49	53.1 (40.0 - 67.5)	0.88 (0.50- 1.55), 0.6563
Male	76	63.4 (52.7 - 74.1)	65	44.6 (33.5 - 57.5)	0.59 (0.37- 0.93), 0.0231
Hazard Ratio (95%CI), P-value [b]		1.12 (0.68- 1.86), 0.6548		0.76 (0.45- 1.29), 0.3047	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.48- 0.98), 0.0401			
Hazard Ratio (95%CI), P-value [d]		0.68 (0.33- 1.41), 0.2954			
Race					
Other	29	66.7 (49.5 - 83.0)	17	58.8 (37.4 - 81.4)	0.88 (0.41- 1.89), 0.7391
White	86	59.3 (49.2 - 69.7)	97	46.5 (37.1 - 56.9)	0.68 (0.46- 1.02), 0.0579
Hazard Ratio (95%CI), P-value [b]		0.90 (0.53- 1.53), 0.7066		0.70 (0.35- 1.38), 0.2963	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.50- 1.03), 0.0690			
Hazard Ratio (95%CI), P-value [d]		0.77 (0.33- 1.84), 0.5614			
Body Mass Index (kg/m^2)					
< 30 kg/m2	60	56.9 (44.9 - 69.6)	60	43.4 (32.0 - 56.8)	0.70 (0.42- 1.16), 0.1630
>=30 kg/m2	54	64.8 (52.2 - 77.2)	52	51.9 (39.2 - 65.9)	0.67 (0.41- 1.11), 0.1192
Hazard Ratio (95%CI), P-value [b]		1.34 (0.83- 2.14), 0.2276		1.28 (0.75- 2.19), 0.3678	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.48- 0.98), 0.0380			
Hazard Ratio (95%CI), P-value [d]		0.95 (0.47- 1.95), 0.8972			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1d
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Albumin (g/dL)					
>=2.5 g/dL	47	47.1 (34.0 - 62.3)	27	40.7 (25.0 - 61.4)	0.77 (0.37- 1.58), 0.4682
< 2.5 g/dL	67	70.1 (59.0 - 80.6)	82	51.3 (41.0 - 62.5)	0.61 (0.40- 0.93), 0.0201
Hazard Ratio (95%CI), P-value [b]		1.94 (1.16- 3.22), 0.0096		1.52 (0.78- 2.94), 0.2163	
Hazard Ratio (95%CI), P-value [c]		0.65 (0.45- 0.93), 0.0189			
Hazard Ratio (95%CI), P-value [d]		0.78 (0.34- 1.81), 0.5681			
Geographic Region					
Rest of World	17	47.7 (27.3 - 73.2)	17	29.4 (13.4 - 56.9)	0.57 (0.19- 1.76), 0.3245
US/Canada	98	63.3 (53.8 - 72.7)	97	51.6 (42.1 - 61.9)	0.71 (0.49- 1.03), 0.0714
Hazard Ratio (95%CI), P-value [b]		1.52 (0.73- 3.18), 0.2630		1.94 (0.77- 4.87), 0.1496	
Hazard Ratio (95%CI), P-value [c]		0.70 (0.49- 0.99), 0.0441			
Hazard Ratio (95%CI), P-value [d]		1.27 (0.39- 4.13), 0.6906			
Baseline MAP					
>=65 mmHg	70	51.4 (40.4 - 63.5)	74	43.2 (32.9 - 55.3)	0.75 (0.47- 1.21), 0.2403
< 65 mmHg	45	76.1 (62.8 - 87.3)	40	57.6 (43.1 - 73.0)	0.66 (0.39- 1.13), 0.1286
Hazard Ratio (95%CI), P-value [b]		1.97 (1.23- 3.16), 0.0040		1.71 (1.00- 2.93), 0.0464	
Hazard Ratio (95%CI), P-value [c]		0.71 (0.50- 1.01), 0.0596			
Hazard Ratio (95%CI), P-value [d]		0.86 (0.42- 1.76), 0.6838			
Baseline APACHE II Score					
<=30	63	47.8 (36.3 - 60.8)	74	46.0 (35.5 - 58.0)	0.92 (0.56- 1.50), 0.7318
> 30	52	76.9 (64.8 - 87.2)	40	52.5 (38.2 - 68.4)	0.55 (0.32- 0.94), 0.0252
Hazard Ratio (95%CI), P-value [b]		2.14 (1.33- 3.44), 0.0013		1.28 (0.74- 2.20), 0.3775	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.51- 1.03), 0.0716			
Hazard Ratio (95%CI), P-value [d]		0.60 (0.29- 1.23), 0.1598			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1d
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Exposure to ACEi					
No	102	62.9 (53.6 - 72.2)	106	50.1 (41.0 - 59.9)	0.70 (0.48- 1.00), 0.0517
Yes	13	46.2 (24.0 - 75.2)	8	25.0 (6.9 - 68.5)	0.49 (0.10- 2.44), 0.3731
Hazard Ratio (95%CI), P-value [b]		0.67 (0.29- 1.55), 0.3451		0.44 (0.11- 1.81), 0.2432	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.48- 0.98), 0.0361			
Hazard Ratio (95%CI), P-value [d]		0.66 (0.13- 3.40), 0.6189			
Exposure to ARBs					
No	108	62.2 (53.1 - 71.3)	106	47.2 (38.2 - 57.1)	0.64 (0.45- 0.93), 0.0178
Yes	7	42.9 (16.3 - 82.8)	8	62.5 (32.6 - 91.3)	2.07 (0.49- 8.70), 0.3123
Hazard Ratio (95%CI), P-value [b]		0.51 (0.16- 1.64), 0.2522		1.74 (0.69- 4.37), 0.2318	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.49- 0.99), 0.0424			
Hazard Ratio (95%CI), P-value [d]		3.36 (0.77-14.71), 0.1084			
Medical History of ARDS					
No	85	58.9 (48.7 - 69.4)	95	46.4 (37.0 - 56.9)	0.67 (0.44- 1.00), 0.0486
Yes	30	66.7 (50.0 - 82.5)	19	57.9 (37.5 - 79.6)	0.93 (0.45- 1.95), 0.8534
Hazard Ratio (95%CI), P-value [b]		1.09 (0.65- 1.83), 0.7441		1.55 (0.80- 3.00), 0.1917	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.50- 1.03), 0.0716			
Hazard Ratio (95%CI), P-value [d]		1.41 (0.61- 3.27), 0.4226			
Chest X-ray Finding of ARDS					
No	72	55.7 (44.7 - 67.4)	88	43.3 (33.7 - 54.3)	0.67 (0.43- 1.04), 0.0752
Yes	43	69.8 (55.9 - 82.6)	25	68.0 (49.8 - 84.8)	1.02 (0.56- 1.85), 0.9444
Hazard Ratio (95%CI), P-value [b]		1.43 (0.89- 2.29), 0.1381		2.23 (1.25- 3.97), 0.0051	
Hazard Ratio (95%CI), P-value [c]		0.78 (0.54- 1.11), 0.1691			
Hazard Ratio (95%CI), P-value [d]		1.55 (0.74- 3.25), 0.2500			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1d
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
History of Sepsis					
No	15	53.3 (31.3 - 78.8)	17	23.5 (9.6 - 51.2)	0.31 (0.09- 1.04), 0.0457
Yes	100	62.2 (52.8 - 71.6)	97	52.7 (43.1 - 62.9)	0.78 (0.54- 1.13), 0.1896
Hazard Ratio (95%CI), P-value [b]		1.00 (0.48- 2.08), 0.9897		2.73 (0.99- 7.56), 0.0438	
Hazard Ratio (95%CI), P-value [c]		0.72 (0.50- 1.02), 0.0651			
Hazard Ratio (95%CI), P-value [d]		2.74 (0.78- 9.62), 0.1159			
Baseline Norep Eq Dose					
< 0.5 ug/kg/min	77	57.3 (46.6 - 68.5)	81	42.1 (32.2 - 53.6)	0.64 (0.41- 1.01), 0.0516
>=0.5 ug/kg/min	38	68.4 (53.6 - 82.3)	33	63.6 (47.7 - 79.4)	0.82 (0.46- 1.45), 0.4931
Hazard Ratio (95%CI), P-value [b]		1.75 (1.07- 2.84), 0.0229		2.16 (1.25- 3.73), 0.0046	
Hazard Ratio (95%CI), P-value [c]		0.70 (0.49- 1.00), 0.0517			
Hazard Ratio (95%CI), P-value [d]		1.23 (0.59- 2.55), 0.5809			
Sensitivity to Therapy at 30 Minutes					
< 20 ng/kg/min	1	100.0 (. - .)	73	43.8 (33.4 - 55.9)	0.34 (0.05- 2.52), 0.2680
>=20 ng/kg/min	114	60.7 (51.8 - 69.6)	41	56.1 (41.8 - 71.4)	0.98 (0.61- 1.57), 0.9283
Hazard Ratio (95%CI), P-value [b]		0.64 (0.09- 4.65), 0.6584		1.69 (0.99- 2.90), 0.0518	
Hazard Ratio (95%CI), P-value [c]		0.94 (0.59- 1.51), 0.8078			
Hazard Ratio (95%CI), P-value [d]		2.59 (0.33-20.11), 0.3615			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1d
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I (pg/mL)					
<72.3 pg/mL	23	52.2 (33.9 - 73.2)	27	48.1 (31.5 - 68.1)	0.82 (0.37- 1.79), 0.6136
72.3 - <253 pg/mL	26	65.4 (47.5 - 82.5)	22	50.0 (31.6 - 71.8)	0.73 (0.34- 1.56), 0.4120
253 - <676 pg/mL	25	60.0 (41.9 - 78.7)	27	48.6 (31.8 - 68.7)	0.70 (0.33- 1.47), 0.3432
>=676 pg/mL	27	70.4 (53.0 - 85.9)	26	50.0 (32.8 - 70.1)	0.63 (0.31- 1.27), 0.1927
Baseline Angiotensin I (pg/mL)					
>=253 pg/mL	52	65.4 (52.6 - 77.9)	53	49.2 (36.7 - 63.3)	0.66 (0.39- 1.09), 0.1042
< 253 pg/mL	49	59.5 (46.2 - 73.2)	49	49.0 (36.1 - 63.6)	0.73 (0.43- 1.26), 0.2555
Hazard Ratio (95%CI), P-value [b]		0.86 (0.52- 1.41), 0.5496		0.95 (0.55- 1.66), 0.8611	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.48- 1.00), 0.0510			
Hazard Ratio (95%CI), P-value [d]		1.12 (0.53- 2.35), 0.7736			
Baseline Angiotensin II (pg/mL)					
<23.85 pg/mL	29	58.6 (41.7 - 76.3)	28	46.4 (30.2 - 66.2)	0.63 (0.31- 1.31), 0.2128
23.85 - <83.75 pg/mL	28	64.3 (47.0 - 81.1)	25	44.0 (27.3 - 65.2)	0.56 (0.27- 1.20), 0.1303
83.75 - <299.5 pg/mL	12	41.7 (19.9 - 73.0)	28	57.4 (40.2 - 75.8)	1.67 (0.61- 4.57), 0.3104
>=299.5 pg/mL	31	72.0 (55.6 - 86.5)	20	45.0 (26.5 - 68.7)	0.52 (0.24- 1.13), 0.0919
Baseline Angiotensin II (pg/mL)					
>=83.75 pg/mL	43	63.3 (49.1 - 77.4)	48	52.3 (39.0 - 66.9)	0.82 (0.48- 1.42), 0.4802
< 83.75 pg/mL	57	61.4 (49.1 - 73.9)	53	45.3 (33.1 - 59.6)	0.59 (0.35- 0.99), 0.0435
Hazard Ratio (95%CI), P-value [b]		1.06 (0.64- 1.75), 0.8159		0.76 (0.43- 1.33), 0.3301	
Hazard Ratio (95%CI), P-value [c]		0.69 (0.47- 1.00), 0.0517			
Hazard Ratio (95%CI), P-value [d]		0.71 (0.34- 1.52), 0.3811			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.9.5.1d
Mortality at Day 28: Univariate Analyses (mITT Population with >=2 Vasopressors)

Characteristic	Placebo N	Placebo Day 28 Mortality	LJPC-501 N	LJPC-501 Day 28 Mortality	Hazard Ratio (95%CI), p-value [a]
Baseline Angiotensin I/II Ratio					
>=1.63	52	71.2 (58.6 - 82.7)	53	50.9 (38.4 - 64.9)	0.55 (0.34- 0.91), 0.0174
< 1.63	47	53.5 (40.1 - 68.2)	46	48.0 (34.8 - 63.3)	0.89 (0.50- 1.58), 0.6865
Hazard Ratio (95%CI), P-value [b]		0.57 (0.34- 0.94), 0.0270		0.93 (0.53- 1.63), 0.7936	
Hazard Ratio (95%CI), P-value [c]		0.67 (0.46- 0.98), 0.0405			
Hazard Ratio (95%CI), P-value [d]		1.63 (0.77- 3.49), 0.2048			
Vasopressin Use at Baseline					
No	11	36.4 (15.5 - 70.3)	6	50.0 (19.6 - 88.9)	1.30 (0.29- 5.80), 0.7337
Yes	104	63.6 (54.4 - 72.8)	108	48.2 (39.3 - 58.0)	0.66 (0.46- 0.95), 0.0229
Hazard Ratio (95%CI), P-value [b]		2.14 (0.78- 5.88), 0.1297		1.09 (0.34- 3.50), 0.8800	
Hazard Ratio (95%CI), P-value [c]		0.68 (0.48- 0.97), 0.0337			
Hazard Ratio (95%CI), P-value [d]		0.51 (0.11- 2.37), 0.3884			
Baseline AKI (Acute Kidney Injury)					
No	63	49.2 (37.7 - 62.1)	82	48.9 (38.7 - 60.1)	1.00 (0.63- 1.61), 0.9844
Yes	52	75.5 (63.1 - 86.2)	32	46.9 (31.5 - 65.3)	0.46 (0.25- 0.85), 0.0103
Hazard Ratio (95%CI), P-value [b]		2.18 (1.36- 3.50), 0.0010		0.99 (0.55- 1.79), 0.9723	
Hazard Ratio (95%CI), P-value [c]		0.74 (0.52- 1.06), 0.0969			
Hazard Ratio (95%CI), P-value [d]		0.45 (0.21- 0.96), 0.0398			

Note: Hazard ratio compares the first characteristic to second characteristic.
[a] Hazard Ratio/Chi-square test of treatment effect within subgroup.
[b] Hazard Ratio/Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Hazard Ratio/Chi-square test of treatment stratified by characteristic
[d] Hazard Ratio/Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.2, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.2.20.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Number of Patients	54	62	116
Screening			
N	54	62	116
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	54 (100.0%)	62 (100.0%)	116 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Number of Patients	54	62	116
Hour 3 [a]			
N	54	62	116
3	0 (0.0%)	5 (8.1%)	5 (4.3%)
4	54 (100.0%)	57 (91.9%)	111 (95.7%)
Mean (SD)	4.00 (0.000)	3.92 (0.275)	3.96 (0.204)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	54	62	116
Mean (SD)	0.00 (0.000)	-0.08 (0.275)	-0.04 (0.204)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0311			
P-value [c] 0.0897			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.06 - 0.04)		
LS-Mean LJ501 (95%CI) [c]	-0.07 (-0.12 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.06 (-0.01 - 0.14)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Number of Patients	54	62	116
Hour 48 [a]			
N	54	62	116
0	7 (13.0%)	20 (32.3%)	27 (23.3%)
1	2 (3.7%)	3 (4.8%)	5 (4.3%)
2	0 (0.0%)	2 (3.2%)	2 (1.7%)
3	11 (20.4%)	9 (14.5%)	20 (17.2%)
4	19 (35.2%)	17 (27.4%)	36 (31.0%)
4 (LOCF)	1 (1.9%)	0 (0.0%)	1 (0.9%)
4 (WC)	14 (25.9%)	11 (17.7%)	25 (21.6%)
Mean (SD)	3.17 (1.397)	2.35 (1.793)	2.73 (1.665)
Median	4.00	3.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	54	62	116
Mean (SD)	-0.83 (1.397)	-1.65 (1.793)	-1.27 (1.665)
Median	0.00	-1.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0039			
P-value [c] 0.0153			
LS-Mean Placebo (95%CI) [c]	-0.90 (-1.30 - -0.49)		
LS-Mean LJ501 (95%CI) [c]	-1.59 (-1.97 - -1.21)		
LS-Mean Difference (95%CI) [c]	0.70 (0.14 - 1.26)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Number of Patients	54	62	116
Screening			
N	54	61	115
Mean (SD)	13.94 (3.043)	12.44 (2.930)	13.15 (3.064)
Median	14.00	12.00	13.00
Range	8 - 20	5 - 18	5 - 20

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Number of Patients	54	62	116
Hour 3			
N	54	62	116
Mean (SD)	14.30 (3.207)	13.35 (3.137)	13.79 (3.191)
Median	14.00	13.00	14.00
Range	7 - 20	5 - 20	5 - 20
Change from Screening			
N	54	61	115
Mean (SD)	0.35 (1.532)	0.95 (1.707)	0.67 (1.648)
Median	0.00	1.00	1.00
Range	-3 - 5	-2 - 5	-3 - 5
P-value [b] 0.1055			
P-value [c] 0.1435			
LS-Mean Placebo (95%CI) [c]	0.43 (-0.02 - 0.87)		
LS-Mean LJ501 (95%CI) [c]	0.89 (0.47 - 1.30)		
LS-Mean Difference (95%CI) [c]	-0.46 (-1.08 - 0.16)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Number of Patients	54	62	116
Hour 48			
N	54	62	116
Mean (SD)	16.33 (5.962)	13.82 (6.447)	14.99 (6.325)
Median	16.00	14.00	15.00
Range	4 - 24	3 - 24	3 - 24
Change from Screening			
N	54	61	115
Mean (SD)	2.39 (5.003)	1.51 (5.623)	1.92 (5.336)
Median	1.00	1.00	1.00
Range	-6 - 13	-8 - 13	-8 - 13
P-value [b]	0.4906		
P-value [c]	0.4010		
LS-Mean Placebo (95%CI) [c]	2.35 (0.98 - 3.73)		
LS-Mean LJ501 (95%CI) [c]	1.54 (0.25 - 2.83)		
LS-Mean Difference (95%CI) [c]	0.81 (-1.10 - 2.73)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Total Number of Patients	51	57	108
Total Number of Events	8	16	24
Total Number of Censored for CSH	43	41	84
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(5 -)	5 (4 -)	7 (5 -)
Median (95% CI)	(-)	(7 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	2% (0%- 14%)	4% (1%- 14%)	3% (1%- 9%)
3-day Estimate	5% (1%- 17%)	8% (3%- 19%)	6% (3%- 14%)
4-day Estimate	5% (1%- 17%)	14% (7%- 28%)	10% (5%- 18%)
5-day Estimate	10% (4%- 26%)	26% (16%- 42%)	19% (12%- 29%)
6-day Estimate	17% (8%- 34%)	31% (20%- 47%)	25% (17%- 36%)
7-day Estimate	23% (12%- 42%)	36% (24%- 52%)	30% (21%- 42%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	2% (0%- 13%)	4% (1%- 13%)	3% (1%- 8%)
3-day Estimate	4% (1%- 15%)	7% (3%- 18%)	6% (3%- 12%)
4-day Estimate	4% (1%- 15%)	12% (6%- 24%)	8% (4%- 15%)
5-day Estimate	8% (3%- 20%)	21% (13%- 34%)	15% (9%- 23%)
6-day Estimate	12% (5%- 24%)	25% (15%- 38%)	19% (12%- 27%)
7-day Estimate	16% (8%- 29%)	28% (18%- 42%)	22% (15%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.75, 1, 0.1863
Log hazard (SE), Relative Risk (95% CI) [b]: 0.565 (0.433), 1.759 (0.753 - 4.111)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.46, 1, 0.1168
Log hazard (SE), Relative Risk (95% CI) [b]: 0.667 (0.433), 1.948 (0.834 - 4.554)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.20.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Total Number of Patients	54	62	116
Total Number of Events	18	30	48
Total Number of Censored for CSH	36	32	68
Days to ICU Discharge			
25% Quartile (95% CI)	12 (7 - 17)	8 (6 - 12)	10 (7 - 13)
Median (95% CI)	19 (13 - 28)	15 (11 - 23)	17 (14 - 23)
75% Quartile (95% CI)	(20 -)	(20 -)	(23 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	11% (4%- 27%)	23% (13%- 38%)	18% (11%- 28%)
14-day Estimate	31% (18%- 50%)	44% (31%- 60%)	38% (28%- 50%)
21-day Estimate	58% (40%- 78%)	60% (46%- 75%)	59% (47%- 71%)
28-day Estimate	72% (51%- 90%)	72% (57%- 85%)	71% (59%- 82%)
ICU Discharge Cumulative Incidence			
7-day Estimate	7% (3%- 19%)	18% (10%- 30%)	13% (8%- 21%)
14-day Estimate	19% (10%- 32%)	32% (22%- 45%)	26% (19%- 35%)
21-day Estimate	30% (19%- 44%)	42% (31%- 55%)	36% (28%- 46%)
28-day Estimate	33% (22%- 48%)	48% (37%- 61%)	41% (33%- 51%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.77, 1, 0.3798
Log hazard (SE), Relative Risk (95% CI) [b]: 0.262 (0.299), 1.299 (0.723 - 2.335)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 3.11, 1, 0.0776
Log hazard (SE), Relative Risk (95% CI) [b]: 0.521 (0.298), 1.683 (0.938 - 3.021)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.20.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Age <65)

	Placebo	LJPC-501	Total
Total Number of Patients	54	62	116
Total Number of Events	12	20	32
Total Number of Censored for CSH	42	42	84
Days to Hospital Discharge			
25% Quartile (95% CI)	23 (14 - 28)	18 (15 - 22)	18 (16 - 23)
Median (95% CI)	28 (23 -)	(20 -)	28 (23 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 19%)	2% (0%- 14%)	3% (1%- 10%)
14-day Estimate	10% (3%- 28%)	11% (5%- 25%)	11% (5%- 20%)
21-day Estimate	22% (11%- 43%)	37% (24%- 53%)	31% (22%- 44%)
28-day Estimate	52% (33%- 74%)	49% (35%- 65%)	50% (38%- 63%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 12%)	2% (0%- 11%)	2% (0%- 7%)
14-day Estimate	6% (2%- 16%)	8% (3%- 18%)	7% (4%- 13%)
21-day Estimate	11% (5%- 23%)	24% (15%- 37%)	18% (12%- 26%)
28-day Estimate	22% (13%- 36%)	32% (22%- 45%)	28% (20%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8873
Log hazard (SE), Relative Risk (95% CI) [b]: 0.052 (0.366), 1.053 (0.514 - 2.155)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.60, 1, 0.2065
Log hazard (SE), Relative Risk (95% CI) [b]: 0.458 (0.365), 1.580 (0.772 - 3.233)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.20.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Number of Patients	61	52	113
Screening			
N	61	52	113
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	61 (100.0%)	52 (100.0%)	113 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:10:59

Table 14.2.20.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Number of Patients	61	52	113
Hour 3 [a]			
N	61	52	113
3	1 (1.6%)	1 (1.9%)	2 (1.8%)
4	59 (96.7%)	51 (98.1%)	110 (97.3%)
4 (LOCF)	1 (1.6%)	0 (0.0%)	1 (0.9%)
Mean (SD)	3.98 (0.128)	3.98 (0.139)	3.98 (0.132)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	61	52	113
Mean (SD)	-0.02 (0.128)	-0.02 (0.139)	-0.02 (0.132)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.5677			
P-value [c] 0.5982			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.05 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.03 (-0.06 - 0.01)		
LS-Mean Difference (95%CI) [c]	0.01 (-0.04 - 0.07)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Number of Patients	61	52	113
Hour 48 [a]			
N	61	52	113
0	14 (23.0%)	17 (32.7%)	31 (27.4%)
1	4 (6.6%)	4 (7.7%)	8 (7.1%)
3	11 (18.0%)	11 (21.2%)	22 (19.5%)
4	17 (27.9%)	13 (25.0%)	30 (26.5%)
4 (LOCF)	1 (1.6%)	0 (0.0%)	1 (0.9%)
4 (WC)	14 (23.0%)	7 (13.5%)	21 (18.6%)
Mean (SD)	2.70 (1.677)	2.25 (1.770)	2.50 (1.728)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	61	52	113
Mean (SD)	-1.30 (1.677)	-1.75 (1.770)	-1.50 (1.728)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.3846			
P-value [c] 0.5844			
LS-Mean Placebo (95%CI) [c]	-1.42 (-1.85 - -0.99)		
LS-Mean LJ501 (95%CI) [c]	-1.60 (-2.07 - -1.13)		
LS-Mean Difference (95%CI) [c]	0.18 (-0.47 - 0.83)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Number of Patients	61	52	113
Screening			
N	61	49	110
Mean (SD)	12.79 (3.317)	11.04 (2.491)	12.01 (3.090)
Median	13.00	11.00	12.00
Range	5 - 21	6 - 16	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Number of Patients	61	52	113
Hour 3			
N	61	52	113
Mean (SD)	13.36 (3.271)	11.92 (2.950)	12.70 (3.196)
Median	13.00	12.00	13.00
Range	8 - 21	5 - 17	5 - 21
Change from Screening			
N	61	49	110
Mean (SD)	0.57 (2.225)	0.94 (1.886)	0.74 (2.080)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.3829			
P-value [c] 0.7950			
LS-Mean Placebo (95%CI) [c]	0.69 (0.16 - 1.22)		
LS-Mean LJ501 (95%CI) [c]	0.80 (0.20 - 1.40)		
LS-Mean Difference (95%CI) [c]	-0.11 (-0.94 - 0.72)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Number of Patients	61	52	113
Hour 48			
N	61	52	113
Mean (SD)	14.30 (7.126)	11.98 (6.201)	13.23 (6.786)
Median	14.00	11.00	12.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	61	49	110
Mean (SD)	1.51 (5.963)	1.24 (6.040)	1.39 (5.971)
Median	0.00	1.00	0.00
Range	-8 - 16	-10 - 15	-10 - 16
P-value [b] 0.4888			
P-value [c] 0.6366			
LS-Mean Placebo (95%CI) [c]	1.14 (-0.36 - 2.64)		
LS-Mean LJ501 (95%CI) [c]	1.70 (0.01 - 3.39)		
LS-Mean Difference (95%CI) [c]	-0.56 (-2.89 - 1.78)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.20.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Total Number of Patients	57	46	103
Total Number of Events	16	12	28
Total Number of Censored for CSH	41	34	75
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 - 7)	6 (3 -)	6 (4 - 7)
Median (95% CI)	(6 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 12%)	2% (0%- 14%)	2% (0%- 8%)
2-day Estimate	7% (3%- 18%)	9% (3%- 22%)	8% (4%- 15%)
3-day Estimate	9% (4%- 21%)	16% (8%- 31%)	13% (7%- 21%)
4-day Estimate	20% (11%- 35%)	16% (8%- 31%)	18% (11%- 27%)
5-day Estimate	23% (13%- 39%)	21% (12%- 37%)	22% (14%- 32%)
6-day Estimate	35% (22%- 52%)	30% (18%- 47%)	32% (23%- 44%)
7-day Estimate	41% (27%- 58%)	30% (18%- 47%)	35% (26%- 47%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 12%)	2% (0%- 14%)	2% (0%- 8%)
2-day Estimate	7% (3%- 18%)	9% (3%- 22%)	8% (4%- 15%)
3-day Estimate	9% (4%- 20%)	15% (8%- 29%)	12% (7%- 20%)
4-day Estimate	16% (9%- 28%)	15% (8%- 29%)	16% (10%- 24%)
5-day Estimate	18% (10%- 30%)	20% (11%- 34%)	18% (12%- 27%)
6-day Estimate	25% (15%- 38%)	26% (16%- 41%)	25% (18%- 35%)
7-day Estimate	28% (18%- 42%)	26% (16%- 41%)	27% (20%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.36, 1, 0.5504
Log hazard (SE), Relative Risk (95% CI) [b]: -0.228 (0.382), 0.796 (0.376 - 1.685)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8909
Log hazard (SE), Relative Risk (95% CI) [b]: -0.052 (0.382), 0.949 (0.449 - 2.006)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.20.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Total Number of Patients	61	52	113
Total Number of Events	24	17	41
Total Number of Censored for CSH	37	35	72
Days to ICU Discharge			
25% Quartile (95% CI)	7 (5 - 12)	9 (7 - 12)	8 (6 - 11)
Median (95% CI)	14 (11 - 20)	14 (10 -)	14 (12 - 20)
75% Quartile (95% CI)	25 (18 -)	(18 -)	(20 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	26% (16%- 43%)	16% (7%- 32%)	21% (14%- 32%)
14-day Estimate	50% (35%- 68%)	54% (36%- 73%)	51% (39%- 65%)
21-day Estimate	70% (51%- 86%)	59% (40%- 78%)	64% (51%- 78%)
28-day Estimate	81% (62%- 94%)	59% (40%- 78%)	71% (57%- 83%)
ICU Discharge Cumulative Incidence			
7-day Estimate	18% (10%- 30%)	12% (5%- 24%)	15% (10%- 23%)
14-day Estimate	30% (20%- 43%)	31% (20%- 45%)	30% (23%- 39%)
21-day Estimate	36% (25%- 49%)	33% (22%- 47%)	35% (27%- 44%)
28-day Estimate	39% (28%- 53%)	33% (22%- 47%)	36% (28%- 46%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.82, 1, 0.3651
Log hazard (SE), Relative Risk (95% CI) [b]: -0.287 (0.318), 0.751 (0.403 - 1.400)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.44, 1, 0.5055
Log hazard (SE), Relative Risk (95% CI) [b]: -0.211 (0.317), 0.810 (0.435 - 1.508)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.20.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Age >=65)

	Placebo	LJPC-501	Total
Total Number of Patients	61	52	113
Total Number of Events	14	13	27
Total Number of Censored for CSH	47	39	86
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (12 - 22)	19 (11 - 23)	18 (13 - 21)
Median (95% CI)	25 (18 -)	28 (19 -)	25 (21 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 16%)	6% (1%- 20%)	4% (1%- 12%)
14-day Estimate	20% (9%- 39%)	17% (7%- 36%)	18% (10%- 31%)
21-day Estimate	41% (25%- 62%)	34% (19%- 56%)	37% (26%- 52%)
28-day Estimate	54% (36%- 74%)	53% (34%- 74%)	53% (40%- 68%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 11%)	4% (1%- 15%)	3% (1%- 8%)
14-day Estimate	10% (5%- 21%)	10% (4%- 22%)	10% (6%- 17%)
21-day Estimate	18% (10%- 30%)	17% (9%- 31%)	18% (12%- 26%)
28-day Estimate	23% (14%- 36%)	25% (15%- 39%)	24% (17%- 33%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9207
Log hazard (SE), Relative Risk (95% CI) [b]: -0.038 (0.386), 0.962 (0.452 - 2.049)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.06, 1, 0.8102
Log hazard (SE), Relative Risk (95% CI) [b]: 0.093 (0.385), 1.097 (0.516 - 2.334)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.21.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Number of Patients	39	49	88
Screening			
N	39	49	88
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	39 (100.0%)	49 (100.0%)	88 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Number of Patients	39	49	88
Hour 3 [a]			
N	39	49	88
3	0 (0.0%)	1 (2.0%)	1 (1.1%)
4	38 (97.4%)	48 (98.0%)	86 (97.7%)
4 (LOCF)	1 (2.6%)	0 (0.0%)	1 (1.1%)
Mean (SD)	4.00 (0.000)	3.98 (0.143)	3.99 (0.107)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	39	49	88
Mean (SD)	0.00 (0.000)	-0.02 (0.143)	-0.01 (0.107)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.3545			
P-value [c] 0.3751			
LS-Mean Placebo (95%CI) [c]	0.00 (-0.03 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.02 (-0.05 - 0.01)		
LS-Mean Difference (95%CI) [c]	0.02 (-0.03 - 0.07)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Number of Patients	39	49	88
Hour 48 [a]			
N	39	49	88
0	9 (23.1%)	16 (32.7%)	25 (28.4%)
1	2 (5.1%)	1 (2.0%)	3 (3.4%)
3	7 (17.9%)	9 (18.4%)	16 (18.2%)
4	10 (25.6%)	14 (28.6%)	24 (27.3%)
4 (WC)	11 (28.2%)	9 (18.4%)	20 (22.7%)
Mean (SD)	2.74 (1.681)	2.45 (1.803)	2.58 (1.747)
Median	4.00	3.00	3.50
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	39	49	88
Mean (SD)	-1.26 (1.681)	-1.55 (1.803)	-1.42 (1.747)
Median	0.00	-1.00	-0.50
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.5479			
P-value [c] 0.4917			
LS-Mean Placebo (95%CI) [c]	-1.28 (-1.82 - -0.74)		
LS-Mean LJ501 (95%CI) [c]	-1.53 (-2.02 - -1.05)		
LS-Mean Difference (95%CI) [c]	0.25 (-0.48 - 0.98)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Number of Patients	39	49	88
Screening			
N	39	47	86
Mean (SD)	12.26 (3.093)	12.00 (2.670)	12.12 (2.855)
Median	12.00	12.00	12.00
Range	5 - 19	7 - 18	5 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Number of Patients	39	49	88
Hour 3			
N	39	49	88
Mean (SD)	13.00 (3.052)	13.29 (2.937)	13.16 (2.975)
Median	13.00	13.00	13.00
Range	8 - 19	7 - 20	7 - 20
Change from Screening			
N	39	47	86
Mean (SD)	0.74 (2.209)	1.32 (1.855)	1.06 (2.031)
Median	0.00	1.00	1.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.1444			
P-value [c] 0.2261			
LS-Mean Placebo (95%CI) [c]	0.77 (0.14 - 1.40)		
LS-Mean LJ501 (95%CI) [c]	1.30 (0.72 - 1.87)		
LS-Mean Difference (95%CI) [c]	-0.52 (-1.38 - 0.33)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Number of Patients	39	49	88
Hour 48			
N	39	49	88
Mean (SD)	15.00 (7.101)	14.18 (6.330)	14.55 (6.656)
Median	14.00	14.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	39	47	86
Mean (SD)	2.74 (6.120)	2.45 (5.967)	2.58 (6.003)
Median	1.00	3.00	1.50
Range	-7 - 16	-10 - 15	-10 - 16
P-value [b] 0.7988			
P-value [c] 0.8766			
LS-Mean Placebo (95%CI) [c]	2.69 (0.82 - 4.56)		
LS-Mean LJ501 (95%CI) [c]	2.49 (0.79 - 4.19)		
LS-Mean Difference (95%CI) [c]	0.20 (-2.33 - 2.73)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Total Number of Patients	35	45	80
Total Number of Events	11	8	19
Total Number of Censored for CSH	24	37	61
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	5 (3 - 7)	7 (5 -)	6 (5 -)
Median (95% CI)	(5 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	6% (2%- 22%)	0% (0%- 0%)	3% (1%- 10%)
3-day Estimate	10% (3%- 28%)	0% (0%- 0%)	4% (1%- 13%)
4-day Estimate	14% (6%- 34%)	3% (0%- 19%)	8% (3%- 17%)
5-day Estimate	28% (14%- 50%)	12% (5%- 29%)	19% (11%- 31%)
6-day Estimate	37% (21%- 60%)	22% (11%- 41%)	28% (18%- 42%)
7-day Estimate	48% (29%- 70%)	26% (14%- 45%)	35% (24%- 49%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	6% (1%- 21%)	0% (0%- 0%)	3% (1%- 10%)
3-day Estimate	9% (3%- 24%)	0% (0%- 0%)	4% (1%- 11%)
4-day Estimate	11% (4%- 28%)	2% (0%- 15%)	6% (3%- 14%)
5-day Estimate	20% (10%- 37%)	9% (3%- 22%)	14% (8%- 23%)
6-day Estimate	26% (14%- 44%)	16% (8%- 30%)	20% (13%- 31%)
7-day Estimate	31% (19%- 50%)	18% (9%- 32%)	24% (16%- 35%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 3.37, 1, 0.0664
Log hazard (SE), Relative Risk (95% CI) [b]: -0.830 (0.465), 0.436 (0.175 - 1.085)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.14, 1, 0.1431
Log hazard (SE), Relative Risk (95% CI) [b]: -0.668 (0.465), 0.513 (0.206 - 1.275)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.21.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Total Number of Patients	39	49	88
Total Number of Events	18	19	37
Total Number of Censored for CSH	21	30	51
Days to ICU Discharge			
25% Quartile (95% CI)	7 (4 - 10)	9 (7 - 14)	8 (6 - 10)
Median (95% CI)	12 (7 - 19)	15 (10 - 28)	15 (10 - 19)
75% Quartile (95% CI)	20 (17 -)	(17 -)	28 (18 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	34% (19%- 55%)	15% (6%- 32%)	23% (14%- 36%)
14-day Estimate	52% (34%- 73%)	48% (31%- 68%)	50% (37%- 64%)
21-day Estimate	79% (57%- 94%)	61% (43%- 79%)	69% (55%- 82%)
28-day Estimate	86% (65%- 97%)	72% (53%- 88%)	78% (64%- 90%)
ICU Discharge Cumulative Incidence			
7-day Estimate	23% (13%- 40%)	10% (4%- 23%)	16% (10%- 25%)
14-day Estimate	33% (21%- 50%)	29% (18%- 43%)	31% (22%- 41%)
21-day Estimate	44% (30%- 60%)	35% (23%- 50%)	39% (29%- 50%)
28-day Estimate	46% (32%- 63%)	39% (27%- 54%)	42% (33%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.56, 1, 0.2119
Log hazard (SE), Relative Risk (95% CI) [b]: -0.409 (0.330), 0.664 (0.348 - 1.268)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.66, 1, 0.4171
Log hazard (SE), Relative Risk (95% CI) [b]: -0.266 (0.329), 0.766 (0.402 - 1.460)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.21.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Female)

	Placebo	LJPC-501	Total
Total Number of Patients	39	49	88
Total Number of Events	10	13	23
Total Number of Censored for CSH	29	36	65
Days to Hospital Discharge			
25% Quartile (95% CI)	17 (10 - 23)	21 (11 - 24)	18 (15 - 23)
Median (95% CI)	24 (17 -)	28 (22 -)	26 (22 -)
75% Quartile (95% CI)	(24 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	15% (5%- 41%)	7% (2%- 25%)	10% (4%- 23%)
21-day Estimate	39% (21%- 65%)	27% (14%- 48%)	32% (20%- 48%)
28-day Estimate	57% (36%- 80%)	53% (35%- 73%)	54% (40%- 70%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	8% (3%- 22%)	4% (1%- 15%)	6% (2%- 13%)
21-day Estimate	18% (9%- 34%)	14% (7%- 28%)	16% (10%- 25%)
28-day Estimate	26% (15%- 42%)	27% (16%- 41%)	26% (18%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.21, 1, 0.6441
Log hazard (SE), Relative Risk (95% CI) [b]: -0.194 (0.421), 0.823 (0.361 - 1.879)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9754
Log hazard (SE), Relative Risk (95% CI) [b]: 0.013 (0.421), 1.013 (0.444 - 2.310)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.21.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Number of Patients	76	65	141
Screening			
N	76	65	141
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	76 (100.0%)	65 (100.0%)	141 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Number of Patients	76	65	141
Hour 3 [a]			
N	76	65	141
3	1 (1.3%)	5 (7.7%)	6 (4.3%)
4	75 (98.7%)	60 (92.3%)	135 (95.7%)
Mean (SD)	3.99 (0.115)	3.92 (0.269)	3.96 (0.203)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	76	65	141
Mean (SD)	-0.01 (0.115)	-0.08 (0.269)	-0.04 (0.203)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.0673			
P-value [c] 0.1571			
LS-Mean Placebo (95%CI) [c]	-0.02 (-0.07 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.07 (-0.12 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.05 (-0.02 - 0.12)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Number of Patients	76	65	141
Hour 48 [a]			
N	76	65	141
0	12 (15.8%)	21 (32.3%)	33 (23.4%)
1	4 (5.3%)	6 (9.2%)	10 (7.1%)
2	0 (0.0%)	2 (3.1%)	2 (1.4%)
3	15 (19.7%)	11 (16.9%)	26 (18.4%)
4	26 (34.2%)	16 (24.6%)	42 (29.8%)
4 (LOCF)	2 (2.6%)	0 (0.0%)	2 (1.4%)
4 (WC)	17 (22.4%)	9 (13.8%)	26 (18.4%)
Mean (SD)	3.01 (1.501)	2.20 (1.761)	2.64 (1.670)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	76	65	141
Mean (SD)	-0.99 (1.501)	-1.80 (1.761)	-1.36 (1.670)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0143			
P-value [c] 0.0623			
LS-Mean Placebo (95%CI) [c]	-1.13 (-1.48 - -0.78)		
LS-Mean LJ501 (95%CI) [c]	-1.63 (-2.02 - -1.25)		
LS-Mean Difference (95%CI) [c]	0.50 (-0.03 - 1.03)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:00

Table 14.2.21.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Number of Patients	76	65	141
Screening			
N	76	63	139
Mean (SD)	13.88 (3.179)	11.68 (2.939)	12.88 (3.253)
Median	14.00	11.00	13.00
Range	8 - 21	5 - 17	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Number of Patients	76	65	141
Hour 3			
N	76	65	141
Mean (SD)	14.21 (3.308)	12.26 (3.208)	13.31 (3.394)
Median	14.00	13.00	13.00
Range	7 - 21	5 - 19	5 - 21
Change from Screening			
N	76	63	139
Mean (SD)	0.33 (1.762)	0.67 (1.685)	0.48 (1.729)
Median	0.00	0.00	0.00
Range	-3 - 6	-2 - 5	-3 - 6
P-value [b] 0.2976			
P-value [c] 0.5285			
LS-Mean Placebo (95%CI) [c]	0.39 (-0.01 - 0.79)		
LS-Mean LJ501 (95%CI) [c]	0.59 (0.15 - 1.03)		
LS-Mean Difference (95%CI) [c]	-0.20 (-0.82 - 0.42)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Number of Patients	76	65	141
Hour 48			
N	76	65	141
Mean (SD)	15.38 (6.460)	12.08 (6.306)	13.86 (6.578)
Median	15.00	10.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	76	63	139
Mean (SD)	1.50 (5.188)	0.60 (5.566)	1.09 (5.362)
Median	1.00	0.00	0.00
Range	-8 - 15	-8 - 15	-8 - 15
P-value [b] 0.5628			
P-value [c] 0.9543			
LS-Mean Placebo (95%CI) [c]	1.12 (-0.04 - 2.27)		
LS-Mean LJ501 (95%CI) [c]	1.07 (-0.21 - 2.35)		
LS-Mean Difference (95%CI) [c]	0.05 (-1.73 - 1.84)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.21.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Total Number of Patients	73	58	131
Total Number of Events	13	20	33
Total Number of Censored for CSH	60	38	98
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (6 -)	5 (3 - 6)	6 (4 -)
Median (95% CI)	(-)	(6 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	1% (0%- 9%)	2% (0%- 12%)	2% (0%- 6%)
2-day Estimate	4% (1%- 12%)	10% (5%- 22%)	7% (4%- 13%)
3-day Estimate	6% (2%- 15%)	20% (12%- 33%)	12% (8%- 20%)
4-day Estimate	12% (6%- 23%)	24% (15%- 38%)	17% (12%- 26%)
5-day Estimate	12% (6%- 23%)	32% (21%- 47%)	22% (15%- 31%)
6-day Estimate	21% (12%- 35%)	37% (25%- 52%)	28% (21%- 38%)
7-day Estimate	25% (15%- 40%)	39% (27%- 54%)	32% (24%- 42%)
Ventilator Cumulative Incidence			
1-day Estimate	1% (0%- 9%)	2% (0%- 12%)	2% (0%- 6%)
2-day Estimate	4% (1%- 12%)	10% (5%- 22%)	7% (4%- 13%)
3-day Estimate	5% (2%- 14%)	19% (11%- 32%)	11% (7%- 18%)
4-day Estimate	10% (5%- 19%)	22% (14%- 35%)	15% (10%- 23%)
5-day Estimate	10% (5%- 19%)	29% (19%- 43%)	18% (13%- 26%)
6-day Estimate	15% (9%- 26%)	33% (22%- 46%)	23% (17%- 31%)
7-day Estimate	18% (11%- 29%)	34% (24%- 48%)	25% (19%- 34%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 3.25, 1, 0.0713
Log hazard (SE), Relative Risk (95% CI) [b]: 0.632 (0.356), 1.882 (0.936 - 3.783)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 5.06, 1, 0.0244
Log hazard (SE), Relative Risk (95% CI) [b]: 0.783 (0.357), 2.187 (1.087 - 4.400)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.21.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Total Number of Patients	76	65	141
Total Number of Events	24	28	52
Total Number of Censored for CSH	52	37	89
Days to ICU Discharge			
25% Quartile (95% CI)	12 (10 - 15)	8 (5 - 11)	10 (7 - 12)
Median (95% CI)	18 (14 - 28)	15 (10 - 23)	17 (14 - 23)
75% Quartile (95% CI)	(22 -)	(22 -)	(28 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	12% (5%- 24%)	23% (14%- 37%)	17% (11%- 26%)
14-day Estimate	35% (22%- 52%)	47% (33%- 62%)	41% (31%- 52%)
21-day Estimate	56% (40%- 73%)	59% (44%- 74%)	57% (46%- 69%)
28-day Estimate	71% (53%- 88%)	65% (50%- 80%)	67% (55%- 78%)
ICU Discharge Cumulative Incidence			
7-day Estimate	8% (4%- 17%)	18% (11%- 30%)	13% (8%- 19%)
14-day Estimate	20% (12%- 31%)	34% (24%- 47%)	26% (20%- 34%)
21-day Estimate	28% (19%- 39%)	40% (29%- 53%)	33% (26%- 42%)
28-day Estimate	32% (22%- 43%)	43% (32%- 56%)	37% (30%- 45%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.65, 1, 0.4209
Log hazard (SE), Relative Risk (95% CI) [b]: 0.224 (0.279), 1.251 (0.724 - 2.163)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.67, 1, 0.1025
Log hazard (SE), Relative Risk (95% CI) [b]: 0.451 (0.278), 1.569 (0.909 - 2.708)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.21.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Male)

	Placebo	LJPC-501	Total
Total Number of Patients	76	65	141
Total Number of Events	16	20	36
Total Number of Censored for CSH	60	45	105
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (13 - 24)	16 (9 - 20)	18 (14 - 21)
Median (95% CI)	28 (23 -)	(19 -)	(22 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	4% (1%- 15%)	6% (2%- 18%)	5% (2%- 12%)
14-day Estimate	15% (7%- 30%)	18% (9%- 32%)	16% (10%- 26%)
21-day Estimate	28% (16%- 46%)	41% (28%- 58%)	35% (25%- 47%)
28-day Estimate	51% (34%- 70%)	49% (35%- 66%)	50% (38%- 62%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 10%)	5% (2%- 14%)	4% (1%- 8%)
14-day Estimate	8% (4%- 17%)	12% (6%- 23%)	10% (6%- 16%)
21-day Estimate	13% (7%- 23%)	26% (17%- 39%)	19% (14%- 27%)
28-day Estimate	21% (13%- 32%)	31% (21%- 44%)	26% (19%- 34%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.10, 1, 0.7550
Log hazard (SE), Relative Risk (95% CI) [b]: 0.105 (0.336), 1.110 (0.575 - 2.145)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.88, 1, 0.1698
Log hazard (SE), Relative Risk (95% CI) [b]: 0.457 (0.336), 1.579 (0.818 - 3.047)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.22.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Number of Patients	29	17	46
Screening			
N	29	17	46
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	29 (100.0%)	17 (100.0%)	46 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Number of Patients	29	17	46
Hour 3 [a]			
N	29	17	46
3	1 (3.4%)	0 (0.0%)	1 (2.2%)
4	28 (96.6%)	17 (100.0%)	45 (97.8%)
Mean (SD)	3.97 (0.186)	4.00 (0.000)	3.98 (0.147)
Median	4.00	4.00	4.00
Range	3 - 4	4 - 4	3 - 4
Change from Screening			
N	29	17	46
Mean (SD)	-0.03 (0.186)	0.00 (0.000)	-0.02 (0.147)
Median	0.00	0.00	0.00
Range	-1 - 0	0 - 0	-1 - 0
P-value [b] 0.4795			
P-value [c] 0.5044			
LS-Mean Placebo (95%CI) [c]	-0.03 (-0.09 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.00 (-0.08 - 0.07)		
LS-Mean Difference (95%CI) [c]	-0.03 (-0.13 - 0.06)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Number of Patients	29	17	46
Hour 48 [a]			
N	29	17	46
0	1 (3.4%)	5 (29.4%)	6 (13.0%)
1	3 (10.3%)	1 (5.9%)	4 (8.7%)
3	6 (20.7%)	2 (11.8%)	8 (17.4%)
4	10 (34.5%)	5 (29.4%)	15 (32.6%)
4 (LOCF)	1 (3.4%)	0 (0.0%)	1 (2.2%)
4 (WC)	8 (27.6%)	4 (23.5%)	12 (26.1%)
Mean (SD)	3.34 (1.143)	2.53 (1.841)	3.04 (1.475)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	29	17	46
Mean (SD)	-0.66 (1.143)	-1.47 (1.841)	-0.96 (1.475)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.1234			
P-value [c] 0.0857			
LS-Mean Placebo (95%CI) [c]	-0.66 (-1.20 - -0.12)		
LS-Mean LJ501 (95%CI) [c]	-1.47 (-2.18 - -0.75)		
LS-Mean Difference (95%CI) [c]	0.81 (-0.12 - 1.73)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Number of Patients	29	17	46
Screening			
N	29	17	46
Mean (SD)	13.83 (3.444)	12.94 (2.384)	13.50 (3.097)
Median	14.00	13.00	13.50
Range	8 - 19	8 - 16	8 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Number of Patients	29	17	46
Hour 3			
N	29	17	46
Mean (SD)	14.21 (3.707)	13.94 (2.609)	14.11 (3.315)
Median	14.00	15.00	14.50
Range	7 - 20	8 - 17	7 - 20
Change from Screening			
N	29	17	46
Mean (SD)	0.38 (1.860)	1.00 (1.803)	0.61 (1.844)
Median	0.00	1.00	0.00
Range	-2 - 6	-2 - 4	-2 - 6
P-value [b]	0.1460		
P-value [c]	0.3298		
LS-Mean Placebo (95%CI) [c]	0.39 (-0.32 - 1.09)		
LS-Mean LJ501 (95%CI) [c]	0.98 (0.04 - 1.93)		
LS-Mean Difference (95%CI) [c]	-0.60 (-1.82 - 0.63)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Number of Patients	29	17	46
Hour 48			
N	29	17	46
Mean (SD)	16.07 (6.813)	14.53 (7.409)	15.50 (6.998)
Median	17.00	14.00	16.50
Range	4 - 24	3 - 24	3 - 24
Change from Screening			
N	29	17	46
Mean (SD)	2.24 (5.343)	1.59 (6.462)	2.00 (5.719)
Median	1.00	-1.00	1.00
Range	-7 - 15	-6 - 11	-7 - 15
P-value [b]	0.5650		
P-value [c]	0.6993		
LS-Mean Placebo (95%CI) [c]	2.25 (0.23 - 4.27)		
LS-Mean LJ501 (95%CI) [c]	1.58 (-1.12 - 4.27)		
LS-Mean Difference (95%CI) [c]	0.67 (-2.82 - 4.17)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Total Number of Patients	26	16	42
Total Number of Events	3	4	7
Total Number of Censored for CSH	23	12	35
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(2 -)	6 (5 -)	(4 -)
Median (95% CI)	(-)	(5 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	2+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	4% (1%- 25%)	0% (0%- 0%)	2% (0%- 16%)
3-day Estimate	10% (2%- 34%)	0% (0%- 0%)	6% (1%- 21%)
4-day Estimate	15% (5%- 41%)	0% (0%- 0%)	9% (3%- 25%)
5-day Estimate	15% (5%- 41%)	25% (9%- 59%)	19% (9%- 39%)
6-day Estimate	15% (5%- 41%)	25% (9%- 59%)	19% (9%- 39%)
7-day Estimate	15% (5%- 41%)	36% (15%- 70%)	24% (12%- 44%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	4% (1%- 24%)	0% (0%- 0%)	2% (0%- 16%)
3-day Estimate	8% (2%- 27%)	0% (0%- 0%)	5% (1%- 18%)
4-day Estimate	12% (4%- 32%)	0% (0%- 0%)	7% (2%- 21%)
5-day Estimate	12% (4%- 32%)	19% (6%- 48%)	14% (7%- 29%)
6-day Estimate	12% (4%- 32%)	19% (6%- 48%)	14% (7%- 29%)
7-day Estimate	12% (4%- 32%)	25% (10%- 54%)	17% (8%- 32%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.56, 1, 0.4557
Log hazard (SE), Relative Risk (95% CI) [b]: 0.564 (0.766), 1.757 (0.392 - 7.883)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.92, 1, 0.3385
Log hazard (SE), Relative Risk (95% CI) [b]: 0.716 (0.764), 2.046 (0.458 - 9.152)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.22.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Total Number of Patients	29	17	46
Total Number of Events	7	3	10
Total Number of Censored for CSH	22	14	36
Days to ICU Discharge			
25% Quartile (95% CI)	15 (4 -)	16 (6 -)	15 (5 -)
Median (95% CI)	(15 -)	(9 -)	(16 -)
75% Quartile (95% CI)	(-)	(16 -)	(-)
Range	1+ - 28+	2+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	20% (8%- 45%)	8% (1%- 46%)	16% (7%- 34%)
14-day Estimate	20% (8%- 45%)	19% (5%- 56%)	19% (9%- 38%)
21-day Estimate	33% (16%- 61%)	35% (12%- 77%)	33% (19%- 55%)
28-day Estimate	45% (23%- 74%)	35% (12%- 77%)	40% (23%- 64%)
ICU Discharge Cumulative Incidence			
7-day Estimate	14% (5%- 33%)	6% (1%- 35%)	11% (5%- 24%)
14-day Estimate	14% (5%- 33%)	12% (3%- 39%)	13% (6%- 27%)
21-day Estimate	21% (10%- 40%)	18% (6%- 45%)	20% (11%- 34%)
28-day Estimate	24% (12%- 44%)	18% (6%- 45%)	22% (12%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.29, 1, 0.5890
Log hazard (SE), Relative Risk (95% CI) [b]: -0.371 (0.691), 0.690 (0.178 - 2.674)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.29, 1, 0.5895
Log hazard (SE), Relative Risk (95% CI) [b]: -0.370 (0.690), 0.691 (0.179 - 2.671)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.22.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Race: Non-white)

	Placebo	LJPC-501	Total
Total Number of Patients	29	17	46
Total Number of Events	5	2	7
Total Number of Censored for CSH	24	15	39
Days to Hospital Discharge			
25% Quartile (95% CI)	22 (7 -)	(11 -)	22 (11 -)
Median (95% CI)	(18 -)	(11 -)	(22 -)
75% Quartile (95% CI)	(23 -)	(-)	(-)
Range	1+ - 28+	2+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	6% (1%- 33%)	0% (0%- 0%)	4% (1%- 23%)
14-day Estimate	12% (3%- 40%)	10% (1%- 53%)	11% (4%- 31%)
21-day Estimate	21% (7%- 53%)	25% (7%- 70%)	22% (10%- 47%)
28-day Estimate	42% (19%- 76%)	25% (7%- 70%)	35% (18%- 61%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (0%- 22%)	0% (0%- 0%)	2% (0%- 14%)
14-day Estimate	7% (2%- 25%)	6% (1%- 35%)	7% (2%- 19%)
21-day Estimate	10% (3%- 29%)	12% (3%- 39%)	11% (5%- 24%)
28-day Estimate	17% (8%- 37%)	12% (3%- 39%)	15% (8%- 29%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.36, 1, 0.5504
Log hazard (SE), Relative Risk (95% CI) [b]: -0.495 (0.838), 0.610 (0.118 - 3.149)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.23, 1, 0.6287
Log hazard (SE), Relative Risk (95% CI) [b]: -0.402 (0.837), 0.669 (0.130 - 3.449)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.22.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Number of Patients	86	97	183
Screening			
N	86	97	183
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	86 (100.0%)	97 (100.0%)	183 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Number of Patients	86	97	183
Hour 3 [a]			
N	86	97	183
3	0 (0.0%)	6 (6.2%)	6 (3.3%)
4	85 (98.8%)	91 (93.8%)	176 (96.2%)
4 (LOCF)	1 (1.2%)	0 (0.0%)	1 (0.5%)
Mean (SD)	4.00 (0.000)	3.94 (0.242)	3.97 (0.179)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	86	97	183
Mean (SD)	0.00 (0.000)	-0.06 (0.242)	-0.03 (0.179)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0328			
P-value [c] 0.0546			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.04 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.06 (-0.09 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.05 (-0.00 - 0.10)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Number of Patients	86	97	183
Hour 48 [a]			
N	86	97	183
0	20 (23.3%)	32 (33.0%)	52 (28.4%)
1	3 (3.5%)	6 (6.2%)	9 (4.9%)
2	0 (0.0%)	2 (2.1%)	2 (1.1%)
3	16 (18.6%)	18 (18.6%)	34 (18.6%)
4	26 (30.2%)	25 (25.8%)	51 (27.9%)
4 (LOCF)	1 (1.2%)	0 (0.0%)	1 (0.5%)
4 (WC)	20 (23.3%)	14 (14.4%)	34 (18.6%)
Mean (SD)	2.78 (1.662)	2.27 (1.771)	2.51 (1.735)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	86	97	183
Mean (SD)	-1.22 (1.662)	-1.73 (1.771)	-1.49 (1.735)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0720			
P-value [c] 0.1504			
LS-Mean Placebo (95%CI) [c]	-1.31 (-1.65 - -0.96)		
LS-Mean LJ501 (95%CI) [c]	-1.66 (-1.98 - -1.33)		
LS-Mean Difference (95%CI) [c]	0.35 (-0.13 - 0.83)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Number of Patients	86	97	183
Screening			
N	86	93	179
Mean (SD)	13.16 (3.158)	11.61 (2.855)	12.36 (3.095)
Median	13.00	11.00	12.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Number of Patients	86	97	183
Hour 3			
N	86	97	183
Mean (SD)	13.66 (3.108)	12.48 (3.166)	13.04 (3.185)
Median	14.00	12.00	13.00
Range	8 - 21	5 - 20	5 - 21
Change from Screening			
N	86	93	179
Mean (SD)	0.50 (1.957)	0.94 (1.786)	0.73 (1.878)
Median	0.00	1.00	1.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.1861			
P-value [c] 0.4532			
LS-Mean Placebo (95%CI) [c]	0.62 (0.22 - 1.01)		
LS-Mean LJ501 (95%CI) [c]	0.83 (0.45 - 1.21)		
LS-Mean Difference (95%CI) [c]	-0.21 (-0.77 - 0.34)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Number of Patients	86	97	183
Hour 48			
N	86	97	183
Mean (SD)	14.98 (6.619)	12.71 (6.180)	13.78 (6.472)
Median	14.50	11.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	86	93	179
Mean (SD)	1.81 (5.614)	1.35 (5.693)	1.58 (5.644)
Median	0.00	1.00	1.00
Range	-8 - 16	-10 - 15	-10 - 16
P-value [b] 0.9628			
P-value [c] 0.7755			
LS-Mean Placebo (95%CI) [c]	1.70 (0.55 - 2.84)		
LS-Mean LJ501 (95%CI) [c]	1.46 (0.36 - 2.56)		
LS-Mean Difference (95%CI) [c]	0.23 (-1.38 - 1.85)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.22.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Total Number of Patients	82	87	169
Total Number of Events	21	24	45
Total Number of Censored for CSH	61	63	124
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (5 - 7)	6 (4 -)	6 (5 - 7)
Median (95% CI)	(7 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	1% (0%- 8%)	1% (0%- 8%)	1% (0%- 5%)
2-day Estimate	5% (2%- 13%)	7% (3%- 15%)	6% (3%- 11%)
3-day Estimate	7% (3%- 15%)	14% (8%- 23%)	10% (6%- 16%)
4-day Estimate	12% (6%- 23%)	18% (11%- 28%)	15% (10%- 22%)
5-day Estimate	17% (10%- 30%)	24% (16%- 35%)	21% (15%- 29%)
6-day Estimate	30% (19%- 44%)	31% (22%- 44%)	30% (23%- 39%)
7-day Estimate	38% (26%- 52%)	33% (23%- 45%)	35% (27%- 44%)
Ventilator Cumulative Incidence			
1-day Estimate	1% (0%- 8%)	1% (0%- 8%)	1% (0%- 5%)
2-day Estimate	5% (2%- 12%)	7% (3%- 15%)	6% (3%- 11%)
3-day Estimate	6% (3%- 14%)	13% (7%- 22%)	9% (6%- 15%)
4-day Estimate	10% (5%- 19%)	16% (10%- 26%)	13% (9%- 19%)
5-day Estimate	13% (8%- 23%)	21% (14%- 31%)	17% (12%- 24%)
6-day Estimate	21% (13%- 31%)	26% (18%- 37%)	24% (18%- 31%)
7-day Estimate	26% (18%- 37%)	28% (19%- 38%)	27% (21%- 34%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9768
Log hazard (SE), Relative Risk (95% CI) [b]: -0.009 (0.299), 0.991 (0.552 - 1.781)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.18, 1, 0.6686
Log hazard (SE), Relative Risk (95% CI) [b]: 0.128 (0.299), 1.136 (0.632 - 2.041)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.22.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Total Number of Patients	86	97	183
Total Number of Events	35	44	79
Total Number of Censored for CSH	51	53	104
Days to ICU Discharge			
25% Quartile (95% CI)	10 (7 - 12)	8 (6 - 10)	8 (7 - 10)
Median (95% CI)	15 (12 - 19)	14 (11 - 20)	14 (12 - 18)
75% Quartile (95% CI)	20 (18 -)	(20 -)	28 (20 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	19% (11%- 31%)	21% (14%- 33%)	20% (14%- 28%)
14-day Estimate	49% (35%- 64%)	52% (40%- 65%)	50% (41%- 60%)
21-day Estimate	75% (60%- 88%)	64% (52%- 76%)	68% (58%- 77%)
28-day Estimate	86% (71%- 95%)	73% (60%- 84%)	78% (68%- 86%)
ICU Discharge Cumulative Incidence			
7-day Estimate	13% (7%- 22%)	16% (10%- 26%)	15% (10%- 21%)
14-day Estimate	28% (20%- 39%)	35% (26%- 45%)	32% (25%- 39%)
21-day Estimate	37% (28%- 48%)	41% (32%- 52%)	39% (33%- 47%)
28-day Estimate	41% (31%- 52%)	45% (36%- 56%)	43% (36%- 51%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.08, 1, 0.7717
Log hazard (SE), Relative Risk (95% CI) [b]: -0.066 (0.227), 0.936 (0.599 - 1.462)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.61, 1, 0.4335
Log hazard (SE), Relative Risk (95% CI) [b]: 0.177 (0.227), 1.194 (0.766 - 1.861)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.22.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Race: White)

	Placebo	LJPC-501	Total
Total Number of Patients	86	97	183
Total Number of Events	21	31	52
Total Number of Censored for CSH	65	66	131
Days to Hospital Discharge			
25% Quartile (95% CI)	17 (14 - 23)	17 (15 - 21)	17 (15 - 21)
Median (95% CI)	25 (21 -)	26 (21 -)	26 (23 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	2% (0%- 12%)	4% (1%- 12%)	3% (1%- 8%)
14-day Estimate	16% (8%- 31%)	14% (7%- 25%)	15% (9%- 23%)
21-day Estimate	36% (23%- 53%)	37% (26%- 51%)	36% (28%- 47%)
28-day Estimate	56% (41%- 73%)	54% (41%- 67%)	55% (45%- 65%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	1% (0%- 8%)	3% (1%- 9%)	2% (1%- 6%)
14-day Estimate	8% (4%- 16%)	9% (5%- 17%)	9% (5%- 14%)
21-day Estimate	16% (10%- 26%)	23% (16%- 32%)	20% (15%- 26%)
28-day Estimate	24% (17%- 35%)	32% (24%- 42%)	28% (22%- 36%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9822
Log hazard (SE), Relative Risk (95% CI) [b]: -0.006 (0.283), 0.994 (0.571 - 1.730)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.31, 1, 0.2525
Log hazard (SE), Relative Risk (95% CI) [b]: 0.322 (0.283), 1.380 (0.793 - 2.402)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.23.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	60	60	120
Screening			
N	60	60	120
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	60 (100.0%)	60 (100.0%)	120 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	60	60	120
Hour 3 [a]			
N	60	60	120
3	0 (0.0%)	3 (5.0%)	3 (2.5%)
4	60 (100.0%)	57 (95.0%)	117 (97.5%)
Mean (SD)	4.00 (0.000)	3.95 (0.220)	3.98 (0.157)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	60	60	120
Mean (SD)	0.00 (0.000)	-0.05 (0.220)	-0.03 (0.157)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.1145			
P-value [c] 0.1697			
LS-Mean Placebo (95%CI) [c]	-0.00 (-0.05 - 0.04)		
LS-Mean LJ501 (95%CI) [c]	-0.05 (-0.09 - -0.00)		
LS-Mean Difference (95%CI) [c]	0.04 (-0.02 - 0.10)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	60	60	120
Hour 48 [a]			
N	60	60	120
0	13 (21.7%)	21 (35.0%)	34 (28.3%)
1	4 (6.7%)	5 (8.3%)	9 (7.5%)
2	0 (0.0%)	2 (3.3%)	2 (1.7%)
3	11 (18.3%)	12 (20.0%)	23 (19.2%)
4	21 (35.0%)	13 (21.7%)	34 (28.3%)
4 (LOCF)	1 (1.7%)	0 (0.0%)	1 (0.8%)
4 (WC)	10 (16.7%)	7 (11.7%)	17 (14.2%)
Mean (SD)	2.75 (1.653)	2.08 (1.749)	2.42 (1.728)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	60	60	120
Mean (SD)	-1.25 (1.653)	-1.92 (1.749)	-1.58 (1.728)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0435			
P-value [c] 0.2121			
LS-Mean Placebo (95%CI) [c]	-1.40 (-1.81 - -0.99)		
LS-Mean LJ501 (95%CI) [c]	-1.77 (-2.18 - -1.36)		
LS-Mean Difference (95%CI) [c]	0.37 (-0.22 - 0.96)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	60	60	120
Screening			
N	60	57	117
Mean (SD)	13.12 (3.136)	11.28 (3.016)	12.22 (3.201)
Median	13.50	11.00	12.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	60	60	120
Hour 3			
N	60	60	120
Mean (SD)	13.62 (3.195)	12.30 (3.274)	12.96 (3.288)
Median	13.00	12.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	60	57	117
Mean (SD)	0.50 (1.864)	1.04 (1.783)	0.76 (1.837)
Median	0.00	1.00	1.00
Range	-3 - 6	-2 - 5	-3 - 6
P-value [b] 0.1547			
P-value [c] 0.3041			
LS-Mean Placebo (95%CI) [c]	0.59 (0.12 - 1.05)		
LS-Mean LJ501 (95%CI) [c]	0.94 (0.47 - 1.42)		
LS-Mean Difference (95%CI) [c]	-0.36 (-1.04 - 0.33)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	60	60	120
Hour 48			
N	60	60	120
Mean (SD)	13.97 (6.787)	11.83 (6.201)	12.90 (6.561)
Median	14.00	10.00	11.50
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	60	57	117
Mean (SD)	0.85 (5.246)	0.79 (5.424)	0.82 (5.310)
Median	0.00	0.00	0.00
Range	-8 - 15	-7 - 15	-8 - 15
P-value [b] 0.7121			
P-value [c] 0.3442			
LS-Mean Placebo (95%CI) [c]	0.37 (-0.94 - 1.68)		
LS-Mean LJ501 (95%CI) [c]	1.29 (-0.05 - 2.64)		
LS-Mean Difference (95%CI) [c]	-0.92 (-2.84 - 1.00)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Total Number of Patients	57	51	108
Total Number of Events	14	15	29
Total Number of Censored for CSH	43	36	79
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 -)	6 (5 -)	6 (5 -)
Median (95% CI)	(-)	(7 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	2 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 12%)	0% (0%- 0%)	1% (0%- 6%)
2-day Estimate	9% (4%- 20%)	2% (0%- 13%)	6% (3%- 12%)
3-day Estimate	9% (4%- 20%)	8% (3%- 20%)	9% (5%- 16%)
4-day Estimate	13% (7%- 26%)	10% (4%- 23%)	12% (7%- 20%)
5-day Estimate	13% (7%- 26%)	22% (13%- 37%)	18% (12%- 28%)
6-day Estimate	27% (16%- 43%)	32% (20%- 48%)	29% (21%- 40%)
7-day Estimate	32% (20%- 49%)	35% (22%- 51%)	34% (25%- 45%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 12%)	0% (0%- 0%)	1% (0%- 6%)
2-day Estimate	9% (4%- 20%)	2% (0%- 13%)	6% (3%- 12%)
3-day Estimate	9% (4%- 20%)	8% (3%- 20%)	8% (4%- 15%)
4-day Estimate	12% (6%- 24%)	10% (4%- 22%)	11% (6%- 19%)
5-day Estimate	12% (6%- 24%)	20% (11%- 33%)	16% (10%- 24%)
6-day Estimate	21% (13%- 34%)	27% (17%- 42%)	24% (17%- 33%)
7-day Estimate	25% (15%- 38%)	29% (19%- 44%)	27% (20%- 36%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.04, 1, 0.8346
Log hazard (SE), Relative Risk (95% CI) [b]: 0.078 (0.372), 1.081 (0.521 - 2.240)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.29, 1, 0.5905
Log hazard (SE), Relative Risk (95% CI) [b]: 0.200 (0.372), 1.221 (0.589 - 2.530)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.23.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Total Number of Patients	60	60	120
Total Number of Events	25	27	52
Total Number of Censored for CSH	35	33	68
Days to ICU Discharge			
25% Quartile (95% CI)	10 (5 - 14)	7 (6 - 10)	8 (6 - 12)
Median (95% CI)	17 (13 - 25)	14 (9 - 22)	15 (13 - 22)
75% Quartile (95% CI)	28 (19 -)	(15 -)	(22 -)
Range	2+ - 28+	2+ - 28+	2+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	18% (9%- 32%)	25% (15%- 40%)	21% (14%- 31%)
14-day Estimate	41% (27%- 58%)	53% (38%- 69%)	47% (36%- 59%)
21-day Estimate	61% (44%- 79%)	63% (47%- 79%)	61% (50%- 73%)
28-day Estimate	83% (64%- 95%)	71% (54%- 85%)	75% (63%- 86%)
ICU Discharge Cumulative Incidence			
7-day Estimate	13% (7%- 25%)	20% (12%- 33%)	17% (11%- 25%)
14-day Estimate	27% (17%- 40%)	37% (26%- 50%)	32% (24%- 41%)
21-day Estimate	35% (24%- 48%)	42% (30%- 55%)	38% (30%- 48%)
28-day Estimate	42% (30%- 55%)	45% (33%- 58%)	43% (35%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.13, 1, 0.7142
Log hazard (SE), Relative Risk (95% CI) [b]: 0.102 (0.279), 1.108 (0.641 - 1.913)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.33, 1, 0.5634
Log hazard (SE), Relative Risk (95% CI) [b]: 0.160 (0.278), 1.174 (0.681 - 2.023)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.23.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, BMI <30 kg/m2)

	Placebo	LJPC-501	Total
Total Number of Patients	60	60	120
Total Number of Events	15	19	34
Total Number of Censored for CSH	45	41	86
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (12 - 24)	17 (11 - 21)	17 (13 - 21)
Median (95% CI)	28 (18 -)	28 (18 -)	28 (22 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	2+ - 28+	2+ - 28+	2+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	5% (1%- 18%)	4% (1%- 17%)	5% (2%- 12%)
14-day Estimate	20% (10%- 37%)	15% (7%- 30%)	17% (10%- 27%)
21-day Estimate	31% (18%- 51%)	41% (27%- 59%)	37% (26%- 50%)
28-day Estimate	53% (35%- 72%)	53% (38%- 70%)	53% (41%- 66%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 13%)	3% (1%- 13%)	3% (1%- 9%)
14-day Estimate	12% (6%- 23%)	10% (5%- 21%)	11% (6%- 18%)
21-day Estimate	17% (9%- 29%)	25% (16%- 38%)	21% (15%- 29%)
28-day Estimate	25% (16%- 38%)	32% (22%- 45%)	28% (21%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8995
Log hazard (SE), Relative Risk (95% CI) [b]: 0.044 (0.346), 1.045 (0.530 - 2.058)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.63, 1, 0.4263
Log hazard (SE), Relative Risk (95% CI) [b]: 0.274 (0.345), 1.315 (0.668 - 2.588)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.23.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	54	52	106
Screening			
N	54	52	106
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	54 (100.0%)	52 (100.0%)	106 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	54	52	106
Hour 3 [a]			
N	54	52	106
3	1 (1.9%)	3 (5.8%)	4 (3.8%)
4	52 (96.3%)	49 (94.2%)	101 (95.3%)
4 (LOCF)	1 (1.9%)	0 (0.0%)	1 (0.9%)
Mean (SD)	3.98 (0.136)	3.94 (0.235)	3.96 (0.191)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	54	52	106
Mean (SD)	-0.02 (0.136)	-0.06 (0.235)	-0.04 (0.191)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.2361			
P-value [c] 0.3485			
LS-Mean Placebo (95%CI) [c]	-0.02 (-0.07 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.06 (-0.11 - -0.00)		
LS-Mean Difference (95%CI) [c]	0.04 (-0.04 - 0.11)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	54	52	106
Hour 48 [a]			
N	54	52	106
0	7 (13.0%)	16 (30.8%)	23 (21.7%)
1	2 (3.7%)	2 (3.8%)	4 (3.8%)
3	11 (20.4%)	8 (15.4%)	19 (17.9%)
4	15 (27.8%)	16 (30.8%)	31 (29.2%)
4 (LOCF)	1 (1.9%)	0 (0.0%)	1 (0.9%)
4 (WC)	18 (33.3%)	10 (19.2%)	28 (26.4%)
Mean (SD)	3.17 (1.397)	2.50 (1.799)	2.84 (1.634)
Median	4.00	3.50	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	54	52	106
Mean (SD)	-0.83 (1.397)	-1.50 (1.799)	-1.16 (1.634)
Median	0.00	-0.50	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0997			
P-value [c] 0.0779			
LS-Mean Placebo (95%CI) [c]	-0.89 (-1.32 - -0.46)		
LS-Mean LJ501 (95%CI) [c]	-1.44 (-1.88 - -1.01)		
LS-Mean Difference (95%CI) [c]	0.55 (-0.06 - 1.16)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	54	52	106
Screening			
N	54	51	105
Mean (SD)	13.61 (3.356)	12.47 (2.509)	13.06 (3.015)
Median	13.00	13.00	13.00
Range	8 - 20	7 - 17	7 - 20

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	54	52	106
Hour 3			
N	54	52	106
Mean (SD)	14.07 (3.336)	13.25 (2.903)	13.67 (3.143)
Median	14.00	13.00	14.00
Range	7 - 19	7 - 19	7 - 19
Change from Screening			
N	54	51	105
Mean (SD)	0.46 (2.016)	0.88 (1.807)	0.67 (1.920)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.2982			
P-value [c] 0.5170			
LS-Mean Placebo (95%CI) [c]	0.55 (0.04 - 1.06)		
LS-Mean LJ501 (95%CI) [c]	0.79 (0.26 - 1.32)		
LS-Mean Difference (95%CI) [c]	-0.24 (-0.99 - 0.50)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Number of Patients	54	52	106
Hour 48			
N	54	52	106
Mean (SD)	16.83 (6.188)	14.06 (6.354)	15.47 (6.394)
Median	16.50	14.00	15.00
Range	4 - 24	3 - 24	3 - 24
Change from Screening			
N	54	51	105
Mean (SD)	3.22 (5.602)	1.76 (6.045)	2.51 (5.839)
Median	1.00	1.00	1.00
Range	-7 - 16	-10 - 15	-10 - 16
P-value [b] 0.2503			
P-value [c] 0.2294			
LS-Mean Placebo (95%CI) [c]	3.16 (1.66 - 4.66)		
LS-Mean LJ501 (95%CI) [c]	1.83 (0.28 - 3.38)		
LS-Mean Difference (95%CI) [c]	1.33 (-0.85 - 3.51)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.23.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Total Number of Patients	50	51	101
Total Number of Events	9	13	22
Total Number of Censored for CSH	41	38	79
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (4 -)	5 (3 -)	6 (5 -)
Median (95% CI)	(7 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	2% (0%- 13%)	1% (0%- 7%)
2-day Estimate	0% (0%- 0%)	10% (4%- 23%)	5% (2%- 12%)
3-day Estimate	3% (0%- 18%)	15% (8%- 30%)	9% (5%- 18%)
4-day Estimate	9% (3%- 26%)	20% (11%- 36%)	15% (9%- 25%)
5-day Estimate	20% (9%- 39%)	26% (15%- 42%)	23% (15%- 34%)
6-day Estimate	24% (12%- 43%)	29% (17%- 45%)	26% (17%- 38%)
7-day Estimate	31% (17%- 52%)	32% (20%- 49%)	31% (21%- 43%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	2% (0%- 13%)	1% (0%- 7%)
2-day Estimate	0% (0%- 0%)	10% (4%- 22%)	5% (2%- 11%)
3-day Estimate	2% (0%- 13%)	14% (7%- 27%)	8% (4%- 15%)
4-day Estimate	6% (2%- 17%)	18% (10%- 31%)	12% (7%- 20%)
5-day Estimate	12% (6%- 25%)	22% (13%- 36%)	17% (11%- 26%)
6-day Estimate	14% (7%- 27%)	24% (14%- 38%)	19% (12%- 28%)
7-day Estimate	18% (10%- 32%)	25% (16%- 40%)	22% (15%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.39, 1, 0.5302
Log hazard (SE), Relative Risk (95% CI) [b]: 0.272 (0.434), 1.312 (0.561 - 3.071)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.07, 1, 0.3004
Log hazard (SE), Relative Risk (95% CI) [b]: 0.446 (0.434), 1.561 (0.667 - 3.653)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.23.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Total Number of Patients	54	52	106
Total Number of Events	16	20	36
Total Number of Censored for CSH	38	32	70
Days to ICU Discharge			
25% Quartile (95% CI)	10 (6 - 15)	10 (7 - 14)	10 (7 - 12)
Median (95% CI)	17 (11 -)	18 (11 -)	18 (12 - 28)
75% Quartile (95% CI)	(18 -)	(23 -)	(23 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	19% (9%- 38%)	13% (6%- 28%)	16% (9%- 27%)
14-day Estimate	40% (24%- 61%)	40% (26%- 59%)	40% (29%- 54%)
21-day Estimate	67% (47%- 86%)	56% (39%- 74%)	61% (48%- 74%)
28-day Estimate	67% (47%- 86%)	65% (47%- 82%)	66% (53%- 79%)
ICU Discharge Cumulative Incidence			
7-day Estimate	11% (5%- 23%)	10% (4%- 22%)	10% (6%- 18%)
14-day Estimate	20% (12%- 34%)	27% (17%- 41%)	24% (17%- 33%)
21-day Estimate	30% (19%- 44%)	35% (23%- 49%)	32% (24%- 42%)
28-day Estimate	30% (19%- 44%)	38% (27%- 53%)	34% (26%- 44%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.06, 1, 0.8058
Log hazard (SE), Relative Risk (95% CI) [b]: -0.083 (0.336), 0.921 (0.476 - 1.779)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.84, 1, 0.3591
Log hazard (SE), Relative Risk (95% CI) [b]: 0.306 (0.335), 1.359 (0.704 - 2.622)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.23.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, BMI >=30 kg/m2)

	Placebo	LJPC-501	Total
Total Number of Patients	54	52	106
Total Number of Events	11	14	25
Total Number of Censored for CSH	43	38	81
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (11 - 24)	20 (14 - 23)	20 (15 - 23)
Median (95% CI)	28 (18 -)	(22 -)	28 (23 -)
75% Quartile (95% CI)	(28 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	3% (0%- 18%)	1% (0%- 10%)
14-day Estimate	9% (2%- 31%)	12% (5%- 28%)	10% (5%- 22%)
21-day Estimate	32% (17%- 56%)	29% (16%- 49%)	30% (20%- 45%)
28-day Estimate	54% (34%- 76%)	48% (32%- 68%)	50% (37%- 65%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	2% (0%- 13%)	1% (0%- 7%)
14-day Estimate	4% (1%- 14%)	8% (3%- 19%)	6% (3%- 12%)
21-day Estimate	13% (6%- 25%)	17% (9%- 31%)	15% (10%- 23%)
28-day Estimate	20% (12%- 34%)	27% (17%- 41%)	24% (17%- 33%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.03, 1, 0.8539
Log hazard (SE), Relative Risk (95% CI) [b]: -0.074 (0.403), 0.928 (0.421 - 2.047)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.68, 1, 0.4080
Log hazard (SE), Relative Risk (95% CI) [b]: 0.332 (0.403), 1.394 (0.633 - 3.070)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.24.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	47	27	74
Screening			
N	47	27	74
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	47 (100.0%)	27 (100.0%)	74 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	47	27	74
Hour 3 [a]			
N	47	27	74
3	0 (0.0%)	3 (11.1%)	3 (4.1%)
4	47 (100.0%)	24 (88.9%)	71 (95.9%)
Mean (SD)	4.00 (0.000)	3.89 (0.320)	3.96 (0.199)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	47	27	74
Mean (SD)	0.00 (0.000)	-0.11 (0.320)	-0.04 (0.199)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0277			
P-value [c] 0.0498			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.06 - 0.05)		
LS-Mean LJ501 (95%CI) [c]	-0.10 (-0.17 - -0.03)		
LS-Mean Difference (95%CI) [c]	0.09 (0.00 - 0.19)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	47	27	74
Hour 48 [a]			
N	47	27	74
0	13 (27.7%)	11 (40.7%)	24 (32.4%)
1	2 (4.3%)	1 (3.7%)	3 (4.1%)
2	0 (0.0%)	1 (3.7%)	1 (1.4%)
3	11 (23.4%)	8 (29.6%)	19 (25.7%)
4	10 (21.3%)	4 (14.8%)	14 (18.9%)
4 (LOCF)	1 (2.1%)	0 (0.0%)	1 (1.4%)
4 (WC)	10 (21.3%)	2 (7.4%)	12 (16.2%)
Mean (SD)	2.53 (1.718)	1.89 (1.717)	2.30 (1.734)
Median	3.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	47	27	74
Mean (SD)	-1.47 (1.718)	-2.11 (1.717)	-1.70 (1.734)
Median	-1.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.1305			
P-value [c] 0.4276			
LS-Mean Placebo (95%CI) [c]	-1.59 (-2.06 - -1.11)		
LS-Mean LJ501 (95%CI) [c]	-1.91 (-2.54 - -1.28)		
LS-Mean Difference (95%CI) [c]	0.32 (-0.48 - 1.12)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	47	27	74
Screening			
N	47	24	71
Mean (SD)	12.98 (3.339)	11.46 (3.148)	12.46 (3.333)
Median	13.00	11.00	12.00
Range	5 - 21	5 - 16	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	47	27	74
Hour 3			
N	47	27	74
Mean (SD)	13.77 (2.943)	12.30 (3.099)	13.23 (3.063)
Median	13.00	12.00	13.00
Range	8 - 21	5 - 18	5 - 21
Change from Screening			
N	47	24	71
Mean (SD)	0.79 (1.887)	1.00 (2.064)	0.86 (1.937)
Median	1.00	1.00	1.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b]	0.5803		
P-value [c]	0.9737		
LS-Mean Placebo (95%CI) [c]	0.86 (0.35 - 1.37)		
LS-Mean LJ501 (95%CI) [c]	0.85 (0.13 - 1.57)		
LS-Mean Difference (95%CI) [c]	0.01 (-0.88 - 0.91)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	47	27	74
Hour 48			
N	47	27	74
Mean (SD)	14.19 (6.710)	10.89 (6.135)	12.99 (6.659)
Median	13.00	10.00	11.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	47	24	71
Mean (SD)	1.21 (5.568)	-0.08 (5.610)	0.77 (5.576)
Median	0.00	-1.00	0.00
Range	-7 - 15	-10 - 13	-10 - 15
P-value [b] 0.4443			
P-value [c] 0.7787			
LS-Mean Placebo (95%CI) [c]	0.90 (-0.60 - 2.40)		
LS-Mean LJ501 (95%CI) [c]	0.53 (-1.60 - 2.65)		
LS-Mean Difference (95%CI) [c]	0.37 (-2.27 - 3.02)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Total Number of Patients	44	25	69
Total Number of Events	13	9	22
Total Number of Censored for CSH	31	16	47
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 - 7)	5 (1 -)	5 (3 - 7)
Median (95% CI)	(6 -)	(5 -)	(7 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	4% (1%- 25%)	1% (0%- 10%)
2-day Estimate	5% (1%- 17%)	8% (2%- 28%)	6% (2%- 15%)
3-day Estimate	7% (2%- 21%)	24% (12%- 46%)	14% (8%- 25%)
4-day Estimate	16% (8%- 33%)	24% (12%- 46%)	19% (12%- 32%)
5-day Estimate	23% (12%- 41%)	34% (18%- 56%)	27% (18%- 41%)
6-day Estimate	33% (20%- 52%)	38% (22%- 61%)	35% (24%- 49%)
7-day Estimate	40% (25%- 59%)	38% (22%- 61%)	39% (28%- 53%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	4% (1%- 25%)	1% (0%- 10%)
2-day Estimate	5% (1%- 17%)	8% (2%- 28%)	6% (2%- 15%)
3-day Estimate	7% (2%- 20%)	24% (12%- 46%)	13% (7%- 24%)
4-day Estimate	14% (6%- 28%)	24% (12%- 46%)	17% (10%- 29%)
5-day Estimate	18% (10%- 33%)	32% (17%- 54%)	23% (15%- 35%)
6-day Estimate	25% (15%- 41%)	36% (21%- 58%)	29% (20%- 41%)
7-day Estimate	30% (18%- 45%)	36% (21%- 58%)	32% (22%- 44%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.09, 1, 0.7595
Log hazard (SE), Relative Risk (95% CI) [b]: 0.133 (0.434), 1.142 (0.488 - 2.673)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.52, 1, 0.4729
Log hazard (SE), Relative Risk (95% CI) [b]: 0.310 (0.434), 1.364 (0.583 - 3.192)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.24.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Total Number of Patients	47	27	74
Total Number of Events	22	14	36
Total Number of Censored for CSH	25	13	38
Days to ICU Discharge			
25% Quartile (95% CI)	10 (5 - 13)	6 (4 - 11)	8 (5 - 11)
Median (95% CI)	15 (10 - 28)	14 (6 -)	14 (11 - 22)
75% Quartile (95% CI)	(19 -)	(14 -)	(20 -)
Range	1+ - 28+	3 - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	17% (8%- 34%)	33% (18%- 55%)	24% (15%- 37%)
14-day Estimate	47% (32%- 65%)	63% (42%- 85%)	53% (40%- 67%)
21-day Estimate	63% (46%- 80%)	63% (42%- 85%)	63% (49%- 76%)
28-day Estimate	73% (55%- 88%)	71% (48%- 90%)	72% (58%- 85%)
ICU Discharge Cumulative Incidence			
7-day Estimate	13% (6%- 26%)	30% (16%- 51%)	19% (12%- 30%)
14-day Estimate	34% (22%- 49%)	48% (31%- 68%)	39% (29%- 51%)
21-day Estimate	43% (30%- 58%)	48% (31%- 68%)	45% (34%- 57%)
28-day Estimate	47% (34%- 62%)	52% (35%- 71%)	49% (38%- 61%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.28, 1, 0.5979
Log hazard (SE), Relative Risk (95% CI) [b]: 0.181 (0.344), 1.199 (0.611 - 2.354)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.51, 1, 0.4759
Log hazard (SE), Relative Risk (95% CI) [b]: 0.243 (0.342), 1.275 (0.652 - 2.494)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.24.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Albumin >=2.5 g/dL)

	Placebo	LJPC-501	Total
Total Number of Patients	47	27	74
Total Number of Events	13	12	25
Total Number of Censored for CSH	34	15	49
Days to Hospital Discharge			
25% Quartile (95% CI)	22 (14 - 24)	11 (6 - 19)	16 (13 - 22)
Median (95% CI)	(23 -)	21 (11 -)	28 (21 -)
75% Quartile (95% CI)	(-)	(21 -)	(-)
Range	1+ - 28+	3+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	13% (4%- 35%)	5% (2%- 15%)
14-day Estimate	13% (5%- 30%)	33% (17%- 58%)	21% (12%- 34%)
21-day Estimate	24% (12%- 44%)	51% (31%- 75%)	35% (23%- 50%)
28-day Estimate	49% (32%- 70%)	63% (42%- 84%)	55% (41%- 70%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	11% (4%- 31%)	4% (1%- 12%)
14-day Estimate	9% (3%- 21%)	26% (13%- 47%)	15% (9%- 25%)
21-day Estimate	15% (7%- 29%)	37% (22%- 58%)	23% (15%- 34%)
28-day Estimate	28% (17%- 43%)	44% (28%- 65%)	34% (24%- 46%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 2.39, 1, 0.1218
Log hazard (SE), Relative Risk (95% CI) [b]: 0.612 (0.401), 1.844 (0.839 - 4.049)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.91, 1, 0.0882
Log hazard (SE), Relative Risk (95% CI) [b]: 0.670 (0.401), 1.955 (0.892 - 4.287)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.24.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	67	82	149
Screening			
N	67	82	149
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	67 (100.0%)	82 (100.0%)	149 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	67	82	149
Hour 3 [a]			
N	67	82	149
3	1 (1.5%)	3 (3.7%)	4 (2.7%)
4	65 (97.0%)	79 (96.3%)	144 (96.6%)
4 (LOCF)	1 (1.5%)	0 (0.0%)	1 (0.7%)
Mean (SD)	3.99 (0.122)	3.96 (0.189)	3.97 (0.162)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	67	82	149
Mean (SD)	-0.01 (0.122)	-0.04 (0.189)	-0.03 (0.162)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.3100			
P-value [c] 0.4497			
LS-Mean Placebo (95%CI) [c]	-0.02 (-0.06 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.04 (-0.07 - -0.00)		
LS-Mean Difference (95%CI) [c]	0.02 (-0.03 - 0.08)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	67	82	149
Hour 48 [a]			
N	67	82	149
0	8 (11.9%)	25 (30.5%)	33 (22.1%)
1	4 (6.0%)	6 (7.3%)	10 (6.7%)
2	0 (0.0%)	1 (1.2%)	1 (0.7%)
3	11 (16.4%)	12 (14.6%)	23 (15.4%)
4	26 (38.8%)	23 (28.0%)	49 (32.9%)
4 (LOCF)	1 (1.5%)	0 (0.0%)	1 (0.7%)
4 (WC)	17 (25.4%)	15 (18.3%)	32 (21.5%)
Mean (SD)	3.18 (1.403)	2.39 (1.783)	2.74 (1.665)
Median	4.00	3.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	67	82	149
Mean (SD)	-0.82 (1.403)	-1.61 (1.783)	-1.26 (1.665)
Median	0.00	-1.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0133			
P-value [c] 0.0236			
LS-Mean Placebo (95%CI) [c]	-0.92 (-1.31 - -0.54)		
LS-Mean LJ501 (95%CI) [c]	-1.53 (-1.87 - -1.18)		
LS-Mean Difference (95%CI) [c]	0.61 (0.08 - 1.13)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	67	82	149
Screening			
N	67	81	148
Mean (SD)	13.60 (3.172)	11.80 (2.727)	12.61 (3.061)
Median	14.00	12.00	13.00
Range	8 - 20	6 - 18	6 - 20

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	67	82	149
Hour 3			
N	67	82	149
Mean (SD)	13.82 (3.512)	12.71 (3.168)	13.21 (3.362)
Median	14.00	13.00	13.00
Range	7 - 20	5 - 20	5 - 20
Change from Screening			
N	67	81	148
Mean (SD)	0.22 (1.937)	0.93 (1.730)	0.61 (1.854)
Median	0.00	1.00	0.00
Range	-3 - 6	-2 - 5	-3 - 6
P-value [b] 0.0331			
P-value [c] 0.0485			
LS-Mean Placebo (95%CI) [c]	0.26 (-0.19 - 0.72)		
LS-Mean LJ501 (95%CI) [c]	0.89 (0.48 - 1.30)		
LS-Mean Difference (95%CI) [c]	-0.63 (-1.25 - -0.00)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Number of Patients	67	82	149
Hour 48			
N	67	82	149
Mean (SD)	15.87 (6.541)	13.34 (6.362)	14.48 (6.544)
Median	15.00	12.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	67	81	148
Mean (SD)	2.27 (5.398)	1.63 (5.889)	1.92 (5.662)
Median	1.00	1.00	1.00
Range	-8 - 16	-8 - 15	-8 - 16
P-value [b]	0.8999		
P-value [c]	0.8864		
LS-Mean Placebo (95%CI) [c]	1.99 (0.64 - 3.34)		
LS-Mean LJ501 (95%CI) [c]	1.86 (0.64 - 3.08)		
LS-Mean Difference (95%CI) [c]	0.14 (-1.73 - 2.00)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.24.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Total Number of Patients	63	73	136
Total Number of Events	11	19	30
Total Number of Censored for CSH	52	54	106
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (5 -)	6 (5 -)	6 (5 -)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1+ - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 11%)	0% (0%- 0%)	1% (0%- 5%)
2-day Estimate	5% (2%- 14%)	6% (2%- 15%)	5% (3%- 11%)
3-day Estimate	7% (3%- 18%)	7% (3%- 17%)	7% (4%- 13%)
4-day Estimate	9% (4%- 22%)	12% (6%- 23%)	11% (7%- 19%)
5-day Estimate	12% (5%- 25%)	22% (13%- 35%)	18% (12%- 26%)
6-day Estimate	21% (11%- 37%)	30% (19%- 43%)	26% (18%- 36%)
7-day Estimate	26% (15%- 43%)	34% (23%- 48%)	31% (22%- 41%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 11%)	0% (0%- 0%)	1% (0%- 5%)
2-day Estimate	5% (2%- 14%)	5% (2%- 14%)	5% (2%- 10%)
3-day Estimate	6% (2%- 16%)	7% (3%- 16%)	7% (3%- 12%)
4-day Estimate	8% (3%- 18%)	11% (6%- 21%)	10% (6%- 16%)
5-day Estimate	10% (4%- 20%)	18% (11%- 29%)	14% (9%- 21%)
6-day Estimate	14% (8%- 26%)	23% (15%- 35%)	19% (13%- 27%)
7-day Estimate	17% (10%- 29%)	26% (17%- 38%)	22% (16%- 30%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.62, 1, 0.4322
Log hazard (SE), Relative Risk (95% CI) [b]: 0.297 (0.379), 1.345 (0.640 - 2.828)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.38, 1, 0.2403
Log hazard (SE), Relative Risk (95% CI) [b]: 0.441 (0.379), 1.555 (0.740 - 3.268)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.24.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Total Number of Patients	67	82	149
Total Number of Events	20	32	52
Total Number of Censored for CSH	47	50	97
Days to ICU Discharge			
25% Quartile (95% CI)	12 (6 - 17)	9 (7 - 11)	9 (7 - 12)
Median (95% CI)	18 (12 - 25)	15 (10 - 23)	17 (14 - 22)
75% Quartile (95% CI)	28 (18 -)	(20 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	21% (11%- 36%)	16% (8%- 28%)	18% (12%- 27%)
14-day Estimate	33% (19%- 52%)	45% (32%- 60%)	40% (30%- 52%)
21-day Estimate	65% (45%- 84%)	61% (46%- 75%)	62% (50%- 73%)
28-day Estimate	83% (60%- 97%)	70% (55%- 83%)	73% (60%- 84%)
ICU Discharge Cumulative Incidence			
7-day Estimate	13% (7%- 24%)	11% (6%- 20%)	12% (8%- 18%)
14-day Estimate	18% (11%- 29%)	28% (20%- 39%)	23% (17%- 31%)
21-day Estimate	27% (18%- 39%)	35% (26%- 47%)	32% (25%- 40%)
28-day Estimate	30% (20%- 42%)	39% (29%- 50%)	35% (28%- 43%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9983
Log hazard (SE), Relative Risk (95% CI) [b]: 0.001 (0.286), 1.001 (0.571 - 1.753)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.32, 1, 0.2504
Log hazard (SE), Relative Risk (95% CI) [b]: 0.326 (0.285), 1.386 (0.792 - 2.424)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.24.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Albumin <2.5 g/dL)

	Placebo	LJPC-501	Total
Total Number of Patients	67	82	149
Total Number of Events	13	20	33
Total Number of Censored for CSH	54	62	116
Days to Hospital Discharge			
25% Quartile (95% CI)	15 (12 - 24)	19 (16 - 23)	18 (16 - 22)
Median (95% CI)	25 (17 -)	(22 -)	(22 -)
75% Quartile (95% CI)	(28 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	5% (1%- 19%)	0% (0%- 0%)	2% (1%- 8%)
14-day Estimate	17% (7%- 37%)	6% (2%- 17%)	10% (5%- 19%)
21-day Estimate	40% (23%- 63%)	32% (20%- 47%)	35% (25%- 47%)
28-day Estimate	58% (38%- 79%)	46% (33%- 62%)	50% (38%- 63%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 11%)	0% (0%- 0%)	1% (0%- 5%)
14-day Estimate	7% (3%- 17%)	4% (1%- 11%)	5% (3%- 10%)
21-day Estimate	15% (8%- 26%)	17% (10%- 27%)	16% (11%- 23%)
28-day Estimate	19% (12%- 31%)	24% (16%- 35%)	22% (16%- 30%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.05, 1, 0.3063
Log hazard (SE), Relative Risk (95% CI) [b]: -0.364 (0.357), 0.695 (0.345 - 1.401)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.42, 1, 0.5162
Log hazard (SE), Relative Risk (95% CI) [b]: 0.231 (0.356), 1.260 (0.627 - 2.533)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.25.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Number of Patients	17	17	34
Screening			
N	17	17	34
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	17 (100.0%)	17 (100.0%)	34 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Number of Patients	17	17	34
Hour 3 [a]			
N	17	17	34
4	16 (94.1%)	17 (100.0%)	33 (97.1%)
4 (LOCF)	1 (5.9%)	0 (0.0%)	1 (2.9%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4
Change from Screening			
N	17	17	34
Mean (SD)	0.00 (0.000)	0.00 (0.000)	0.00 (0.000)
Median	0.00	0.00	0.00
Range	0 - 0	0 - 0	0 - 0
P-value [b] N/A			
P-value [c] N/A			
LS-Mean Placebo (95%CI) [c]	N/A		
LS-Mean LJ501 (95%CI) [c]	N/A		
LS-Mean Difference (95%CI) [c]	N/A		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Number of Patients	17	17	34
Hour 48 [a]			
N	17	17	34
0	4 (23.5%)	4 (23.5%)	8 (23.5%)
1	1 (5.9%)	1 (5.9%)	2 (5.9%)
3	3 (17.6%)	5 (29.4%)	8 (23.5%)
4	4 (23.5%)	4 (23.5%)	8 (23.5%)
4 (LOCF)	1 (5.9%)	0 (0.0%)	1 (2.9%)
4 (WC)	4 (23.5%)	3 (17.6%)	7 (20.6%)
Mean (SD)	2.71 (1.724)	2.59 (1.661)	2.65 (1.668)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	17	17	34
Mean (SD)	-1.29 (1.724)	-1.41 (1.661)	-1.35 (1.668)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.6122			
P-value [c] 0.9395			
LS-Mean Placebo (95%CI) [c]	-1.37 (-2.08 - -0.67)		
LS-Mean LJ501 (95%CI) [c]	-1.33 (-2.04 - -0.63)		
LS-Mean Difference (95%CI) [c]	-0.04 (-1.04 - 0.96)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Number of Patients	17	17	34
Screening			
N	17	16	33
Mean (SD)	12.47 (4.110)	11.50 (2.921)	12.00 (3.562)
Median	12.00	11.00	11.00
Range	5 - 19	7 - 17	5 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Number of Patients	17	17	34
Hour 3			
N	17	17	34
Mean (SD)	13.65 (3.499)	12.29 (3.687)	12.97 (3.605)
Median	13.00	12.00	12.00
Range	8 - 18	5 - 19	5 - 19
Change from Screening			
N	17	16	33
Mean (SD)	1.18 (2.580)	0.81 (2.167)	1.00 (2.358)
Median	1.00	0.00	0.00
Range	-3 - 7	-2 - 5	-3 - 7
P-value [b] 0.6141			
P-value [c] 0.4155			
LS-Mean Placebo (95%CI) [c]	1.33 (0.16 - 2.50)		
LS-Mean LJ501 (95%CI) [c]	0.65 (-0.56 - 1.85)		
LS-Mean Difference (95%CI) [c]	0.69 (-1.01 - 2.39)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Number of Patients	17	17	34
Hour 48			
N	17	17	34
Mean (SD)	14.29 (7.363)	12.82 (6.858)	13.56 (7.046)
Median	14.00	10.00	13.00
Range	2 - 24	4 - 24	2 - 24
Change from Screening			
N	17	16	33
Mean (SD)	1.82 (5.950)	1.75 (5.483)	1.79 (5.639)
Median	1.00	1.00	1.00
Range	-8 - 16	-6 - 13	-8 - 16
P-value [b] 0.7940			
P-value [c] 0.5983			
LS-Mean Placebo (95%CI) [c]	1.39 (-0.78 - 3.56)		
LS-Mean LJ501 (95%CI) [c]	2.21 (-0.03 - 4.45)		
LS-Mean Difference (95%CI) [c]	-0.82 (-3.98 - 2.34)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Total Number of Patients	16	17	33
Total Number of Events	5	6	11
Total Number of Censored for CSH	11	11	22
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (1 -)	6 (2 -)	6 (3 -)
Median (95% CI)	(5 -)	(6 -)	(6 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	2 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	6% (1%- 37%)	0% (0%- 0%)	3% (0%- 20%)
2-day Estimate	6% (1%- 37%)	6% (1%- 35%)	6% (2%- 22%)
3-day Estimate	14% (4%- 46%)	12% (3%- 41%)	13% (5%- 31%)
4-day Estimate	14% (4%- 46%)	12% (3%- 41%)	13% (5%- 31%)
5-day Estimate	23% (8%- 56%)	19% (7%- 49%)	21% (10%- 41%)
6-day Estimate	40% (19%- 71%)	41% (21%- 70%)	41% (25%- 62%)
7-day Estimate	40% (19%- 71%)	41% (21%- 70%)	41% (25%- 62%)
Ventilator Cumulative Incidence			
1-day Estimate	6% (1%- 37%)	0% (0%- 0%)	3% (0%- 20%)
2-day Estimate	6% (1%- 37%)	6% (1%- 35%)	6% (2%- 22%)
3-day Estimate	13% (3%- 41%)	12% (3%- 39%)	12% (5%- 29%)
4-day Estimate	13% (3%- 41%)	12% (3%- 39%)	12% (5%- 29%)
5-day Estimate	19% (6%- 48%)	18% (6%- 45%)	18% (9%- 36%)
6-day Estimate	31% (14%- 60%)	35% (18%- 62%)	33% (20%- 52%)
7-day Estimate	31% (14%- 60%)	35% (18%- 62%)	33% (20%- 52%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9925
Log hazard (SE), Relative Risk (95% CI) [b]: -0.006 (0.606), 0.994 (0.303 - 3.259)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.03, 1, 0.8591
Log hazard (SE), Relative Risk (95% CI) [b]: 0.107 (0.606), 1.113 (0.340 - 3.647)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.25.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Total Number of Patients	17	17	34
Total Number of Events	7	8	15
Total Number of Censored for CSH	10	9	19
Days to ICU Discharge			
25% Quartile (95% CI)	5 (3 - 28)	8 (4 - 14)	7 (4 - 12)
Median (95% CI)	28 (4 -)	14 (7 -)	15 (8 -)
75% Quartile (95% CI)	(15 -)	(12 -)	(20 -)
Range	1+ - 28+	2+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	30% (13%- 62%)	23% (8%- 55%)	26% (13%- 47%)
14-day Estimate	38% (18%- 69%)	56% (31%- 83%)	47% (30%- 68%)
21-day Estimate	48% (25%- 78%)	65% (39%- 89%)	58% (38%- 78%)
28-day Estimate	66% (35%- 93%)	65% (39%- 89%)	64% (44%- 83%)
ICU Discharge Cumulative Incidence			
7-day Estimate	24% (10%- 51%)	18% (6%- 45%)	21% (10%- 38%)
14-day Estimate	29% (13%- 57%)	41% (22%- 67%)	35% (22%- 54%)
21-day Estimate	35% (18%- 62%)	47% (27%- 72%)	41% (27%- 59%)
28-day Estimate	41% (22%- 67%)	47% (27%- 72%)	44% (29%- 62%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9800
Log hazard (SE), Relative Risk (95% CI) [b]: -0.013 (0.519), 0.987 (0.357 - 2.732)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.04, 1, 0.8348
Log hazard (SE), Relative Risk (95% CI) [b]: 0.108 (0.518), 1.114 (0.403 - 3.077)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.25.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Rest of World)

	Placebo	LJPC-501	Total
Total Number of Patients	17	17	34
Total Number of Events	3	6	9
Total Number of Censored for CSH	14	11	25
Days to Hospital Discharge			
25% Quartile (95% CI)	(6 -)	19 (8 - 24)	17 (8 -)
Median (95% CI)	(14 -)	(16 -)	(19 -)
75% Quartile (95% CI)	(-)	(24 -)	(-)
Range	1+ - 28+	2+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	8% (1%- 43%)	0% (0%- 0%)	4% (1%- 24%)
14-day Estimate	25% (9%- 59%)	8% (1%- 43%)	16% (6%- 37%)
21-day Estimate	25% (9%- 59%)	41% (20%- 73%)	36% (20%- 60%)
28-day Estimate	25% (9%- 59%)	50% (26%- 79%)	42% (24%- 66%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	6% (1%- 35%)	0% (0%- 0%)	3% (0%- 19%)
14-day Estimate	18% (6%- 45%)	6% (1%- 35%)	12% (5%- 28%)
21-day Estimate	18% (6%- 45%)	29% (13%- 57%)	24% (13%- 42%)
28-day Estimate	18% (6%- 45%)	35% (18%- 62%)	26% (15%- 45%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.31, 1, 0.5778
Log hazard (SE), Relative Risk (95% CI) [b]: 0.394 (0.712), 1.482 (0.367 - 5.979)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.97, 1, 0.3250
Log hazard (SE), Relative Risk (95% CI) [b]: 0.683 (0.708), 1.980 (0.495 - 7.924)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.25.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Number of Patients	98	97	195
Screening			
N	98	97	195
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	98 (100.0%)	97 (100.0%)	195 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Number of Patients	98	97	195
Hour 3 [a]			
N	98	97	195
3	1 (1.0%)	6 (6.2%)	7 (3.6%)
4	97 (99.0%)	91 (93.8%)	188 (96.4%)
Mean (SD)	3.99 (0.101)	3.94 (0.242)	3.96 (0.187)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	98	97	195
Mean (SD)	-0.01 (0.101)	-0.06 (0.242)	-0.04 (0.187)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.0627			
P-value [c] 0.0999			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.05 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.06 (-0.10 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.04 (-0.01 - 0.10)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Number of Patients	98	97	195
Hour 48 [a]			
N	98	97	195
0	17 (17.3%)	33 (34.0%)	50 (25.6%)
1	5 (5.1%)	6 (6.2%)	11 (5.6%)
2	0 (0.0%)	2 (2.1%)	2 (1.0%)
3	19 (19.4%)	15 (15.5%)	34 (17.4%)
4	32 (32.7%)	26 (26.8%)	58 (29.7%)
4 (LOCF)	1 (1.0%)	0 (0.0%)	1 (0.5%)
4 (WC)	24 (24.5%)	15 (15.5%)	39 (20.0%)
Mean (SD)	2.96 (1.539)	2.26 (1.799)	2.61 (1.706)
Median	4.00	3.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	98	97	195
Mean (SD)	-1.04 (1.539)	-1.74 (1.799)	-1.39 (1.706)
Median	0.00	-1.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0245			
P-value [c] 0.0383			
LS-Mean Placebo (95%CI) [c]	-1.15 (-1.47 - -0.82)		
LS-Mean LJ501 (95%CI) [c]	-1.64 (-1.96 - -1.31)		
LS-Mean Difference (95%CI) [c]	0.49 (0.03 - 0.95)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Number of Patients	98	97	195
Screening			
N	98	94	192
Mean (SD)	13.48 (3.054)	11.87 (2.814)	12.69 (3.040)
Median	14.00	12.00	13.00
Range	8 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:02

Table 14.2.25.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Number of Patients	98	97	195
Hour 3			
N	98	97	195
Mean (SD)	13.83 (3.236)	12.77 (3.029)	13.30 (3.171)
Median	14.00	13.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	98	94	192
Mean (SD)	0.35 (1.777)	0.97 (1.719)	0.65 (1.772)
Median	0.00	1.00	0.50
Range	-3 - 6	-2 - 7	-3 - 7
P-value [b] 0.0153			
P-value [c] 0.0648			
LS-Mean Placebo (95%CI) [c]	0.41 (0.06 - 0.77)		
LS-Mean LJ501 (95%CI) [c]	0.90 (0.54 - 1.26)		
LS-Mean Difference (95%CI) [c]	-0.48 (-1.00 - 0.03)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Number of Patients	98	97	195
Hour 48			
N	98	97	195
Mean (SD)	15.42 (6.552)	13.01 (6.324)	14.22 (6.535)
Median	15.00	11.00	14.00
Range	3 - 24	3 - 24	3 - 24
Change from Screening			
N	98	94	192
Mean (SD)	1.94 (5.483)	1.33 (5.863)	1.64 (5.665)
Median	1.00	0.50	1.00
Range	-7 - 15	-10 - 15	-10 - 15
P-value [b] 0.8835			
P-value [c] 0.8074			
LS-Mean Placebo (95%CI) [c]	1.74 (0.63 - 2.85)		
LS-Mean LJ501 (95%CI) [c]	1.54 (0.41 - 2.67)		
LS-Mean Difference (95%CI) [c]	0.20 (-1.42 - 1.82)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.25.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Total Number of Patients	92	86	178
Total Number of Events	19	22	41
Total Number of Censored for CSH	73	64	137
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (5 -)	6 (4 -)	6 (5 -)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	1% (0%- 8%)	1% (0%- 4%)
2-day Estimate	4% (2%- 12%)	6% (3%- 14%)	5% (3%- 10%)
3-day Estimate	6% (2%- 14%)	11% (6%- 21%)	9% (5%- 14%)
4-day Estimate	12% (7%- 23%)	16% (9%- 26%)	14% (9%- 21%)
5-day Estimate	16% (9%- 27%)	25% (16%- 36%)	20% (15%- 28%)
6-day Estimate	23% (15%- 36%)	28% (19%- 40%)	26% (19%- 34%)
7-day Estimate	31% (21%- 45%)	31% (22%- 44%)	31% (24%- 40%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	1% (0%- 8%)	1% (0%- 4%)
2-day Estimate	4% (2%- 11%)	6% (2%- 13%)	5% (3%- 9%)
3-day Estimate	5% (2%- 13%)	10% (6%- 19%)	8% (5%- 13%)
4-day Estimate	10% (5%- 18%)	14% (8%- 23%)	12% (8%- 18%)
5-day Estimate	12% (7%- 21%)	21% (14%- 31%)	16% (12%- 23%)
6-day Estimate	16% (10%- 26%)	23% (16%- 34%)	20% (15%- 26%)
7-day Estimate	21% (14%- 30%)	26% (18%- 36%)	23% (18%- 30%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.15, 1, 0.7006
Log hazard (SE), Relative Risk (95% CI) [b]: 0.120 (0.313), 1.128 (0.610 - 2.084)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.72, 1, 0.3957
Log hazard (SE), Relative Risk (95% CI) [b]: 0.265 (0.313), 1.304 (0.706 - 2.409)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.25.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Total Number of Patients	98	97	195
Total Number of Events	35	39	74
Total Number of Censored for CSH	63	58	121
Days to ICU Discharge			
25% Quartile (95% CI)	11 (7 - 13)	9 (6 - 11)	10 (7 - 11)
Median (95% CI)	17 (13 - 20)	15 (11 - 23)	16 (14 - 19)
75% Quartile (95% CI)	28 (19 -)	(23 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	17% (10%- 29%)	19% (12%- 30%)	18% (13%- 26%)
14-day Estimate	42% (30%- 57%)	45% (34%- 59%)	44% (35%- 54%)
21-day Estimate	67% (53%- 81%)	59% (46%- 72%)	63% (53%- 72%)
28-day Estimate	79% (64%- 91%)	69% (56%- 82%)	73% (63%- 82%)
ICU Discharge Cumulative Incidence			
7-day Estimate	11% (6%- 19%)	14% (9%- 23%)	13% (9%- 18%)
14-day Estimate	23% (16%- 33%)	30% (22%- 40%)	27% (21%- 33%)
21-day Estimate	33% (24%- 43%)	36% (27%- 46%)	34% (28%- 41%)
28-day Estimate	36% (27%- 46%)	40% (31%- 51%)	38% (32%- 45%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9567
Log hazard (SE), Relative Risk (95% CI) [b]: -0.013 (0.234), 0.987 (0.625 - 1.561)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.64, 1, 0.4235
Log hazard (SE), Relative Risk (95% CI) [b]: 0.186 (0.233), 1.205 (0.763 - 1.902)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.25.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, USA/Canada)

	Placebo	LJPC-501	Total
Total Number of Patients	98	97	195
Total Number of Events	23	27	50
Total Number of Censored for CSH	75	70	145
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (14 - 23)	18 (14 - 22)	18 (15 - 22)
Median (95% CI)	25 (22 -)	28 (22 -)	28 (23 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	2% (0%- 11%)	4% (1%- 13%)	3% (1%- 8%)
14-day Estimate	13% (6%- 26%)	14% (8%- 26%)	13% (8%- 21%)
21-day Estimate	32% (21%- 49%)	34% (23%- 48%)	33% (25%- 44%)
28-day Estimate	58% (43%- 74%)	51% (38%- 65%)	54% (44%- 64%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	1% (0%- 7%)	3% (1%- 9%)	2% (1%- 5%)
14-day Estimate	6% (3%- 13%)	9% (5%- 17%)	8% (5%- 12%)
21-day Estimate	14% (9%- 23%)	20% (13%- 29%)	17% (12%- 23%)
28-day Estimate	23% (16%- 33%)	28% (20%- 38%)	26% (20%- 32%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.08, 1, 0.7740
Log hazard (SE), Relative Risk (95% CI) [b]: -0.082 (0.284), 0.921 (0.528 - 1.608)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.59, 1, 0.4423
Log hazard (SE), Relative Risk (95% CI) [b]: 0.217 (0.284), 1.243 (0.713 - 2.167)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.26.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	70	74	144
Screening			
N	70	74	144
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	70 (100.0%)	74 (100.0%)	144 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	70	74	144
Hour 3 [a]			
N	70	74	144
3	0 (0.0%)	4 (5.4%)	4 (2.8%)
4	70 (100.0%)	70 (94.6%)	140 (97.2%)
Mean (SD)	4.00 (0.000)	3.95 (0.228)	3.97 (0.165)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	70	74	144
Mean (SD)	0.00 (0.000)	-0.05 (0.228)	-0.03 (0.165)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0546			
P-value [c] 0.0807			
LS-Mean Placebo (95%CI) [c]	-0.00 (-0.04 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.05 (-0.09 - -0.01)		
LS-Mean Difference (95%CI) [c]	0.05 (-0.01 - 0.10)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	70	74	144
Hour 48 [a]			
N	70	74	144
0	17 (24.3%)	29 (39.2%)	46 (31.9%)
1	4 (5.7%)	5 (6.8%)	9 (6.3%)
2	0 (0.0%)	2 (2.7%)	2 (1.4%)
3	17 (24.3%)	14 (18.9%)	31 (21.5%)
4	19 (27.1%)	17 (23.0%)	36 (25.0%)
4 (WC)	13 (18.6%)	7 (9.5%)	20 (13.9%)
Mean (SD)	2.61 (1.662)	1.99 (1.779)	2.29 (1.746)
Median	3.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	70	74	144
Mean (SD)	-1.39 (1.662)	-2.01 (1.779)	-1.71 (1.746)
Median	-1.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0512			
P-value [c] 0.0696			
LS-Mean Placebo (95%CI) [c]	-1.44 (-1.84 - -1.04)		
LS-Mean LJ501 (95%CI) [c]	-1.96 (-2.35 - -1.57)		
LS-Mean Difference (95%CI) [c]	0.52 (-0.04 - 1.08)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	70	74	144
Screening			
N	70	70	140
Mean (SD)	13.47 (3.225)	12.00 (2.909)	12.74 (3.148)
Median	13.00	12.00	13.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	70	74	144
Hour 3			
N	70	74	144
Mean (SD)	13.86 (3.241)	12.69 (3.029)	13.26 (3.177)
Median	14.00	13.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	70	70	140
Mean (SD)	0.39 (1.980)	0.79 (1.702)	0.59 (1.850)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.2119			
P-value [c] 0.5442			
LS-Mean Placebo (95%CI) [c]	0.49 (0.06 - 0.92)		
LS-Mean LJ501 (95%CI) [c]	0.68 (0.25 - 1.11)		
LS-Mean Difference (95%CI) [c]	-0.19 (-0.81 - 0.43)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	70	74	144
Hour 48			
N	70	74	144
Mean (SD)	14.47 (6.502)	11.73 (5.994)	13.06 (6.374)
Median	14.00	10.00	13.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	70	70	140
Mean (SD)	1.00 (5.158)	0.01 (5.317)	0.51 (5.243)
Median	0.50	-1.00	0.00
Range	-8 - 13	-10 - 13	-10 - 13
P-value [b]	0.3147		
P-value [c]	0.4093		
LS-Mean Placebo (95%CI) [c]	0.88 (-0.37 - 2.13)		
LS-Mean LJ501 (95%CI) [c]	0.13 (-1.11 - 1.38)		
LS-Mean Difference (95%CI) [c]	0.75 (-1.04 - 2.54)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Total Number of Patients	66	68	134
Total Number of Events	16	22	38
Total Number of Censored for CSH	50	46	96
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (5 -)	5 (3 - 7)	6 (5 - 7)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 10%)	1% (0%- 10%)	1% (0%- 6%)
2-day Estimate	5% (2%- 14%)	9% (4%- 19%)	7% (4%- 13%)
3-day Estimate	6% (2%- 16%)	15% (8%- 26%)	11% (7%- 18%)
4-day Estimate	12% (6%- 24%)	15% (8%- 26%)	14% (9%- 21%)
5-day Estimate	16% (9%- 29%)	25% (16%- 38%)	21% (15%- 30%)
6-day Estimate	23% (14%- 37%)	34% (24%- 48%)	29% (21%- 38%)
7-day Estimate	32% (21%- 47%)	36% (25%- 50%)	34% (26%- 44%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 10%)	1% (0%- 10%)	1% (0%- 6%)
2-day Estimate	5% (1%- 13%)	9% (4%- 19%)	7% (4%- 13%)
3-day Estimate	6% (2%- 15%)	15% (8%- 26%)	10% (6%- 17%)
4-day Estimate	11% (5%- 21%)	15% (8%- 26%)	13% (8%- 20%)
5-day Estimate	14% (7%- 25%)	24% (15%- 36%)	19% (13%- 26%)
6-day Estimate	18% (11%- 30%)	31% (21%- 43%)	25% (18%- 33%)
7-day Estimate	24% (16%- 36%)	32% (23%- 45%)	28% (22%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.52, 1, 0.4718
Log hazard (SE), Relative Risk (95% CI) [b]: 0.236 (0.329), 1.266 (0.665 - 2.411)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.21, 1, 0.2707
Log hazard (SE), Relative Risk (95% CI) [b]: 0.360 (0.329), 1.433 (0.753 - 2.730)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.26.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Total Number of Patients	70	74	144
Total Number of Events	33	33	66
Total Number of Censored for CSH	37	41	78
Days to ICU Discharge			
25% Quartile (95% CI)	10 (6 - 12)	8 (6 - 10)	8 (7 - 10)
Median (95% CI)	15 (12 - 19)	16 (10 - 28)	15 (12 - 19)
75% Quartile (95% CI)	25 (18 -)	(22 -)	(20 -)
Range	1+ - 28+	2+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	21% (12%- 34%)	21% (13%- 34%)	21% (14%- 30%)
14-day Estimate	49% (36%- 65%)	42% (30%- 56%)	45% (36%- 56%)
21-day Estimate	72% (57%- 85%)	61% (47%- 75%)	66% (56%- 76%)
28-day Estimate	80% (65%- 92%)	66% (52%- 80%)	72% (62%- 82%)
ICU Discharge Cumulative Incidence			
7-day Estimate	16% (9%- 27%)	18% (11%- 28%)	17% (11%- 24%)
14-day Estimate	33% (23%- 45%)	32% (23%- 44%)	33% (26%- 41%)
21-day Estimate	44% (34%- 57%)	42% (32%- 54%)	43% (35%- 52%)
28-day Estimate	47% (36%- 59%)	45% (34%- 57%)	46% (38%- 54%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.45, 1, 0.5031
Log hazard (SE), Relative Risk (95% CI) [b]: -0.165 (0.247), 0.848 (0.522 - 1.376)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9054
Log hazard (SE), Relative Risk (95% CI) [b]: -0.029 (0.246), 0.971 (0.599 - 1.574)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.26.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline MAP >=65 mmHg)

	Placebo	LJPC-501	Total
Total Number of Patients	70	74	144
Total Number of Events	22	24	46
Total Number of Censored for CSH	48	50	98
Days to Hospital Discharge			
25% Quartile (95% CI)	16 (13 - 23)	17 (11 - 21)	17 (13 - 19)
Median (95% CI)	24 (18 -)	28 (20 -)	25 (21 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	2+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	4% (1%- 15%)	5% (2%- 15%)	5% (2%- 11%)
14-day Estimate	21% (12%- 37%)	16% (9%- 29%)	18% (12%- 28%)
21-day Estimate	38% (24%- 55%)	41% (29%- 57%)	40% (30%- 51%)
28-day Estimate	59% (43%- 75%)	51% (37%- 66%)	54% (44%- 65%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 11%)	4% (1%- 12%)	3% (1%- 8%)
14-day Estimate	13% (7%- 23%)	12% (7%- 22%)	12% (8%- 19%)
21-day Estimate	21% (14%- 33%)	27% (18%- 39%)	24% (18%- 32%)
28-day Estimate	31% (22%- 44%)	32% (23%- 44%)	32% (25%- 40%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.19, 1, 0.6650
Log hazard (SE), Relative Risk (95% CI) [b]: -0.128 (0.295), 0.880 (0.493 - 1.570)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.04, 1, 0.8409
Log hazard (SE), Relative Risk (95% CI) [b]: 0.059 (0.295), 1.061 (0.595 - 1.892)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.26.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	45	40	85
Screening			
N	45	40	85
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	45 (100.0%)	40 (100.0%)	85 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	45	40	85
Hour 3 [a]			
N	45	40	85
3	1 (2.2%)	2 (5.0%)	3 (3.5%)
4	43 (95.6%)	38 (95.0%)	81 (95.3%)
4 (LOCF)	1 (2.2%)	0 (0.0%)	1 (1.2%)
Mean (SD)	3.98 (0.149)	3.95 (0.221)	3.96 (0.186)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	45	40	85
Mean (SD)	-0.02 (0.149)	-0.05 (0.221)	-0.04 (0.186)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.4832			
P-value [c] 0.5969			
LS-Mean Placebo (95%CI) [c]	-0.02 (-0.08 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.05 (-0.11 - 0.01)		
LS-Mean Difference (95%CI) [c]	0.02 (-0.06 - 0.11)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	45	40	85
Hour 48 [a]			
N	45	40	85
0	4 (8.9%)	8 (20.0%)	12 (14.1%)
1	2 (4.4%)	2 (5.0%)	4 (4.7%)
3	5 (11.1%)	6 (15.0%)	11 (12.9%)
4	17 (37.8%)	13 (32.5%)	30 (35.3%)
4 (LOCF)	2 (4.4%)	0 (0.0%)	2 (2.4%)
4 (WC)	15 (33.3%)	11 (27.5%)	26 (30.6%)
Mean (SD)	3.40 (1.268)	2.90 (1.630)	3.16 (1.463)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	45	40	85
Mean (SD)	-0.60 (1.268)	-1.10 (1.630)	-0.84 (1.463)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b]	0.2011		
P-value [c]	0.4349		
LS-Mean Placebo (95%CI) [c]	-0.72 (-1.15 - -0.29)		
LS-Mean LJ501 (95%CI) [c]	-0.97 (-1.43 - -0.51)		
LS-Mean Difference (95%CI) [c]	0.25 (-0.39 - 0.90)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	45	40	85
Screening			
N	45	40	85
Mean (SD)	13.11 (3.263)	11.50 (2.660)	12.35 (3.085)
Median	14.00	11.00	12.00
Range	6 - 19	6 - 16	6 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	45	40	85
Hour 3			
N	45	40	85
Mean (SD)	13.71 (3.328)	12.73 (3.328)	13.25 (3.345)
Median	14.00	12.00	13.00
Range	7 - 20	6 - 19	6 - 20
Change from Screening			
N	45	40	85
Mean (SD)	0.60 (1.851)	1.23 (1.901)	0.89 (1.890)
Median	0.00	1.00	1.00
Range	-2 - 6	-2 - 5	-2 - 6
P-value [b]	0.1269		
P-value [c]	0.2123		
LS-Mean Placebo (95%CI) [c]	0.64 (0.06 - 1.21)		
LS-Mean LJ501 (95%CI) [c]	1.18 (0.57 - 1.80)		
LS-Mean Difference (95%CI) [c]	-0.55 (-1.42 - 0.32)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Number of Patients	45	40	85
Hour 48			
N	45	40	85
Mean (SD)	16.47 (6.781)	15.30 (6.482)	15.92 (6.628)
Median	16.00	14.00	15.00
Range	4 - 24	4 - 24	4 - 24
Change from Screening			
N	45	40	85
Mean (SD)	3.36 (5.828)	3.80 (5.849)	3.56 (5.807)
Median	1.00	3.00	2.00
Range	-7 - 16	-7 - 15	-7 - 16
P-value [b] 0.3048			
P-value [c] 0.2961			
LS-Mean Placebo (95%CI) [c]	2.92 (1.21 - 4.64)		
LS-Mean LJ501 (95%CI) [c]	4.28 (2.46 - 6.11)		
LS-Mean Difference (95%CI) [c]	-1.36 (-3.93 - 1.21)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.26.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Total Number of Patients	42	35	77
Total Number of Events	8	6	14
Total Number of Censored for CSH	34	29	63
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 -)	7 (4 -)	6 (4 -)
Median (95% CI)	(6 -)	(7 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	5% (1%- 19%)	0% (0%- 0%)	3% (1%- 11%)
3-day Estimate	9% (3%- 25%)	4% (1%- 24%)	6% (2%- 16%)
4-day Estimate	13% (5%- 31%)	16% (6%- 38%)	15% (8%- 28%)
5-day Estimate	18% (7%- 38%)	21% (9%- 44%)	20% (11%- 34%)
6-day Estimate	33% (18%- 57%)	21% (9%- 44%)	27% (17%- 43%)
7-day Estimate	33% (18%- 57%)	26% (13%- 50%)	30% (19%- 46%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	5% (1%- 18%)	0% (0%- 0%)	3% (1%- 10%)
3-day Estimate	7% (2%- 21%)	3% (0%- 19%)	5% (2%- 13%)
4-day Estimate	10% (4%- 23%)	11% (4%- 28%)	10% (5%- 20%)
5-day Estimate	12% (5%- 26%)	14% (6%- 31%)	13% (7%- 23%)
6-day Estimate	19% (10%- 34%)	14% (6%- 31%)	17% (10%- 27%)
7-day Estimate	19% (10%- 34%)	17% (8%- 34%)	18% (11%- 29%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.26, 1, 0.6101
Log hazard (SE), Relative Risk (95% CI) [b]: -0.275 (0.541), 0.760 (0.263 - 2.192)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.05, 1, 0.8234
Log hazard (SE), Relative Risk (95% CI) [b]: -0.120 (0.540), 0.886 (0.308 - 2.555)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.26.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Total Number of Patients	45	40	85
Total Number of Events	9	14	23
Total Number of Censored for CSH	36	26	62
Days to ICU Discharge			
25% Quartile (95% CI)	15 (5 - 22)	10 (5 - 13)	11 (6 - 14)
Median (95% CI)	22 (15 -)	14 (10 - 23)	22 (13 - 28)
75% Quartile (95% CI)	(22 -)	(14 -)	(23 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	16% (6%- 37%)	16% (6%- 38%)	16% (8%- 30%)
14-day Estimate	21% (9%- 44%)	60% (40%- 82%)	42% (28%- 59%)
21-day Estimate	41% (19%- 72%)	60% (40%- 82%)	49% (34%- 67%)
28-day Estimate	68% (38%- 94%)	74% (52%- 91%)	69% (51%- 86%)
ICU Discharge Cumulative Incidence			
7-day Estimate	9% (3%- 22%)	10% (4%- 24%)	9% (5%- 18%)
14-day Estimate	11% (5%- 25%)	30% (18%- 47%)	20% (13%- 30%)
21-day Estimate	16% (8%- 30%)	30% (18%- 47%)	22% (15%- 33%)
28-day Estimate	20% (11%- 35%)	35% (22%- 52%)	27% (19%- 38%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.97, 1, 0.3259
Log hazard (SE), Relative Risk (95% CI) [b]: 0.419 (0.430), 1.521 (0.655 - 3.533)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.34, 1, 0.1257
Log hazard (SE), Relative Risk (95% CI) [b]: 0.644 (0.428), 1.903 (0.823 - 4.401)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.26.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline MAP <65 mmHg)

	Placebo	LJPC-501	Total
Total Number of Patients	45	40	85
Total Number of Events	4	9	13
Total Number of Censored for CSH	41	31	72
Days to Hospital Discharge			
25% Quartile (95% CI)	22 (15 -)	22 (14 - 26)	22 (16 - 26)
Median (95% CI)	(18 -)	(22 -)	(23 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	0% (0%- 0%)	5% (1%- 32%)	3% (0%- 19%)
21-day Estimate	16% (4%- 52%)	21% (9%- 48%)	19% (9%- 38%)
28-day Estimate	36% (15%- 71%)	49% (30%- 74%)	45% (29%- 65%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	0% (0%- 0%)	3% (0%- 16%)	1% (0%- 8%)
21-day Estimate	4% (1%- 17%)	10% (4%- 24%)	7% (3%- 15%)
28-day Estimate	9% (3%- 22%)	23% (12%- 39%)	15% (9%- 25%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.43, 1, 0.5103
Log hazard (SE), Relative Risk (95% CI) [b]: 0.394 (0.602), 1.483 (0.455 - 4.827)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.97, 1, 0.0846
Log hazard (SE), Relative Risk (95% CI) [b]: 0.995 (0.601), 2.705 (0.833 - 8.786)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.27.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Number of Patients	63	74	137
Screening			
N	63	74	137
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	63 (100.0%)	74 (100.0%)	137 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Number of Patients	63	74	137
Hour 3 [a]			
N	63	74	137
3	0 (0.0%)	6 (8.1%)	6 (4.4%)
4	62 (98.4%)	68 (91.9%)	130 (94.9%)
4 (LOCF)	1 (1.6%)	0 (0.0%)	1 (0.7%)
Mean (SD)	4.00 (0.000)	3.92 (0.275)	3.96 (0.205)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	63	74	137
Mean (SD)	0.00 (0.000)	-0.08 (0.275)	-0.04 (0.205)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0214			
P-value [c] 0.0423			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.06 - 0.04)		
LS-Mean LJ501 (95%CI) [c]	-0.08 (-0.12 - -0.03)		
LS-Mean Difference (95%CI) [c]	0.07 (0.00 - 0.14)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Number of Patients	63	74	137
Hour 48 [a]			
N	63	74	137
0	12 (19.0%)	28 (37.8%)	40 (29.2%)
1	5 (7.9%)	5 (6.8%)	10 (7.3%)
2	0 (0.0%)	2 (2.7%)	2 (1.5%)
3	16 (25.4%)	12 (16.2%)	28 (20.4%)
4	18 (28.6%)	17 (23.0%)	35 (25.5%)
4 (LOCF)	1 (1.6%)	0 (0.0%)	1 (0.7%)
4 (WC)	11 (17.5%)	10 (13.5%)	21 (15.3%)
Mean (SD)	2.75 (1.576)	2.07 (1.801)	2.38 (1.728)
Median	3.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	63	74	137
Mean (SD)	-1.25 (1.576)	-1.93 (1.801)	-1.62 (1.728)
Median	-1.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0218			
P-value [c] 0.0359			
LS-Mean Placebo (95%CI) [c]	-1.30 (-1.71 - -0.89)		
LS-Mean LJ501 (95%CI) [c]	-1.90 (-2.27 - -1.52)		
LS-Mean Difference (95%CI) [c]	0.60 (0.04 - 1.16)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Number of Patients	63	74	137
Screening			
N	63	71	134
Mean (SD)	12.41 (3.191)	10.97 (2.580)	11.65 (2.962)
Median	12.00	11.00	12.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:02

Table 14.2.27.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Number of Patients	63	74	137
Hour 3			
N	63	74	137
Mean (SD)	12.90 (3.349)	12.04 (2.926)	12.44 (3.146)
Median	13.00	12.00	12.00
Range	7 - 21	5 - 19	5 - 21
Change from Screening			
N	63	71	134
Mean (SD)	0.49 (1.625)	1.13 (1.919)	0.83 (1.809)
Median	0.00	1.00	1.00
Range	-3 - 6	-2 - 7	-3 - 7
P-value [b] 0.0634			
P-value [c] 0.1300			
LS-Mean Placebo (95%CI) [c]	0.57 (0.12 - 1.02)		
LS-Mean LJ501 (95%CI) [c]	1.06 (0.63 - 1.48)		
LS-Mean Difference (95%CI) [c]	-0.48 (-1.11 - 0.14)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Number of Patients	63	74	137
Hour 48			
N	63	74	137
Mean (SD)	13.38 (6.598)	11.89 (6.278)	12.58 (6.446)
Median	12.00	10.00	11.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	63	71	134
Mean (SD)	0.97 (5.498)	1.13 (5.821)	1.05 (5.651)
Median	0.00	0.00	0.00
Range	-8 - 16	-8 - 15	-8 - 16
P-value [b]	0.9260		
P-value [c]	0.6797		
LS-Mean Placebo (95%CI) [c]	0.84 (-0.53 - 2.21)		
LS-Mean LJ501 (95%CI) [c]	1.24 (-0.05 - 2.53)		
LS-Mean Difference (95%CI) [c]	-0.40 (-2.31 - 1.51)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Total Number of Patients	57	64	121
Total Number of Events	17	19	36
Total Number of Censored for CSH	40	45	85
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (3 - 7)	5 (3 -)	5 (4 - 6)
Median (95% CI)	(6 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 12%)	2% (0%- 11%)	2% (0%- 6%)
2-day Estimate	9% (4%- 20%)	8% (3%- 18%)	8% (5%- 15%)
3-day Estimate	13% (7%- 26%)	16% (9%- 28%)	15% (10%- 23%)
4-day Estimate	18% (10%- 32%)	20% (12%- 33%)	19% (13%- 28%)
5-day Estimate	23% (13%- 38%)	30% (20%- 44%)	27% (19%- 37%)
6-day Estimate	34% (22%- 50%)	34% (23%- 48%)	34% (25%- 44%)
7-day Estimate	39% (26%- 56%)	34% (23%- 48%)	36% (27%- 47%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 12%)	2% (0%- 11%)	2% (0%- 6%)
2-day Estimate	9% (4%- 20%)	8% (3%- 18%)	8% (5%- 15%)
3-day Estimate	12% (6%- 24%)	16% (9%- 27%)	14% (9%- 22%)
4-day Estimate	16% (9%- 28%)	19% (11%- 31%)	17% (12%- 25%)
5-day Estimate	19% (11%- 32%)	27% (17%- 39%)	23% (17%- 32%)
6-day Estimate	26% (17%- 40%)	30% (20%- 43%)	28% (21%- 37%)
7-day Estimate	30% (20%- 44%)	30% (20%- 43%)	30% (22%- 39%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.05, 1, 0.8158
Log hazard (SE), Relative Risk (95% CI) [b]: -0.078 (0.334), 0.925 (0.481 - 1.780)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9461
Log hazard (SE), Relative Risk (95% CI) [b]: 0.023 (0.334), 1.023 (0.532 - 1.968)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.27.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Total Number of Patients	63	74	137
Total Number of Events	27	34	61
Total Number of Censored for CSH	36	40	76
Days to ICU Discharge			
25% Quartile (95% CI)	10 (6 - 13)	8 (6 - 10)	8 (7 - 10)
Median (95% CI)	17 (12 - 25)	14 (10 - 22)	15 (12 - 18)
75% Quartile (95% CI)	(18 -)	(17 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	21% (12%- 36%)	24% (15%- 37%)	22% (16%- 32%)
14-day Estimate	44% (30%- 60%)	52% (39%- 67%)	48% (38%- 59%)
21-day Estimate	60% (45%- 77%)	63% (49%- 77%)	61% (51%- 72%)
28-day Estimate	72% (56%- 87%)	72% (58%- 85%)	72% (61%- 82%)
ICU Discharge Cumulative Incidence			
7-day Estimate	16% (9%- 27%)	19% (12%- 30%)	18% (12%- 25%)
14-day Estimate	30% (20%- 43%)	36% (27%- 49%)	34% (26%- 42%)
21-day Estimate	38% (27%- 51%)	42% (32%- 54%)	40% (32%- 49%)
28-day Estimate	43% (32%- 56%)	46% (35%- 58%)	45% (37%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.23, 1, 0.6297
Log hazard (SE), Relative Risk (95% CI) [b]: 0.124 (0.258), 1.133 (0.683 - 1.879)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.22, 1, 0.6398
Log hazard (SE), Relative Risk (95% CI) [b]: 0.121 (0.258), 1.128 (0.681 - 1.870)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.27.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline APACHE II Score <=30)

	Placebo	LJPC-501	Total
Total Number of Patients	63	74	137
Total Number of Events	18	25	43
Total Number of Censored for CSH	45	49	94
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (13 - 23)	17 (9 - 21)	17 (14 - 21)
Median (95% CI)	25 (21 -)	26 (19 -)	25 (22 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	4% (1%- 17%)	5% (2%- 15%)	5% (2%- 11%)
14-day Estimate	15% (7%- 30%)	17% (9%- 30%)	16% (10%- 25%)
21-day Estimate	33% (20%- 52%)	39% (26%- 54%)	36% (27%- 48%)
28-day Estimate	53% (37%- 71%)	56% (42%- 71%)	55% (44%- 66%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 12%)	4% (1%- 12%)	4% (2%- 9%)
14-day Estimate	10% (4%- 20%)	12% (7%- 22%)	11% (7%- 18%)
21-day Estimate	19% (11%- 31%)	24% (16%- 36%)	22% (16%- 30%)
28-day Estimate	29% (19%- 41%)	34% (24%- 46%)	31% (24%- 40%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.12, 1, 0.7281
Log hazard (SE), Relative Risk (95% CI) [b]: 0.108 (0.309), 1.113 (0.607 - 2.042)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.45, 1, 0.5020
Log hazard (SE), Relative Risk (95% CI) [b]: 0.207 (0.309), 1.230 (0.671 - 2.255)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.27.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Number of Patients	52	40	92
Screening			
N	52	40	92
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	52 (100.0%)	40 (100.0%)	92 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Number of Patients	52	40	92
Hour 3 [a]			
N	52	40	92
3	1 (1.9%)	0 (0.0%)	1 (1.1%)
4	51 (98.1%)	40 (100.0%)	91 (98.9%)
Mean (SD)	3.98 (0.139)	4.00 (0.000)	3.99 (0.104)
Median	4.00	4.00	4.00
Range	3 - 4	4 - 4	3 - 4
Change from Screening			
N	52	40	92
Mean (SD)	-0.02 (0.139)	0.00 (0.000)	-0.01 (0.104)
Median	0.00	0.00	0.00
Range	-1 - 0	0 - 0	-1 - 0
P-value [b] 0.4795			
P-value [c] 0.5089			
LS-Mean Placebo (95%CI) [c]	-0.02 (-0.05 - 0.01)		
LS-Mean LJ501 (95%CI) [c]	-0.00 (-0.04 - 0.03)		
LS-Mean Difference (95%CI) [c]	-0.02 (-0.06 - 0.03)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Number of Patients	52	40	92
Hour 48 [a]			
N	52	40	92
0	9 (17.3%)	9 (22.5%)	18 (19.6%)
1	1 (1.9%)	2 (5.0%)	3 (3.3%)
3	6 (11.5%)	8 (20.0%)	14 (15.2%)
4	18 (34.6%)	13 (32.5%)	31 (33.7%)
4 (LOCF)	1 (1.9%)	0 (0.0%)	1 (1.1%)
4 (WC)	17 (32.7%)	8 (20.0%)	25 (27.2%)
Mean (SD)	3.13 (1.534)	2.75 (1.660)	2.97 (1.593)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	52	40	92
Mean (SD)	-0.87 (1.534)	-1.25 (1.660)	-1.03 (1.593)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b]	0.4257		
P-value [c]	0.6932		
LS-Mean Placebo (95%CI) [c]	-0.98 (-1.40 - -0.55)		
LS-Mean LJ501 (95%CI) [c]	-1.11 (-1.60 - -0.62)		
LS-Mean Difference (95%CI) [c]	0.13 (-0.53 - 0.79)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Number of Patients	52	40	92
Screening			
N	52	39	91
Mean (SD)	14.44 (2.940)	13.36 (2.600)	13.98 (2.836)
Median	14.50	14.00	14.00
Range	9 - 20	8 - 18	8 - 20

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:03

Table 14.2.27.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Number of Patients	52	40	92
Hour 3			
N	52	40	92
Mean (SD)	14.88 (2.819)	13.93 (3.141)	14.47 (2.985)
Median	15.00	15.00	15.00
Range	8 - 20	7 - 20	7 - 20
Change from Screening			
N	52	39	91
Mean (SD)	0.44 (2.253)	0.62 (1.462)	0.52 (1.946)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 4	-3 - 7
P-value [b] 0.4565			
P-value [c] 0.7963			
LS-Mean Placebo (95%CI) [c]	0.47 (-0.06 - 1.00)		
LS-Mean LJ501 (95%CI) [c]	0.58 (-0.04 - 1.19)		
LS-Mean Difference (95%CI) [c]	-0.11 (-0.94 - 0.72)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Number of Patients	52	40	92
Hour 48			
N	52	40	92
Mean (SD)	17.52 (6.044)	15.00 (6.127)	16.42 (6.176)
Median	18.00	15.00	16.00
Range	4 - 24	3 - 24	3 - 24
Change from Screening			
N	52	39	91
Mean (SD)	3.08 (5.390)	1.87 (5.768)	2.56 (5.556)
Median	2.50	1.00	2.00
Range	-7 - 15	-10 - 13	-10 - 15
P-value [b] 0.8600			
P-value [c] 0.6337			
LS-Mean Placebo (95%CI) [c]	2.80 (1.31 - 4.29)		
LS-Mean LJ501 (95%CI) [c]	2.24 (0.51 - 3.97)		
LS-Mean Difference (95%CI) [c]	0.56 (-1.77 - 2.89)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.27.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Total Number of Patients	51	39	90
Total Number of Events	7	9	16
Total Number of Censored for CSH	44	30	74
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(5 -)	7 (5 -)	7 (6 -)
Median (95% CI)	(-)	(7 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	3% (0%- 18%)	1% (0%- 8%)
3-day Estimate	0% (0%- 0%)	3% (0%- 18%)	1% (0%- 8%)
4-day Estimate	6% (2%- 23%)	6% (1%- 21%)	6% (2%- 15%)
5-day Estimate	10% (3%- 27%)	13% (5%- 31%)	11% (5%- 22%)
6-day Estimate	17% (7%- 36%)	24% (12%- 44%)	20% (12%- 33%)
7-day Estimate	24% (12%- 44%)	33% (19%- 55%)	28% (18%- 42%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	3% (0%- 17%)	1% (0%- 8%)
3-day Estimate	0% (0%- 0%)	3% (0%- 17%)	1% (0%- 8%)
4-day Estimate	4% (1%- 15%)	5% (1%- 19%)	4% (2%- 11%)
5-day Estimate	6% (2%- 17%)	10% (4%- 25%)	8% (4%- 16%)
6-day Estimate	10% (4%- 22%)	18% (9%- 34%)	13% (8%- 22%)
7-day Estimate	14% (7%- 27%)	23% (13%- 40%)	18% (11%- 27%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.61, 1, 0.4365
Log hazard (SE), Relative Risk (95% CI) [b]: 0.391 (0.505), 1.478 (0.550 - 3.975)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.29, 1, 0.2556
Log hazard (SE), Relative Risk (95% CI) [b]: 0.565 (0.504), 1.760 (0.655 - 4.727)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.27.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Total Number of Patients	52	40	92
Total Number of Events	15	13	28
Total Number of Censored for CSH	37	27	64
Days to ICU Discharge			
25% Quartile (95% CI)	12 (5 - 17)	9 (6 - 15)	11 (7 - 15)
Median (95% CI)	19 (12 - 28)	20 (11 -)	19 (14 - 28)
75% Quartile (95% CI)	28 (19 - 28)	(20 -)	(20 -)
Range	1+ - 28	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	16% (7%- 35%)	11% (4%- 30%)	14% (7%- 26%)
14-day Estimate	36% (20%- 59%)	37% (21%- 60%)	36% (24%- 52%)
21-day Estimate	71% (49%- 91%)	53% (34%- 75%)	61% (46%- 77%)
28-day Estimate	100% (%- %)	59% (39%- 80%)	69% (53%- 84%)
ICU Discharge Cumulative Incidence			
7-day Estimate	10% (4%- 22%)	8% (2%- 21%)	9% (4%- 17%)
14-day Estimate	17% (9%- 31%)	23% (12%- 39%)	20% (13%- 29%)
21-day Estimate	27% (17%- 41%)	30% (18%- 47%)	28% (20%- 39%)
28-day Estimate	29% (19%- 43%)	33% (20%- 49%)	30% (22%- 41%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.75, 1, 0.3872
Log hazard (SE), Relative Risk (95% CI) [b]: -0.334 (0.387), 0.716 (0.335 - 1.531)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.16, 1, 0.6884
Log hazard (SE), Relative Risk (95% CI) [b]: 0.152 (0.379), 1.164 (0.554 - 2.447)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.27.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline APACHE II Score >30)

	Placebo	LJPC-501	Total
Total Number of Patients	52	40	92
Total Number of Events	8	8	16
Total Number of Censored for CSH	44	32	76
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (12 - 28)	21 (14 -)	20 (15 - 28)
Median (95% CI)	28 (15 -)	(21 -)	(23 -)
75% Quartile (95% CI)	(28 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	17% (6%- 44%)	5% (1%- 28%)	10% (4%- 25%)
21-day Estimate	30% (14%- 58%)	29% (14%- 54%)	29% (17%- 47%)
28-day Estimate	55% (32%- 82%)	39% (22%- 63%)	45% (30%- 63%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	6% (2%- 17%)	3% (0%- 16%)	4% (2%- 11%)
21-day Estimate	10% (4%- 22%)	15% (7%- 30%)	12% (7%- 21%)
28-day Estimate	15% (8%- 28%)	20% (11%- 36%)	17% (11%- 27%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.64, 1, 0.4249
Log hazard (SE), Relative Risk (95% CI) [b]: -0.397 (0.500), 0.672 (0.252 - 1.794)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.31, 1, 0.5758
Log hazard (SE), Relative Risk (95% CI) [b]: 0.279 (0.500), 1.322 (0.496 - 3.523)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.28.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	102	106	208
Screening			
N	102	106	208
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	102 (100.0%)	106 (100.0%)	208 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	102	106	208
Hour 3 [a]			
N	102	106	208
3	1 (1.0%)	5 (4.7%)	6 (2.9%)
4	100 (98.0%)	101 (95.3%)	201 (96.6%)
4 (LOCF)	1 (1.0%)	0 (0.0%)	1 (0.5%)
Mean (SD)	3.99 (0.099)	3.95 (0.213)	3.97 (0.168)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	102	106	208
Mean (SD)	-0.01 (0.099)	-0.05 (0.213)	-0.03 (0.168)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.1060			
P-value [c] 0.1857			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.05 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.04 (-0.08 - -0.01)		
LS-Mean Difference (95%CI) [c]	0.03 (-0.02 - 0.08)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	102	106	208
Hour 48 [a]			
N	102	106	208
0	15 (14.7%)	31 (29.2%)	46 (22.1%)
1	6 (5.9%)	7 (6.6%)	13 (6.3%)
2	0 (0.0%)	2 (1.9%)	2 (1.0%)
3	19 (18.6%)	19 (17.9%)	38 (18.3%)
4	35 (34.3%)	30 (28.3%)	65 (31.3%)
4 (LOCF)	2 (2.0%)	0 (0.0%)	2 (1.0%)
4 (WC)	25 (24.5%)	17 (16.0%)	42 (20.2%)
Mean (SD)	3.05 (1.478)	2.42 (1.745)	2.73 (1.647)
Median	4.00	3.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	102	106	208
Mean (SD)	-0.95 (1.478)	-1.58 (1.745)	-1.27 (1.647)
Median	0.00	-1.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0178			
P-value [c] 0.0570			
LS-Mean Placebo (95%CI) [c]	-1.06 (-1.37 - -0.75)		
LS-Mean LJ501 (95%CI) [c]	-1.48 (-1.78 - -1.18)		
LS-Mean Difference (95%CI) [c]	0.42 (-0.01 - 0.86)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	102	106	208
Screening			
N	102	102	204
Mean (SD)	13.44 (3.263)	11.76 (2.843)	12.60 (3.166)
Median	13.50	12.00	13.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	102	106	208
Hour 3			
N	102	106	208
Mean (SD)	13.89 (3.291)	12.71 (3.129)	13.29 (3.256)
Median	14.00	13.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	102	102	204
Mean (SD)	0.45 (1.907)	1.01 (1.794)	0.73 (1.868)
Median	0.00	1.00	0.50
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.0416			
P-value [c] 0.1869			
LS-Mean Placebo (95%CI) [c]	0.55 (0.19 - 0.92)		
LS-Mean LJ501 (95%CI) [c]	0.91 (0.54 - 1.27)		
LS-Mean Difference (95%CI) [c]	-0.35 (-0.88 - 0.17)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	102	106	208
Hour 48			
N	102	106	208
Mean (SD)	15.48 (6.493)	13.20 (6.272)	14.32 (6.468)
Median	15.00	11.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	102	102	204
Mean (SD)	2.04 (5.349)	1.69 (5.747)	1.86 (5.541)
Median	1.00	1.00	1.00
Range	-7 - 16	-10 - 15	-10 - 16
P-value [b] 0.9062			
P-value [c] 0.8976			
LS-Mean Placebo (95%CI) [c]	1.81 (0.75 - 2.87)		
LS-Mean LJ501 (95%CI) [c]	1.91 (0.85 - 2.97)		
LS-Mean Difference (95%CI) [c]	-0.10 (-1.63 - 1.43)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Total Number of Patients	95	95	190
Total Number of Events	19	23	42
Total Number of Censored for CSH	76	72	148
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (6 -)	6 (5 -)	6 (6 -)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	1% (0%- 7%)	1% (0%- 4%)
2-day Estimate	3% (1%- 10%)	5% (2%- 12%)	4% (2%- 8%)
3-day Estimate	5% (2%- 12%)	9% (5%- 17%)	7% (4%- 12%)
4-day Estimate	9% (4%- 19%)	13% (7%- 22%)	11% (7%- 17%)
5-day Estimate	14% (8%- 25%)	20% (12%- 30%)	17% (12%- 24%)
6-day Estimate	25% (16%- 37%)	27% (18%- 38%)	26% (19%- 34%)
7-day Estimate	30% (20%- 43%)	30% (21%- 42%)	30% (23%- 38%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	1% (0%- 7%)	1% (0%- 4%)
2-day Estimate	3% (1%- 9%)	5% (2%- 12%)	4% (2%- 8%)
3-day Estimate	4% (2%- 11%)	8% (4%- 16%)	6% (4%- 11%)
4-day Estimate	7% (4%- 15%)	12% (7%- 20%)	9% (6%- 15%)
5-day Estimate	11% (6%- 19%)	17% (11%- 26%)	14% (10%- 19%)
6-day Estimate	17% (11%- 26%)	22% (15%- 32%)	19% (15%- 26%)
7-day Estimate	20% (13%- 30%)	24% (17%- 34%)	22% (17%- 29%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.09, 1, 0.7704
Log hazard (SE), Relative Risk (95% CI) [b]: 0.090 (0.310), 1.094 (0.596 - 2.010)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.59, 1, 0.4432
Log hazard (SE), Relative Risk (95% CI) [b]: 0.237 (0.310), 1.268 (0.690 - 2.328)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.28.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Total Number of Patients	102	106	208
Total Number of Events	36	42	78
Total Number of Censored for CSH	66	64	130
Days to ICU Discharge			
25% Quartile (95% CI)	11 (6 - 14)	9 (7 - 11)	10 (8 - 12)
Median (95% CI)	18 (14 - 22)	16 (12 - 23)	17 (14 - 20)
75% Quartile (95% CI)	28 (20 -)	(23 -)	(23 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	17% (10%- 29%)	18% (11%- 28%)	18% (12%- 25%)
14-day Estimate	36% (25%- 50%)	46% (35%- 59%)	42% (33%- 51%)
21-day Estimate	64% (49%- 78%)	58% (46%- 71%)	60% (51%- 70%)
28-day Estimate	79% (64%- 91%)	67% (54%- 79%)	71% (62%- 80%)
ICU Discharge Cumulative Incidence			
7-day Estimate	12% (7%- 20%)	13% (8%- 21%)	13% (9%- 18%)
14-day Estimate	22% (15%- 31%)	30% (22%- 40%)	26% (21%- 32%)
21-day Estimate	31% (23%- 41%)	36% (28%- 46%)	34% (28%- 41%)
28-day Estimate	35% (27%- 45%)	40% (31%- 50%)	38% (31%- 44%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8941
Log hazard (SE), Relative Risk (95% CI) [b]: -0.030 (0.228), 0.970 (0.620 - 1.517)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.56, 1, 0.4546
Log hazard (SE), Relative Risk (95% CI) [b]: 0.169 (0.227), 1.185 (0.759 - 1.849)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.28.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, No Exposure to ACEi)

	Placebo	LJPC-501	Total
Total Number of Patients	102	106	208
Total Number of Events	21	28	49
Total Number of Censored for CSH	81	78	159
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (14 - 23)	18 (15 - 22)	18 (16 - 22)
Median (95% CI)	(23 -)	(23 -)	(24 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	2% (0%- 11%)	4% (1%- 12%)	3% (1%- 7%)
14-day Estimate	15% (8%- 29%)	13% (7%- 23%)	14% (9%- 22%)
21-day Estimate	30% (19%- 45%)	32% (22%- 46%)	31% (23%- 41%)
28-day Estimate	50% (35%- 66%)	47% (35%- 61%)	48% (39%- 59%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	1% (0%- 7%)	3% (1%- 9%)	2% (1%- 5%)
14-day Estimate	8% (4%- 15%)	8% (5%- 16%)	8% (5%- 13%)
21-day Estimate	14% (8%- 22%)	19% (13%- 28%)	16% (12%- 22%)
28-day Estimate	21% (14%- 30%)	26% (19%- 36%)	24% (18%- 30%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9405
Log hazard (SE), Relative Risk (95% CI) [b]: -0.022 (0.289), 0.979 (0.555 - 1.725)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.98, 1, 0.3210
Log hazard (SE), Relative Risk (95% CI) [b]: 0.286 (0.289), 1.331 (0.756 - 2.343)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.28.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	13	8	21
Screening			
N	13	8	21
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	13 (100.0%)	8 (100.0%)	21 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	13	8	21
Hour 3 [a]			
N	13	8	21
3	0 (0.0%)	1 (12.5%)	1 (4.8%)
4	13 (100.0%)	7 (87.5%)	20 (95.2%)
Mean (SD)	4.00 (0.000)	3.88 (0.354)	3.95 (0.218)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	13	8	21
Mean (SD)	0.00 (0.000)	-0.13 (0.354)	-0.05 (0.218)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.3173			
P-value [c] 0.1962			
LS-Mean Placebo (95%CI) [c]	0.00 (-0.12 - 0.13)		
LS-Mean LJ501 (95%CI) [c]	-0.13 (-0.30 - 0.03)		
LS-Mean Difference (95%CI) [c]	0.14 (-0.08 - 0.35)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	13	8	21
Hour 48 [a]			
N	13	8	21
0	6 (46.2%)	6 (75.0%)	12 (57.1%)
3	3 (23.1%)	1 (12.5%)	4 (19.0%)
4	1 (7.7%)	0 (0.0%)	1 (4.8%)
4 (WC)	3 (23.1%)	1 (12.5%)	4 (19.0%)
Mean (SD)	1.92 (1.891)	0.88 (1.642)	1.52 (1.834)
Median	3.00	0.00	0.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	13	8	21
Mean (SD)	-2.08 (1.891)	-3.13 (1.642)	-2.48 (1.834)
Median	-1.00	-4.00	-4.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b]	0.2077		
P-value [c]	0.3707		
LS-Mean Placebo (95%CI) [c]	-2.22 (-3.13 - -1.31)		
LS-Mean LJ501 (95%CI) [c]	-2.89 (-4.06 - -1.71)		
LS-Mean Difference (95%CI) [c]	0.66 (-0.85 - 2.18)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	13	8	21
Screening			
N	13	8	21
Mean (SD)	12.46 (2.933)	12.50 (2.563)	12.48 (2.732)
Median	12.00	11.50	12.00
Range	9 - 19	9 - 16	9 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	13	8	21
Hour 3			
N	13	8	21
Mean (SD)	13.08 (3.040)	12.63 (3.249)	12.90 (3.048)
Median	12.00	12.00	12.00
Range	8 - 18	8 - 18	8 - 18
Change from Screening			
N	13	8	21
Mean (SD)	0.62 (2.142)	0.13 (1.458)	0.43 (1.886)
Median	1.00	0.00	0.00
Range	-3 - 6	-2 - 2	-3 - 6
P-value [b] 0.3930			
P-value [c] 0.9535			
LS-Mean Placebo (95%CI) [c]	0.45 (-0.52 - 1.41)		
LS-Mean LJ501 (95%CI) [c]	0.40 (-0.84 - 1.64)		
LS-Mean Difference (95%CI) [c]	0.04 (-1.56 - 1.65)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Number of Patients	13	8	21
Hour 48			
N	13	8	21
Mean (SD)	13.46 (7.881)	10.13 (7.473)	12.19 (7.718)
Median	13.00	7.50	10.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	13	8	21
Mean (SD)	1.00 (6.952)	-2.38 (5.236)	-0.29 (6.435)
Median	0.00	-3.50	-2.00
Range	-8 - 15	-8 - 8	-8 - 15
P-value [b] 0.2225			
P-value [c] 0.2712			
LS-Mean Placebo (95%CI) [c]	0.67 (-2.11 - 3.44)		
LS-Mean LJ501 (95%CI) [c]	-1.83 (-5.41 - 1.75)		
LS-Mean Difference (95%CI) [c]	2.50 (-2.15 - 7.14)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.28.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Total Number of Patients	13	8	21
Total Number of Events	5	5	10
Total Number of Censored for CSH	8	3	11
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	4 (1 -)	3 (2 - 5)	3 (1 - 5)
Median (95% CI)	(3 -)	5 (2 -)	5 (3 -)
75% Quartile (95% CI)	(7 -)	(3 -)	(5 -)
Range	1 - 7+	1+ - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	8% (1%- 43%)	0% (0%- 0%)	5% (1%- 29%)
2-day Estimate	15% (4%- 49%)	14% (2%- 67%)	15% (5%- 39%)
3-day Estimate	25% (9%- 59%)	43% (16%- 83%)	32% (16%- 58%)
4-day Estimate	37% (15%- 73%)	43% (16%- 83%)	39% (20%- 65%)
5-day Estimate	37% (15%- 73%)	71% (39%- 96%)	52% (31%- 77%)
6-day Estimate	37% (15%- 73%)	71% (39%- 96%)	52% (31%- 77%)
7-day Estimate	50% (23%- 83%)	71% (39%- 96%)	59% (37%- 82%)
Ventilator Cumulative Incidence			
1-day Estimate	8% (1%- 43%)	0% (0%- 0%)	5% (1%- 29%)
2-day Estimate	15% (4%- 49%)	13% (2%- 61%)	14% (5%- 38%)
3-day Estimate	23% (8%- 56%)	38% (14%- 77%)	29% (14%- 53%)
4-day Estimate	31% (13%- 63%)	38% (14%- 77%)	33% (17%- 57%)
5-day Estimate	31% (13%- 63%)	63% (33%- 91%)	43% (25%- 66%)
6-day Estimate	31% (13%- 63%)	63% (33%- 91%)	43% (25%- 66%)
7-day Estimate	38% (18%- 69%)	63% (33%- 91%)	48% (29%- 70%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.52, 1, 0.4708
Log hazard (SE), Relative Risk (95% CI) [b]: 0.454 (0.635), 1.575 (0.454 - 5.469)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.80, 1, 0.3715
Log hazard (SE), Relative Risk (95% CI) [b]: 0.561 (0.636), 1.752 (0.504 - 6.088)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.28.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Total Number of Patients	13	8	21
Total Number of Events	6	5	11
Total Number of Censored for CSH	7	3	10
Days to ICU Discharge			
25% Quartile (95% CI)	7 (3 - 12)	4 (4 - 9)	6 (3 - 10)
Median (95% CI)	12 (4 -)	9 (4 -)	10 (4 - 15)
75% Quartile (95% CI)	(10 -)	15 (6 -)	15 (10 -)
Range	2+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	32% (11%- 70%)	43% (16%- 83%)	37% (19%- 65%)
14-day Estimate	73% (41%- 96%)	62% (28%- 94%)	69% (44%- 90%)
21-day Estimate	73% (41%- 96%)	81% (44%- 99%)	76% (52%- 94%)
28-day Estimate	73% (41%- 96%)	81% (44%- 99%)	76% (52%- 94%)
ICU Discharge Cumulative Incidence			
7-day Estimate	23% (8%- 56%)	38% (14%- 77%)	29% (14%- 53%)
14-day Estimate	46% (24%- 75%)	50% (23%- 85%)	48% (29%- 70%)
21-day Estimate	46% (24%- 75%)	63% (33%- 91%)	52% (33%- 74%)
28-day Estimate	46% (24%- 75%)	63% (33%- 91%)	52% (33%- 74%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.11, 1, 0.7397
Log hazard (SE), Relative Risk (95% CI) [b]: 0.203 (0.611), 1.225 (0.370 - 4.053)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.51, 1, 0.4741
Log hazard (SE), Relative Risk (95% CI) [b]: 0.432 (0.608), 1.540 (0.468 - 5.067)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.28.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Exposure to ACEi)

	Placebo	LJPC-501	Total
Total Number of Patients	13	8	21
Total Number of Events	5	5	10
Total Number of Censored for CSH	8	3	11
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (6 - 24)	15 (11 - 19)	16 (6 - 19)
Median (95% CI)	24 (6 -)	18 (11 -)	19 (15 - 25)
75% Quartile (95% CI)	(18 -)	25 (15 -)	25 (19 -)
Range	2+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	11% (2%- 57%)	0% (0%- 0%)	6% (1%- 37%)
14-day Estimate	11% (2%- 57%)	17% (3%- 73%)	13% (4%- 44%)
21-day Estimate	41% (15%- 81%)	67% (32%- 95%)	53% (29%- 80%)
28-day Estimate	70% (38%- 96%)	83% (48%- 99%)	76% (52%- 94%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	8% (1%- 43%)	0% (0%- 0%)	5% (1%- 29%)
14-day Estimate	8% (1%- 43%)	13% (2%- 61%)	10% (2%- 33%)
21-day Estimate	23% (8%- 56%)	50% (23%- 85%)	33% (17%- 57%)
28-day Estimate	38% (18%- 69%)	63% (33%- 91%)	48% (29%- 70%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.41, 1, 0.5222
Log hazard (SE), Relative Risk (95% CI) [b]: 0.405 (0.638), 1.500 (0.430 - 5.233)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.30, 1, 0.2541
Log hazard (SE), Relative Risk (95% CI) [b]: 0.709 (0.635), 2.033 (0.586 - 7.056)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.29.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	108	106	214
Screening			
N	108	106	214
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	108 (100.0%)	106 (100.0%)	214 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	108	106	214
Hour 3 [a]			
N	108	106	214
3	1 (0.9%)	6 (5.7%)	7 (3.3%)
4	106 (98.1%)	100 (94.3%)	206 (96.3%)
4 (LOCF)	1 (0.9%)	0 (0.0%)	1 (0.5%)
Mean (SD)	3.99 (0.096)	3.94 (0.232)	3.97 (0.178)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	108	106	214
Mean (SD)	-0.01 (0.096)	-0.06 (0.232)	-0.03 (0.178)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.0565			
P-value [c] 0.1031			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.05 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.05 (-0.09 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.04 (-0.01 - 0.09)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	108	106	214
Hour 48 [a]			
N	108	106	214
0	19 (17.6%)	34 (32.1%)	53 (24.8%)
1	6 (5.6%)	7 (6.6%)	13 (6.1%)
2	0 (0.0%)	2 (1.9%)	2 (0.9%)
3	20 (18.5%)	20 (18.9%)	40 (18.7%)
4	33 (30.6%)	28 (26.4%)	61 (28.5%)
4 (LOCF)	2 (1.9%)	0 (0.0%)	2 (0.9%)
4 (WC)	28 (25.9%)	15 (14.2%)	43 (20.1%)
Mean (SD)	2.94 (1.552)	2.29 (1.762)	2.62 (1.687)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	108	106	214
Mean (SD)	-1.06 (1.552)	-1.71 (1.762)	-1.38 (1.687)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0175			
P-value [c] 0.0581			
LS-Mean Placebo (95%CI) [c]	-1.17 (-1.47 - -0.87)		
LS-Mean LJ501 (95%CI) [c]	-1.59 (-1.90 - -1.29)		
LS-Mean Difference (95%CI) [c]	0.42 (-0.01 - 0.85)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	108	106	214
Screening			
N	108	102	210
Mean (SD)	13.41 (3.241)	11.69 (2.856)	12.57 (3.172)
Median	14.00	12.00	13.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	108	106	214
Hour 3			
N	108	106	214
Mean (SD)	13.96 (3.221)	12.62 (3.188)	13.30 (3.267)
Median	14.00	12.50	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	108	102	210
Mean (SD)	0.56 (1.940)	1.00 (1.791)	0.77 (1.878)
Median	0.00	1.00	1.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.0959			
P-value [c] 0.3511			
LS-Mean Placebo (95%CI) [c]	0.65 (0.30 - 1.01)		
LS-Mean LJ501 (95%CI) [c]	0.90 (0.53 - 1.26)		
LS-Mean Difference (95%CI) [c]	-0.25 (-0.77 - 0.27)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	108	106	214
Hour 48			
N	108	106	214
Mean (SD)	15.50 (6.750)	12.80 (6.263)	14.16 (6.637)
Median	15.00	11.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	108	102	210
Mean (SD)	2.09 (5.621)	1.35 (5.661)	1.73 (5.640)
Median	1.00	0.50	1.00
Range	-8 - 16	-8 - 15	-8 - 16
P-value [b] 0.7805			
P-value [c] 0.8323			
LS-Mean Placebo (95%CI) [c]	1.81 (0.78 - 2.85)		
LS-Mean LJ501 (95%CI) [c]	1.65 (0.58 - 2.72)		
LS-Mean Difference (95%CI) [c]	0.16 (-1.36 - 1.69)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Total Number of Patients	102	96	198
Total Number of Events	22	27	49
Total Number of Censored for CSH	80	69	149
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (5 -)	5 (4 -)	6 (5 - 7)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	1% (0%- 7%)	1% (0%- 7%)	1% (0%- 4%)
2-day Estimate	5% (2%- 12%)	6% (3%- 14%)	6% (3%- 10%)
3-day Estimate	6% (3%- 14%)	12% (7%- 21%)	9% (6%- 15%)
4-day Estimate	12% (7%- 22%)	16% (10%- 25%)	14% (10%- 20%)
5-day Estimate	17% (10%- 28%)	25% (17%- 36%)	21% (16%- 29%)
6-day Estimate	25% (16%- 37%)	31% (22%- 42%)	28% (22%- 36%)
7-day Estimate	32% (22%- 45%)	34% (24%- 46%)	33% (26%- 41%)
Ventilator Cumulative Incidence			
1-day Estimate	1% (0%- 7%)	1% (0%- 7%)	1% (0%- 4%)
2-day Estimate	5% (2%- 11%)	6% (3%- 13%)	6% (3%- 10%)
3-day Estimate	6% (3%- 13%)	11% (7%- 20%)	9% (5%- 13%)
4-day Estimate	10% (5%- 17%)	15% (9%- 23%)	12% (8%- 18%)
5-day Estimate	13% (8%- 21%)	22% (15%- 32%)	17% (13%- 23%)
6-day Estimate	18% (12%- 27%)	26% (18%- 36%)	22% (17%- 28%)
7-day Estimate	22% (15%- 31%)	28% (20%- 38%)	25% (19%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.27, 1, 0.6006
Log hazard (SE), Relative Risk (95% CI) [b]: 0.150 (0.287), 1.162 (0.662 - 2.041)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.26, 1, 0.2623
Log hazard (SE), Relative Risk (95% CI) [b]: 0.321 (0.287), 1.378 (0.785 - 2.420)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.29.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Total Number of Patients	108	106	214
Total Number of Events	38	44	82
Total Number of Censored for CSH	70	62	132
Days to ICU Discharge			
25% Quartile (95% CI)	10 (7 - 14)	8 (6 - 11)	9 (7 - 12)
Median (95% CI)	17 (14 - 22)	15 (12 - 23)	17 (14 - 20)
75% Quartile (95% CI)	28 (20 -)	(23 -)	(25 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	18% (11%- 29%)	19% (12%- 30%)	19% (13%- 26%)
14-day Estimate	38% (27%- 52%)	45% (35%- 58%)	42% (34%- 51%)
21-day Estimate	64% (50%- 78%)	59% (47%- 71%)	61% (51%- 70%)
28-day Estimate	78% (63%- 90%)	67% (55%- 79%)	71% (62%- 80%)
ICU Discharge Cumulative Incidence			
7-day Estimate	12% (7%- 20%)	15% (10%- 23%)	14% (10%- 19%)
14-day Estimate	22% (15%- 31%)	31% (23%- 41%)	27% (21%- 33%)
21-day Estimate	31% (24%- 41%)	38% (29%- 48%)	35% (29%- 41%)
28-day Estimate	35% (27%- 45%)	42% (33%- 51%)	38% (32%- 45%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9205
Log hazard (SE), Relative Risk (95% CI) [b]: -0.022 (0.222), 0.978 (0.633 - 1.512)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.14, 1, 0.2863
Log hazard (SE), Relative Risk (95% CI) [b]: 0.236 (0.222), 1.266 (0.820 - 1.954)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.29.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, No Exposure to ARBs)

	Placebo	LJPC-501	Total
Total Number of Patients	108	106	214
Total Number of Events	23	30	53
Total Number of Censored for CSH	85	76	161
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (14 - 23)	19 (15 - 22)	18 (16 - 22)
Median (95% CI)	28 (23 -)	(23 -)	(24 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (1%- 11%)	4% (1%- 12%)	3% (1%- 8%)
14-day Estimate	16% (9%- 29%)	14% (8%- 25%)	15% (10%- 23%)
21-day Estimate	30% (19%- 45%)	32% (22%- 46%)	31% (24%- 41%)
28-day Estimate	51% (37%- 67%)	48% (36%- 61%)	49% (40%- 59%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 7%)	3% (1%- 9%)	2% (1%- 6%)
14-day Estimate	8% (4%- 15%)	9% (5%- 17%)	9% (6%- 14%)
21-day Estimate	14% (9%- 22%)	20% (13%- 29%)	17% (12%- 23%)
28-day Estimate	21% (15%- 30%)	28% (21%- 38%)	25% (20%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8887
Log hazard (SE), Relative Risk (95% CI) [b]: -0.039 (0.278), 0.962 (0.558 - 1.657)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.40, 1, 0.2368
Log hazard (SE), Relative Risk (95% CI) [b]: 0.326 (0.277), 1.386 (0.805 - 2.386)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.29.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	7	8	15
Screening			
N	7	8	15
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	7 (100.0%)	8 (100.0%)	15 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	7	8	15
Hour 3 [a]			
N	7	8	15
4	7 (100.0%)	8 (100.0%)	15 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4
Change from Screening			
N	7	8	15
Mean (SD)	0.00 (0.000)	0.00 (0.000)	0.00 (0.000)
Median	0.00	0.00	0.00
Range	0 - 0	0 - 0	0 - 0
P-value [b] N/A			
P-value [c] N/A			
LS-Mean Placebo (95%CI) [c]	N/A		
LS-Mean LJ501 (95%CI) [c]	N/A		
LS-Mean Difference (95%CI) [c]	N/A		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	7	8	15
Hour 48 [a]			
N	7	8	15
0	2 (28.6%)	3 (37.5%)	5 (33.3%)
3	2 (28.6%)	0 (0.0%)	2 (13.3%)
4	3 (42.9%)	2 (25.0%)	5 (33.3%)
4 (WC)	0 (0.0%)	3 (37.5%)	3 (20.0%)
Mean (SD)	2.57 (1.813)	2.50 (2.070)	2.53 (1.885)
Median	3.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	7	8	15
Mean (SD)	-1.43 (1.813)	-1.50 (2.070)	-1.47 (1.885)
Median	-1.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b]	0.7671		
P-value [c]	0.5993		
LS-Mean Placebo (95%CI) [c]	-1.16 (-2.82 - 0.50)		
LS-Mean LJ501 (95%CI) [c]	-1.73 (-3.28 - -0.19)		
LS-Mean Difference (95%CI) [c]	0.57 (-1.76 - 2.90)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	7	8	15
Screening			
N	7	8	15
Mean (SD)	12.14 (3.024)	13.50 (1.604)	12.87 (2.386)
Median	12.00	13.50	13.00
Range	8 - 18	11 - 16	8 - 18

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:04

Table 14.2.29.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	7	8	15
Hour 3			
N	7	8	15
Mean (SD)	11.29 (3.039)	13.75 (1.909)	12.60 (2.720)
Median	10.00	13.50	13.00
Range	8 - 17	11 - 17	8 - 17
Change from Screening			
N	7	8	15
Mean (SD)	-0.86 (1.069)	0.25 (1.581)	-0.27 (1.438)
Median	-1.00	0.50	0.00
Range	-3 - 0	-2 - 3	-3 - 3
P-value [b] 0.2570			
P-value [c] 0.2041			
LS-Mean Placebo (95%CI) [c]	-0.90 (-2.24 - 0.45)		
LS-Mean LJ501 (95%CI) [c]	0.28 (-0.97 - 1.54)		
LS-Mean Difference (95%CI) [c]	-1.18 (-3.11 - 0.75)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Number of Patients	7	8	15
Hour 48			
N	7	8	15
Mean (SD)	11.43 (3.309)	15.38 (7.782)	13.53 (6.255)
Median	11.00	14.50	12.00
Range	7 - 17	6 - 24	6 - 24
Change from Screening			
N	7	8	15
Mean (SD)	-0.71 (2.870)	1.88 (7.661)	0.67 (5.888)
Median	0.00	1.50	0.00
Range	-4 - 4	-10 - 11	-10 - 11
P-value [b] 0.4559			
P-value [c] 0.6610			
LS-Mean Placebo (95%CI) [c]	-0.03 (-4.55 - 4.48)		
LS-Mean LJ501 (95%CI) [c]	1.28 (-2.91 - 5.47)		
LS-Mean Difference (95%CI) [c]	-1.31 (-7.78 - 5.16)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.29.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Total Number of Patients	6	7	13
Total Number of Events	2	1	3
Total Number of Censored for CSH	4	6	10
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (3 -)	(6 -)	6 (3 -)
Median (95% CI)	(3 -)	(6 -)	(3 -)
75% Quartile (95% CI)	(6 -)	(6 -)	(-)
Range	3 - 7+	2+ - 7+	2+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
3-day Estimate	17% (3%- 73%)	0% (0%- 0%)	10% (1%- 53%)
4-day Estimate	17% (3%- 73%)	0% (0%- 0%)	10% (1%- 53%)
5-day Estimate	17% (3%- 73%)	0% (0%- 0%)	10% (1%- 53%)
6-day Estimate	38% (11%- 86%)	25% (4%- 87%)	33% (12%- 71%)
7-day Estimate	38% (11%- 86%)	25% (4%- 87%)	33% (12%- 71%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
3-day Estimate	17% (3%- 73%)	0% (0%- 0%)	8% (1%- 43%)
4-day Estimate	17% (3%- 73%)	0% (0%- 0%)	8% (1%- 43%)
5-day Estimate	17% (3%- 73%)	0% (0%- 0%)	8% (1%- 43%)
6-day Estimate	33% (10%- 81%)	14% (2%- 67%)	23% (8%- 56%)
7-day Estimate	33% (10%- 81%)	14% (2%- 67%)	23% (8%- 56%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.22, 1, 0.6419
Log hazard (SE), Relative Risk (95% CI) [b]: -0.564 (1.229), 0.569 (0.051 - 6.331)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.68, 1, 0.4107
Log hazard (SE), Relative Risk (95% CI) [b]: -0.970 (1.226), 0.379 (0.034 - 4.188)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.29.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Total Number of Patients	7	8	15
Total Number of Events	4	3	7
Total Number of Censored for CSH	3	5	8
Days to ICU Discharge			
25% Quartile (95% CI)	6 (4 - 12)	10 (7 - 11)	7 (4 - 11)
Median (95% CI)	12 (4 -)	11 (7 -)	11 (6 -)
75% Quartile (95% CI)	(6 -)	(7 -)	(11 -)
Range	4 - 28+	2+ - 13+	2+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	31% (9%- 79%)	20% (3%- 80%)	27% (9%- 62%)
14-day Estimate	66% (31%- 95%)	73% (31%- 99%)	69% (41%- 92%)
21-day Estimate	66% (31%- 95%)	73% (31%- 99%)	69% (41%- 92%)
28-day Estimate	66% (31%- 95%)	73% (31%- 99%)	69% (41%- 92%)
ICU Discharge Cumulative Incidence			
7-day Estimate	29% (8%- 74%)	13% (2%- 61%)	20% (7%- 50%)
14-day Estimate	57% (27%- 90%)	38% (14%- 77%)	47% (26%- 74%)
21-day Estimate	57% (27%- 90%)	38% (14%- 77%)	47% (26%- 74%)
28-day Estimate	57% (27%- 90%)	38% (14%- 77%)	47% (26%- 74%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8858
Log hazard (SE), Relative Risk (95% CI) [b]: 0.112 (0.780), 1.118 (0.243 - 5.155)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.53, 1, 0.4684
Log hazard (SE), Relative Risk (95% CI) [b]: -0.548 (0.765), 0.578 (0.129 - 2.589)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.29.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Exposure to ARBs)

	Placebo	LJPC-501	Total
Total Number of Patients	7	8	15
Total Number of Events	3	3	6
Total Number of Censored for CSH	4	5	9
Days to Hospital Discharge			
25% Quartile (95% CI)	21 (15 - 24)	15 (15 - 17)	16 (15 - 21)
Median (95% CI)	24 (15 -)	17 (15 - 17)	19 (15 -)
75% Quartile (95% CI)	(15 -)	17 (15 - 17)	24 (17 -)
Range	4+ - 28+	2+ - 17	2+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
21-day Estimate	47% (14%- 93%)	100% (%- %)	67% (34%- 94%)
28-day Estimate	73% (31%- 99%)	100% (%- %)	83% (49%- 99%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
21-day Estimate	29% (8%- 74%)	38% (14%- 77%)	33% (15%- 62%)
28-day Estimate	43% (16%- 83%)	38% (14%- 77%)	40% (20%- 68%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 2.75, 1, 0.0975
Log hazard (SE), Relative Risk (95% CI) [b]: 1.702 (1.156), 5.487 (0.570 - 52.84)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9360
Log hazard (SE), Relative Risk (95% CI) [b]: -0.066 (0.818), 0.936 (0.188 - 4.653)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.30.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	85	95	180
Screening			
N	85	95	180
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	85 (100.0%)	95 (100.0%)	180 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	85	95	180
Hour 3 [a]			
N	85	95	180
3	1 (1.2%)	6 (6.3%)	7 (3.9%)
4	83 (97.6%)	89 (93.7%)	172 (95.6%)
4 (LOCF)	1 (1.2%)	0 (0.0%)	1 (0.6%)
Mean (SD)	3.99 (0.108)	3.94 (0.245)	3.96 (0.194)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	85	95	180
Mean (SD)	-0.01 (0.108)	-0.06 (0.245)	-0.04 (0.194)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.0621			
P-value [c] 0.1202			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.06 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.06 (-0.10 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.05 (-0.01 - 0.10)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	85	95	180
Hour 48 [a]			
N	85	95	180
0	15 (17.6%)	35 (36.8%)	50 (27.8%)
1	4 (4.7%)	6 (6.3%)	10 (5.6%)
2	0 (0.0%)	1 (1.1%)	1 (0.6%)
3	18 (21.2%)	17 (17.9%)	35 (19.4%)
4	25 (29.4%)	23 (24.2%)	48 (26.7%)
4 (LOCF)	1 (1.2%)	0 (0.0%)	1 (0.6%)
4 (WC)	22 (25.9%)	13 (13.7%)	35 (19.4%)
Mean (SD)	2.94 (1.538)	2.14 (1.802)	2.52 (1.726)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	85	95	180
Mean (SD)	-1.06 (1.538)	-1.86 (1.802)	-1.48 (1.726)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0118			
P-value [c] 0.0152			
LS-Mean Placebo (95%CI) [c]	-1.17 (-1.51 - -0.82)		
LS-Mean LJ501 (95%CI) [c]	-1.77 (-2.10 - -1.44)		
LS-Mean Difference (95%CI) [c]	0.60 (0.12 - 1.09)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	85	95	180
Screening			
N	85	91	176
Mean (SD)	12.66 (3.198)	11.44 (2.821)	12.03 (3.062)
Median	12.00	11.00	12.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:04

Table 14.2.30.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	85	95	180
Hour 3			
N	85	95	180
Mean (SD)	13.24 (3.176)	12.26 (3.085)	12.72 (3.157)
Median	13.00	12.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	85	91	176
Mean (SD)	0.58 (1.972)	0.88 (1.861)	0.73 (1.916)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b]	0.2823		
P-value [c]	0.6022		
LS-Mean Placebo (95%CI) [c]	0.65 (0.25 - 1.06)		
LS-Mean LJ501 (95%CI) [c]	0.81 (0.41 - 1.20)		
LS-Mean Difference (95%CI) [c]	-0.15 (-0.72 - 0.42)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	85	95	180
Hour 48			
N	85	95	180
Mean (SD)	14.89 (6.925)	12.23 (6.256)	13.49 (6.696)
Median	14.00	10.00	12.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	85	91	176
Mean (SD)	2.24 (5.771)	1.03 (5.820)	1.61 (5.811)
Median	1.00	0.00	1.00
Range	-8 - 16	-10 - 15	-10 - 16
P-value [b]	0.3255		
P-value [c]	0.4634		
LS-Mean Placebo (95%CI) [c]	1.94 (0.75 - 3.13)		
LS-Mean LJ501 (95%CI) [c]	1.31 (0.16 - 2.46)		
LS-Mean Difference (95%CI) [c]	0.63 (-1.05 - 2.31)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	79	84	163
Total Number of Events	22	26	48
Total Number of Censored for CSH	57	58	115
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 - 7)	5 (4 - 7)	5 (4 - 6)
Median (95% CI)	(7 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	1% (0%- 9%)	1% (0%- 8%)	1% (0%- 5%)
2-day Estimate	7% (3%- 15%)	7% (3%- 16%)	7% (4%- 12%)
3-day Estimate	10% (5%- 20%)	14% (8%- 24%)	12% (8%- 19%)
4-day Estimate	17% (10%- 30%)	18% (11%- 29%)	18% (12%- 25%)
5-day Estimate	24% (14%- 37%)	27% (18%- 39%)	26% (19%- 34%)
6-day Estimate	32% (21%- 46%)	33% (24%- 46%)	33% (25%- 42%)
7-day Estimate	41% (29%- 55%)	37% (27%- 49%)	38% (30%- 48%)
Ventilator Cumulative Incidence			
1-day Estimate	1% (0%- 9%)	1% (0%- 8%)	1% (0%- 5%)
2-day Estimate	6% (3%- 15%)	7% (3%- 15%)	7% (4%- 12%)
3-day Estimate	9% (4%- 18%)	13% (7%- 22%)	11% (7%- 17%)
4-day Estimate	14% (8%- 24%)	17% (10%- 27%)	15% (11%- 22%)
5-day Estimate	18% (11%- 28%)	24% (16%- 34%)	21% (15%- 28%)
6-day Estimate	23% (15%- 34%)	29% (20%- 40%)	26% (20%- 33%)
7-day Estimate	28% (19%- 39%)	31% (22%- 42%)	29% (23%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.03, 1, 0.8722
Log hazard (SE), Relative Risk (95% CI) [b]: -0.047 (0.290), 0.954 (0.541 - 1.685)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.24, 1, 0.6227
Log hazard (SE), Relative Risk (95% CI) [b]: 0.142 (0.290), 1.153 (0.653 - 2.034)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.30.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	85	95	180
Total Number of Events	31	43	74
Total Number of Censored for CSH	54	52	106
Days to ICU Discharge			
25% Quartile (95% CI)	10 (6 - 12)	8 (7 - 10)	8 (7 - 10)
Median (95% CI)	17 (12 - 20)	15 (11 - 22)	15 (12 - 18)
75% Quartile (95% CI)	(18 -)	(22 -)	(23 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	22% (14%- 35%)	20% (13%- 31%)	21% (15%- 29%)
14-day Estimate	43% (30%- 58%)	49% (38%- 62%)	47% (38%- 56%)
21-day Estimate	67% (51%- 82%)	62% (49%- 75%)	64% (54%- 73%)
28-day Estimate	75% (59%- 89%)	72% (59%- 83%)	73% (63%- 82%)
ICU Discharge Cumulative Incidence			
7-day Estimate	15% (9%- 25%)	16% (10%- 25%)	16% (11%- 22%)
14-day Estimate	26% (18%- 37%)	35% (26%- 45%)	31% (24%- 38%)
21-day Estimate	34% (25%- 45%)	41% (32%- 52%)	38% (31%- 45%)
28-day Estimate	36% (27%- 48%)	45% (36%- 56%)	41% (34%- 49%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9089
Log hazard (SE), Relative Risk (95% CI) [b]: 0.027 (0.236), 1.027 (0.647 - 1.632)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.40, 1, 0.2370
Log hazard (SE), Relative Risk (95% CI) [b]: 0.278 (0.236), 1.320 (0.832 - 2.096)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.30.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, No Medical History of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	85	95	180
Total Number of Events	18	29	47
Total Number of Censored for CSH	67	66	133
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (14 - 23)	17 (14 - 22)	17 (15 - 21)
Median (95% CI)	(21 -)	28 (22 -)	(23 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	4% (1%- 14%)	4% (1%- 13%)	4% (2%- 9%)
14-day Estimate	13% (6%- 27%)	15% (8%- 26%)	14% (9%- 22%)
21-day Estimate	33% (21%- 51%)	35% (24%- 49%)	34% (26%- 45%)
28-day Estimate	49% (34%- 67%)	51% (38%- 64%)	50% (40%- 61%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (1%- 9%)	3% (1%- 9%)	3% (1%- 7%)
14-day Estimate	7% (3%- 15%)	11% (6%- 19%)	9% (6%- 14%)
21-day Estimate	15% (9%- 25%)	22% (15%- 32%)	19% (14%- 25%)
28-day Estimate	21% (14%- 31%)	31% (22%- 41%)	26% (20%- 33%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.08, 1, 0.7802
Log hazard (SE), Relative Risk (95% CI) [b]: 0.084 (0.300), 1.087 (0.604 - 1.959)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.02, 1, 0.1547
Log hazard (SE), Relative Risk (95% CI) [b]: 0.424 (0.300), 1.528 (0.848 - 2.751)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.30.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	30	19	49
Screening			
N	30	19	49
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	30 (100.0%)	19 (100.0%)	49 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	30	19	49
Hour 3 [a]			
N	30	19	49
4	30 (100.0%)	19 (100.0%)	49 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4
Change from Screening			
N	30	19	49
Mean (SD)	0.00 (0.000)	0.00 (0.000)	0.00 (0.000)
Median	0.00	0.00	0.00
Range	0 - 0	0 - 0	0 - 0
P-value [b] N/A			
P-value [c] N/A			
LS-Mean Placebo (95%CI) [c]	N/A		
LS-Mean LJ501 (95%CI) [c]	N/A		
LS-Mean Difference (95%CI) [c]	N/A		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	30	19	49
Hour 48 [a]			
N	30	19	49
0	6 (20.0%)	2 (10.5%)	8 (16.3%)
1	2 (6.7%)	1 (5.3%)	3 (6.1%)
2	0 (0.0%)	1 (5.3%)	1 (2.0%)
3	4 (13.3%)	3 (15.8%)	7 (14.3%)
4	11 (36.7%)	7 (36.8%)	18 (36.7%)
4 (LOCF)	1 (3.3%)	0 (0.0%)	1 (2.0%)
4 (WC)	6 (20.0%)	5 (26.3%)	11 (22.4%)
Mean (SD)	2.87 (1.655)	3.16 (1.385)	2.98 (1.548)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	30	19	49
Mean (SD)	-1.13 (1.655)	-0.84 (1.385)	-1.02 (1.548)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.7951			
P-value [c] 0.2881			
LS-Mean Placebo (95%CI) [c]	-1.20 (-1.73 - -0.67)		
LS-Mean LJ501 (95%CI) [c]	-0.74 (-1.41 - -0.07)		
LS-Mean Difference (95%CI) [c]	-0.46 (-1.32 - 0.40)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	30	19	49
Screening			
N	30	19	49
Mean (SD)	15.23 (2.515)	13.63 (2.033)	14.61 (2.448)
Median	15.00	14.00	14.00
Range	11 - 19	9 - 18	9 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	30	19	49
Hour 3			
N	30	19	49
Mean (SD)	15.40 (3.001)	14.89 (2.331)	15.20 (2.746)
Median	15.50	15.00	15.00
Range	9 - 20	9 - 18	9 - 20
Change from Screening			
N	30	19	49
Mean (SD)	0.17 (1.783)	1.26 (1.327)	0.59 (1.695)
Median	0.00	1.00	1.00
Range	-3 - 3	-1 - 4	-3 - 4
P-value [b] 0.0447			
P-value [c] 0.0482			
LS-Mean Placebo (95%CI) [c]	0.19 (-0.43 - 0.81)		
LS-Mean LJ501 (95%CI) [c]	1.23 (0.44 - 2.01)		
LS-Mean Difference (95%CI) [c]	-1.04 (-2.07 - -0.01)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	30	19	49
Hour 48			
N	30	19	49
Mean (SD)	16.27 (5.813)	16.74 (5.733)	16.45 (5.727)
Median	16.50	17.00	17.00
Range	4 - 24	6 - 24	4 - 24
Change from Screening			
N	30	19	49
Mean (SD)	1.03 (4.745)	3.11 (5.446)	1.84 (5.076)
Median	0.00	3.00	1.00
Range	-7 - 11	-7 - 11	-7 - 11
P-value [b] 0.2867			
P-value [c] 0.0866			
LS-Mean Placebo (95%CI) [c]	0.81 (-1.03 - 2.64)		
LS-Mean LJ501 (95%CI) [c]	3.46 (1.12 - 5.79)		
LS-Mean Difference (95%CI) [c]	-2.65 (-5.70 - 0.40)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.30.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	29	19	48
Total Number of Events	2	2	4
Total Number of Censored for CSH	27	17	44
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(6 -)	(5 -)	(6 -)
Median (95% CI)	(-)	(6 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	2+ - 7+	2+ - 7+	2+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
3-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
4-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
5-day Estimate	0% (0%- 0%)	8% (1%- 46%)	3% (0%- 20%)
6-day Estimate	11% (3%- 38%)	17% (4%- 52%)	13% (5%- 31%)
7-day Estimate	11% (3%- 38%)	17% (4%- 52%)	13% (5%- 31%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
3-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
4-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
5-day Estimate	0% (0%- 0%)	5% (1%- 32%)	2% (0%- 14%)
6-day Estimate	7% (2%- 25%)	11% (3%- 36%)	8% (3%- 21%)
7-day Estimate	7% (2%- 25%)	11% (3%- 36%)	8% (3%- 21%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.25, 1, 0.6155
Log hazard (SE), Relative Risk (95% CI) [b]: 0.497 (1.000), 1.644 (0.232 - 11.67)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.22, 1, 0.6401
Log hazard (SE), Relative Risk (95% CI) [b]: 0.463 (1.000), 1.589 (0.224 - 11.29)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.30.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	30	19	49
Total Number of Events	11	4	15
Total Number of Censored for CSH	19	15	34
Days to ICU Discharge			
25% Quartile (95% CI)	12 (4 - 19)	14 (6 -)	13 (6 - 15)
Median (95% CI)	20 (12 - 28)	(6 -)	20 (13 -)
75% Quartile (95% CI)	28 (19 -)	(15 -)	(22 -)
Range	2+ - 28+	2+ - 28+	2+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	10% (3%- 34%)	17% (4%- 52%)	13% (5%- 30%)
14-day Estimate	34% (17%- 62%)	31% (10%- 70%)	34% (19%- 56%)
21-day Estimate	58% (34%- 83%)	44% (19%- 81%)	53% (34%- 74%)
28-day Estimate	84% (54%- 99%)	44% (19%- 81%)	66% (45%- 85%)
ICU Discharge Cumulative Incidence			
7-day Estimate	7% (2%- 24%)	11% (3%- 36%)	8% (3%- 20%)
14-day Estimate	20% (10%- 39%)	16% (5%- 41%)	18% (10%- 32%)
21-day Estimate	30% (17%- 50%)	21% (8%- 47%)	27% (16%- 41%)
28-day Estimate	37% (22%- 56%)	21% (8%- 47%)	31% (20%- 46%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.94, 1, 0.3314
Log hazard (SE), Relative Risk (95% CI) [b]: -0.570 (0.594), 0.565 (0.176 - 1.812)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.10, 1, 0.2938
Log hazard (SE), Relative Risk (95% CI) [b]: -0.604 (0.584), 0.547 (0.174 - 1.717)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.30.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Medical History of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	30	19	49
Total Number of Events	8	4	12
Total Number of Censored for CSH	22	15	37
Days to Hospital Discharge			
25% Quartile (95% CI)	15 (12 - 28)	20 (18 -)	18 (12 - 24)
Median (95% CI)	28 (15 -)	(18 -)	28 (18 -)
75% Quartile (95% CI)	(28 -)	(21 -)	(28 -)
Range	2+ - 28+	2+ - 28+	2+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	20% (7%- 49%)	0% (0%- 0%)	13% (4%- 35%)
21-day Estimate	26% (11%- 56%)	38% (14%- 77%)	32% (17%- 56%)
28-day Estimate	67% (39%- 91%)	50% (23%- 85%)	59% (39%- 81%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	10% (3%- 28%)	0% (0%- 0%)	6% (2%- 18%)
21-day Estimate	13% (5%- 32%)	16% (5%- 41%)	14% (7%- 28%)
28-day Estimate	27% (14%- 46%)	21% (8%- 47%)	24% (15%- 39%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.30, 1, 0.5856
Log hazard (SE), Relative Risk (95% CI) [b]: -0.333 (0.614), 0.717 (0.215 - 2.388)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.21, 1, 0.6490
Log hazard (SE), Relative Risk (95% CI) [b]: -0.278 (0.613), 0.757 (0.228 - 2.516)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.31.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	72	88	160
Screening			
N	72	88	160
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	72 (100.0%)	88 (100.0%)	160 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	72	88	160
Hour 3 [a]			
N	72	88	160
3	1 (1.4%)	6 (6.8%)	7 (4.4%)
4	70 (97.2%)	82 (93.2%)	152 (95.0%)
4 (LOCF)	1 (1.4%)	0 (0.0%)	1 (0.6%)
Mean (SD)	3.99 (0.118)	3.93 (0.254)	3.96 (0.205)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	72	88	160
Mean (SD)	-0.01 (0.118)	-0.07 (0.254)	-0.04 (0.205)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.0847			
P-value [c] 0.1398			
LS-Mean Placebo (95%CI) [c]	-0.02 (-0.06 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.07 (-0.11 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.05 (-0.02 - 0.12)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	72	88	160
Hour 48 [a]			
N	72	88	160
0	13 (18.1%)	33 (37.5%)	46 (28.8%)
1	5 (6.9%)	5 (5.7%)	10 (6.3%)
2	0 (0.0%)	2 (2.3%)	2 (1.3%)
3	15 (20.8%)	16 (18.2%)	31 (19.4%)
4	22 (30.6%)	21 (23.9%)	43 (26.9%)
4 (LOCF)	2 (2.8%)	0 (0.0%)	2 (1.3%)
4 (WC)	15 (20.8%)	11 (12.5%)	26 (16.3%)
Mean (SD)	2.86 (1.568)	2.10 (1.794)	2.44 (1.733)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	72	88	160
Mean (SD)	-1.14 (1.568)	-1.90 (1.794)	-1.56 (1.733)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0168			
P-value [c] 0.0591			
LS-Mean Placebo (95%CI) [c]	-1.28 (-1.66 - -0.90)		
LS-Mean LJ501 (95%CI) [c]	-1.78 (-2.13 - -1.44)		
LS-Mean Difference (95%CI) [c]	0.50 (-0.02 - 1.03)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	72	88	160
Screening			
N	72	84	156
Mean (SD)	12.64 (3.078)	11.50 (2.826)	12.03 (2.990)
Median	13.00	11.00	12.00
Range	5 - 20	5 - 18	5 - 20

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	72	88	160
Hour 3			
N	72	88	160
Mean (SD)	13.10 (3.082)	12.36 (3.137)	12.69 (3.124)
Median	13.00	12.00	13.00
Range	7 - 18	5 - 20	5 - 20
Change from Screening			
N	72	84	156
Mean (SD)	0.46 (2.021)	0.93 (1.855)	0.71 (1.941)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b]	0.1190		
P-value [c]	0.2626		
LS-Mean Placebo (95%CI) [c]	0.52 (0.07 - 0.97)		
LS-Mean LJ501 (95%CI) [c]	0.88 (0.46 - 1.29)		
LS-Mean Difference (95%CI) [c]	-0.35 (-0.98 - 0.27)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	72	88	160
Hour 48			
N	72	88	160
Mean (SD)	14.19 (6.694)	12.03 (6.073)	13.01 (6.431)
Median	14.00	10.00	12.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	72	84	156
Mean (SD)	1.56 (5.576)	0.79 (5.765)	1.14 (5.673)
Median	1.00	0.00	0.00
Range	-8 - 16	-10 - 15	-10 - 16
P-value [b] 0.6810			
P-value [c] 0.9657			
LS-Mean Placebo (95%CI) [c]	1.16 (-0.09 - 2.41)		
LS-Mean LJ501 (95%CI) [c]	1.12 (-0.03 - 2.28)		
LS-Mean Difference (95%CI) [c]	0.04 (-1.69 - 1.77)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	66	78	144
Total Number of Events	21	24	45
Total Number of Censored for CSH	45	54	99
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	5 (4 - 7)	5 (3 - 7)	5 (4 - 6)
Median (95% CI)	(6 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 10%)	1% (0%- 9%)	1% (0%- 5%)
2-day Estimate	8% (3%- 18%)	8% (4%- 17%)	8% (4%- 14%)
3-day Estimate	12% (6%- 23%)	15% (9%- 26%)	14% (9%- 21%)
4-day Estimate	20% (12%- 34%)	18% (11%- 29%)	19% (13%- 27%)
5-day Estimate	27% (17%- 42%)	27% (18%- 40%)	27% (20%- 36%)
6-day Estimate	37% (25%- 53%)	32% (22%- 45%)	34% (26%- 44%)
7-day Estimate	44% (31%- 60%)	36% (26%- 49%)	39% (31%- 49%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 10%)	1% (0%- 9%)	1% (0%- 5%)
2-day Estimate	8% (3%- 17%)	8% (4%- 16%)	8% (4%- 13%)
3-day Estimate	11% (5%- 21%)	14% (8%- 24%)	13% (8%- 19%)
4-day Estimate	17% (10%- 28%)	17% (10%- 27%)	17% (11%- 24%)
5-day Estimate	21% (13%- 33%)	24% (16%- 35%)	23% (17%- 31%)
6-day Estimate	27% (18%- 40%)	28% (20%- 40%)	28% (21%- 36%)
7-day Estimate	32% (22%- 45%)	31% (22%- 42%)	31% (24%- 40%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.39, 1, 0.5331
Log hazard (SE), Relative Risk (95% CI) [b]: -0.186 (0.299), 0.830 (0.462 - 1.492)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9448
Log hazard (SE), Relative Risk (95% CI) [b]: -0.021 (0.299), 0.980 (0.545 - 1.759)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.31.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	72	88	160
Total Number of Events	31	41	72
Total Number of Censored for CSH	41	47	88
Days to ICU Discharge			
25% Quartile (95% CI)	7 (5 - 11)	8 (6 - 10)	8 (6 - 10)
Median (95% CI)	15 (10 - 18)	15 (11 - 23)	15 (11 - 18)
75% Quartile (95% CI)	22 (17 -)	(23 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	27% (17%- 42%)	21% (13%- 33%)	24% (17%- 32%)
14-day Estimate	47% (33%- 63%)	47% (36%- 60%)	47% (38%- 57%)
21-day Estimate	72% (56%- 86%)	60% (47%- 73%)	64% (54%- 74%)
28-day Estimate	83% (65%- 94%)	69% (56%- 81%)	74% (64%- 83%)
ICU Discharge Cumulative Incidence			
7-day Estimate	19% (12%- 31%)	17% (11%- 27%)	18% (13%- 25%)
14-day Estimate	31% (21%- 43%)	35% (26%- 46%)	33% (26%- 41%)
21-day Estimate	40% (30%- 53%)	42% (33%- 53%)	41% (34%- 49%)
28-day Estimate	43% (33%- 55%)	47% (37%- 58%)	45% (38%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.56, 1, 0.4526
Log hazard (SE), Relative Risk (95% CI) [b]: -0.180 (0.240), 0.835 (0.522 - 1.336)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.19, 1, 0.6640
Log hazard (SE), Relative Risk (95% CI) [b]: 0.103 (0.238), 1.109 (0.695 - 1.768)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.31.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, No Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	72	88	160
Total Number of Events	19	29	48
Total Number of Censored for CSH	53	59	112
Days to Hospital Discharge			
25% Quartile (95% CI)	17 (13 - 22)	17 (14 - 22)	17 (15 - 19)
Median (95% CI)	24 (18 -)	28 (22 -)	26 (22 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	4% (1%- 15%)	4% (1%- 13%)	4% (2%- 10%)
14-day Estimate	14% (7%- 29%)	16% (9%- 27%)	15% (9%- 23%)
21-day Estimate	39% (25%- 57%)	36% (25%- 50%)	37% (28%- 48%)
28-day Estimate	57% (40%- 74%)	52% (39%- 65%)	53% (43%- 64%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 11%)	3% (1%- 10%)	3% (1%- 7%)
14-day Estimate	8% (4%- 18%)	11% (6%- 20%)	10% (6%- 16%)
21-day Estimate	19% (12%- 31%)	24% (16%- 34%)	22% (16%- 29%)
28-day Estimate	26% (18%- 38%)	33% (24%- 44%)	30% (24%- 38%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.09, 1, 0.7604
Log hazard (SE), Relative Risk (95% CI) [b]: -0.090 (0.296), 0.914 (0.512 - 1.632)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.79, 1, 0.3741
Log hazard (SE), Relative Risk (95% CI) [b]: 0.262 (0.295), 1.299 (0.728 - 2.317)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.31.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	43	25	68
Screening			
N	43	25	68
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	43 (100.0%)	25 (100.0%)	68 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	43	25	68
Hour 3 [a]			
N	43	25	68
4	43 (100.0%)	25 (100.0%)	68 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4
Change from Screening			
N	43	25	68
Mean (SD)	0.00 (0.000)	0.00 (0.000)	0.00 (0.000)
Median	0.00	0.00	0.00
Range	0 - 0	0 - 0	0 - 0
P-value [b] N/A			
P-value [c] N/A			
LS-Mean Placebo (95%CI) [c]	N/A		
LS-Mean LJ501 (95%CI) [c]	N/A		
LS-Mean Difference (95%CI) [c]	N/A		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	43	25	68
Hour 48 [a]			
N	43	25	68
0	8 (18.6%)	4 (16.0%)	12 (17.6%)
1	1 (2.3%)	2 (8.0%)	3 (4.4%)
3	7 (16.3%)	4 (16.0%)	11 (16.2%)
4	14 (32.6%)	8 (32.0%)	22 (32.4%)
4 (WC)	13 (30.2%)	7 (28.0%)	20 (29.4%)
Mean (SD)	3.02 (1.566)	2.96 (1.567)	3.00 (1.555)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	43	25	68
Mean (SD)	-0.98 (1.566)	-1.04 (1.567)	-1.00 (1.555)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.9018			
P-value [c] 0.9415			
LS-Mean Placebo (95%CI) [c]	-0.99 (-1.45 - -0.53)		
LS-Mean LJ501 (95%CI) [c]	-1.02 (-1.62 - -0.41)		
LS-Mean Difference (95%CI) [c]	0.03 (-0.73 - 0.79)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	43	25	68
Screening			
N	43	25	68
Mean (SD)	14.49 (3.180)	12.68 (2.495)	13.82 (3.056)
Median	14.00	13.00	14.00
Range	8 - 21	8 - 18	8 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	43	25	68
Hour 3			
N	43	25	68
Mean (SD)	14.98 (3.248)	13.72 (2.821)	14.51 (3.136)
Median	15.00	14.00	15.00
Range	7 - 21	7 - 18	7 - 21
Change from Screening			
N	43	25	68
Mean (SD)	0.49 (1.778)	1.04 (1.567)	0.69 (1.713)
Median	0.00	1.00	1.00
Range	-3 - 5	-2 - 4	-3 - 5
P-value [b] 0.2848			
P-value [c] 0.5184			
LS-Mean Placebo (95%CI) [c]	0.59 (0.07 - 1.10)		
LS-Mean LJ501 (95%CI) [c]	0.87 (0.18 - 1.56)		
LS-Mean Difference (95%CI) [c]	-0.29 (-1.17 - 0.59)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Number of Patients	43	25	68
Hour 48			
N	43	25	68
Mean (SD)	17.02 (6.273)	16.12 (6.559)	16.69 (6.346)
Median	18.00	17.00	18.00
Range	4 - 24	3 - 24	3 - 24
Change from Screening			
N	43	25	68
Mean (SD)	2.53 (5.453)	3.44 (5.613)	2.87 (5.488)
Median	2.00	3.00	2.00
Range	-7 - 14	-5 - 13	-7 - 14
P-value [b] 0.3012			
P-value [c] 0.5114			
LS-Mean Placebo (95%CI) [c]	2.52 (0.83 - 4.21)		
LS-Mean LJ501 (95%CI) [c]	3.47 (1.23 - 5.71)		
LS-Mean Difference (95%CI) [c]	-0.95 (-3.81 - 1.92)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.31.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	42	24	66
Total Number of Events	3	4	7
Total Number of Censored for CSH	39	20	59
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(6 -)	6 (4 -)	(6 -)
Median (95% CI)	(-)	(6 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	2+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
3-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
4-day Estimate	0% (0%- 0%)	6% (1%- 35%)	2% (0%- 15%)
5-day Estimate	0% (0%- 0%)	13% (3%- 42%)	5% (1%- 17%)
6-day Estimate	8% (2%- 29%)	27% (11%- 58%)	15% (7%- 31%)
7-day Estimate	13% (4%- 34%)	27% (11%- 58%)	18% (9%- 34%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
3-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
4-day Estimate	0% (0%- 0%)	4% (1%- 26%)	2% (0%- 10%)
5-day Estimate	0% (0%- 0%)	8% (2%- 29%)	3% (1%- 12%)
6-day Estimate	5% (1%- 18%)	17% (7%- 39%)	9% (4%- 19%)
7-day Estimate	7% (2%- 21%)	17% (7%- 39%)	11% (5%- 21%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.74, 1, 0.1870
Log hazard (SE), Relative Risk (95% CI) [b]: 0.971 (0.765), 2.639 (0.590 - 11.81)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.56, 1, 0.2111
Log hazard (SE), Relative Risk (95% CI) [b]: 0.922 (0.764), 2.515 (0.563 - 11.24)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.31.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	43	25	68
Total Number of Events	11	5	16
Total Number of Censored for CSH	32	20	52
Days to ICU Discharge			
25% Quartile (95% CI)	13 (10 - 20)	12 (6 -)	12 (8 - 15)
Median (95% CI)	28 (13 -)	14 (8 -)	20 (13 -)
75% Quartile (95% CI)	(28 -)	(12 -)	(28 -)
Range	1+ - 28+	2+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 22%)	15% (4%- 48%)	7% (2%- 21%)
14-day Estimate	29% (14%- 54%)	54% (25%- 88%)	37% (22%- 57%)
21-day Estimate	49% (28%- 74%)	54% (25%- 88%)	51% (33%- 71%)
28-day Estimate	66% (42%- 88%)	54% (25%- 88%)	62% (42%- 81%)
ICU Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 15%)	8% (2%- 28%)	4% (1%- 13%)
14-day Estimate	14% (7%- 28%)	20% (9%- 42%)	16% (9%- 27%)
21-day Estimate	21% (11%- 36%)	20% (9%- 42%)	21% (13%- 32%)
28-day Estimate	26% (15%- 41%)	20% (9%- 42%)	24% (15%- 36%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.16, 1, 0.6892
Log hazard (SE), Relative Risk (95% CI) [b]: 0.218 (0.545), 1.243 (0.427 - 3.619)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.14, 1, 0.7037
Log hazard (SE), Relative Risk (95% CI) [b]: -0.205 (0.539), 0.815 (0.283 - 2.345)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.31.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Chest X-ray Finding of ARDS)

	Placebo	LJPC-501	Total
Total Number of Patients	43	25	68
Total Number of Events	7	3	10
Total Number of Censored for CSH	36	22	58
Days to Hospital Discharge			
25% Quartile (95% CI)	24 (12 -)	23 (17 -)	24 (13 - 28)
Median (95% CI)	(24 -)	(17 -)	(24 -)
75% Quartile (95% CI)	(-)	(24 -)	(-)
Range	1+ - 28+	2+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	16% (6%- 43%)	0% (0%- 0%)	11% (4%- 31%)
21-day Estimate	16% (6%- 43%)	25% (7%- 69%)	20% (9%- 42%)
28-day Estimate	46% (25%- 74%)	38% (14%- 77%)	43% (26%- 65%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	7% (2%- 20%)	0% (0%- 0%)	4% (1%- 13%)
21-day Estimate	7% (2%- 20%)	8% (2%- 28%)	7% (3%- 17%)
28-day Estimate	16% (8%- 31%)	12% (4%- 33%)	15% (8%- 26%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.08, 1, 0.7826
Log hazard (SE), Relative Risk (95% CI) [b]: -0.190 (0.691), 0.827 (0.213 - 3.202)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.21, 1, 0.6431
Log hazard (SE), Relative Risk (95% CI) [b]: -0.318 (0.690), 0.727 (0.188 - 2.813)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.32.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	15	17	32
Screening			
N	15	17	32
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	15 (100.0%)	17 (100.0%)	32 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	15	17	32
Hour 3 [a]			
N	15	17	32
3	0 (0.0%)	2 (11.8%)	2 (6.3%)
4	14 (93.3%)	15 (88.2%)	29 (90.6%)
4 (LOCF)	1 (6.7%)	0 (0.0%)	1 (3.1%)
Mean (SD)	4.00 (0.000)	3.88 (0.332)	3.94 (0.246)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	15	17	32
Mean (SD)	0.00 (0.000)	-0.12 (0.332)	-0.06 (0.246)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.3237			
P-value [c] 0.5279			
LS-Mean Placebo (95%CI) [c]	-0.03 (-0.16 - 0.09)		
LS-Mean LJ501 (95%CI) [c]	-0.09 (-0.21 - 0.03)		
LS-Mean Difference (95%CI) [c]	0.06 (-0.12 - 0.23)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	15	17	32
Hour 48 [a]			
N	15	17	32
0	4 (26.7%)	7 (41.2%)	11 (34.4%)
1	0 (0.0%)	1 (5.9%)	1 (3.1%)
2	0 (0.0%)	1 (5.9%)	1 (3.1%)
3	2 (13.3%)	5 (29.4%)	7 (21.9%)
4	2 (13.3%)	2 (11.8%)	4 (12.5%)
4 (WC)	7 (46.7%)	1 (5.9%)	8 (25.0%)
Mean (SD)	2.80 (1.781)	1.76 (1.678)	2.25 (1.778)
Median	4.00	2.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	15	17	32
Mean (SD)	-1.20 (1.781)	-2.24 (1.678)	-1.75 (1.778)
Median	0.00	-2.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.1297			
P-value [c] 0.4949			
LS-Mean Placebo (95%CI) [c]	-1.55 (-2.34 - -0.76)		
LS-Mean LJ501 (95%CI) [c]	-1.93 (-2.66 - -1.19)		
LS-Mean Difference (95%CI) [c]	0.38 (-0.74 - 1.49)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	15	17	32
Screening			
N	15	15	30
Mean (SD)	13.00 (2.928)	11.27 (3.494)	12.13 (3.288)
Median	13.00	11.00	12.00
Range	8 - 20	5 - 18	5 - 20

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	15	17	32
Hour 3			
N	15	17	32
Mean (SD)	13.00 (2.619)	11.71 (3.704)	12.31 (3.257)
Median	13.00	12.00	12.00
Range	8 - 17	5 - 20	5 - 20
Change from Screening			
N	15	15	30
Mean (SD)	0.00 (1.690)	0.60 (1.183)	0.30 (1.466)
Median	0.00	0.00	0.00
Range	-3 - 4	-1 - 2	-3 - 4
P-value [b] 0.6308			
P-value [c] 0.1574			
LS-Mean Placebo (95%CI) [c]	-0.07 (-0.79 - 0.65)		
LS-Mean LJ501 (95%CI) [c]	0.67 (-0.05 - 1.39)		
LS-Mean Difference (95%CI) [c]	-0.74 (-1.78 - 0.31)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	15	17	32
Hour 48			
N	15	17	32
Mean (SD)	16.40 (8.262)	9.53 (6.094)	12.75 (7.882)
Median	19.00	8.00	10.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	15	15	30
Mean (SD)	3.40 (7.538)	-1.47 (4.438)	0.97 (6.563)
Median	4.00	-2.00	-1.00
Range	-8 - 16	-7 - 9	-8 - 16
P-value [b] 0.1156			
P-value [c] 0.1524			
LS-Mean Placebo (95%CI) [c]	2.41 (-0.36 - 5.17)		
LS-Mean LJ501 (95%CI) [c]	-0.47 (-3.24 - 2.29)		
LS-Mean Difference (95%CI) [c]	2.88 (-1.14 - 6.90)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Total Number of Patients	15	16	31
Total Number of Events	5	9	14
Total Number of Censored for CSH	10	7	17
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	4 (1 - 7)	2 (1 - 3)	3 (2 - 5)
Median (95% CI)	7 (4 -)	3 (2 -)	6 (3 -)
75% Quartile (95% CI)	(6 -)	(3 -)	(7 -)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	7% (1%- 39%)	6% (1%- 37%)	6% (2%- 23%)
2-day Estimate	14% (4%- 45%)	31% (14%- 60%)	23% (12%- 43%)
3-day Estimate	14% (4%- 45%)	52% (30%- 78%)	36% (21%- 57%)
4-day Estimate	28% (9%- 68%)	52% (30%- 78%)	41% (25%- 62%)
5-day Estimate	28% (9%- 68%)	60% (37%- 84%)	46% (29%- 68%)
6-day Estimate	43% (17%- 81%)	60% (37%- 84%)	52% (33%- 73%)
7-day Estimate	62% (29%- 93%)	60% (37%- 84%)	59% (38%- 80%)
Ventilator Cumulative Incidence			
1-day Estimate	7% (1%- 39%)	6% (1%- 37%)	6% (2%- 23%)
2-day Estimate	13% (4%- 44%)	31% (14%- 60%)	23% (11%- 42%)
3-day Estimate	13% (4%- 44%)	50% (29%- 75%)	32% (19%- 52%)
4-day Estimate	20% (7%- 50%)	50% (29%- 75%)	35% (21%- 55%)
5-day Estimate	20% (7%- 50%)	56% (34%- 80%)	39% (24%- 58%)
6-day Estimate	27% (11%- 56%)	56% (34%- 80%)	42% (27%- 61%)
7-day Estimate	33% (15%- 62%)	56% (34%- 80%)	45% (30%- 64%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.62, 1, 0.4313
Log hazard (SE), Relative Risk (95% CI) [b]: 0.436 (0.558), 1.546 (0.518 - 4.617)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.77, 1, 0.1832
Log hazard (SE), Relative Risk (95% CI) [b]: 0.731 (0.561), 2.078 (0.692 - 6.243)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.32.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Total Number of Patients	15	17	32
Total Number of Events	7	12	19
Total Number of Censored for CSH	8	5	13
Days to ICU Discharge			
25% Quartile (95% CI)	6 (3 - 12)	5 (3 - 7)	5 (3 - 7)
Median (95% CI)	12 (3 - 15)	7 (4 - 14)	8 (5 - 14)
75% Quartile (95% CI)	15 (6 -)	14 (7 -)	14 (10 -)
Range	1+ - 28+	2+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	36% (13%- 76%)	55% (32%- 80%)	48% (30%- 70%)
14-day Estimate	74% (43%- 96%)	81% (56%- 97%)	79% (59%- 93%)
21-day Estimate	87% (57%- 99%)	91% (66%- 99%)	89% (71%- 98%)
28-day Estimate	87% (57%- 99%)	91% (66%- 99%)	89% (71%- 98%)
ICU Discharge Cumulative Incidence			
7-day Estimate	20% (7%- 50%)	47% (27%- 72%)	34% (21%- 53%)
14-day Estimate	40% (20%- 68%)	65% (43%- 86%)	53% (37%- 71%)
21-day Estimate	47% (26%- 74%)	71% (49%- 89%)	59% (43%- 76%)
28-day Estimate	47% (26%- 74%)	71% (49%- 89%)	59% (43%- 76%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.14, 1, 0.7072
Log hazard (SE), Relative Risk (95% CI) [b]: 0.180 (0.481), 1.198 (0.467 - 3.075)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.96, 1, 0.1613
Log hazard (SE), Relative Risk (95% CI) [b]: 0.658 (0.478), 1.931 (0.756 - 4.931)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.32.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, No History of Sepsis)

	Placebo	LJPC-501	Total
Total Number of Patients	15	17	32
Total Number of Events	3	10	13
Total Number of Censored for CSH	12	7	19
Days to Hospital Discharge			
25% Quartile (95% CI)	16 (6 -)	8 (7 - 16)	9 (6 - 16)
Median (95% CI)	(6 -)	16 (8 - 28)	24 (9 -)
75% Quartile (95% CI)	(24 -)	28 (16 -)	(24 -)
Range	1+ - 28+	2+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	13% (2%- 61%)	14% (4%- 46%)	14% (5%- 37%)
14-day Estimate	13% (2%- 61%)	43% (22%- 72%)	33% (17%- 57%)
21-day Estimate	27% (7%- 72%)	59% (35%- 84%)	48% (30%- 71%)
28-day Estimate	42% (16%- 82%)	76% (51%- 94%)	64% (44%- 84%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	7% (1%- 39%)	12% (3%- 39%)	9% (3%- 26%)
14-day Estimate	7% (1%- 39%)	35% (18%- 62%)	22% (11%- 40%)
21-day Estimate	13% (4%- 44%)	47% (27%- 72%)	31% (18%- 50%)
28-day Estimate	20% (7%- 50%)	59% (37%- 81%)	41% (26%- 59%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.57, 1, 0.2107
Log hazard (SE), Relative Risk (95% CI) [b]: 0.809 (0.663), 2.246 (0.612 - 8.244)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 4.55, 1, 0.0329
Log hazard (SE), Relative Risk (95% CI) [b]: 1.315 (0.661), 3.727 (1.021 - 13.61)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.32.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	100	97	197
Screening			
N	100	97	197
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	100 (100.0%)	97 (100.0%)	197 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	100	97	197
Hour 3 [a]			
N	100	97	197
3	1 (1.0%)	4 (4.1%)	5 (2.5%)
4	99 (99.0%)	93 (95.9%)	192 (97.5%)
Mean (SD)	3.99 (0.100)	3.96 (0.200)	3.97 (0.158)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	100	97	197
Mean (SD)	-0.01 (0.100)	-0.04 (0.200)	-0.03 (0.158)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.1485			
P-value [c] 0.1743			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.04 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.04 (-0.07 - -0.01)		
LS-Mean Difference (95%CI) [c]	0.03 (-0.01 - 0.08)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	100	97	197
Hour 48 [a]			
N	100	97	197
0	17 (17.0%)	30 (30.9%)	47 (23.9%)
1	6 (6.0%)	6 (6.2%)	12 (6.1%)
2	0 (0.0%)	1 (1.0%)	1 (0.5%)
3	20 (20.0%)	15 (15.5%)	35 (17.8%)
4	34 (34.0%)	28 (28.9%)	62 (31.5%)
4 (LOCF)	2 (2.0%)	0 (0.0%)	2 (1.0%)
4 (WC)	21 (21.0%)	17 (17.5%)	38 (19.3%)
Mean (SD)	2.94 (1.536)	2.40 (1.783)	2.68 (1.680)
Median	4.00	3.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	100	97	197
Mean (SD)	-1.06 (1.536)	-1.60 (1.783)	-1.32 (1.680)
Median	0.00	-1.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b]	0.0926		
P-value [c]	0.1022		
LS-Mean Placebo (95%CI) [c]	-1.14 (-1.46 - -0.82)		
LS-Mean LJ501 (95%CI) [c]	-1.52 (-1.84 - -1.19)		
LS-Mean Difference (95%CI) [c]	0.38 (-0.08 - 0.84)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	100	97	197
Screening			
N	100	95	195
Mean (SD)	13.38 (3.284)	11.91 (2.710)	12.66 (3.099)
Median	13.00	12.00	13.00
Range	5 - 21	6 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:05

Table 14.2.32.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	100	97	197
Hour 3			
N	100	97	197
Mean (SD)	13.92 (3.341)	12.88 (2.997)	13.41 (3.212)
Median	14.00	13.00	13.00
Range	7 - 21	5 - 19	5 - 21
Change from Screening			
N	100	95	195
Mean (SD)	0.54 (1.956)	1.00 (1.857)	0.76 (1.917)
Median	0.00	1.00	1.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.0856			
P-value [c] 0.3465			
LS-Mean Placebo (95%CI) [c]	0.64 (0.26 - 1.01)		
LS-Mean LJ501 (95%CI) [c]	0.90 (0.51 - 1.28)		
LS-Mean Difference (95%CI) [c]	-0.26 (-0.81 - 0.29)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Number of Patients	100	97	197
Hour 48			
N	100	97	197
Mean (SD)	15.08 (6.413)	13.59 (6.258)	14.35 (6.365)
Median	15.00	13.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	100	95	195
Mean (SD)	1.70 (5.173)	1.84 (5.864)	1.77 (5.507)
Median	1.00	1.00	1.00
Range	-7 - 15	-10 - 15	-10 - 15
P-value [b] 0.4582			
P-value [c] 0.5096			
LS-Mean Placebo (95%CI) [c]	1.52 (0.45 - 2.58)		
LS-Mean LJ501 (95%CI) [c]	2.04 (0.94 - 3.13)		
LS-Mean Difference (95%CI) [c]	-0.52 (-2.07 - 1.03)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.32.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Total Number of Patients	93	87	180
Total Number of Events	19	19	38
Total Number of Censored for CSH	74	68	142
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (5 -)	7 (5 -)	7 (6 -)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	3% (1%- 10%)	1% (0%- 8%)	2% (1%- 6%)
3-day Estimate	6% (3%- 14%)	4% (1%- 11%)	5% (3%- 10%)
4-day Estimate	11% (5%- 20%)	8% (4%- 17%)	9% (6%- 15%)
5-day Estimate	15% (9%- 26%)	17% (10%- 28%)	16% (11%- 24%)
6-day Estimate	24% (15%- 36%)	25% (16%- 37%)	24% (18%- 33%)
7-day Estimate	29% (20%- 42%)	28% (19%- 41%)	29% (22%- 37%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	3% (1%- 10%)	1% (0%- 8%)	2% (1%- 6%)
3-day Estimate	5% (2%- 12%)	3% (1%- 10%)	4% (2%- 9%)
4-day Estimate	9% (4%- 16%)	7% (3%- 15%)	8% (5%- 13%)
5-day Estimate	12% (7%- 20%)	14% (8%- 23%)	13% (9%- 19%)
6-day Estimate	17% (11%- 27%)	20% (13%- 30%)	18% (13%- 25%)
7-day Estimate	20% (14%- 30%)	22% (15%- 32%)	21% (16%- 28%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.03, 1, 0.8683
Log hazard (SE), Relative Risk (95% CI) [b]: -0.054 (0.325), 0.948 (0.502 - 1.790)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.04, 1, 0.8374
Log hazard (SE), Relative Risk (95% CI) [b]: 0.067 (0.324), 1.069 (0.566 - 2.019)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.32.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Total Number of Patients	100	97	197
Total Number of Events	35	35	70
Total Number of Censored for CSH	65	62	127
Days to ICU Discharge			
25% Quartile (95% CI)	11 (7 - 14)	10 (8 - 13)	10 (8 - 12)
Median (95% CI)	18 (15 - 25)	18 (14 - 28)	18 (15 - 23)
75% Quartile (95% CI)	28 (20 -)	(28 -)	(28 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	17% (10%- 28%)	13% (7%- 23%)	15% (10%- 22%)
14-day Estimate	36% (25%- 50%)	40% (29%- 54%)	38% (30%- 48%)
21-day Estimate	61% (47%- 76%)	54% (41%- 68%)	57% (47%- 67%)
28-day Estimate	76% (60%- 89%)	63% (50%- 77%)	68% (58%- 78%)
ICU Discharge Cumulative Incidence			
7-day Estimate	12% (7%- 20%)	9% (5%- 17%)	11% (7%- 16%)
14-day Estimate	22% (15%- 31%)	26% (18%- 36%)	24% (19%- 30%)
21-day Estimate	31% (23%- 41%)	32% (24%- 42%)	31% (25%- 38%)
28-day Estimate	35% (27%- 45%)	36% (27%- 46%)	36% (29%- 43%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.27, 1, 0.6063
Log hazard (SE), Relative Risk (95% CI) [b]: -0.124 (0.240), 0.883 (0.552 - 1.414)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.04, 1, 0.8477
Log hazard (SE), Relative Risk (95% CI) [b]: 0.046 (0.239), 1.047 (0.655 - 1.673)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.32.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, History of Sepsis)

	Placebo	LJPC-501	Total
Total Number of Patients	100	97	197
Total Number of Events	23	23	46
Total Number of Censored for CSH	77	74	151
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (14 - 23)	20 (17 - 23)	18 (17 - 22)
Median (95% CI)	28 (22 -)	(23 -)	(23 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	2% (0%- 10%)	1% (0%- 10%)	1% (0%- 6%)
14-day Estimate	15% (8%- 29%)	7% (3%- 17%)	11% (6%- 18%)
21-day Estimate	33% (21%- 49%)	30% (20%- 45%)	31% (23%- 42%)
28-day Estimate	55% (41%- 71%)	45% (32%- 59%)	49% (40%- 60%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	1% (0%- 7%)	1% (0%- 7%)	1% (0%- 4%)
14-day Estimate	8% (4%- 15%)	4% (2%- 11%)	6% (4%- 10%)
21-day Estimate	15% (9%- 24%)	16% (10%- 26%)	16% (11%- 22%)
28-day Estimate	23% (16%- 33%)	24% (16%- 33%)	23% (18%- 30%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.91, 1, 0.3404
Log hazard (SE), Relative Risk (95% CI) [b]: -0.281 (0.295), 0.755 (0.423 - 1.347)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9275
Log hazard (SE), Relative Risk (95% CI) [b]: 0.027 (0.295), 1.027 (0.576 - 1.831)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.33.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	77	81	158
Screening			
N	77	81	158
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	77 (100.0%)	81 (100.0%)	158 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	77	81	158
Hour 3 [a]			
N	77	81	158
3	1 (1.3%)	6 (7.4%)	7 (4.4%)
4	76 (98.7%)	75 (92.6%)	151 (95.6%)
Mean (SD)	3.99 (0.114)	3.93 (0.264)	3.96 (0.206)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	77	81	158
Mean (SD)	-0.01 (0.114)	-0.07 (0.264)	-0.04 (0.206)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.0730			
P-value [c] 0.0771			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.06 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.07 (-0.12 - -0.03)		
LS-Mean Difference (95%CI) [c]	0.06 (-0.01 - 0.12)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	77	81	158
Hour 48 [a]			
N	77	81	158
0	16 (20.8%)	31 (38.3%)	47 (29.7%)
1	6 (7.8%)	7 (8.6%)	13 (8.2%)
2	0 (0.0%)	1 (1.2%)	1 (0.6%)
3	19 (24.7%)	17 (21.0%)	36 (22.8%)
4	24 (31.2%)	18 (22.2%)	42 (26.6%)
4 (LOCF)	2 (2.6%)	0 (0.0%)	2 (1.3%)
4 (WC)	10 (13.0%)	7 (8.6%)	17 (10.8%)
Mean (SD)	2.69 (1.608)	1.98 (1.761)	2.32 (1.720)
Median	3.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	77	81	158
Mean (SD)	-1.31 (1.608)	-2.02 (1.761)	-1.68 (1.720)
Median	-1.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0189			
P-value [c] 0.0321			
LS-Mean Placebo (95%CI) [c]	-1.38 (-1.76 - -1.01)		
LS-Mean LJ501 (95%CI) [c]	-1.96 (-2.32 - -1.59)		
LS-Mean Difference (95%CI) [c]	0.57 (0.05 - 1.10)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	77	81	158
Screening			
N	77	78	155
Mean (SD)	13.14 (3.207)	11.69 (2.880)	12.41 (3.123)
Median	13.00	11.50	12.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	77	81	158
Hour 3			
N	77	81	158
Mean (SD)	13.45 (3.311)	12.51 (3.186)	12.97 (3.272)
Median	13.00	13.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	77	78	155
Mean (SD)	0.31 (1.901)	0.90 (1.799)	0.61 (1.867)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b]	0.0510		
P-value [c]	0.1503		
LS-Mean Placebo (95%CI) [c]	0.38 (-0.04 - 0.80)		
LS-Mean LJ501 (95%CI) [c]	0.83 (0.41 - 1.24)		
LS-Mean Difference (95%CI) [c]	-0.44 (-1.05 - 0.16)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	77	81	158
Hour 48			
N	77	81	158
Mean (SD)	13.42 (6.214)	11.65 (5.743)	12.51 (6.023)
Median	13.00	10.00	12.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	77	78	155
Mean (SD)	0.27 (4.765)	0.19 (5.525)	0.23 (5.144)
Median	0.00	0.00	0.00
Range	-8 - 15	-10 - 15	-10 - 15
P-value [b] 0.8670			
P-value [c] 0.9509			
LS-Mean Placebo (95%CI) [c]	0.21 (-0.94 - 1.35)		
LS-Mean LJ501 (95%CI) [c]	0.26 (-0.88 - 1.40)		
LS-Mean Difference (95%CI) [c]	-0.05 (-1.70 - 1.60)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	70	75	145
Total Number of Events	20	27	47
Total Number of Censored for CSH	50	48	98
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 -)	5 (3 - 6)	5 (4 - 6)
Median (95% CI)	(7 -)	(6 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	1% (0%- 10%)	1% (0%- 9%)	1% (0%- 5%)
2-day Estimate	6% (2%- 15%)	8% (4%- 17%)	7% (4%- 13%)
3-day Estimate	9% (4%- 19%)	15% (9%- 26%)	12% (8%- 19%)
4-day Estimate	16% (9%- 28%)	20% (12%- 31%)	18% (12%- 26%)
5-day Estimate	22% (13%- 35%)	30% (21%- 43%)	26% (20%- 35%)
6-day Estimate	30% (20%- 44%)	38% (28%- 51%)	35% (27%- 44%)
7-day Estimate	36% (25%- 51%)	40% (30%- 53%)	38% (30%- 48%)
Ventilator Cumulative Incidence			
1-day Estimate	1% (0%- 10%)	1% (0%- 9%)	1% (0%- 5%)
2-day Estimate	6% (2%- 15%)	8% (4%- 17%)	7% (4%- 12%)
3-day Estimate	9% (4%- 18%)	15% (8%- 25%)	12% (7%- 18%)
4-day Estimate	14% (8%- 25%)	19% (12%- 29%)	17% (11%- 24%)
5-day Estimate	19% (11%- 30%)	28% (19%- 40%)	23% (17%- 31%)
6-day Estimate	24% (16%- 36%)	35% (25%- 47%)	30% (23%- 38%)
7-day Estimate	29% (19%- 41%)	36% (26%- 48%)	32% (25%- 41%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.42, 1, 0.5192
Log hazard (SE), Relative Risk (95% CI) [b]: 0.190 (0.295), 1.209 (0.678 - 2.156)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.99, 1, 0.3202
Log hazard (SE), Relative Risk (95% CI) [b]: 0.292 (0.295), 1.340 (0.751 - 2.389)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.33.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	77	81	158
Total Number of Events	33	38	71
Total Number of Censored for CSH	44	43	87
Days to ICU Discharge			
25% Quartile (95% CI)	10 (5 - 11)	8 (6 - 10)	8 (6 - 10)
Median (95% CI)	17 (11 - 20)	15 (10 - 23)	15 (12 - 18)
75% Quartile (95% CI)	28 (18 -)	(22 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	25% (16%- 38%)	22% (14%- 34%)	23% (17%- 32%)
14-day Estimate	47% (34%- 62%)	49% (37%- 62%)	48% (39%- 58%)
21-day Estimate	68% (52%- 82%)	60% (47%- 73%)	63% (53%- 73%)
28-day Estimate	77% (60%- 91%)	68% (54%- 80%)	71% (61%- 81%)
ICU Discharge Cumulative Incidence			
7-day Estimate	19% (12%- 30%)	19% (12%- 29%)	19% (14%- 26%)
14-day Estimate	32% (23%- 44%)	37% (28%- 49%)	35% (28%- 43%)
21-day Estimate	40% (30%- 52%)	43% (33%- 55%)	42% (35%- 50%)
28-day Estimate	43% (33%- 55%)	47% (37%- 58%)	45% (38%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.07, 1, 0.7880
Log hazard (SE), Relative Risk (95% CI) [b]: -0.064 (0.239), 0.938 (0.587 - 1.498)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.27, 1, 0.6029
Log hazard (SE), Relative Risk (95% CI) [b]: 0.124 (0.238), 1.131 (0.710 - 1.804)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.33.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose <0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	77	81	158
Total Number of Events	22	24	46
Total Number of Censored for CSH	55	57	112
Days to Hospital Discharge			
25% Quartile (95% CI)	16 (13 - 21)	19 (15 - 22)	18 (15 - 21)
Median (95% CI)	23 (18 -)	(22 -)	28 (22 -)
75% Quartile (95% CI)	(28 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	4% (1%- 13%)	5% (2%- 14%)	4% (2%- 10%)
14-day Estimate	17% (9%- 32%)	13% (7%- 24%)	15% (9%- 23%)
21-day Estimate	40% (27%- 58%)	33% (22%- 47%)	36% (27%- 47%)
28-day Estimate	60% (44%- 77%)	45% (33%- 59%)	51% (41%- 62%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 10%)	4% (1%- 11%)	3% (1%- 7%)
14-day Estimate	10% (5%- 20%)	10% (5%- 19%)	10% (6%- 16%)
21-day Estimate	21% (13%- 32%)	22% (15%- 33%)	22% (16%- 29%)
28-day Estimate	29% (20%- 40%)	30% (21%- 41%)	29% (23%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.27, 1, 0.2592
Log hazard (SE), Relative Risk (95% CI) [b]: -0.334 (0.297), 0.716 (0.400 - 1.282)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8751
Log hazard (SE), Relative Risk (95% CI) [b]: 0.046 (0.295), 1.047 (0.587 - 1.868)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.33.2.1

CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	38	33	71
Screening			
N	38	33	71
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	38 (100.0%)	33 (100.0%)	71 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	38	33	71
Hour 3 [a]			
N	38	33	71
4	37 (97.4%)	33 (100.0%)	70 (98.6%)
4 (LOCF)	1 (2.6%)	0 (0.0%)	1 (1.4%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4
Change from Screening			
N	38	33	71
Mean (SD)	0.00 (0.000)	0.00 (0.000)	0.00 (0.000)
Median	0.00	0.00	0.00
Range	0 - 0	0 - 0	0 - 0
P-value [b] N/A			
P-value [c] N/A			
LS-Mean Placebo (95%CI) [c]	N/A		
LS-Mean LJ501 (95%CI) [c]	N/A		
LS-Mean Difference (95%CI) [c]	N/A		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	38	33	71
Hour 48 [a]			
N	38	33	71
0	5 (13.2%)	6 (18.2%)	11 (15.5%)
2	0 (0.0%)	1 (3.0%)	1 (1.4%)
3	3 (7.9%)	3 (9.1%)	6 (8.5%)
4	12 (31.6%)	12 (36.4%)	24 (33.8%)
4 (WC)	18 (47.4%)	11 (33.3%)	29 (40.8%)
Mean (SD)	3.39 (1.366)	3.12 (1.556)	3.27 (1.454)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	38	33	71
Mean (SD)	-0.61 (1.366)	-0.88 (1.556)	-0.73 (1.454)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b]	0.5904		
P-value [c]	0.9164		
LS-Mean Placebo (95%CI) [c]	-0.72 (-1.17 - -0.26)		
LS-Mean LJ501 (95%CI) [c]	-0.75 (-1.24 - -0.26)		
LS-Mean Difference (95%CI) [c]	0.04 (-0.65 - 0.72)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.2.2

Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	38	33	71
Screening			
N	38	32	70
Mean (SD)	13.71 (3.287)	12.13 (2.685)	12.99 (3.109)
Median	14.00	13.00	13.00
Range	6 - 20	7 - 17	6 - 20

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:06

Table 14.2.33.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	38	33	71
Hour 3			
N	38	33	71
Mean (SD)	14.50 (3.082)	13.18 (2.952)	13.89 (3.073)
Median	14.50	13.00	14.00
Range	7 - 20	5 - 19	5 - 20
Change from Screening			
N	38	32	70
Mean (SD)	0.79 (1.961)	1.06 (1.759)	0.91 (1.863)
Median	1.00	1.00	1.00
Range	-3 - 5	-2 - 5	-3 - 5
P-value [b]	0.5897		
P-value [c]	0.7693		
LS-Mean Placebo (95%CI) [c]	0.98 (0.38 - 1.57)		
LS-Mean LJ501 (95%CI) [c]	0.84 (0.19 - 1.49)		
LS-Mean Difference (95%CI) [c]	0.13 (-0.77 - 1.04)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	38	33	71
Hour 48			
N	38	33	71
Mean (SD)	18.97 (5.993)	16.24 (6.755)	17.70 (6.460)
Median	21.00	16.00	18.00
Range	4 - 24	4 - 24	4 - 24
Change from Screening			
N	38	32	70
Mean (SD)	5.26 (5.510)	4.31 (5.433)	4.83 (5.456)
Median	5.00	4.00	4.50
Range	-7 - 16	-4 - 13	-7 - 16
P-value [b] 0.5689			
P-value [c] 0.7271			
LS-Mean Placebo (95%CI) [c]	5.05 (3.26 - 6.83)		
LS-Mean LJ501 (95%CI) [c]	4.57 (2.61 - 6.52)		
LS-Mean Difference (95%CI) [c]	0.48 (-2.25 - 3.20)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.33.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	38	28	66
Total Number of Events	4	1	5
Total Number of Censored for CSH	34	27	61
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(6 -)	(7 -)	(7 -)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	3% (0%- 19%)	0% (0%- 0%)	2% (0%- 11%)
3-day Estimate	3% (0%- 19%)	0% (0%- 0%)	2% (0%- 11%)
4-day Estimate	3% (0%- 19%)	0% (0%- 0%)	2% (0%- 11%)
5-day Estimate	3% (0%- 19%)	0% (0%- 0%)	2% (0%- 11%)
6-day Estimate	15% (5%- 41%)	0% (0%- 0%)	8% (3%- 24%)
7-day Estimate	21% (8%- 48%)	8% (1%- 43%)	15% (6%- 33%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	3% (0%- 17%)	0% (0%- 0%)	2% (0%- 10%)
3-day Estimate	3% (0%- 17%)	0% (0%- 0%)	2% (0%- 10%)
4-day Estimate	3% (0%- 17%)	0% (0%- 0%)	2% (0%- 10%)
5-day Estimate	3% (0%- 17%)	0% (0%- 0%)	2% (0%- 10%)
6-day Estimate	8% (3%- 23%)	0% (0%- 0%)	5% (1%- 13%)
7-day Estimate	11% (4%- 26%)	4% (1%- 23%)	8% (3%- 17%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.48, 1, 0.2236
Log hazard (SE), Relative Risk (95% CI) [b]: -1.274 (1.119), 0.280 (0.031 - 2.506)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.12, 1, 0.2892
Log hazard (SE), Relative Risk (95% CI) [b]: -1.125 (1.118), 0.325 (0.036 - 2.906)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.33.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	38	33	71
Total Number of Events	9	9	18
Total Number of Censored for CSH	29	24	53
Days to ICU Discharge			
25% Quartile (95% CI)	15 (8 - 20)	14 (4 - 15)	14 (8 - 15)
Median (95% CI)	20 (12 -)	20 (9 -)	20 (14 - 28)
75% Quartile (95% CI)	(20 -)	(15 -)	(20 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	10% (3%- 36%)	5% (1%- 20%)
14-day Estimate	20% (7%- 51%)	41% (20%- 71%)	30% (17%- 50%)
21-day Estimate	52% (29%- 80%)	60% (34%- 86%)	56% (38%- 76%)
28-day Estimate	71% (45%- 93%)	70% (43%- 92%)	70% (51%- 87%)
ICU Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	6% (2%- 22%)	3% (1%- 11%)
14-day Estimate	8% (3%- 23%)	18% (9%- 36%)	13% (7%- 23%)
21-day Estimate	18% (9%- 35%)	24% (13%- 43%)	21% (13%- 33%)
28-day Estimate	24% (13%- 41%)	27% (15%- 46%)	25% (17%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.28, 1, 0.5958
Log hazard (SE), Relative Risk (95% CI) [b]: 0.250 (0.473), 1.284 (0.508 - 3.244)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.21, 1, 0.6435
Log hazard (SE), Relative Risk (95% CI) [b]: 0.218 (0.471), 1.243 (0.493 - 3.132)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.33.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Norep Eq Dose >=0.5 ug/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	38	33	71
Total Number of Events	4	9	13
Total Number of Censored for CSH	34	24	58
Days to Hospital Discharge			
25% Quartile (95% CI)	28 (12 -)	17 (13 - 23)	20 (13 - 25)
Median (95% CI)	(25 -)	23 (16 -)	28 (23 -)
75% Quartile (95% CI)	(-)	(20 -)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	7% (1%- 41%)	15% (4%- 48%)	11% (4%- 30%)
21-day Estimate	7% (1%- 41%)	47% (24%- 76%)	27% (14%- 48%)
28-day Estimate	32% (14%- 65%)	73% (48%- 93%)	53% (35%- 73%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	3% (0%- 17%)	6% (2%- 22%)	4% (1%- 13%)
21-day Estimate	3% (0%- 17%)	18% (9%- 36%)	10% (5%- 20%)
28-day Estimate	11% (4%- 26%)	27% (15%- 46%)	18% (11%- 29%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 4.99, 1, 0.0255
Log hazard (SE), Relative Risk (95% CI) [b]: 1.279 (0.609), 3.594 (1.089 - 11.86)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 3.49, 1, 0.0618
Log hazard (SE), Relative Risk (95% CI) [b]: 1.072 (0.601), 2.920 (0.898 - 9.491)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.34.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	1	73	74
Screening			
N	1	73	74
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	1 (100.0%)	73 (100.0%)	74 (100.0%)
Mean (SD)	4.00 (NA)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	1	73	74
Hour 3 [a]			
N	1	73	74
3	0 (0.0%)	5 (6.8%)	5 (6.8%)
4	1 (100.0%)	68 (93.2%)	69 (93.2%)
Mean (SD)	4.00 (NA)	3.93 (0.254)	3.93 (0.253)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	1	73	74
Mean (SD)	0.00 (NA)	-0.07 (0.254)	-0.07 (0.253)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.6547			
P-value [c] 0.4519			
LS-Mean Placebo (95%CI) [c]	0.12 (-0.37 - 0.61)		
LS-Mean LJ501 (95%CI) [c]	-0.07 (-0.13 - -0.01)		
LS-Mean Difference (95%CI) [c]	0.19 (-0.31 - 0.68)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	1	73	74
Hour 48 [a]			
N	1	73	74
0	1 (100.0%)	26 (35.6%)	27 (36.5%)
1	0 (0.0%)	6 (8.2%)	6 (8.1%)
2	0 (0.0%)	2 (2.7%)	2 (2.7%)
3	0 (0.0%)	17 (23.3%)	17 (23.0%)
4	0 (0.0%)	16 (21.9%)	16 (21.6%)
4 (WC)	0 (0.0%)	6 (8.2%)	6 (8.1%)
Mean (SD)	0.00 (NA)	2.04 (1.728)	2.01 (1.732)
Median	0.00	3.00	3.00
Range	0 - 0	0 - 4	0 - 4
Change from Screening			
N	1	73	74
Mean (SD)	-4.00 (NA)	-1.96 (1.728)	-1.99 (1.732)
Median	-4.00	-1.00	-1.00
Range	-4 - -4	-4 - 0	-4 - 0
P-value [b]	0.3487		
P-value [c]	0.3521		
LS-Mean Placebo (95%CI) [c]	-3.57 (-6.98 - -0.17)		
LS-Mean LJ501 (95%CI) [c]	-1.96 (-2.36 - -1.57)		
LS-Mean Difference (95%CI) [c]	-1.61 (-5.04 - 1.82)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	1	73	74
Screening			
N	1	71	72
Mean (SD)	11.00 (NA)	11.63 (2.934)	11.63 (2.914)
Median	11.00	12.00	12.00
Range	11 - 11	5 - 18	5 - 18

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	1	73	74
Hour 3			
N	1	73	74
Mean (SD)	10.00 (NA)	12.47 (3.198)	12.43 (3.189)
Median	10.00	13.00	12.50
Range	10 - 10	5 - 20	5 - 20
Change from Screening			
N	1	71	72
Mean (SD)	-1.00 (NA)	0.90 (1.798)	0.88 (1.799)
Median	-1.00	1.00	1.00
Range	-1 - -1	-2 - 7	-2 - 7
P-value [b]	0.2356		
P-value [c]	0.2807		
LS-Mean Placebo (95%CI) [c]	-1.12 (-4.81 - 2.57)		
LS-Mean LJ501 (95%CI) [c]	0.90 (0.47 - 1.33)		
LS-Mean Difference (95%CI) [c]	-2.03 (-5.74 - 1.69)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	1	73	74
Hour 48			
N	1	73	74
Mean (SD)	7.00 (NA)	11.68 (5.833)	11.62 (5.818)
Median	7.00	10.00	10.00
Range	7 - 7	3 - 24	3 - 24
Change from Screening			
N	1	71	72
Mean (SD)	-4.00 (NA)	0.23 (5.555)	0.17 (5.539)
Median	-4.00	0.00	0.00
Range	-4 - -4	-10 - 15	-10 - 15
P-value [b] 0.3055			
P-value [c] 0.5677			
LS-Mean Placebo (95%CI) [c]	-2.89 (-13.6 - 7.80)		
LS-Mean LJ501 (95%CI) [c]	0.21 (-1.03 - 1.45)		
LS-Mean Difference (95%CI) [c]	-3.10 (-13.9 - 7.67)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	1	66	67
Total Number of Events	1	23	24
Total Number of Censored for CSH	0	43	43
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	3 (-)	5 (3 - 7)	5 (3 - 6)
Median (95% CI)	3 (-)	(7 -)	(7 -)
75% Quartile (95% CI)	3 (-)	(-)	(-)
Range	3 - 3	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	2% (0%- 10%)	1% (0%- 10%)
2-day Estimate	0% (0%- 0%)	9% (4%- 19%)	9% (4%- 19%)
3-day Estimate	100% (%- %)	16% (9%- 27%)	17% (10%- 29%)
4-day Estimate	100% (%- %)	19% (11%- 31%)	20% (12%- 32%)
5-day Estimate	100% (%- %)	28% (18%- 41%)	29% (19%- 42%)
6-day Estimate	100% (%- %)	35% (24%- 49%)	36% (25%- 50%)
7-day Estimate	100% (%- %)	39% (28%- 53%)	40% (29%- 54%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	2% (0%- 10%)	1% (0%- 10%)
2-day Estimate	0% (0%- 0%)	9% (4%- 19%)	9% (4%- 19%)
3-day Estimate	100% (%- %)	15% (8%- 26%)	16% (9%- 28%)
4-day Estimate	100% (%- %)	18% (11%- 30%)	19% (12%- 31%)
5-day Estimate	100% (%- %)	26% (17%- 38%)	27% (18%- 39%)
6-day Estimate	100% (%- %)	32% (22%- 45%)	33% (23%- 45%)
7-day Estimate	100% (%- %)	35% (25%- 48%)	36% (26%- 49%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 3.81, 1, 0.0509
Log hazard (SE), Relative Risk (95% CI) [b]: -1.797 (1.049), 0.166 (0.021 - 1.295)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 4.03, 1, 0.0447
Log hazard (SE), Relative Risk (95% CI) [b]: -1.836 (1.049), 0.159 (0.020 - 1.246)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.34.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	1	73	74
Total Number of Events	1	34	35
Total Number of Censored for CSH	0	39	39
Days to ICU Discharge			
25% Quartile (95% CI)	4 (-)	8 (6 - 11)	8 (6 - 10)
Median (95% CI)	4 (-)	15 (11 - 23)	15 (10 - 23)
75% Quartile (95% CI)	4 (-)	(23 -)	(23 -)
Range	4 - 4	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	100% (%- %)	23% (14%- 36%)	24% (15%- 37%)
14-day Estimate	100% (%- %)	45% (32%- 59%)	45% (33%- 60%)
21-day Estimate	100% (%- %)	60% (46%- 74%)	61% (47%- 75%)
28-day Estimate	100% (%- %)	69% (54%- 82%)	69% (55%- 82%)
ICU Discharge Cumulative Incidence			
7-day Estimate	100% (%- %)	19% (12%- 30%)	20% (13%- 31%)
14-day Estimate	100% (%- %)	34% (25%- 46%)	35% (25%- 47%)
21-day Estimate	100% (%- %)	42% (32%- 55%)	43% (33%- 55%)
28-day Estimate	100% (%- %)	47% (36%- 59%)	47% (37%- 59%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 11.6, 1, 0.0007
Log hazard (SE), Relative Risk (95% CI) [b]: -2.800 (1.118), 0.061 (0.007 - 0.544)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 12.9, 1, 0.0003
Log hazard (SE), Relative Risk (95% CI) [b]: -2.893 (1.118), 0.055 (0.006 - 0.496)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.34.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min <20 ng/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	1	73	74
Total Number of Events	0	22	22
Total Number of Censored for CSH	1	51	52
Days to Hospital Discharge			
25% Quartile (95% CI)	(-)	16 (11 - 23)	16 (11 - 23)
Median (95% CI)	(-)	(22 -)	(22 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	11+ - 11+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	5% (2%- 15%)	5% (2%- 15%)
14-day Estimate	0% (0%- 0%)	16% (9%- 29%)	16% (9%- 29%)
21-day Estimate	0% (0%- 0%)	34% (23%- 50%)	34% (23%- 49%)
28-day Estimate	0% (0%- 0%)	46% (33%- 61%)	46% (33%- 61%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	4% (1%- 12%)	4% (1%- 12%)
14-day Estimate	0% (0%- 0%)	12% (7%- 22%)	12% (7%- 22%)
21-day Estimate	0% (0%- 0%)	23% (15%- 35%)	23% (15%- 34%)
28-day Estimate	0% (0%- 0%)	30% (21%- 42%)	30% (21%- 42%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.15, 1, 0.6980
Log hazard (SE), Relative Risk (95% CI) [b]: 13.030 (1740), 456E3 (0.000 -)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.35, 1, 0.5519
Log hazard (SE), Relative Risk (95% CI) [b]: 13.026 (1132), 454E3 (0.000 -)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.34.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	114	41	155
Screening			
N	114	41	155
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	114 (100.0%)	41 (100.0%)	155 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	114	41	155
Hour 3 [a]			
N	114	41	155
3	1 (0.9%)	1 (2.4%)	2 (1.3%)
4	112 (98.2%)	40 (97.6%)	152 (98.1%)
4 (LOCF)	1 (0.9%)	0 (0.0%)	1 (0.6%)
Mean (SD)	3.99 (0.094)	3.98 (0.156)	3.99 (0.113)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	114	41	155
Mean (SD)	-0.01 (0.094)	-0.02 (0.156)	-0.01 (0.113)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.0429			
P-value [c] 0.3674			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.03 - 0.01)		
LS-Mean LJ501 (95%CI) [c]	-0.03 (-0.06 - 0.01)		
LS-Mean Difference (95%CI) [c]	0.02 (-0.02 - 0.06)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	114	41	155
Hour 48 [a]			
N	114	41	155
0	20 (17.5%)	11 (26.8%)	31 (20.0%)
1	6 (5.3%)	1 (2.4%)	7 (4.5%)
3	22 (19.3%)	3 (7.3%)	25 (16.1%)
4	36 (31.6%)	14 (34.1%)	50 (32.3%)
4 (LOCF)	2 (1.8%)	0 (0.0%)	2 (1.3%)
4 (WC)	28 (24.6%)	12 (29.3%)	40 (25.8%)
Mean (SD)	2.95 (1.545)	2.78 (1.782)	2.90 (1.607)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	114	41	155
Mean (SD)	-1.05 (1.545)	-1.22 (1.782)	-1.10 (1.607)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.9691			
P-value [c] 0.6213			
LS-Mean Placebo (95%CI) [c]	-1.06 (-1.34 - -0.78)		
LS-Mean LJ501 (95%CI) [c]	-1.20 (-1.67 - -0.72)		
LS-Mean Difference (95%CI) [c]	0.14 (-0.42 - 0.70)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	114	41	155
Screening			
N	114	39	153
Mean (SD)	13.35 (3.237)	12.15 (2.601)	13.05 (3.123)
Median	13.00	13.00	13.00
Range	5 - 21	7 - 17	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:06

Table 14.2.34.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	114	41	155
Hour 3			
N	114	41	155
Mean (SD)	13.83 (3.256)	13.12 (2.977)	13.65 (3.190)
Median	14.00	13.00	14.00
Range	7 - 21	5 - 19	5 - 21
Change from Screening			
N	114	39	153
Mean (SD)	0.48 (1.929)	1.03 (1.769)	0.62 (1.899)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 5	-3 - 7
P-value [b] 0.1755			
P-value [c] 0.3700			
LS-Mean Placebo (95%CI) [c]	0.54 (0.20 - 0.88)		
LS-Mean LJ501 (95%CI) [c]	0.85 (0.26 - 1.45)		
LS-Mean Difference (95%CI) [c]	-0.31 (-1.00 - 0.38)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Number of Patients	114	41	155
Hour 48			
N	114	41	155
Mean (SD)	15.32 (6.639)	15.29 (6.709)	15.32 (6.636)
Median	15.00	14.00	15.00
Range	2 - 24	4 - 24	2 - 24
Change from Screening			
N	114	39	153
Mean (SD)	1.97 (5.523)	3.51 (5.661)	2.37 (5.580)
Median	1.00	3.00	1.00
Range	-8 - 16	-4 - 15	-8 - 16
P-value [b]	0.1703		
P-value [c]	0.0775		
LS-Mean Placebo (95%CI) [c]	1.91 (0.93 - 2.89)		
LS-Mean LJ501 (95%CI) [c]	3.69 (1.99 - 5.38)		
LS-Mean Difference (95%CI) [c]	-1.77 (-3.75 - 0.20)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.34.2.3

Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	107	37	144
Total Number of Events	23	5	28
Total Number of Censored for CSH	84	32	116
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (5 -)	(4 -)	7 (6 -)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1+ - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	1% (0%- 6%)	0% (0%- 0%)	1% (0%- 5%)
2-day Estimate	5% (2%- 11%)	0% (0%- 0%)	4% (2%- 8%)
3-day Estimate	6% (3%- 13%)	3% (0%- 22%)	5% (3%- 11%)
4-day Estimate	11% (6%- 21%)	7% (2%- 26%)	10% (6%- 18%)
5-day Estimate	16% (9%- 26%)	16% (6%- 38%)	16% (10%- 25%)
6-day Estimate	25% (17%- 37%)	21% (9%- 43%)	24% (17%- 34%)
7-day Estimate	32% (22%- 44%)	21% (9%- 43%)	29% (21%- 39%)
Ventilator Cumulative Incidence			
1-day Estimate	1% (0%- 6%)	0% (0%- 0%)	1% (0%- 5%)
2-day Estimate	5% (2%- 11%)	0% (0%- 0%)	3% (1%- 8%)
3-day Estimate	6% (3%- 12%)	3% (0%- 18%)	5% (2%- 10%)
4-day Estimate	9% (5%- 17%)	5% (1%- 20%)	8% (5%- 14%)
5-day Estimate	12% (7%- 20%)	11% (4%- 26%)	12% (8%- 18%)
6-day Estimate	18% (12%- 26%)	14% (6%- 29%)	17% (11%- 24%)
7-day Estimate	21% (15%- 31%)	14% (6%- 29%)	19% (14%- 27%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.96, 1, 0.3280
Log hazard (SE), Relative Risk (95% CI) [b]: -0.478 (0.493), 0.620 (0.236 - 1.631)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.02, 1, 0.3129
Log hazard (SE), Relative Risk (95% CI) [b]: -0.493 (0.493), 0.611 (0.232 - 1.607)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.34.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	114	41	155
Total Number of Events	41	13	54
Total Number of Censored for CSH	73	28	101
Days to ICU Discharge			
25% Quartile (95% CI)	10 (7 - 13)	9 (6 - 14)	10 (7 - 12)
Median (95% CI)	17 (14 - 20)	14 (9 -)	17 (14 - 20)
75% Quartile (95% CI)	28 (20 -)	(14 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	18% (11%- 29%)	12% (4%- 33%)	17% (11%- 25%)
14-day Estimate	40% (29%- 53%)	54% (34%- 76%)	43% (33%- 55%)
21-day Estimate	64% (50%- 77%)	60% (39%- 82%)	62% (51%- 74%)
28-day Estimate	77% (62%- 88%)	67% (45%- 87%)	73% (61%- 84%)
ICU Discharge Cumulative Incidence			
7-day Estimate	12% (7%- 20%)	7% (2%- 21%)	11% (7%- 17%)
14-day Estimate	24% (17%- 33%)	27% (16%- 43%)	25% (18%- 32%)
21-day Estimate	32% (25%- 42%)	29% (18%- 46%)	32% (25%- 40%)
28-day Estimate	36% (28%- 45%)	32% (20%- 48%)	35% (28%- 43%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.06, 1, 0.8092
Log hazard (SE), Relative Risk (95% CI) [b]: -0.077 (0.319), 0.926 (0.495 - 1.731)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.20, 1, 0.6585
Log hazard (SE), Relative Risk (95% CI) [b]: -0.141 (0.318), 0.869 (0.466 - 1.621)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.34.2.5

Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Sensitivity to Therapy at 30 min >=20 ng/kg/min)

	Placebo	LJPC-501	Total
Total Number of Patients	114	41	155
Total Number of Events	26	11	37
Total Number of Censored for CSH	88	30	118
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (14 - 23)	19 (13 - 23)	18 (15 - 22)
Median (95% CI)	28 (23 -)	24 (19 -)	25 (23 -)
75% Quartile (95% CI)	(-)	(24 -)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (1%- 11%)	0% (0%- 0%)	2% (1%- 8%)
14-day Estimate	15% (8%- 27%)	5% (1%- 31%)	12% (7%- 22%)
21-day Estimate	32% (21%- 46%)	38% (20%- 64%)	34% (24%- 46%)
28-day Estimate	53% (40%- 68%)	61% (40%- 82%)	55% (44%- 68%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 7%)	0% (0%- 0%)	1% (0%- 5%)
14-day Estimate	8% (4%- 15%)	2% (0%- 16%)	6% (4%- 12%)
21-day Estimate	15% (10%- 23%)	17% (9%- 33%)	15% (11%- 22%)
28-day Estimate	23% (16%- 32%)	27% (16%- 43%)	24% (18%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.06, 1, 0.8142
Log hazard (SE), Relative Risk (95% CI) [b]: 0.085 (0.360), 1.088 (0.537 - 2.205)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.17, 1, 0.6771
Log hazard (SE), Relative Risk (95% CI) [b]: 0.150 (0.360), 1.161 (0.574 - 2.351)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.35.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Screening			
N	52	53	105
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	52 (100.0%)	53 (100.0%)	105 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 3 [a]			
N	52	53	105
3	0 (0.0%)	4 (7.5%)	4 (3.8%)
4	51 (98.1%)	49 (92.5%)	100 (95.2%)
4 (LOCF)	1 (1.9%)	0 (0.0%)	1 (1.0%)
Mean (SD)	4.00 (0.000)	3.92 (0.267)	3.96 (0.192)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	52	53	105
Mean (SD)	0.00 (0.000)	-0.08 (0.267)	-0.04 (0.192)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0842			
P-value [c] 0.1309			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.06 - 0.04)		
LS-Mean LJ501 (95%CI) [c]	-0.07 (-0.12 - -0.01)		
LS-Mean Difference (95%CI) [c]	0.06 (-0.02 - 0.13)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 48 [a]			
N	52	53	105
0	12 (23.1%)	16 (30.2%)	28 (26.7%)
1	1 (1.9%)	3 (5.7%)	4 (3.8%)
2	0 (0.0%)	1 (1.9%)	1 (1.0%)
3	8 (15.4%)	8 (15.1%)	16 (15.2%)
4	17 (32.7%)	15 (28.3%)	32 (30.5%)
4 (LOCF)	1 (1.9%)	0 (0.0%)	1 (1.0%)
4 (WC)	13 (25.0%)	10 (18.9%)	23 (21.9%)
Mean (SD)	2.87 (1.669)	2.43 (1.781)	2.65 (1.732)
Median	4.00	3.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	52	53	105
Mean (SD)	-1.13 (1.669)	-1.57 (1.781)	-1.35 (1.732)
Median	0.00	-1.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.2006			
P-value [c] 0.5404			
LS-Mean Placebo (95%CI) [c]	-1.25 (-1.71 - -0.78)		
LS-Mean LJ501 (95%CI) [c]	-1.45 (-1.91 - -0.99)		
LS-Mean Difference (95%CI) [c]	0.21 (-0.46 - 0.87)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Screening			
N	52	53	105
Mean (SD)	13.31 (2.832)	11.64 (2.646)	12.47 (2.852)
Median	14.00	11.00	12.00
Range	8 - 19	7 - 17	7 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 3			
N	52	53	105
Mean (SD)	13.92 (3.336)	12.43 (3.208)	13.17 (3.341)
Median	14.00	12.00	13.00
Range	7 - 20	5 - 19	5 - 20
Change from Screening			
N	52	53	105
Mean (SD)	0.62 (1.838)	0.79 (1.747)	0.70 (1.786)
Median	0.00	1.00	1.00
Range	-3 - 6	-2 - 5	-3 - 6
P-value [b] 0.6744			
P-value [c] 0.5351			
LS-Mean Placebo (95%CI) [c]	0.59 (0.08 - 1.10)		
LS-Mean LJ501 (95%CI) [c]	0.82 (0.32 - 1.32)		
LS-Mean Difference (95%CI) [c]	-0.23 (-0.97 - 0.51)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 48			
N	52	53	105
Mean (SD)	15.52 (6.667)	13.02 (6.652)	14.26 (6.745)
Median	15.00	11.00	13.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	52	53	105
Mean (SD)	2.21 (5.945)	1.38 (6.042)	1.79 (5.980)
Median	1.00	0.00	0.00
Range	-8 - 16	-8 - 15	-8 - 16
P-value [b] 0.3234			
P-value [c] 0.9825			
LS-Mean Placebo (95%CI) [c]	1.80 (0.20 - 3.40)		
LS-Mean LJ501 (95%CI) [c]	1.78 (0.19 - 3.36)		
LS-Mean Difference (95%CI) [c]	0.03 (-2.29 - 2.34)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	49	48	97
Total Number of Events	7	13	20
Total Number of Censored for CSH	42	35	77
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(5 -)	6 (3 -)	7 (5 -)
Median (95% CI)	(-)	(7 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1+ - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 14%)	0% (0%- 0%)	1% (0%- 7%)
2-day Estimate	4% (1%- 16%)	4% (1%- 17%)	4% (2%- 11%)
3-day Estimate	4% (1%- 16%)	12% (5%- 26%)	8% (4%- 16%)
4-day Estimate	7% (2%- 21%)	14% (7%- 29%)	11% (6%- 20%)
5-day Estimate	14% (6%- 30%)	22% (12%- 39%)	18% (11%- 29%)
6-day Estimate	17% (8%- 35%)	28% (16%- 45%)	23% (15%- 34%)
7-day Estimate	21% (10%- 39%)	34% (21%- 52%)	28% (19%- 40%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 14%)	0% (0%- 0%)	1% (0%- 7%)
2-day Estimate	4% (1%- 15%)	4% (1%- 16%)	4% (2%- 11%)
3-day Estimate	4% (1%- 15%)	10% (4%- 23%)	7% (4%- 15%)
4-day Estimate	6% (2%- 18%)	13% (6%- 26%)	9% (5%- 17%)
5-day Estimate	10% (4%- 23%)	19% (10%- 33%)	14% (9%- 23%)
6-day Estimate	12% (6%- 25%)	23% (13%- 38%)	18% (11%- 27%)
7-day Estimate	14% (7%- 28%)	27% (17%- 42%)	21% (14%- 30%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.53, 1, 0.2161
Log hazard (SE), Relative Risk (95% CI) [b]: 0.572 (0.469), 1.772 (0.707 - 4.444)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.29, 1, 0.1300
Log hazard (SE), Relative Risk (95% CI) [b]: 0.696 (0.469), 2.006 (0.800 - 5.028)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.35.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	52	53	105
Total Number of Events	14	21	35
Total Number of Censored for CSH	38	32	70
Days to ICU Discharge			
25% Quartile (95% CI)	12 (7 - 14)	9 (6 - 14)	10 (7 - 12)
Median (95% CI)	15 (12 -)	18 (11 -)	18 (12 -)
75% Quartile (95% CI)	(20 -)	(20 -)	(28 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	11% (4%- 27%)	20% (10%- 36%)	16% (9%- 27%)
14-day Estimate	45% (28%- 67%)	42% (27%- 60%)	43% (32%- 57%)
21-day Estimate	56% (37%- 77%)	58% (41%- 76%)	57% (44%- 71%)
28-day Estimate	56% (37%- 77%)	66% (49%- 83%)	62% (49%- 76%)
ICU Discharge Cumulative Incidence			
7-day Estimate	8% (3%- 19%)	15% (8%- 28%)	11% (7%- 19%)
14-day Estimate	23% (14%- 37%)	28% (18%- 42%)	26% (18%- 35%)
21-day Estimate	27% (17%- 41%)	36% (25%- 50%)	31% (23%- 41%)
28-day Estimate	27% (17%- 41%)	40% (28%- 54%)	33% (25%- 43%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.51, 1, 0.4743
Log hazard (SE), Relative Risk (95% CI) [b]: 0.247 (0.346), 1.280 (0.650 - 2.522)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.89, 1, 0.1688
Log hazard (SE), Relative Risk (95% CI) [b]: 0.471 (0.345), 1.601 (0.814 - 3.149)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.35.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I >=253 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	52	53	105
Total Number of Events	12	16	28
Total Number of Censored for CSH	40	37	77
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (12 - 24)	19 (15 - 22)	19 (16 - 23)
Median (95% CI)	24 (18 -)	24 (21 -)	24 (22 -)
75% Quartile (95% CI)	(24 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 20%)	0% (0%- 0%)	1% (0%- 9%)
14-day Estimate	12% (4%- 33%)	6% (1%- 21%)	8% (4%- 19%)
21-day Estimate	31% (16%- 55%)	33% (19%- 53%)	32% (21%- 47%)
28-day Estimate	61% (40%- 82%)	54% (38%- 73%)	57% (43%- 71%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 13%)	0% (0%- 0%)	1% (0%- 7%)
14-day Estimate	6% (2%- 17%)	4% (1%- 14%)	5% (2%- 11%)
21-day Estimate	13% (7%- 26%)	19% (11%- 32%)	16% (10%- 25%)
28-day Estimate	23% (14%- 37%)	30% (20%- 44%)	27% (19%- 36%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.03, 1, 0.8608
Log hazard (SE), Relative Risk (95% CI) [b]: -0.067 (0.382), 0.935 (0.442 - 1.977)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.72, 1, 0.3977
Log hazard (SE), Relative Risk (95% CI) [b]: 0.322 (0.382), 1.379 (0.652 - 2.917)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.35.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	49	49	98
Screening			
N	49	49	98
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	49 (100.0%)	49 (100.0%)	98 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	49	49	98
Hour 3 [a]			
N	49	49	98
3	0 (0.0%)	1 (2.0%)	1 (1.0%)
4	49 (100.0%)	48 (98.0%)	97 (99.0%)
Mean (SD)	4.00 (0.000)	3.98 (0.143)	3.99 (0.101)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	49	49	98
Mean (SD)	0.00 (0.000)	-0.02 (0.143)	-0.01 (0.101)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.4193			
P-value [c] 0.4704			
LS-Mean Placebo (95%CI) [c]	-0.00 (-0.03 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.02 (-0.05 - 0.01)		
LS-Mean Difference (95%CI) [c]	0.01 (-0.03 - 0.06)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	49	49	98
Hour 48 [a]			
N	49	49	98
0	8 (16.3%)	19 (38.8%)	27 (27.6%)
1	5 (10.2%)	3 (6.1%)	8 (8.2%)
2	0 (0.0%)	1 (2.0%)	1 (1.0%)
3	10 (20.4%)	10 (20.4%)	20 (20.4%)
4	15 (30.6%)	11 (22.4%)	26 (26.5%)
4 (LOCF)	1 (2.0%)	0 (0.0%)	1 (1.0%)
4 (WC)	10 (20.4%)	5 (10.2%)	15 (15.3%)
Mean (SD)	2.84 (1.559)	2.02 (1.785)	2.43 (1.717)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	49	49	98
Mean (SD)	-1.16 (1.559)	-1.98 (1.785)	-1.57 (1.717)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0708			
P-value [c] 0.0911			
LS-Mean Placebo (95%CI) [c]	-1.29 (-1.75 - -0.84)		
LS-Mean LJ501 (95%CI) [c]	-1.85 (-2.30 - -1.40)		
LS-Mean Difference (95%CI) [c]	0.56 (-0.09 - 1.20)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	49	49	98
Screening			
N	49	47	96
Mean (SD)	13.10 (3.704)	12.11 (3.108)	12.61 (3.444)
Median	13.00	13.00	13.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	49	49	98
Hour 3			
N	49	49	98
Mean (SD)	13.43 (3.373)	13.16 (3.138)	13.30 (3.243)
Median	13.00	13.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	49	47	96
Mean (SD)	0.33 (1.983)	1.09 (1.730)	0.70 (1.892)
Median	0.00	1.00	0.00
Range	-3 - 7	-1 - 7	-3 - 7
P-value [b] 0.1111			
P-value [c] 0.1132			
LS-Mean Placebo (95%CI) [c]	0.41 (-0.11 - 0.92)		
LS-Mean LJ501 (95%CI) [c]	1.00 (0.48 - 1.52)		
LS-Mean Difference (95%CI) [c]	-0.60 (-1.34 - 0.14)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	49	49	98
Hour 48			
N	49	49	98
Mean (SD)	14.33 (6.836)	12.76 (6.012)	13.54 (6.452)
Median	14.00	11.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	49	47	96
Mean (SD)	1.22 (5.133)	0.85 (5.509)	1.04 (5.295)
Median	1.00	0.00	0.50
Range	-7 - 15	-10 - 11	-10 - 15
P-value [b] 0.5830			
P-value [c] 0.7710			
LS-Mean Placebo (95%CI) [c]	0.89 (-0.54 - 2.33)		
LS-Mean LJ501 (95%CI) [c]	1.20 (-0.27 - 2.66)		
LS-Mean Difference (95%CI) [c]	-0.31 (-2.38 - 1.77)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.35.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	45	44	89
Total Number of Events	13	13	26
Total Number of Censored for CSH	32	31	63
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 -)	5 (3 -)	5 (4 - 7)
Median (95% CI)	(6 -)	(6 -)	(7 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	2 - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	7% (2%- 20%)	7% (2%- 20%)	7% (3%- 15%)
3-day Estimate	10% (4%- 24%)	12% (5%- 26%)	11% (6%- 20%)
4-day Estimate	18% (9%- 35%)	17% (8%- 33%)	18% (11%- 28%)
5-day Estimate	22% (11%- 39%)	29% (17%- 46%)	25% (17%- 37%)
6-day Estimate	32% (19%- 51%)	35% (22%- 53%)	34% (24%- 46%)
7-day Estimate	40% (25%- 59%)	35% (22%- 53%)	37% (27%- 50%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	7% (2%- 19%)	7% (2%- 20%)	7% (3%- 14%)
3-day Estimate	9% (3%- 22%)	11% (5%- 25%)	10% (5%- 19%)
4-day Estimate	16% (8%- 30%)	16% (8%- 30%)	16% (10%- 25%)
5-day Estimate	18% (9%- 32%)	25% (15%- 41%)	21% (14%- 31%)
6-day Estimate	24% (14%- 40%)	30% (18%- 45%)	27% (19%- 37%)
7-day Estimate	29% (18%- 44%)	30% (18%- 45%)	29% (21%- 40%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.03, 1, 0.8687
Log hazard (SE), Relative Risk (95% CI) [b]: -0.065 (0.392), 0.937 (0.434 - 2.022)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8949
Log hazard (SE), Relative Risk (95% CI) [b]: 0.052 (0.392), 1.053 (0.488 - 2.272)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.35.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	49	49	98
Total Number of Events	22	20	42
Total Number of Censored for CSH	27	29	56
Days to ICU Discharge			
25% Quartile (95% CI)	8 (5 - 14)	8 (6 - 11)	8 (6 - 10)
Median (95% CI)	17 (10 - 20)	14 (9 -)	15 (11 - 20)
75% Quartile (95% CI)	22 (17 -)	(15 -)	28 (18 -)
Range	1+ - 28+	2+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	25% (14%- 43%)	21% (11%- 38%)	23% (15%- 34%)
14-day Estimate	42% (27%- 61%)	53% (37%- 71%)	48% (37%- 61%)
21-day Estimate	73% (52%- 91%)	62% (45%- 80%)	66% (53%- 80%)
28-day Estimate	93% (74%-100%)	62% (45%- 80%)	76% (62%- 87%)
ICU Discharge Cumulative Incidence			
7-day Estimate	18% (10%- 32%)	16% (9%- 30%)	17% (11%- 26%)
14-day Estimate	29% (18%- 43%)	37% (25%- 52%)	33% (24%- 43%)
21-day Estimate	39% (27%- 54%)	41% (29%- 56%)	40% (31%- 50%)
28-day Estimate	45% (32%- 60%)	41% (29%- 56%)	43% (34%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.46, 1, 0.4958
Log hazard (SE), Relative Risk (95% CI) [b]: -0.211 (0.311), 0.810 (0.440 - 1.489)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.06, 1, 0.8115
Log hazard (SE), Relative Risk (95% CI) [b]: -0.074 (0.309), 0.929 (0.507 - 1.703)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.35.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I <253 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	49	49	98
Total Number of Events	11	13	24
Total Number of Censored for CSH	38	36	74
Days to Hospital Discharge			
25% Quartile (95% CI)	17 (13 - 23)	17 (9 - 28)	17 (13 - 21)
Median (95% CI)	28 (17 -)	(18 -)	(21 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	2+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 20%)	5% (1%- 20%)	4% (1%- 13%)
14-day Estimate	14% (6%- 34%)	17% (8%- 35%)	16% (9%- 28%)
21-day Estimate	34% (18%- 58%)	40% (25%- 60%)	37% (26%- 52%)
28-day Estimate	51% (31%- 74%)	44% (28%- 64%)	47% (34%- 62%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 14%)	4% (1%- 15%)	3% (1%- 9%)
14-day Estimate	8% (3%- 20%)	12% (6%- 25%)	10% (6%- 18%)
21-day Estimate	16% (9%- 30%)	24% (15%- 39%)	20% (14%- 30%)
28-day Estimate	22% (13%- 37%)	27% (16%- 41%)	24% (17%- 34%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.01, 1, 0.9423
Log hazard (SE), Relative Risk (95% CI) [b]: -0.030 (0.411), 0.971 (0.434 - 2.171)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.28, 1, 0.5939
Log hazard (SE), Relative Risk (95% CI) [b]: 0.218 (0.410), 1.243 (0.557 - 2.775)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.36.1.1

CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	43	48	91
Screening			
N	43	48	91
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	43 (100.0%)	48 (100.0%)	91 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	43	48	91
Hour 3 [a]			
N	43	48	91
3	0 (0.0%)	3 (6.3%)	3 (3.3%)
4	43 (100.0%)	45 (93.8%)	88 (96.7%)
Mean (SD)	4.00 (0.000)	3.94 (0.245)	3.97 (0.180)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	43	48	91
Mean (SD)	0.00 (0.000)	-0.06 (0.245)	-0.03 (0.180)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.1967			
P-value [c] 0.1737			
LS-Mean Placebo (95%CI) [c]	-0.00 (-0.06 - 0.05)		
LS-Mean LJ501 (95%CI) [c]	-0.06 (-0.11 - -0.01)		
LS-Mean Difference (95%CI) [c]	0.05 (-0.02 - 0.13)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	43	48	91
Hour 48 [a]			
N	43	48	91
0	9 (20.9%)	8 (16.7%)	17 (18.7%)
1	3 (7.0%)	3 (6.3%)	6 (6.6%)
2	0 (0.0%)	1 (2.1%)	1 (1.1%)
3	7 (16.3%)	11 (22.9%)	18 (19.8%)
4	16 (37.2%)	16 (33.3%)	32 (35.2%)
4 (LOCF)	2 (4.7%)	0 (0.0%)	2 (2.2%)
4 (WC)	6 (14.0%)	9 (18.8%)	15 (16.5%)
Mean (SD)	2.79 (1.656)	2.88 (1.525)	2.84 (1.579)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	43	48	91
Mean (SD)	-1.21 (1.656)	-1.13 (1.525)	-1.16 (1.579)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.8414			
P-value [c] 0.3609			
LS-Mean Placebo (95%CI) [c]	-1.32 (-1.78 - -0.86)		
LS-Mean LJ501 (95%CI) [c]	-1.02 (-1.46 - -0.59)		
LS-Mean Difference (95%CI) [c]	-0.30 (-0.95 - 0.35)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.1.2

Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	43	48	91
Screening			
N	43	48	91
Mean (SD)	12.98 (2.915)	11.50 (2.560)	12.20 (2.817)
Median	13.00	11.00	12.00
Range	5 - 19	7 - 18	5 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:07

Table 14.2.36.1.2

Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	43	48	91
Hour 3			
N	43	48	91
Mean (SD)	13.53 (3.383)	12.35 (3.152)	12.91 (3.299)
Median	14.00	12.00	12.00
Range	7 - 20	5 - 19	5 - 20
Change from Screening			
N	43	48	91
Mean (SD)	0.56 (1.736)	0.85 (1.845)	0.71 (1.791)
Median	0.00	1.00	1.00
Range	-3 - 6	-2 - 5	-3 - 6
P-value [b] 0.6418			
P-value [c] 0.5663			
LS-Mean Placebo (95%CI) [c]	0.59 (0.03 - 1.15)		
LS-Mean LJ501 (95%CI) [c]	0.82 (0.29 - 1.35)		
LS-Mean Difference (95%CI) [c]	-0.23 (-1.02 - 0.56)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.1.2

Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	43	48	91
Hour 48			
N	43	48	91
Mean (SD)	13.88 (6.299)	13.71 (6.328)	13.79 (6.280)
Median	14.00	12.00	13.00
Range	2 - 24	4 - 24	2 - 24
Change from Screening			
N	43	48	91
Mean (SD)	0.91 (4.888)	2.21 (5.845)	1.59 (5.424)
Median	0.00	1.00	1.00
Range	-8 - 12	-8 - 15	-8 - 15
P-value [b] 0.3187			
P-value [c] 0.0928			
LS-Mean Placebo (95%CI) [c]	0.56 (-1.08 - 2.19)		
LS-Mean LJ501 (95%CI) [c]	2.52 (0.98 - 4.06)		
LS-Mean Difference (95%CI) [c]	-1.96 (-4.26 - 0.33)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	40	43	83
Total Number of Events	6	7	13
Total Number of Censored for CSH	34	36	70
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(5 -)	(4 -)	(5 -)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1+ - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	3% (0%- 16%)	0% (0%- 0%)	1% (0%- 8%)
2-day Estimate	5% (1%- 19%)	2% (0%- 16%)	4% (1%- 11%)
3-day Estimate	5% (1%- 19%)	8% (3%- 22%)	6% (3%- 15%)
4-day Estimate	8% (3%- 24%)	11% (4%- 26%)	9% (5%- 19%)
5-day Estimate	15% (6%- 33%)	14% (6%- 30%)	14% (8%- 25%)
6-day Estimate	19% (9%- 38%)	17% (8%- 35%)	18% (11%- 30%)
7-day Estimate	19% (9%- 38%)	21% (11%- 40%)	20% (12%- 32%)
Ventilator Cumulative Incidence			
1-day Estimate	3% (0%- 16%)	0% (0%- 0%)	1% (0%- 8%)
2-day Estimate	5% (1%- 19%)	2% (0%- 15%)	4% (1%- 11%)
3-day Estimate	5% (1%- 19%)	7% (2%- 20%)	6% (3%- 14%)
4-day Estimate	8% (2%- 21%)	9% (4%- 23%)	8% (4%- 17%)
5-day Estimate	13% (5%- 27%)	12% (5%- 26%)	12% (7%- 21%)
6-day Estimate	15% (7%- 30%)	14% (7%- 28%)	14% (8%- 24%)
7-day Estimate	15% (7%- 30%)	16% (8%- 31%)	16% (9%- 25%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8868
Log hazard (SE), Relative Risk (95% CI) [b]: 0.079 (0.556), 1.082 (0.364 - 3.221)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8871
Log hazard (SE), Relative Risk (95% CI) [b]: 0.079 (0.556), 1.082 (0.364 - 3.220)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.36.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	43	48	91
Total Number of Events	14	14	28
Total Number of Censored for CSH	29	34	63
Days to ICU Discharge			
25% Quartile (95% CI)	11 (5 - 17)	12 (7 - 15)	12 (7 - 14)
Median (95% CI)	17 (12 -)	23 (14 -)	18 (14 -)
75% Quartile (95% CI)	(17 -)	(-)	(-)
Range	2+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	18% (9%- 37%)	12% (5%- 29%)	15% (8%- 26%)
14-day Estimate	42% (25%- 64%)	35% (20%- 56%)	38% (26%- 53%)
21-day Estimate	60% (40%- 81%)	47% (30%- 68%)	53% (39%- 67%)
28-day Estimate	60% (40%- 81%)	52% (34%- 72%)	56% (42%- 70%)
ICU Discharge Cumulative Incidence			
7-day Estimate	14% (7%- 28%)	8% (3%- 21%)	11% (6%- 19%)
14-day Estimate	26% (15%- 41%)	21% (12%- 35%)	23% (16%- 33%)
21-day Estimate	33% (21%- 49%)	27% (17%- 42%)	30% (21%- 40%)
28-day Estimate	33% (21%- 49%)	29% (18%- 44%)	31% (22%- 41%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.55, 1, 0.4571
Log hazard (SE), Relative Risk (95% CI) [b]: -0.282 (0.380), 0.754 (0.358 - 1.589)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.18, 1, 0.6689
Log hazard (SE), Relative Risk (95% CI) [b]: -0.161 (0.378), 0.851 (0.406 - 1.785)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.36.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin II >=83.75 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	43	48	91
Total Number of Events	10	13	23
Total Number of Censored for CSH	33	35	68
Days to Hospital Discharge			
25% Quartile (95% CI)	17 (10 - 24)	17 (13 - 23)	17 (14 - 23)
Median (95% CI)	28 (17 -)	24 (18 -)	24 (21 -)
75% Quartile (95% CI)	(28 -)	(-)	(-)
Range	2+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 21%)	0% (0%- 0%)	2% (0%- 11%)
14-day Estimate	17% (7%- 41%)	11% (4%- 31%)	14% (7%- 27%)
21-day Estimate	34% (18%- 59%)	35% (20%- 56%)	35% (23%- 50%)
28-day Estimate	57% (34%- 82%)	51% (33%- 71%)	53% (39%- 69%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 15%)	0% (0%- 0%)	1% (0%- 8%)
14-day Estimate	9% (4%- 23%)	6% (2%- 18%)	8% (4%- 15%)
21-day Estimate	16% (8%- 31%)	19% (10%- 33%)	18% (11%- 27%)
28-day Estimate	23% (13%- 39%)	27% (17%- 42%)	25% (18%- 36%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.09, 1, 0.7695
Log hazard (SE), Relative Risk (95% CI) [b]: -0.123 (0.422), 0.884 (0.387 - 2.019)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.15, 1, 0.6989
Log hazard (SE), Relative Risk (95% CI) [b]: 0.163 (0.421), 1.177 (0.516 - 2.684)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.36.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	57	53	110
Screening			
N	57	53	110
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	57 (100.0%)	53 (100.0%)	110 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	57	53	110
Hour 3 [a]			
N	57	53	110
3	0 (0.0%)	2 (3.8%)	2 (1.8%)
4	56 (98.2%)	51 (96.2%)	107 (97.3%)
4 (LOCF)	1 (1.8%)	0 (0.0%)	1 (0.9%)
Mean (SD)	4.00 (0.000)	3.96 (0.192)	3.98 (0.134)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	57	53	110
Mean (SD)	0.00 (0.000)	-0.04 (0.192)	-0.02 (0.134)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.2180			
P-value [c] 0.2774			
LS-Mean Placebo (95%CI) [c]	-0.00 (-0.04 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.03 (-0.07 - 0.00)		
LS-Mean Difference (95%CI) [c]	0.03 (-0.02 - 0.08)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	57	53	110
Hour 48 [a]			
N	57	53	110
0	11 (19.3%)	26 (49.1%)	37 (33.6%)
1	3 (5.3%)	3 (5.7%)	6 (5.5%)
2	0 (0.0%)	1 (1.9%)	1 (0.9%)
3	11 (19.3%)	7 (13.2%)	18 (16.4%)
4	15 (26.3%)	10 (18.9%)	25 (22.7%)
4 (WC)	17 (29.8%)	6 (11.3%)	23 (20.9%)
Mean (SD)	2.88 (1.593)	1.70 (1.825)	2.31 (1.801)
Median	4.00	1.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	57	53	110
Mean (SD)	-1.12 (1.593)	-2.30 (1.825)	-1.69 (1.801)
Median	0.00	-3.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0130			
P-value [c] 0.0060			
LS-Mean Placebo (95%CI) [c]	-1.26 (-1.69 - -0.82)		
LS-Mean LJ501 (95%CI) [c]	-2.16 (-2.61 - -1.71)		
LS-Mean Difference (95%CI) [c]	0.90 (0.27 - 1.54)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	57	53	110
Screening			
N	57	51	108
Mean (SD)	13.30 (3.474)	12.12 (2.998)	12.74 (3.296)
Median	13.00	12.00	13.00
Range	6 - 21	5 - 17	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	57	53	110
Hour 3			
N	57	53	110
Mean (SD)	13.72 (3.326)	12.94 (3.028)	13.35 (3.195)
Median	14.00	13.00	13.00
Range	7 - 21	5 - 19	5 - 21
Change from Screening			
N	57	51	108
Mean (SD)	0.42 (2.052)	0.84 (1.642)	0.62 (1.873)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.2292			
P-value [c] 0.3954			
LS-Mean Placebo (95%CI) [c]	0.48 (-0.00 - 0.95)		
LS-Mean LJ501 (95%CI) [c]	0.78 (0.27 - 1.29)		
LS-Mean Difference (95%CI) [c]	-0.31 (-1.02 - 0.41)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Number of Patients	57	53	110
Hour 48			
N	57	53	110
Mean (SD)	15.68 (7.028)	12.00 (6.208)	13.91 (6.869)
Median	16.00	10.00	14.00
Range	3 - 24	3 - 24	3 - 24
Change from Screening			
N	57	51	108
Mean (SD)	2.39 (6.020)	0.04 (5.600)	1.28 (5.917)
Median	1.00	-1.00	0.00
Range	-7 - 16	-10 - 11	-10 - 16
P-value [b] 0.4164			
P-value [c] 0.2070			
LS-Mean Placebo (95%CI) [c]	1.92 (0.49 - 3.35)		
LS-Mean LJ501 (95%CI) [c]	0.56 (-0.95 - 2.07)		
LS-Mean Difference (95%CI) [c]	1.36 (-0.76 - 3.48)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.36.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	53	48	101
Total Number of Events	14	19	33
Total Number of Censored for CSH	39	29	68
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 - 7)	5 (3 - 6)	5 (4 - 6)
Median (95% CI)	(7 -)	(5 -)	(7 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	6% (2%- 17%)	9% (3%- 21%)	7% (3%- 14%)
3-day Estimate	9% (3%- 22%)	16% (8%- 30%)	12% (7%- 21%)
4-day Estimate	17% (8%- 33%)	20% (11%- 36%)	19% (12%- 29%)
5-day Estimate	20% (10%- 37%)	35% (23%- 52%)	28% (20%- 40%)
6-day Estimate	30% (17%- 48%)	43% (30%- 60%)	37% (27%- 49%)
7-day Estimate	39% (25%- 58%)	46% (32%- 62%)	43% (32%- 55%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	6% (2%- 17%)	8% (3%- 21%)	7% (3%- 14%)
3-day Estimate	8% (3%- 19%)	15% (7%- 28%)	11% (6%- 19%)
4-day Estimate	13% (7%- 26%)	19% (10%- 33%)	16% (10%- 25%)
5-day Estimate	15% (8%- 28%)	31% (20%- 46%)	23% (16%- 32%)
6-day Estimate	21% (12%- 34%)	38% (26%- 53%)	29% (21%- 39%)
7-day Estimate	26% (17%- 40%)	40% (27%- 55%)	33% (24%- 43%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.57, 1, 0.4488
Log hazard (SE), Relative Risk (95% CI) [b]: 0.266 (0.353), 1.305 (0.654 - 2.605)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.07, 1, 0.1505
Log hazard (SE), Relative Risk (95% CI) [b]: 0.502 (0.353), 1.651 (0.828 - 3.296)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.36.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	57	53	110
Total Number of Events	22	26	48
Total Number of Censored for CSH	35	27	62
Days to ICU Discharge			
25% Quartile (95% CI)	10 (5 - 14)	7 (5 - 9)	8 (6 - 10)
Median (95% CI)	18 (11 - 22)	11 (8 - 28)	14 (10 - 20)
75% Quartile (95% CI)	28 (19 -)	(16 -)	28 (20 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	18% (9%- 35%)	27% (16%- 43%)	23% (15%- 34%)
14-day Estimate	45% (30%- 64%)	57% (42%- 73%)	51% (40%- 64%)
21-day Estimate	66% (47%- 84%)	67% (50%- 83%)	67% (54%- 79%)
28-day Estimate	83% (64%- 96%)	73% (55%- 88%)	78% (64%- 89%)
ICU Discharge Cumulative Incidence			
7-day Estimate	12% (6%- 24%)	23% (14%- 36%)	17% (11%- 26%)
14-day Estimate	26% (17%- 40%)	43% (31%- 58%)	35% (26%- 44%)
21-day Estimate	33% (23%- 47%)	47% (35%- 61%)	40% (32%- 50%)
28-day Estimate	39% (27%- 52%)	49% (37%- 63%)	44% (35%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.29, 1, 0.5914
Log hazard (SE), Relative Risk (95% CI) [b]: 0.155 (0.290), 1.168 (0.661 - 2.064)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.83, 1, 0.1757
Log hazard (SE), Relative Risk (95% CI) [b]: 0.390 (0.290), 1.477 (0.837 - 2.609)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.36.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin II <83.75 pg/mL)

	Placebo	LJPC-501	Total
Total Number of Patients	57	53	110
Total Number of Events	13	17	30
Total Number of Censored for CSH	44	36	80
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (14 - 24)	18 (9 - 21)	18 (15 - 21)
Median (95% CI)	28 (18 -)	28 (20 -)	28 (21 -)
75% Quartile (95% CI)	(28 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 18%)	5% (1%- 17%)	4% (1%- 11%)
14-day Estimate	10% (3%- 28%)	15% (7%- 30%)	12% (7%- 23%)
21-day Estimate	32% (17%- 54%)	41% (27%- 60%)	37% (26%- 51%)
28-day Estimate	55% (36%- 75%)	52% (36%- 70%)	53% (40%- 67%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 12%)	4% (1%- 14%)	3% (1%- 8%)
14-day Estimate	5% (2%- 15%)	11% (5%- 23%)	8% (4%- 15%)
21-day Estimate	14% (7%- 26%)	26% (17%- 40%)	20% (14%- 29%)
28-day Estimate	23% (14%- 36%)	32% (21%- 46%)	27% (20%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.03, 1, 0.8519
Log hazard (SE), Relative Risk (95% CI) [b]: 0.069 (0.369), 1.071 (0.520 - 2.206)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.36, 1, 0.2432
Log hazard (SE), Relative Risk (95% CI) [b]: 0.427 (0.369), 1.532 (0.744 - 3.155)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.37.1.1

CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Screening			
N	52	53	105
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	52 (100.0%)	53 (100.0%)	105 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 3 [a]			
N	52	53	105
3	0 (0.0%)	4 (7.5%)	4 (3.8%)
4	51 (98.1%)	49 (92.5%)	100 (95.2%)
4 (LOCF)	1 (1.9%)	0 (0.0%)	1 (1.0%)
Mean (SD)	4.00 (0.000)	3.92 (0.267)	3.96 (0.192)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	52	53	105
Mean (SD)	0.00 (0.000)	-0.08 (0.267)	-0.04 (0.192)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0621			
P-value [c] 0.1052			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.06 - 0.05)		
LS-Mean LJ501 (95%CI) [c]	-0.07 (-0.12 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.06 (-0.01 - 0.14)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 48 [a]			
N	52	53	105
0	12 (23.1%)	16 (30.2%)	28 (26.7%)
1	0 (0.0%)	3 (5.7%)	3 (2.9%)
2	0 (0.0%)	1 (1.9%)	1 (1.0%)
3	7 (13.5%)	6 (11.3%)	13 (12.4%)
4	16 (30.8%)	19 (35.8%)	35 (33.3%)
4 (WC)	17 (32.7%)	8 (15.1%)	25 (23.8%)
Mean (SD)	2.94 (1.662)	2.47 (1.804)	2.70 (1.743)
Median	4.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	52	53	105
Mean (SD)	-1.06 (1.662)	-1.53 (1.804)	-1.30 (1.743)
Median	0.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b]	0.4521		
P-value [c]	0.6228		
LS-Mean Placebo (95%CI) [c]	-1.21 (-1.68 - -0.74)		
LS-Mean LJ501 (95%CI) [c]	-1.38 (-1.84 - -0.91)		
LS-Mean Difference (95%CI) [c]	0.17 (-0.51 - 0.84)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.1.2

Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Screening			
N	52	52	104
Mean (SD)	13.63 (3.236)	12.10 (2.703)	12.87 (3.066)
Median	14.00	12.00	13.00
Range	8 - 21	7 - 17	7 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 3			
N	52	53	105
Mean (SD)	14.15 (3.262)	13.11 (2.867)	13.63 (3.099)
Median	14.00	13.00	14.00
Range	7 - 21	7 - 19	7 - 21
Change from Screening			
N	52	52	104
Mean (SD)	0.52 (1.863)	1.02 (1.799)	0.77 (1.839)
Median	0.00	1.00	1.00
Range	-3 - 6	-2 - 7	-3 - 7
P-value [b]	0.2317		
P-value [c]	0.2373		
LS-Mean Placebo (95%CI) [c]	0.56 (0.06 - 1.05)		
LS-Mean LJ501 (95%CI) [c]	0.98 (0.49 - 1.48)		
LS-Mean Difference (95%CI) [c]	-0.43 (-1.14 - 0.29)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Number of Patients	52	53	105
Hour 48			
N	52	53	105
Mean (SD)	16.79 (6.658)	13.47 (6.262)	15.11 (6.642)
Median	18.00	13.00	15.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	52	52	104
Mean (SD)	3.15 (6.001)	1.44 (5.525)	2.30 (5.804)
Median	2.00	1.00	1.00
Range	-8 - 16	-8 - 13	-8 - 16
P-value [b] 0.3604			
P-value [c] 0.5097			
LS-Mean Placebo (95%CI) [c]	2.67 (1.15 - 4.18)		
LS-Mean LJ501 (95%CI) [c]	1.93 (0.41 - 3.45)		
LS-Mean Difference (95%CI) [c]	0.74 (-1.47 - 2.94)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Total Number of Patients	50	51	101
Total Number of Events	11	14	25
Total Number of Censored for CSH	39	37	76
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 -)	5 (3 -)	6 (5 -)
Median (95% CI)	(7 -)	(7 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1+ - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 13%)	0% (0%- 0%)	1% (0%- 7%)
2-day Estimate	6% (2%- 18%)	6% (2%- 17%)	6% (3%- 13%)
3-day Estimate	9% (3%- 23%)	15% (7%- 29%)	12% (7%- 21%)
4-day Estimate	16% (7%- 32%)	15% (7%- 29%)	15% (9%- 25%)
5-day Estimate	19% (9%- 37%)	25% (15%- 41%)	23% (15%- 34%)
6-day Estimate	27% (15%- 47%)	30% (19%- 47%)	29% (20%- 41%)
7-day Estimate	36% (21%- 57%)	33% (21%- 50%)	34% (24%- 47%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 13%)	0% (0%- 0%)	1% (0%- 7%)
2-day Estimate	6% (2%- 17%)	6% (2%- 17%)	6% (3%- 13%)
3-day Estimate	8% (3%- 20%)	14% (7%- 27%)	11% (6%- 19%)
4-day Estimate	12% (6%- 25%)	14% (7%- 27%)	13% (8%- 21%)
5-day Estimate	14% (7%- 27%)	22% (13%- 36%)	18% (12%- 27%)
6-day Estimate	18% (10%- 32%)	25% (16%- 40%)	22% (15%- 31%)
7-day Estimate	22% (13%- 36%)	27% (17%- 42%)	25% (17%- 34%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.00, 1, 0.9877
Log hazard (SE), Relative Risk (95% CI) [b]: -0.006 (0.404), 0.994 (0.451 - 2.192)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.39, 1, 0.5298
Log hazard (SE), Relative Risk (95% CI) [b]: 0.253 (0.403), 1.287 (0.584 - 2.836)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.37.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Total Number of Patients	52	53	105
Total Number of Events	15	19	34
Total Number of Censored for CSH	37	34	71
Days to ICU Discharge			
25% Quartile (95% CI)	10 (6 - 12)	8 (5 - 14)	9 (6 - 11)
Median (95% CI)	14 (11 -)	20 (9 -)	15 (12 -)
75% Quartile (95% CI)	(15 -)	(28 -)	(28 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	16% (7%- 34%)	25% (14%- 41%)	21% (13%- 32%)
14-day Estimate	53% (34%- 74%)	44% (29%- 63%)	48% (36%- 62%)
21-day Estimate	67% (45%- 87%)	54% (37%- 72%)	59% (45%- 73%)
28-day Estimate	67% (45%- 87%)	58% (41%- 77%)	62% (48%- 76%)
ICU Discharge Cumulative Incidence			
7-day Estimate	10% (4%- 22%)	19% (11%- 32%)	14% (9%- 23%)
14-day Estimate	25% (15%- 39%)	30% (20%- 44%)	28% (20%- 37%)
21-day Estimate	29% (19%- 43%)	34% (23%- 48%)	31% (23%- 41%)
28-day Estimate	29% (19%- 43%)	36% (25%- 50%)	32% (24%- 42%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.07, 1, 0.7985
Log hazard (SE), Relative Risk (95% CI) [b]: -0.089 (0.348), 0.915 (0.463 - 1.810)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.70, 1, 0.4019
Log hazard (SE), Relative Risk (95% CI) [b]: 0.289 (0.346), 1.335 (0.678 - 2.627)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.37.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio >=1.63)

	Placebo	LJPC-501	Total
Total Number of Patients	52	53	105
Total Number of Events	10	15	25
Total Number of Censored for CSH	42	38	80
Days to Hospital Discharge			
25% Quartile (95% CI)	18 (15 - 23)	18 (9 - 24)	18 (15 - 23)
Median (95% CI)	24 (18 -)	28 (20 -)	25 (21 -)
75% Quartile (95% CI)	(24 -)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 22%)	3% (0%- 16%)	3% (1%- 11%)
14-day Estimate	3% (0%- 22%)	14% (6%- 30%)	10% (4%- 20%)
21-day Estimate	33% (16%- 60%)	36% (22%- 56%)	35% (23%- 50%)
28-day Estimate	60% (37%- 83%)	52% (35%- 71%)	54% (40%- 70%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 13%)	2% (0%- 13%)	2% (0%- 7%)
14-day Estimate	2% (0%- 13%)	9% (4%- 21%)	6% (3%- 12%)
21-day Estimate	12% (5%- 24%)	21% (12%- 34%)	16% (10%- 25%)
28-day Estimate	19% (11%- 33%)	28% (18%- 42%)	24% (17%- 33%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.02, 1, 0.8928
Log hazard (SE), Relative Risk (95% CI) [b]: -0.056 (0.410), 0.946 (0.423 - 2.113)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.29, 1, 0.2557
Log hazard (SE), Relative Risk (95% CI) [b]: 0.460 (0.408), 1.584 (0.712 - 3.526)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.37.2.1

CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Number of Patients	47	46	93
Screening			
N	47	46	93
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	47 (100.0%)	46 (100.0%)	93 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.2.1

CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Number of Patients	47	46	93
Hour 3 [a]			
N	47	46	93
3	0 (0.0%)	1 (2.2%)	1 (1.1%)
4	47 (100.0%)	45 (97.8%)	92 (98.9%)
Mean (SD)	4.00 (0.000)	3.98 (0.147)	3.99 (0.104)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	47	46	93
Mean (SD)	0.00 (0.000)	-0.02 (0.147)	-0.01 (0.104)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.3711			
P-value [c] 0.5700			
LS-Mean Placebo (95%CI) [c]	-0.00 (-0.03 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.02 (-0.05 - 0.01)		
LS-Mean Difference (95%CI) [c]	0.01 (-0.03 - 0.06)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Number of Patients	47	46	93
Hour 48 [a]			
N	47	46	93
0	8 (17.0%)	18 (39.1%)	26 (28.0%)
1	6 (12.8%)	3 (6.5%)	9 (9.7%)
2	0 (0.0%)	1 (2.2%)	1 (1.1%)
3	11 (23.4%)	11 (23.9%)	22 (23.7%)
4	14 (29.8%)	6 (13.0%)	20 (21.5%)
4 (LOCF)	2 (4.3%)	0 (0.0%)	2 (2.2%)
4 (WC)	6 (12.8%)	7 (15.2%)	13 (14.0%)
Mean (SD)	2.70 (1.573)	1.96 (1.751)	2.33 (1.696)
Median	3.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	47	46	93
Mean (SD)	-1.30 (1.573)	-2.04 (1.751)	-1.67 (1.696)
Median	-1.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0558			
P-value [c] 0.0836			
LS-Mean Placebo (95%CI) [c]	-1.38 (-1.84 - -0.93)		
LS-Mean LJ501 (95%CI) [c]	-1.96 (-2.41 - -1.50)		
LS-Mean Difference (95%CI) [c]	0.57 (-0.08 - 1.22)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.2.2

Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Number of Patients	47	46	93
Screening			
N	47	45	92
Mean (SD)	12.62 (3.214)	11.40 (2.903)	12.02 (3.110)
Median	12.00	12.00	12.00
Range	5 - 19	5 - 18	5 - 19

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Number of Patients	47	46	93
Hour 3			
N	47	46	93
Mean (SD)	13.09 (3.393)	12.11 (3.288)	12.60 (3.359)
Median	13.00	12.00	12.00
Range	7 - 20	5 - 18	5 - 20
Change from Screening			
N	47	45	92
Mean (SD)	0.47 (1.998)	0.71 (1.646)	0.59 (1.829)
Median	0.00	0.00	0.00
Range	-3 - 7	-2 - 4	-3 - 7
P-value [b] 0.4685			
P-value [c] 0.7559			
LS-Mean Placebo (95%CI) [c]	0.53 (-0.02 - 1.07)		
LS-Mean LJ501 (95%CI) [c]	0.65 (0.09 - 1.21)		
LS-Mean Difference (95%CI) [c]	-0.12 (-0.91 - 0.66)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.2.2

Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Number of Patients	47	46	93
Hour 48			
N	47	46	93
Mean (SD)	12.85 (6.372)	12.02 (6.420)	12.44 (6.375)
Median	12.00	10.00	11.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	47	45	92
Mean (SD)	0.23 (4.747)	0.76 (6.238)	0.49 (5.502)
Median	0.00	-1.00	0.00
Range	-7 - 12	-10 - 15	-10 - 15
P-value [b] 0.5173			
P-value [c] 0.3771			
LS-Mean Placebo (95%CI) [c]	-0.01 (-1.57 - 1.56)		
LS-Mean LJ501 (95%CI) [c]	1.01 (-0.59 - 2.61)		
LS-Mean Difference (95%CI) [c]	-1.01 (-3.29 - 1.26)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.37.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Total Number of Patients	42	38	80
Total Number of Events	9	12	21
Total Number of Censored for CSH	33	26	59
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (4 -)	5 (4 -)	6 (5 -)
Median (95% CI)	(-)	(6 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	2 - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	5% (1%- 18%)	6% (1%- 20%)	5% (2%- 13%)
3-day Estimate	5% (1%- 18%)	9% (3%- 25%)	7% (3%- 15%)
4-day Estimate	11% (4%- 26%)	18% (9%- 36%)	14% (8%- 25%)
5-day Estimate	17% (8%- 34%)	28% (16%- 47%)	22% (14%- 34%)
6-day Estimate	23% (12%- 41%)	35% (21%- 54%)	29% (19%- 41%)
7-day Estimate	26% (15%- 45%)	39% (24%- 59%)	32% (22%- 45%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	5% (1%- 18%)	5% (1%- 19%)	5% (2%- 13%)
3-day Estimate	5% (1%- 18%)	8% (3%- 23%)	6% (3%- 14%)
4-day Estimate	10% (4%- 23%)	16% (7%- 32%)	13% (7%- 22%)
5-day Estimate	14% (7%- 29%)	24% (13%- 41%)	19% (12%- 29%)
6-day Estimate	19% (10%- 34%)	29% (17%- 46%)	24% (16%- 35%)
7-day Estimate	21% (12%- 37%)	32% (19%- 49%)	26% (18%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.16, 1, 0.2823
Log hazard (SE), Relative Risk (95% CI) [b]: 0.470 (0.441), 1.600 (0.674 - 3.800)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.05, 1, 0.3060
Log hazard (SE), Relative Risk (95% CI) [b]: 0.448 (0.441), 1.565 (0.659 - 3.715)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.37.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Total Number of Patients	47	46	93
Total Number of Events	20	20	40
Total Number of Censored for CSH	27	26	53
Days to ICU Discharge			
25% Quartile (95% CI)	10 (5 - 17)	8 (6 - 11)	8 (7 - 12)
Median (95% CI)	18 (12 - 28)	12 (10 - 23)	17 (12 - 23)
75% Quartile (95% CI)	28 (20 -)	(16 -)	(22 -)
Range	2+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	21% (11%- 38%)	17% (8%- 34%)	19% (12%- 30%)
14-day Estimate	38% (24%- 57%)	52% (35%- 70%)	44% (33%- 58%)
21-day Estimate	58% (40%- 78%)	64% (46%- 81%)	60% (47%- 74%)
28-day Estimate	76% (56%- 92%)	69% (51%- 85%)	72% (58%- 84%)
ICU Discharge Cumulative Incidence			
7-day Estimate	17% (9%- 31%)	13% (6%- 27%)	15% (9%- 24%)
14-day Estimate	28% (17%- 43%)	35% (23%- 50%)	31% (23%- 42%)
21-day Estimate	36% (24%- 52%)	41% (29%- 57%)	39% (30%- 49%)
28-day Estimate	43% (30%- 58%)	43% (31%- 59%)	43% (34%- 54%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.11, 1, 0.7425
Log hazard (SE), Relative Risk (95% CI) [b]: 0.104 (0.317), 1.110 (0.596 - 2.065)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.04, 1, 0.8442
Log hazard (SE), Relative Risk (95% CI) [b]: 0.062 (0.316), 1.064 (0.572 - 1.979)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.37.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Baseline Angiotensin I/II Ratio <1.63)

	Placebo	LJPC-501	Total
Total Number of Patients	47	46	93
Total Number of Events	13	14	27
Total Number of Censored for CSH	34	32	66
Days to Hospital Discharge			
25% Quartile (95% CI)	15 (12 - 24)	17 (13 - 22)	17 (14 - 21)
Median (95% CI)	28 (17 -)	23 (18 -)	28 (21 -)
75% Quartile (95% CI)	(28 -)	(-)	(-)
Range	2+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	3% (0%- 18%)	3% (0%- 20%)	3% (1%- 11%)
14-day Estimate	21% (10%- 41%)	10% (3%- 27%)	15% (8%- 27%)
21-day Estimate	34% (19%- 56%)	39% (24%- 60%)	37% (26%- 52%)
28-day Estimate	54% (35%- 76%)	51% (34%- 71%)	53% (40%- 67%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	2% (0%- 14%)	2% (0%- 14%)	2% (1%- 8%)
14-day Estimate	13% (6%- 26%)	7% (2%- 19%)	10% (5%- 18%)
21-day Estimate	19% (10%- 34%)	24% (14%- 39%)	22% (14%- 31%)
28-day Estimate	28% (17%- 43%)	30% (19%- 46%)	29% (21%- 39%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.04, 1, 0.8469
Log hazard (SE), Relative Risk (95% CI) [b]: -0.075 (0.386), 0.928 (0.436 - 1.977)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.07, 1, 0.7923
Log hazard (SE), Relative Risk (95% CI) [b]: 0.101 (0.385), 1.107 (0.520 - 2.355)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.38.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	11	6	17
Screening			
N	11	6	17
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	11 (100.0%)	6 (100.0%)	17 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	11	6	17
Hour 3 [a]			
N	11	6	17
3	0 (0.0%)	1 (16.7%)	1 (5.9%)
4	11 (100.0%)	5 (83.3%)	16 (94.1%)
Mean (SD)	4.00 (0.000)	3.83 (0.408)	3.94 (0.243)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	11	6	17
Mean (SD)	0.00 (0.000)	-0.17 (0.408)	-0.06 (0.243)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.1573			
P-value [c] 0.2031			
LS-Mean Placebo (95%CI) [c]	0.00 (-0.16 - 0.17)		
LS-Mean LJ501 (95%CI) [c]	-0.17 (-0.40 - 0.05)		
LS-Mean Difference (95%CI) [c]	0.17 (-0.11 - 0.46)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	11	6	17
Hour 48 [a]			
N	11	6	17
0	3 (27.3%)	2 (33.3%)	5 (29.4%)
1	1 (9.1%)	0 (0.0%)	1 (5.9%)
3	2 (18.2%)	0 (0.0%)	2 (11.8%)
4	3 (27.3%)	4 (66.7%)	7 (41.2%)
4 (WC)	2 (18.2%)	0 (0.0%)	2 (11.8%)
Mean (SD)	2.45 (1.809)	2.67 (2.066)	2.53 (1.841)
Median	3.00	4.00	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	11	6	17
Mean (SD)	-1.55 (1.809)	-1.33 (2.066)	-1.47 (1.841)
Median	-1.00	0.00	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 1.0000			
P-value [c] 0.7902			
LS-Mean Placebo (95%CI) [c]	-1.57 (-2.87 - -0.27)		
LS-Mean LJ501 (95%CI) [c]	-1.29 (-3.06 - 0.48)		
LS-Mean Difference (95%CI) [c]	-0.28 (-2.49 - 1.94)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	11	6	17
Screening			
N	11	5	16
Mean (SD)	10.27 (3.319)	11.20 (3.421)	10.56 (3.265)
Median	9.00	10.00	10.00
Range	6 - 18	8 - 17	6 - 18

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	11	6	17
Hour 3			
N	11	6	17
Mean (SD)	11.18 (3.157)	11.50 (3.082)	11.29 (3.037)
Median	11.00	10.50	11.00
Range	7 - 18	9 - 17	7 - 18
Change from Screening			
N	11	5	16
Mean (SD)	0.91 (1.868)	0.40 (1.140)	0.75 (1.653)
Median	1.00	0.00	0.50
Range	-2 - 4	-1 - 2	-2 - 4
P-value [b] 0.4418			
P-value [c] 0.6391			
LS-Mean Placebo (95%CI) [c]	0.65 (-0.12 - 1.42)		
LS-Mean LJ501 (95%CI) [c]	0.96 (-0.20 - 2.12)		
LS-Mean Difference (95%CI) [c]	-0.31 (-1.73 - 1.11)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	11	6	17
Hour 48			
N	11	6	17
Mean (SD)	11.64 (8.286)	11.00 (5.177)	11.41 (7.168)
Median	9.00	11.00	9.00
Range	2 - 24	5 - 18	2 - 24
Change from Screening			
N	11	5	16
Mean (SD)	1.36 (6.757)	0.80 (3.493)	1.19 (5.811)
Median	1.00	1.00	1.00
Range	-8 - 14	-5 - 4	-8 - 14
P-value [b] 0.9100			
P-value [c] 0.7859			
LS-Mean Placebo (95%CI) [c]	0.93 (-2.67 - 4.52)		
LS-Mean LJ501 (95%CI) [c]	1.76 (-3.66 - 7.18)		
LS-Mean Difference (95%CI) [c]	-0.84 (-7.46 - 5.78)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Total Number of Patients	9	6	15
Total Number of Events	4	0	4
Total Number of Censored for CSH	5	6	11
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	4 (1 - 6)	(-)	6 (1 -)
Median (95% CI)	6 (1 -)	(-)	(4 -)
75% Quartile (95% CI)	(4 -)	(-)	(-)
Range	1 - 7+	4+ - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	11% (2%- 57%)	0% (0%- 0%)	7% (1%- 39%)
2-day Estimate	22% (6%- 64%)	0% (0%- 0%)	13% (4%- 44%)
3-day Estimate	22% (6%- 64%)	0% (0%- 0%)	13% (4%- 44%)
4-day Estimate	38% (14%- 79%)	0% (0%- 0%)	21% (7%- 53%)
5-day Estimate	38% (14%- 79%)	0% (0%- 0%)	21% (7%- 53%)
6-day Estimate	59% (25%- 93%)	0% (0%- 0%)	31% (13%- 64%)
7-day Estimate	59% (25%- 93%)	0% (0%- 0%)	31% (13%- 64%)
Ventilator Cumulative Incidence			
1-day Estimate	11% (2%- 57%)	0% (0%- 0%)	7% (1%- 39%)
2-day Estimate	22% (6%- 64%)	0% (0%- 0%)	13% (4%- 44%)
3-day Estimate	22% (6%- 64%)	0% (0%- 0%)	13% (4%- 44%)
4-day Estimate	33% (12%- 72%)	0% (0%- 0%)	20% (7%- 50%)
5-day Estimate	33% (12%- 72%)	0% (0%- 0%)	20% (7%- 50%)
6-day Estimate	44% (20%- 80%)	0% (0%- 0%)	27% (11%- 56%)
7-day Estimate	44% (20%- 80%)	0% (0%- 0%)	27% (11%- 56%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 4.13, 1, 0.0421
Log hazard (SE), Relative Risk (95% CI) [b]: -18.29 (4530), 0.000 (0.000 -)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 3.26, 1, 0.0711
Log hazard (SE), Relative Risk (95% CI) [b]: -18.02 (4530), 0.000 (0.000 -)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.38.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Total Number of Patients	11	6	17
Total Number of Events	7	2	9
Total Number of Censored for CSH	4	4	8
Days to ICU Discharge			
25% Quartile (95% CI)	5 (3 - 11)	20 (20 -)	8 (3 - 17)
Median (95% CI)	11 (3 - 17)	22 (20 -)	17 (5 - 22)
75% Quartile (95% CI)	17 (5 - 17)	(20 -)	22 (14 -)
Range	2+ - 17	4+ - 28+	2+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	36% (13%- 76%)	0% (0%- 0%)	22% (8%- 54%)
14-day Estimate	74% (43%- 96%)	0% (0%- 0%)	46% (24%- 76%)
21-day Estimate	100% (%- %)	33% (5%- 95%)	71% (42%- 94%)
28-day Estimate	100% (%- %)	67% (23%- 99%)	86% (55%- 99%)
ICU Discharge Cumulative Incidence			
7-day Estimate	27% (10%- 63%)	0% (0%- 0%)	18% (6%- 45%)
14-day Estimate	55% (29%- 83%)	0% (0%- 0%)	35% (18%- 62%)
21-day Estimate	64% (37%- 89%)	17% (3%- 73%)	47% (27%- 72%)
28-day Estimate	64% (37%- 89%)	33% (10%- 81%)	53% (32%- 77%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 8.15, 1, 0.0043
Log hazard (SE), Relative Risk (95% CI) [b]: -18.55 (3441), 0.000 (0.000 -)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.21, 1, 0.1369
Log hazard (SE), Relative Risk (95% CI) [b]: -1.146 (0.810), 0.318 (0.065 - 1.556)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.38.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, No Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Total Number of Patients	11	6	17
Total Number of Events	6	1	7
Total Number of Censored for CSH	5	5	10
Days to Hospital Discharge			
25% Quartile (95% CI)	12 (6 - 18)	20 (20 -)	18 (6 - 20)
Median (95% CI)	18 (6 - 21)	(20 -)	20 (17 -)
75% Quartile (95% CI)	21 (17 -)	(20 -)	(18 -)
Range	2+ - 28+	4+ - 28+	2+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	25% (7%- 69%)	0% (0%- 0%)	15% (4%- 49%)
14-day Estimate	25% (7%- 69%)	0% (0%- 0%)	15% (4%- 49%)
21-day Estimate	85% (52%- 99%)	33% (5%- 95%)	66% (38%- 91%)
28-day Estimate	85% (52%- 99%)	33% (5%- 95%)	66% (38%- 91%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	18% (5%- 55%)	0% (0%- 0%)	12% (3%- 39%)
14-day Estimate	18% (5%- 55%)	0% (0%- 0%)	12% (3%- 39%)
21-day Estimate	55% (29%- 83%)	17% (3%- 73%)	41% (22%- 67%)
28-day Estimate	55% (29%- 83%)	17% (3%- 73%)	41% (22%- 67%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 3.21, 1, 0.0734
Log hazard (SE), Relative Risk (95% CI) [b]: -1.728 (1.085), 0.178 (0.021 - 1.490)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.23, 1, 0.1357
Log hazard (SE), Relative Risk (95% CI) [b]: -1.478 (1.082), 0.228 (0.027 - 1.902)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.38.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	104	108	212
Screening			
N	104	108	212
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	104 (100.0%)	108 (100.0%)	212 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	104	108	212
Hour 3 [a]			
N	104	108	212
3	1 (1.0%)	5 (4.6%)	6 (2.8%)
4	102 (98.1%)	103 (95.4%)	205 (96.7%)
4 (LOCF)	1 (1.0%)	0 (0.0%)	1 (0.5%)
Mean (SD)	3.99 (0.098)	3.95 (0.211)	3.97 (0.166)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	104	108	212
Mean (SD)	-0.01 (0.098)	-0.05 (0.211)	-0.03 (0.166)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.1122			
P-value [c] 0.2111			
LS-Mean Placebo (95%CI) [c]	-0.01 (-0.05 - 0.02)		
LS-Mean LJ501 (95%CI) [c]	-0.04 (-0.07 - -0.01)		
LS-Mean Difference (95%CI) [c]	0.03 (-0.02 - 0.07)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	104	108	212
Hour 48 [a]			
N	104	108	212
0	18 (17.3%)	35 (32.4%)	53 (25.0%)
1	5 (4.8%)	7 (6.5%)	12 (5.7%)
2	0 (0.0%)	2 (1.9%)	2 (0.9%)
3	20 (19.2%)	20 (18.5%)	40 (18.9%)
4	33 (31.7%)	26 (24.1%)	59 (27.8%)
4 (LOCF)	2 (1.9%)	0 (0.0%)	2 (0.9%)
4 (WC)	26 (25.0%)	18 (16.7%)	44 (20.8%)
Mean (SD)	2.97 (1.536)	2.29 (1.767)	2.62 (1.689)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	104	108	212
Mean (SD)	-1.03 (1.536)	-1.71 (1.767)	-1.38 (1.689)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0095			
P-value [c] 0.0385			
LS-Mean Placebo (95%CI) [c]	-1.14 (-1.45 - -0.84)		
LS-Mean LJ501 (95%CI) [c]	-1.60 (-1.90 - -1.30)		
LS-Mean Difference (95%CI) [c]	0.46 (0.02 - 0.89)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	104	108	212
Screening			
N	104	105	209
Mean (SD)	13.65 (3.062)	11.85 (2.804)	12.75 (3.065)
Median	14.00	12.00	13.00
Range	5 - 21	5 - 18	5 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	104	108	212
Hour 3			
N	104	108	212
Mean (SD)	14.08 (3.161)	12.77 (3.125)	13.41 (3.203)
Median	14.00	13.00	13.00
Range	7 - 21	5 - 20	5 - 21
Change from Screening			
N	104	105	209
Mean (SD)	0.42 (1.934)	0.97 (1.805)	0.70 (1.886)
Median	0.00	1.00	0.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b] 0.0444			
P-value [c] 0.2135			
LS-Mean Placebo (95%CI) [c]	0.53 (0.17 - 0.90)		
LS-Mean LJ501 (95%CI) [c]	0.86 (0.50 - 1.23)		
LS-Mean Difference (95%CI) [c]	-0.33 (-0.86 - 0.19)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Number of Patients	104	108	212
Hour 48			
N	104	108	212
Mean (SD)	15.63 (6.389)	13.09 (6.437)	14.34 (6.524)
Median	15.00	11.00	14.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	104	105	209
Mean (SD)	1.98 (5.417)	1.42 (5.883)	1.70 (5.649)
Median	1.00	0.00	1.00
Range	-7 - 16	-10 - 15	-10 - 16
P-value [b]	0.7111		
P-value [c]	0.8857		
LS-Mean Placebo (95%CI) [c]	1.76 (0.69 - 2.82)		
LS-Mean LJ501 (95%CI) [c]	1.64 (0.58 - 2.71)		
LS-Mean Difference (95%CI) [c]	0.11 (-1.43 - 1.66)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.38.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Total Number of Patients	99	97	196
Total Number of Events	20	28	48
Total Number of Censored for CSH	79	69	148
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	7 (5 -)	5 (4 - 7)	6 (5 - 7)
Median (95% CI)	(-)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	1% (0%- 7%)	1% (0%- 4%)
2-day Estimate	3% (1%- 9%)	6% (3%- 14%)	5% (2%- 9%)
3-day Estimate	6% (2%- 13%)	12% (7%- 21%)	9% (6%- 15%)
4-day Estimate	10% (5%- 20%)	16% (10%- 26%)	13% (9%- 19%)
5-day Estimate	15% (8%- 25%)	26% (17%- 37%)	20% (15%- 28%)
6-day Estimate	23% (15%- 35%)	33% (23%- 44%)	28% (21%- 36%)
7-day Estimate	30% (20%- 43%)	36% (26%- 48%)	33% (26%- 41%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	1% (0%- 7%)	1% (0%- 4%)
2-day Estimate	3% (1%- 9%)	6% (3%- 13%)	5% (2%- 9%)
3-day Estimate	5% (2%- 12%)	11% (6%- 20%)	8% (5%- 13%)
4-day Estimate	8% (4%- 16%)	14% (9%- 23%)	11% (8%- 17%)
5-day Estimate	11% (6%- 19%)	22% (15%- 31%)	16% (12%- 22%)
6-day Estimate	16% (10%- 25%)	27% (19%- 37%)	21% (16%- 28%)
7-day Estimate	20% (14%- 30%)	29% (21%- 39%)	24% (19%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 1.07, 1, 0.3011
Log hazard (SE), Relative Risk (95% CI) [b]: 0.302 (0.293), 1.352 (0.762 - 2.400)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 2.19, 1, 0.1386
Log hazard (SE), Relative Risk (95% CI) [b]: 0.430 (0.293), 1.538 (0.866 - 2.730)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.38.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Total Number of Patients	104	108	212
Total Number of Events	35	45	80
Total Number of Censored for CSH	69	63	132
Days to ICU Discharge			
25% Quartile (95% CI)	11 (7 - 14)	8 (6 - 10)	9 (7 - 11)
Median (95% CI)	18 (14 - 25)	14 (11 - 18)	15 (14 - 20)
75% Quartile (95% CI)	(22 -)	(23 -)	(25 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	17% (10%- 28%)	21% (14%- 32%)	19% (14%- 27%)
14-day Estimate	36% (25%- 50%)	50% (39%- 63%)	44% (36%- 53%)
21-day Estimate	60% (46%- 74%)	62% (50%- 74%)	61% (51%- 70%)
28-day Estimate	74% (59%- 87%)	68% (56%- 80%)	70% (60%- 79%)
ICU Discharge Cumulative Incidence			
7-day Estimate	12% (7%- 19%)	16% (10%- 24%)	14% (10%- 19%)
14-day Estimate	21% (14%- 30%)	33% (25%- 43%)	27% (22%- 34%)
21-day Estimate	30% (22%- 40%)	39% (30%- 49%)	34% (28%- 41%)
28-day Estimate	34% (25%- 44%)	42% (33%- 52%)	38% (32%- 45%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.52, 1, 0.4705
Log hazard (SE), Relative Risk (95% CI) [b]: 0.163 (0.226), 1.177 (0.756 - 1.833)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 1.90, 1, 0.1686
Log hazard (SE), Relative Risk (95% CI) [b]: 0.309 (0.225), 1.362 (0.876 - 2.120)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.38.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Vasopressin Use at Baseline)

	Placebo	LJPC-501	Total
Total Number of Patients	104	108	212
Total Number of Events	20	32	52
Total Number of Censored for CSH	84	76	160
Days to Hospital Discharge			
25% Quartile (95% CI)	22 (14 - 24)	17 (15 - 21)	18 (15 - 22)
Median (95% CI)	(24 -)	28 (22 -)	28 (24 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	4% (1%- 12%)	2% (1%- 6%)
14-day Estimate	14% (7%- 27%)	14% (8%- 25%)	14% (9%- 21%)
21-day Estimate	23% (13%- 38%)	36% (25%- 49%)	31% (23%- 40%)
28-day Estimate	48% (34%- 65%)	52% (40%- 65%)	50% (41%- 60%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	3% (1%- 8%)	1% (0%- 4%)
14-day Estimate	7% (3%- 14%)	9% (5%- 17%)	8% (5%- 13%)
21-day Estimate	11% (6%- 18%)	21% (15%- 30%)	16% (12%- 22%)
28-day Estimate	19% (13%- 28%)	30% (22%- 39%)	25% (19%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.51, 1, 0.4758
Log hazard (SE), Relative Risk (95% CI) [b]: 0.203 (0.285), 1.225 (0.700 - 2.143)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 3.26, 1, 0.0708
Log hazard (SE), Relative Risk (95% CI) [b]: 0.510 (0.285), 1.665 (0.952 - 2.911)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.39.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	63	82	145
Screening			
N	63	82	145
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	63 (100.0%)	82 (100.0%)	145 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	63	82	145
Hour 3 [a]			
N	63	82	145
3	0 (0.0%)	5 (6.1%)	5 (3.4%)
4	62 (98.4%)	77 (93.9%)	139 (95.9%)
4 (LOCF)	1 (1.6%)	0 (0.0%)	1 (0.7%)
Mean (SD)	4.00 (0.000)	3.94 (0.241)	3.97 (0.183)
Median	4.00	4.00	4.00
Range	4 - 4	3 - 4	3 - 4
Change from Screening			
N	63	82	145
Mean (SD)	0.00 (0.000)	-0.06 (0.241)	-0.03 (0.183)
Median	0.00	0.00	0.00
Range	0 - 0	-1 - 0	-1 - 0
P-value [b] 0.0516			
P-value [c] 0.0855			
LS-Mean Placebo (95%CI) [c]	-0.00 (-0.05 - 0.04)		
LS-Mean LJ501 (95%CI) [c]	-0.06 (-0.10 - -0.02)		
LS-Mean Difference (95%CI) [c]	0.05 (-0.01 - 0.11)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.1.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	63	82	145
Hour 48 [a]			
N	63	82	145
0	14 (22.2%)	29 (35.4%)	43 (29.7%)
1	5 (7.9%)	5 (6.1%)	10 (6.9%)
2	0 (0.0%)	1 (1.2%)	1 (0.7%)
3	12 (19.0%)	15 (18.3%)	27 (18.6%)
4	23 (36.5%)	21 (25.6%)	44 (30.3%)
4 (WC)	9 (14.3%)	11 (13.4%)	20 (13.8%)
Mean (SD)	2.68 (1.664)	2.20 (1.795)	2.41 (1.750)
Median	4.00	3.00	3.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	63	82	145
Mean (SD)	-1.32 (1.664)	-1.80 (1.795)	-1.59 (1.750)
Median	0.00	-1.00	-1.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.1592			
P-value [c] 0.1710			
LS-Mean Placebo (95%CI) [c]	-1.37 (-1.79 - -0.96)		
LS-Mean LJ501 (95%CI) [c]	-1.76 (-2.13 - -1.40)		
LS-Mean Difference (95%CI) [c]	0.39 (-0.17 - 0.94)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	63	82	145
Screening			
N	63	78	141
Mean (SD)	12.06 (2.711)	11.17 (2.611)	11.57 (2.684)
Median	12.00	11.00	12.00
Range	5 - 18	5 - 18	5 - 18

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	63	82	145
Hour 3			
N	63	82	145
Mean (SD)	12.56 (3.141)	12.21 (2.849)	12.36 (2.974)
Median	13.00	12.00	12.00
Range	7 - 20	5 - 19	5 - 20
Change from Screening			
N	63	78	141
Mean (SD)	0.49 (1.991)	1.10 (1.835)	0.83 (1.923)
Median	0.00	1.00	1.00
Range	-3 - 7	-2 - 7	-3 - 7
P-value [b]	0.0455		
P-value [c]	0.1289		
LS-Mean Placebo (95%CI) [c]	0.55 (0.08 - 1.03)		
LS-Mean LJ501 (95%CI) [c]	1.05 (0.62 - 1.48)		
LS-Mean Difference (95%CI) [c]	-0.50 (-1.14 - 0.15)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.1.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	63	82	145
Hour 48			
N	63	82	145
Mean (SD)	12.59 (6.544)	12.16 (6.235)	12.34 (6.352)
Median	12.00	11.00	11.00
Range	2 - 24	3 - 24	2 - 24
Change from Screening			
N	63	78	141
Mean (SD)	0.52 (5.582)	1.27 (5.702)	0.94 (5.641)
Median	0.00	0.00	0.00
Range	-8 - 16	-8 - 15	-8 - 16
P-value [b] 0.2487			
P-value [c] 0.3054			
LS-Mean Placebo (95%CI) [c]	0.40 (-0.96 - 1.77)		
LS-Mean LJ501 (95%CI) [c]	1.37 (0.14 - 2.59)		
LS-Mean Difference (95%CI) [c]	-0.96 (-2.81 - 0.89)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.1.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Total Number of Patients	59	73	132
Total Number of Events	19	20	39
Total Number of Censored for CSH	40	53	93
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	6 (4 - 7)	6 (5 -)	6 (5 - 7)
Median (95% CI)	(7 -)	(-)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1 - 7+	1 - 7+	1 - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	2% (0%- 11%)	1% (0%- 9%)	2% (0%- 6%)
2-day Estimate	9% (4%- 20%)	6% (2%- 14%)	7% (4%- 13%)
3-day Estimate	11% (5%- 22%)	12% (6%- 22%)	11% (7%- 18%)
4-day Estimate	17% (9%- 30%)	13% (7%- 24%)	15% (10%- 23%)
5-day Estimate	21% (12%- 36%)	22% (14%- 34%)	22% (15%- 31%)
6-day Estimate	31% (20%- 46%)	29% (19%- 42%)	30% (22%- 40%)
7-day Estimate	40% (27%- 55%)	33% (23%- 47%)	36% (28%- 46%)
Ventilator Cumulative Incidence			
1-day Estimate	2% (0%- 11%)	1% (0%- 9%)	2% (0%- 6%)
2-day Estimate	8% (4%- 19%)	5% (2%- 14%)	7% (4%- 13%)
3-day Estimate	10% (5%- 21%)	11% (6%- 21%)	11% (6%- 17%)
4-day Estimate	15% (8%- 27%)	12% (7%- 22%)	14% (9%- 21%)
5-day Estimate	19% (11%- 31%)	19% (12%- 30%)	19% (13%- 27%)
6-day Estimate	25% (16%- 39%)	25% (16%- 36%)	25% (18%- 33%)
7-day Estimate	32% (22%- 46%)	27% (19%- 39%)	30% (23%- 38%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.35, 1, 0.5545
Log hazard (SE), Relative Risk (95% CI) [b]: -0.189 (0.320), 0.828 (0.442 - 1.551)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.29, 1, 0.5914
Log hazard (SE), Relative Risk (95% CI) [b]: -0.172 (0.320), 0.842 (0.449 - 1.578)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.39.1.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Total Number of Patients	63	82	145
Total Number of Events	31	34	65
Total Number of Censored for CSH	32	48	80
Days to ICU Discharge			
25% Quartile (95% CI)	10 (5 - 12)	8 (6 - 10)	9 (7 - 10)
Median (95% CI)	15 (12 - 18)	16 (10 - 23)	15 (12 - 18)
75% Quartile (95% CI)	25 (18 -)	(23 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	22% (13%- 36%)	20% (12%- 33%)	21% (15%- 30%)
14-day Estimate	49% (35%- 65%)	47% (34%- 62%)	48% (38%- 59%)
21-day Estimate	73% (57%- 86%)	58% (44%- 72%)	64% (54%- 75%)
28-day Estimate	80% (65%- 92%)	69% (55%- 82%)	74% (63%- 83%)
ICU Discharge Cumulative Incidence			
7-day Estimate	17% (10%- 29%)	16% (10%- 26%)	17% (11%- 24%)
14-day Estimate	35% (25%- 48%)	32% (23%- 43%)	33% (26%- 41%)
21-day Estimate	46% (35%- 59%)	37% (27%- 48%)	41% (33%- 49%)
28-day Estimate	49% (38%- 62%)	41% (32%- 53%)	45% (37%- 53%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.33, 1, 0.5640
Log hazard (SE), Relative Risk (95% CI) [b]: -0.144 (0.249), 0.866 (0.531 - 1.412)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.62, 1, 0.4311
Log hazard (SE), Relative Risk (95% CI) [b]: -0.195 (0.248), 0.823 (0.505 - 1.339)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.39.1.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, No Acute Kidney Injury)

	Placebo	LJPC-501	Total
Total Number of Patients	63	82	145
Total Number of Events	19	23	42
Total Number of Censored for CSH	44	59	103
Days to Hospital Discharge			
25% Quartile (95% CI)	16 (13 - 24)	17 (11 - 23)	17 (14 - 21)
Median (95% CI)	25 (18 -)	(23 -)	28 (23 -)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	4% (1%- 16%)	5% (2%- 15%)	5% (2%- 11%)
14-day Estimate	20% (10%- 36%)	19% (10%- 32%)	19% (12%- 29%)
21-day Estimate	38% (24%- 56%)	32% (21%- 47%)	34% (25%- 46%)
28-day Estimate	54% (38%- 72%)	49% (35%- 64%)	51% (40%- 62%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	3% (1%- 12%)	4% (1%- 11%)	3% (1%- 8%)
14-day Estimate	13% (7%- 24%)	12% (7%- 21%)	12% (8%- 19%)
21-day Estimate	22% (14%- 35%)	20% (12%- 30%)	21% (15%- 28%)
28-day Estimate	30% (20%- 43%)	28% (20%- 39%)	29% (22%- 37%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.08, 1, 0.7761
Log hazard (SE), Relative Risk (95% CI) [b]: -0.088 (0.310), 0.915 (0.498 - 1.682)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 0.06, 1, 0.8115
Log hazard (SE), Relative Risk (95% CI) [b]: -0.074 (0.310), 0.928 (0.506 - 1.705)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.39.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	52	32	84
Screening			
N	52	32	84
0	0 (0.0%)	0 (0.0%)	0 (0.0%)
1	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	0 (0.0%)	0 (0.0%)	0 (0.0%)
3	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	52 (100.0%)	32 (100.0%)	84 (100.0%)
Mean (SD)	4.00 (0.000)	4.00 (0.000)	4.00 (0.000)
Median	4.00	4.00	4.00
Range	4 - 4	4 - 4	4 - 4

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	52	32	84
Hour 3 [a]			
N	52	32	84
3	1 (1.9%)	1 (3.1%)	2 (2.4%)
4	51 (98.1%)	31 (96.9%)	82 (97.6%)
Mean (SD)	3.98 (0.139)	3.97 (0.177)	3.98 (0.153)
Median	4.00	4.00	4.00
Range	3 - 4	3 - 4	3 - 4
Change from Screening			
N	52	32	84
Mean (SD)	-0.02 (0.139)	-0.03 (0.177)	-0.02 (0.153)
Median	0.00	0.00	0.00
Range	-1 - 0	-1 - 0	-1 - 0
P-value [b] 0.8780			
P-value [c] 0.5926			
LS-Mean Placebo (95%CI) [c]	-0.02 (-0.06 - 0.03)		
LS-Mean LJ501 (95%CI) [c]	-0.04 (-0.09 - 0.02)		
LS-Mean Difference (95%CI) [c]	0.02 (-0.05 - 0.09)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.2.1
CV SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	52	32	84
Hour 48 [a]			
N	52	32	84
0	7 (13.5%)	8 (25.0%)	15 (17.9%)
1	1 (1.9%)	2 (6.3%)	3 (3.6%)
2	0 (0.0%)	1 (3.1%)	1 (1.2%)
3	10 (19.2%)	5 (15.6%)	15 (17.9%)
4	13 (25.0%)	9 (28.1%)	22 (26.2%)
4 (LOCF)	2 (3.8%)	0 (0.0%)	2 (2.4%)
4 (WC)	19 (36.5%)	7 (21.9%)	26 (31.0%)
Mean (SD)	3.21 (1.391)	2.59 (1.720)	2.98 (1.544)
Median	4.00	3.50	4.00
Range	0 - 4	0 - 4	0 - 4
Change from Screening			
N	52	32	84
Mean (SD)	-0.79 (1.391)	-1.41 (1.720)	-1.02 (1.544)
Median	0.00	-0.50	0.00
Range	-4 - 0	-4 - 0	-4 - 0
P-value [b] 0.0952			
P-value [c] 0.2470			
LS-Mean Placebo (95%CI) [c]	-0.87 (-1.28 - -0.46)		
LS-Mean LJ501 (95%CI) [c]	-1.27 (-1.80 - -0.74)		
LS-Mean Difference (95%CI) [c]	0.40 (-0.28 - 1.07)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	52	32	84
Screening			
N	52	32	84
Mean (SD)	14.87 (3.162)	13.41 (2.710)	14.31 (3.065)
Median	14.50	13.50	14.00
Range	6 - 21	8 - 18	6 - 21

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3
LA JOLLA PHARMACEUTICAL COMPANY CONFIDENTIAL & PROPRIETARY - 16MAR2021:11:09

Table 14.2.39.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	52	32	84
Hour 3			
N	52	32	84
Mean (SD)	15.31 (2.748)	13.97 (3.469)	14.80 (3.092)
Median	15.50	15.00	15.00
Range	10 - 21	7 - 20	7 - 21
Change from Screening			
N	52	32	84
Mean (SD)	0.44 (1.862)	0.56 (1.605)	0.49 (1.760)
Median	0.00	0.00	0.00
Range	-3 - 5	-2 - 4	-3 - 5
P-value [b] 0.8827			
P-value [c] 0.9002			
LS-Mean Placebo (95%CI) [c]	0.47 (-0.01 - 0.95)		
LS-Mean LJ501 (95%CI) [c]	0.52 (-0.10 - 1.14)		
LS-Mean Difference (95%CI) [c]	-0.05 (-0.85 - 0.75)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.2.2
Total SOFA Score: Secondary Efficacy Endpoint (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Number of Patients	52	32	84
Hour 48			
N	52	32	84
Mean (SD)	18.48 (5.249)	15.09 (6.337)	17.19 (5.887)
Median	19.00	15.00	18.00
Range	7 - 24	5 - 24	5 - 24
Change from Screening			
N	52	32	84
Mean (SD)	3.62 (5.006)	1.69 (6.072)	2.88 (5.483)
Median	3.00	1.00	2.00
Range	-7 - 15	-10 - 15	-10 - 15
P-value [b] 0.1497			
P-value [c] 0.1492			
LS-Mean Placebo (95%CI) [c]	3.56 (2.11 - 5.00)		
LS-Mean LJ501 (95%CI) [c]	1.79 (-0.08 - 3.65)		
LS-Mean Difference (95%CI) [c]	1.77 (-0.65 - 4.19)		

[a] LOCF-Last observation carried forward, WC-Worst case for deaths.
[b] van Elteren Wilcoxon rank test of LJPC-501 compared to Placebo stratified by randomization strata for MAP and APACHE II Score.
[c] General linear model of LJPC-501 compared to Placebo adjusting for Baseline MAP, Screening APACHE II Score and Screening SOFA score.
Listing source: 16.1.7, 16.2.6.3.1, 16.2.6.3.2, 16.2.4.3, 16.2.6.2, 16.2.7.3

Table 14.2.39.2.3
Time to Ventilator Discontinuation (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Total Number of Patients	49	30	79
Total Number of Events	5	8	13
Total Number of Censored for CSH	44	22	66
Days to Ventilator Discontinuation			
25% Quartile (95% CI)	(5 -)	5 (3 -)	6 (5 -)
Median (95% CI)	(-)	(5 -)	(-)
75% Quartile (95% CI)	(-)	(-)	(-)
Range	1+ - 7+	1+ - 7+	1+ - 7+
Ventilator Cause-specific Hazard			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	7% (2%- 25%)	3% (1%- 10%)
3-day Estimate	3% (0%- 20%)	11% (4%- 30%)	6% (2%- 16%)
4-day Estimate	7% (2%- 25%)	19% (9%- 41%)	12% (6%- 24%)
5-day Estimate	11% (4%- 30%)	29% (15%- 52%)	19% (10%- 32%)
6-day Estimate	20% (9%- 41%)	34% (18%- 57%)	26% (15%- 40%)
7-day Estimate	20% (9%- 41%)	34% (18%- 57%)	26% (15%- 40%)
Ventilator Cumulative Incidence			
1-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
2-day Estimate	0% (0%- 0%)	7% (2%- 24%)	3% (1%- 10%)
3-day Estimate	2% (0%- 14%)	10% (3%- 28%)	5% (2%- 13%)
4-day Estimate	4% (1%- 15%)	17% (7%- 36%)	9% (4%- 18%)
5-day Estimate	6% (2%- 18%)	23% (12%- 43%)	13% (7%- 22%)
6-day Estimate	10% (4%- 23%)	27% (14%- 46%)	16% (10%- 27%)
7-day Estimate	10% (4%- 23%)	27% (14%- 46%)	16% (10%- 27%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 2.05, 1, 0.1522
Log hazard (SE), Relative Risk (95% CI) [b]: 0.796 (0.571), 2.216 (0.724 - 6.782)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 3.87, 1, 0.0491
Log hazard (SE), Relative Risk (95% CI) [b]: 1.071 (0.570), 2.917 (0.954 - 8.921)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3, 16.2.6.6

Table 14.2.39.2.4
Time to ICU Discharge (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Total Number of Patients	52	32	84
Total Number of Events	11	13	24
Total Number of Censored for CSH	41	19	60
Days to ICU Discharge			
25% Quartile (95% CI)	15 (6 - 20)	10 (4 - 14)	10 (7 - 15)
Median (95% CI)	22 (15 -)	15 (10 -)	20 (14 -)
75% Quartile (95% CI)	(22 -)	(15 -)	(22 -)
Range	1+ - 28+	1+ - 28+	1+ - 28+
ICU Discharge Cause-specific Hazard			
7-day Estimate	15% (6%- 35%)	17% (7%- 40%)	16% (8%- 29%)
14-day Estimate	24% (12%- 46%)	47% (28%- 70%)	36% (23%- 52%)
21-day Estimate	46% (25%- 72%)	65% (44%- 86%)	56% (40%- 73%)
28-day Estimate	71% (42%- 94%)	65% (44%- 86%)	65% (48%- 82%)
ICU Discharge Cumulative Incidence			
7-day Estimate	8% (3%- 19%)	13% (5%- 30%)	10% (5%- 18%)
14-day Estimate	12% (5%- 24%)	31% (18%- 50%)	19% (12%- 29%)
21-day Estimate	17% (9%- 31%)	41% (26%- 59%)	26% (18%- 37%)
28-day Estimate	21% (12%- 35%)	41% (26%- 59%)	29% (20%- 40%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.50, 1, 0.4781
Log hazard (SE), Relative Risk (95% CI) [b]: 0.290 (0.411), 1.337 (0.598 - 2.992)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 3.89, 1, 0.0485
Log hazard (SE), Relative Risk (95% CI) [b]: 0.789 (0.410), 2.201 (0.985 - 4.919)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.2.39.2.5
Time to Hospital Discharge (mITT Population with >=2 Vasopressors, Acute Kidney Injury)

	Placebo	LJPC-501	Total
Total Number of Patients	52	32	84
Total Number of Events	7	10	17
Total Number of Censored for CSH	45	22	67
Days to Hospital Discharge			
25% Quartile (95% CI)	22 (11 - 28)	19 (15 - 22)	20 (16 - 23)
Median (95% CI)	28 (22 -)	24 (19 -)	28 (21 -)
75% Quartile (95% CI)	(28 -)	(24 -)	(-)
Range	1+ - 28+	1+ - 28+	1+ - 28+
Hospital Discharge Cause-specific Hazard			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	5% (1%- 31%)	0% (0%- 0%)	2% (0%- 16%)
21-day Estimate	18% (6%- 48%)	44% (25%- 69%)	33% (20%- 51%)
28-day Estimate	52% (28%- 81%)	55% (34%- 78%)	53% (37%- 71%)
Hospital Discharge Cumulative Incidence			
7-day Estimate	0% (0%- 0%)	0% (0%- 0%)	0% (0%- 0%)
14-day Estimate	2% (0%- 13%)	0% (0%- 0%)	1% (0%- 8%)
21-day Estimate	6% (2%- 17%)	25% (13%- 44%)	13% (7%- 22%)
28-day Estimate	13% (7%- 26%)	31% (18%- 50%)	20% (13%- 31%)

Cause-specific Hazard
Log-rank statistic, d.f., P-value [a]: 0.18, 1, 0.6720
Log hazard (SE), Relative Risk (95% CI) [b]: 0.209 (0.493), 1.232 (0.468 - 3.241)

Cumulative Incidence
Log-rank statistic, d.f., P-value [a]: 4.09, 1, 0.0432
Log hazard (SE), Relative Risk (95% CI) [b]: 0.960 (0.493), 2.613 (0.993 - 6.872)

[Note] A '+' next to a number represents a censored observation.
[a] Log-rank test of LJPC-501 compared to Placebo.
[b] Hazard ratio from Cox proportional hazard model of LJPC-501 compared to Placebo.
Listing source: 16.2.1.1, 16.2.1.3

Table 14.3.20.1.6.1
TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with TEAEs (%)	Number of Patients	Number with TEAEs (%)		
Age (years)						
< 65	54	50 (92.6%)	62	53 (85.5%)	0.47 (0.14 - 1.63)	0.2260
>=65	61	60 (98.4%)	52	48 (92.3%)	0.20 (0.02 - 1.85)	0.1189
Within Treatment Arm [b]	4.80 (0.52 - 44.3), 0.1301		2.04 (0.59 - 7.05), 0.2536			
Across Treatment Arm [c]	0.37 (0.13 - 1.09), 0.0713					
Treatment Interaction [d]	0.42 (0.03 - 5.42), 0.5096					
Gender						
Female	39	38 (97.4%)	49	44 (89.8%)	0.23 (0.03 - 2.07)	0.1578
Male	76	72 (94.7%)	65	57 (87.7%)	0.40 (0.11 - 1.38)	0.1351
Within Treatment Arm [b]	0.47 (0.05 - 4.39), 0.5016		0.81 (0.25 - 2.65), 0.7265			
Across Treatment Arm [c]	0.34 (0.12 - 1.00), 0.0498					
Treatment Interaction [d]	1.71 (0.14 - 21.3), 0.6769					
Race						
Other	29	27 (93.1%)	17	16 (94.1%)	1.19 (0.10 - 14.1)	0.8930
White	86	83 (96.5%)	97	85 (87.6%)	0.26 (0.07 - 0.94)	0.0288
Within Treatment Arm [b]	2.05 (0.33 - 12.9), 0.4364		0.44 (0.05 - 3.65), 0.4375			
Across Treatment Arm [c]	0.36 (0.12 - 1.04), 0.0595					
Treatment Interaction [d]	0.22 (0.01 - 3.55), 0.2834					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	57 (95.0%)	60	52 (86.7%)	0.34 (0.09 - 1.36)	0.1137
>=30 kg/m2	54	52 (96.3%)	52	47 (90.4%)	0.36 (0.07 - 1.95)	0.2205
Within Treatment Arm [b]	1.37 (0.22 - 8.52), 0.7358		1.45 (0.44 - 4.73), 0.5401			
Across Treatment Arm [c]	0.35 (0.12 - 1.02), 0.0538					
Treatment Interaction [d]	1.06 (0.12 - 9.34), 0.9602					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.1
TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo Number of Patients	Placebo Number with TEAEs (%)	LJPC-501 Number of Patients	LJPC-501 Number with TEAEs (%)	Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	45 (95.7%)	27	23 (85.2%)	0.26 (0.04 - 1.50)	0.1092
< 2.5 g/dL	67	64 (95.5%)	82	73 (89.0%)	0.38 (0.10 - 1.47)	0.1471
Within Treatment Arm [b]	0.95 (0.15 - 5.91), 0.9545		1.41 (0.40 - 5.01), 0.5934			
Across Treatment Arm [c]	0.33 (0.11 - 0.97), 0.0431					
Treatment Interaction [d]	1.49 (0.16 - 13.8), 0.7264					
Geographic Region						
Rest of World	17	16 (94.1%)	17	12 (70.6%)	0.15 (0.02 - 1.46)	0.0719
US/Canada	98	94 (95.9%)	97	89 (91.8%)	0.47 (0.14 - 1.63)	0.2262
Within Treatment Arm [b]	1.47 (0.15 - 14.0), 0.7368		4.64 (1.30 - 16.5), 0.0113			
Across Treatment Arm [c]	0.35 (0.12 - 1.02), 0.0533					
Treatment Interaction [d]	3.16 (0.24 - 42.0), 0.3839					
Baseline MAP						
>=65 mmHg	70	66 (94.3%)	74	63 (85.1%)	0.35 (0.11 - 1.15)	0.0724
< 65 mmHg	45	44 (97.8%)	40	38 (95.0%)	0.43 (0.04 - 4.95)	0.4885
Within Treatment Arm [b]	2.67 (0.29 - 24.7), 0.3701		3.32 (0.70 - 15.8), 0.1138			
Across Treatment Arm [c]	0.36 (0.12 - 1.06), 0.0631					
Treatment Interaction [d]	1.24 (0.08 - 18.8), 0.8748					
Baseline APACHE II Score						
<=30	63	59 (93.7%)	74	63 (85.1%)	0.39 (0.12 - 1.29)	0.1116
> 30	52	51 (98.1%)	40	38 (95.0%)	0.37 (0.03 - 4.26)	0.4101
Within Treatment Arm [b]	3.46 (0.37 - 31.9), 0.2467		3.32 (0.70 - 15.8), 0.1138			
Across Treatment Arm [c]	0.39 (0.13 - 1.13), 0.0821					
Treatment Interaction [d]	0.96 (0.06 - 14.5), 0.9762					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.1
TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with TEAEs (%)	Number of Patients	Number with TEAEs (%)		
Exposure to ACEi						
No	102	98 (96.1%)	106	95 (89.6%)	0.35 (0.11 - 1.15)	0.0720
Yes	13	12 (92.3%)	8	6 (75.0%)	0.25 (0.02 - 3.34)	0.2710
Within Treatment Arm [b]	0.49 (0.05 - 4.75), 0.5301		0.35 (0.06 - 1.94), 0.2096			
Across Treatment Arm [c]	0.33 (0.11 - 0.98), 0.0450					
Treatment Interaction [d]	0.71 (0.04 - 12.2), 0.8131					
Exposure to ARBs						
No	108	103 (95.4%)	106	94 (88.7%)	0.38 (0.13 - 1.12)	0.0703
Yes	7	7 (100%)	8	7 (87.5%)		0.3329
Within Treatment Arm [b]	, 0.5605		0.89 (0.10 - 7.90), 0.9194			
Across Treatment Arm [c]	0.35 (0.12 - 1.02), 0.0553					
Treatment Interaction [d]	0.00 (0.00 - 1.11E283), 0.9748					
Medical History of ARDS						
No	85	80 (94.1%)	95	84 (88.4%)	0.48 (0.16 - 1.43)	0.1800
Yes	30	30 (100%)	19	17 (89.5%)		0.0696
Within Treatment Arm [b]	, 0.1744		1.11 (0.23 - 5.48), 0.8952			
Across Treatment Arm [c]	0.37 (0.13 - 1.08), 0.0702					
Treatment Interaction [d]	0.00 (0.00 - 1.06E224), 0.9653					
Chest X-ray Finding of ARDS						
No	72	67 (93.1%)	88	79 (89.8%)	0.66 (0.21 - 2.05)	0.4647
Yes	43	43 (100%)	25	21 (84.0%)		0.0069
Within Treatment Arm [b]	, 0.0772		0.60 (0.17 - 2.13), 0.4247			
Across Treatment Arm [c]	0.36 (0.12 - 1.07), 0.0650					
Treatment Interaction [d]	0.00 (0.00 - 3.49E185), 0.9555					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.1
TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with TEAEs (%)	Number of Patients	Number with TEAEs (%)		
History of Sepsis						
No	15	15 (100%)	17	14 (82.4%)		0.0874
Yes	100	95 (95.0%)	97	87 (89.7%)	0.46 (0.15 - 1.39)	0.1601
Within Treatment Arm [b]	, 0.3759		1.86 (0.46 - 7.62), 0.3799			
Across Treatment Arm [c]	0.35 (0.12 - 1.03), 0.0566					
Treatment Interaction [d]	78E3 (0.00 - 2.63E201), 0.9611					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	73 (94.8%)	81	70 (86.4%)	0.35 (0.11 - 1.15)	0.0723
>=0.5 ug/kg/min	38	37 (97.4%)	33	31 (93.9%)	0.42 (0.04 - 4.84)	0.4738
Within Treatment Arm [b]	2.03 (0.22 - 18.8), 0.5261		2.44 (0.51 - 11.6), 0.2520			
Across Treatment Arm [c]	0.36 (0.12 - 1.05), 0.0618					
Treatment Interaction [d]	1.20 (0.08 - 18.3), 0.8949					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	1 (100%)	73	65 (89.0%)		0.7259
>=20 ng/kg/min	114	109 (95.6%)	41	36 (87.8%)	0.33 (0.09 - 1.21)	0.0809
Within Treatment Arm [b]	, 0.8304		0.89 (0.27 - 2.91), 0.8420			
Across Treatment Arm [c]	0.32 (0.09 - 1.17), 0.0864					
Treatment Interaction [d]	1618 (0.00 - 1.1E173), 0.9705					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.1
TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with TEAEs (%)	Number of Patients	Number with TEAEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	21 (91.3%)	27	25 (92.6%)	1.19 (0.15 - 9.19)	0.8671
72.3 - <253 pg/mL	26	25 (96.2%)	22	18 (81.8%)	0.18 (0.02 - 1.75)	0.1052
253 - <676 pg/mL	25	25 (100%)	27	26 (96.3%)		0.3312
>=676 pg/mL	27	26 (96.3%)	26	22 (84.6%)	0.21 (0.02 - 2.03)	0.1458
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	51 (98.1%)	53	48 (90.6%)	0.19 (0.02 - 1.67)	0.0974
<253 pg/mL	49	46 (93.9%)	49	43 (87.8%)	0.47 (0.11 - 1.99)	0.2940
Within Treatment Arm [b]	0.30 (0.03 - 2.99), 0.2795		0.75 (0.21 - 2.62), 0.6475			
Across Treatment Arm [c]	0.34 (0.10 - 1.10), 0.0727					
Treatment Interaction [d]	2.48 (0.18 - 34.1), 0.4961					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	27 (93.1%)	28	26 (92.9%)	0.96 (0.13 - 7.35)	0.9710
23.85 - <83.75 pg/mL	28	28 (100%)	25	21 (84.0%)		0.0277
83.75 - <299.5 pg/mL	12	10 (83.3%)	28	25 (89.3%)	1.67 (0.24 - 11.5)	0.6019
>=299.5 pg/mL	31	31 (100%)	20	18 (90.0%)		0.0725
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	41 (95.3%)	48	43 (89.6%)	0.42 (0.08 - 2.28)	0.3028
<83.75 pg/mL	57	55 (96.5%)	53	47 (88.7%)	0.28 (0.05 - 1.48)	0.1149
Within Treatment Arm [b]	1.34 (0.18 - 9.92), 0.7729		0.91 (0.26 - 3.20), 0.8842			
Across Treatment Arm [c]	0.34 (0.10 - 1.11), 0.0743					
Treatment Interaction [d]	0.68 (0.06 - 7.21), 0.7483					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.1
TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with TEAEs (%)	Number of Patients	Number with TEAEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	51 (98.1%)	53	46 (86.8%)	0.13 (0.02 - 1.09)	0.0293
< 1.63	47	44 (93.6%)	46	42 (91.3%)	0.72 (0.15 - 3.39)	0.6725
Within Treatment Arm [b]	0.29 (0.03 - 2.87), 0.2604		1.60 (0.44 - 5.85), 0.4762			
Across Treatment Arm [c]	0.34 (0.10 - 1.10), 0.0709					
Treatment Interaction [d]	5.56 (0.40 - 77.8), 0.2029					
Vasopressin Use at Baseline						
No	11	10 (90.9%)	6	6 (100%)		0.4465
Yes	104	100 (96.2%)	108	95 (88.0%)	0.29 (0.09 - 0.93)	0.0281
Within Treatment Arm [b]	2.50 (0.25 - 24.6), 0.4173		, 0.3666			
Across Treatment Arm [c]	0.36 (0.12 - 1.04), 0.0580					
Treatment Interaction [d]	0.00 (0.00 - 2.94E183), 0.9585					
Baseline AKI (Acute Kidney Injury)						
No	63	59 (93.7%)	82	73 (89.0%)	0.55 (0.16 - 1.88)	0.3337
Yes	52	51 (98.1%)	32	28 (87.5%)	0.14 (0.01 - 1.29)	0.0466
Within Treatment Arm [b]	3.46 (0.37 - 31.9), 0.2467		0.86 (0.25 - 3.03), 0.8180			
Across Treatment Arm [c]	0.37 (0.13 - 1.09), 0.0702					
Treatment Interaction [d]	0.25 (0.02 - 3.21), 0.2867					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.2
Grade 3 or 4 TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Grade 3/4 TEAEs (%)	Number of Patients	Number with Grade 3/4 TEAEs (%)		
Age (years)						
< 65	54	39 (72.2%)	62	36 (58.1%)	0.53 (0.24 - 1.16)	0.1116
>=65	61	46 (75.4%)	52	39 (75.0%)	0.98 (0.42 - 2.30)	0.9599
Within Treatment Arm [b]	1.18 (0.51 - 2.71), 0.6976		2.17 (0.97 - 4.85), 0.0576			
Across Treatment Arm [c]	0.70 (0.40 - 1.24), 0.2229					
Treatment Interaction [d]	1.84 (0.58 - 5.85), 0.3035					
Gender						
Female	39	27 (69.2%)	49	34 (69.4%)	1.01 (0.40 - 2.51)	0.9873
Male	76	58 (76.3%)	65	41 (63.1%)	0.53 (0.26 - 1.10)	0.0866
Within Treatment Arm [b]	1.43 (0.61 - 3.39), 0.4127		0.75 (0.34 - 1.66), 0.4820			
Across Treatment Arm [c]	0.68 (0.38 - 1.20), 0.1838					
Treatment Interaction [d]	0.53 (0.16 - 1.69), 0.2816					
Race						
Other	29	22 (75.9%)	17	12 (70.6%)	0.76 (0.20 - 2.93)	0.6942
White	86	63 (73.3%)	97	63 (64.9%)	0.68 (0.36 - 1.28)	0.2258
Within Treatment Arm [b]	0.87 (0.33 - 2.31), 0.7822		0.77 (0.25 - 2.37), 0.6512			
Across Treatment Arm [c]	0.69 (0.39 - 1.23), 0.2070					
Treatment Interaction [d]	0.89 (0.20 - 3.92), 0.8730					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	40 (66.7%)	60	36 (60.0%)	0.75 (0.36 - 1.58)	0.4486
>=30 kg/m2	54	44 (81.5%)	52	37 (71.2%)	0.56 (0.23 - 1.40)	0.2105
Within Treatment Arm [b]	2.20 (0.92 - 5.26), 0.0729		1.64 (0.75 - 3.63), 0.2166			
Across Treatment Arm [c]	0.67 (0.37 - 1.19), 0.1680					
Treatment Interaction [d]	0.75 (0.23 - 2.43), 0.6280					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.2
Grade 3 or 4 TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Grade 3/4 TEAEs (%)	Number of Patients	Number with Grade 3/4 TEAEs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	30 (63.8%)	27	15 (55.6%)	0.71 (0.27 - 1.86)	0.4827
< 2.5 g/dL	67	54 (80.6%)	82	56 (68.3%)	0.52 (0.24 - 1.11)	0.0892
Within Treatment Arm [b]	2.35 (1.01 - 5.50), 0.0454		1.72 (0.71 - 4.20), 0.2283			
Across Treatment Arm [c]	0.58 (0.32 - 1.06), 0.0767					
Treatment Interaction [d]	0.73 (0.21 - 2.50), 0.6192					
Geographic Region						
Rest of World	17	11 (64.7%)	17	10 (58.8%)	0.78 (0.19 - 3.12)	0.7242
US/Canada	98	74 (75.5%)	97	65 (67.0%)	0.66 (0.35 - 1.23)	0.1896
Within Treatment Arm [b]	1.68 (0.56 - 5.03), 0.3490		1.42 (0.50 - 4.08), 0.5116			
Across Treatment Arm [c]	0.68 (0.38 - 1.20), 0.1809					
Treatment Interaction [d]	0.85 (0.18 - 3.87), 0.8289					
Baseline MAP						
>=65 mmHg	70	48 (68.6%)	74	46 (62.2%)	0.75 (0.38 - 1.50)	0.4194
< 65 mmHg	45	37 (82.2%)	40	29 (72.5%)	0.57 (0.20 - 1.60)	0.2829
Within Treatment Arm [b]	2.12 (0.85 - 5.30), 0.1037		1.60 (0.69 - 3.71), 0.2668			
Across Treatment Arm [c]	0.69 (0.39 - 1.22), 0.2054					
Treatment Interaction [d]	0.76 (0.22 - 2.62), 0.6603					
Baseline APACHE II Score						
<=30	63	41 (65.1%)	74	44 (59.5%)	0.79 (0.39 - 1.58)	0.4993
> 30	52	44 (84.6%)	40	31 (77.5%)	0.63 (0.22 - 1.80)	0.3834
Within Treatment Arm [b]	2.95 (1.18 - 7.36), 0.0176		2.35 (0.98 - 5.64), 0.0527			
Across Treatment Arm [c]	0.73 (0.41 - 1.31), 0.2981					
Treatment Interaction [d]	0.80 (0.22 - 2.82), 0.7235					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.2
Grade 3 or 4 TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Grade 3/4 TEAEs (%)	Number of Patients	Number with Grade 3/4 TEAEs (%)		
Exposure to ACEi						
No	102	77 (75.5%)	106	71 (67.0%)	0.66 (0.36 - 1.21)	0.1757
Yes	13	8 (61.5%)	8	4 (50.0%)	0.63 (0.11 - 3.71)	0.6038
Within Treatment Arm [b]	0.52 (0.16 - 1.73), 0.2806		0.49 (0.12 - 2.09), 0.3289			
Across Treatment Arm [c]	0.66 (0.37 - 1.16), 0.1486					
Treatment Interaction [d]	0.95 (0.14 - 6.22), 0.9566					
Exposure to ARBs						
No	108	79 (73.1%)	106	69 (65.1%)	0.68 (0.38 - 1.23)	0.2021
Yes	7	6 (85.7%)	8	6 (75.0%)	0.50 (0.04 - 7.10)	0.6048
Within Treatment Arm [b]	2.20 (0.25 - 19.1), 0.4631		1.61 (0.31 - 8.37), 0.5690			
Across Treatment Arm [c]	0.67 (0.38 - 1.19), 0.1752					
Treatment Interaction [d]	0.73 (0.05 - 11.1), 0.8207					
Medical History of ARDS						
No	85	59 (69.4%)	95	61 (64.2%)	0.79 (0.42 - 1.47)	0.4599
Yes	30	26 (86.7%)	19	14 (73.7%)	0.43 (0.10 - 1.87)	0.2528
Within Treatment Arm [b]	2.86 (0.91 - 9.04), 0.0643		1.56 (0.52 - 4.71), 0.4268			
Across Treatment Arm [c]	0.72 (0.40 - 1.28), 0.2622					
Treatment Interaction [d]	0.54 (0.11 - 2.68), 0.4552					
Chest X-ray Finding of ARDS						
No	72	48 (66.7%)	88	55 (62.5%)	0.83 (0.43 - 1.60)	0.5840
Yes	43	37 (86.0%)	25	19 (76.0%)	0.51 (0.15 - 1.81)	0.2947
Within Treatment Arm [b]	3.08 (1.14 - 8.31), 0.0220		1.90 (0.69 - 5.24), 0.2102			
Across Treatment Arm [c]	0.75 (0.42 - 1.35), 0.3377					
Treatment Interaction [d]	0.62 (0.15 - 2.55), 0.5037					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.2
Grade 3 or 4 TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Grade 3/4 TEAEs (%)	Number of Patients	Number with Grade 3/4 TEAEs (%)		
History of Sepsis						
No	15	12 (80.0%)	17	8 (47.1%)	0.22 (0.05 - 1.08)	0.0548
Yes	100	73 (73.0%)	97	67 (69.1%)	0.83 (0.45 - 1.53)	0.5433
Within Treatment Arm [b]	0.68 (0.18 - 2.58), 0.5648		2.51 (0.88 - 7.15), 0.0776			
Across Treatment Arm [c]	0.68 (0.39 - 1.21), 0.1890					
Treatment Interaction [d]	3.72 (0.68 - 20.3), 0.1300					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	55 (71.4%)	81	50 (61.7%)	0.65 (0.33 - 1.26)	0.1968
>=0.5 ug/kg/min	38	30 (78.9%)	33	25 (75.8%)	0.83 (0.27 - 2.54)	0.7483
Within Treatment Arm [b]	1.50 (0.60 - 3.78), 0.3878		1.94 (0.78 - 4.83), 0.1522			
Across Treatment Arm [c]	0.69 (0.39 - 1.22), 0.2035					
Treatment Interaction [d]	1.29 (0.35 - 4.73), 0.6994					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	1 (100%)	73	44 (60.3%)		0.4189
>=20 ng/kg/min	114	84 (73.7%)	41	31 (75.6%)	1.11 (0.48 - 2.53)	0.8091
Within Treatment Arm [b]	, 0.5507		2.04 (0.87 - 4.80), 0.0977			
Across Treatment Arm [c]	1.03 (0.46 - 2.30), 0.9387					
Treatment Interaction [d]	25E3 (0.00 - 8.43E160), 0.9561					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.2
Grade 3 or 4 TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Grade 3/4 TEAEs (%)	Number of Patients	Number with Grade 3/4 TEAEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	15 (65.2%)	27	16 (59.3%)	0.78 (0.25 - 2.45)	0.6653
72.3 - <253 pg/mL	26	20 (76.9%)	22	14 (63.6%)	0.53 (0.15 - 1.85)	0.3129
253 - <676 pg/mL	25	19 (76.0%)	27	21 (77.8%)	1.11 (0.30 - 4.02)	0.8792
>=676 pg/mL	27	23 (85.2%)	26	17 (65.4%)	0.33 (0.09 - 1.25)	0.0940
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	42 (80.8%)	53	38 (71.7%)	0.60 (0.24 - 1.50)	0.2752
<253 pg/mL	49	35 (71.4%)	49	30 (61.2%)	0.63 (0.27 - 1.47)	0.2852
Within Treatment Arm [b]	0.60 (0.24 - 1.50), 0.2703		0.62 (0.27 - 1.43), 0.2623			
Across Treatment Arm [c]	0.62 (0.33 - 1.15), 0.1285					
Treatment Interaction [d]	1.05 (0.30 - 3.63), 0.9422					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	21 (72.4%)	28	17 (60.7%)	0.59 (0.19 - 1.79)	0.3489
23.85 - <83.75 pg/mL	28	20 (71.4%)	25	16 (64.0%)	0.71 (0.22 - 2.26)	0.5630
83.75 - <299.5 pg/mL	12	8 (66.7%)	28	19 (67.9%)	1.06 (0.25 - 4.45)	0.9413
>=299.5 pg/mL	31	26 (83.9%)	20	13 (65.0%)	0.36 (0.09 - 1.35)	0.1209
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	34 (79.1%)	48	32 (66.7%)	0.53 (0.21 - 1.37)	0.1857
<83.75 pg/mL	57	41 (71.9%)	53	33 (62.3%)	0.64 (0.29 - 1.44)	0.2803
Within Treatment Arm [b]	0.68 (0.27 - 1.73), 0.4143		0.83 (0.36 - 1.87), 0.6446			
Across Treatment Arm [c]	0.59 (0.32 - 1.09), 0.0940					
Treatment Interaction [d]	1.22 (0.35 - 4.21), 0.7573					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.2
Grade 3 or 4 TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Grade 3/4 TEAEs (%)	Number of Patients	Number with Grade 3/4 TEAEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	42 (80.8%)	53	37 (69.8%)	0.55 (0.22 - 1.36)	0.1934
< 1.63	47	33 (70.2%)	46	28 (60.9%)	0.66 (0.28 - 1.56)	0.3430
Within Treatment Arm [b]	0.56 (0.22 - 1.42), 0.2210		0.67 (0.29 - 1.55), 0.3501			
Across Treatment Arm [c]	0.61 (0.32 - 1.13), 0.1144					
Treatment Interaction [d]	1.20 (0.34 - 4.18), 0.7763					
Vasopressin Use at Baseline						
No	11	5 (45.5%)	6	4 (66.7%)	2.40 (0.30 - 19.0)	0.4024
Yes	104	80 (76.9%)	108	71 (65.7%)	0.58 (0.31 - 1.05)	0.0722
Within Treatment Arm [b]	4.00 (1.12 - 14.3), 0.0238		0.96 (0.17 - 5.48), 0.9629			
Across Treatment Arm [c]	0.65 (0.36 - 1.15), 0.1393					
Treatment Interaction [d]	0.24 (0.03 - 2.08), 0.1947					
Baseline AKI (Acute Kidney Injury)						
No	63	41 (65.1%)	82	51 (62.2%)	0.88 (0.45 - 1.75)	0.7207
Yes	52	44 (84.6%)	32	24 (75.0%)	0.55 (0.18 - 1.64)	0.2758
Within Treatment Arm [b]	2.95 (1.18 - 7.36), 0.0176		1.82 (0.73 - 4.56), 0.1953			
Across Treatment Arm [c]	0.77 (0.43 - 1.38), 0.3839					
Treatment Interaction [d]	0.62 (0.17 - 2.25), 0.4660					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.3

Treatment-Emergent Serious Adverse Events Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with SAEs (%)	Number of Patients	Number with SAEs (%)		
Age (years)						
< 65	54	40 (74.1%)	62	34 (54.8%)	0.43 (0.19 - 0.93)	0.0315
>=65	61	44 (72.1%)	52	37 (71.2%)	0.95 (0.42 - 2.16)	0.9085
Within Treatment Arm [b]	0.91 (0.40 - 2.07), 0.8147		2.03 (0.93 - 4.44), 0.0734			
Across Treatment Arm [c]	0.62 (0.35 - 1.09), 0.0987					
Treatment Interaction [d]	2.24 (0.72 - 6.99), 0.1641					
Gender						
Female	39	26 (66.7%)	49	33 (67.3%)	1.03 (0.42 - 2.52)	0.9462
Male	76	58 (76.3%)	65	38 (58.5%)	0.44 (0.21 - 0.90)	0.0234
Within Treatment Arm [b]	1.61 (0.69 - 3.77), 0.2696		0.68 (0.31 - 1.48), 0.3325			
Across Treatment Arm [c]	0.61 (0.35 - 1.07), 0.0841					
Treatment Interaction [d]	0.42 (0.13 - 1.34), 0.1432					
Race						
Other	29	22 (75.9%)	17	12 (70.6%)	0.76 (0.20 - 2.93)	0.6942
White	86	62 (72.1%)	97	59 (60.8%)	0.60 (0.32 - 1.12)	0.1080
Within Treatment Arm [b]	0.82 (0.31 - 2.17), 0.6924		0.65 (0.21 - 1.98), 0.4436			
Across Treatment Arm [c]	0.63 (0.36 - 1.10), 0.1048					
Treatment Interaction [d]	0.79 (0.18 - 3.47), 0.7514					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	41 (68.3%)	60	33 (55.0%)	0.57 (0.27 - 1.19)	0.1331
>=30 kg/m2	54	42 (77.8%)	52	36 (69.2%)	0.64 (0.27 - 1.54)	0.3184
Within Treatment Arm [b]	1.62 (0.70 - 3.76), 0.2578		1.84 (0.85 - 4.01), 0.1225			
Across Treatment Arm [c]	0.60 (0.34 - 1.05), 0.0745					
Treatment Interaction [d]	1.13 (0.36 - 3.57), 0.8285					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.3

Treatment-Emergent Serious Adverse Events Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with SAEs (%)	Number of Patients	Number with SAEs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	32 (68.1%)	27	14 (51.9%)	0.50 (0.19 - 1.34)	0.1657
< 2.5 g/dL	67	51 (76.1%)	82	53 (64.6%)	0.57 (0.28 - 1.18)	0.1288
Within Treatment Arm [b]	1.49 (0.65 - 3.43), 0.3426		1.70 (0.70 - 4.09), 0.2365			
Across Treatment Arm [c]	0.55 (0.31 - 0.98), 0.0422					
Treatment Interaction [d]	1.14 (0.34 - 3.81), 0.8367					
Geographic Region						
Rest of World	17	11 (64.7%)	17	9 (52.9%)	0.61 (0.15 - 2.43)	0.4858
US/Canada	98	73 (74.5%)	97	62 (63.9%)	0.61 (0.33 - 1.12)	0.1097
Within Treatment Arm [b]	1.59 (0.53 - 4.75), 0.4013		1.57 (0.56 - 4.45), 0.3891			
Across Treatment Arm [c]	0.61 (0.35 - 1.07), 0.0822					
Treatment Interaction [d]	0.99 (0.22 - 4.47), 0.9883					
Baseline MAP						
>=65 mmHg	70	47 (67.1%)	74	44 (59.5%)	0.72 (0.36 - 1.42)	0.3393
< 65 mmHg	45	37 (82.2%)	40	27 (67.5%)	0.45 (0.16 - 1.23)	0.1162
Within Treatment Arm [b]	2.26 (0.91 - 5.64), 0.0753		1.42 (0.63 - 3.18), 0.3979			
Across Treatment Arm [c]	0.62 (0.35 - 1.09), 0.0947					
Treatment Interaction [d]	0.63 (0.18 - 2.12), 0.4509					
Baseline APACHE II Score						
<=30	63	41 (65.1%)	74	42 (56.8%)	0.70 (0.35 - 1.41)	0.3205
> 30	52	43 (82.7%)	40	29 (72.5%)	0.55 (0.20 - 1.50)	0.2400
Within Treatment Arm [b]	2.56 (1.06 - 6.22), 0.0341		2.01 (0.87 - 4.62), 0.0979			
Across Treatment Arm [c]	0.65 (0.37 - 1.15), 0.1388					
Treatment Interaction [d]	0.78 (0.23 - 2.64), 0.6941					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.3

Treatment-Emergent Serious Adverse Events Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with SAEs (%)	Number of Patients	Number with SAEs (%)		
Exposure to ACEi						
No	102	75 (73.5%)	106	68 (64.2%)	0.64 (0.36 - 1.17)	0.1446
Yes	13	9 (69.2%)	8	3 (37.5%)	0.27 (0.04 - 1.70)	0.1536
Within Treatment Arm [b]	0.81 (0.23 - 2.85), 0.7422		0.34 (0.08 - 1.48), 0.1337			
Across Treatment Arm [c]	0.59 (0.34 - 1.04), 0.0681					
Treatment Interaction [d]	0.41 (0.06 - 2.90), 0.3744					
Exposure to ARBs						
No	108	80 (74.1%)	106	65 (61.3%)	0.55 (0.31 - 0.99)	0.0460
Yes	7	4 (57.1%)	8	6 (75.0%)	2.25 (0.25 - 20.1)	0.4642
Within Treatment Arm [b]	0.47 (0.10 - 2.22), 0.3279		1.89 (0.36 - 9.83), 0.4414			
Across Treatment Arm [c]	0.61 (0.35 - 1.07), 0.0830					
Treatment Interaction [d]	4.05 (0.42 - 39.1), 0.2262					
Medical History of ARDS						
No	85	61 (71.8%)	95	57 (60.0%)	0.59 (0.32 - 1.10)	0.0973
Yes	30	23 (76.7%)	19	14 (73.7%)	0.85 (0.23 - 3.21)	0.8130
Within Treatment Arm [b]	1.29 (0.49 - 3.41), 0.6029		1.87 (0.62 - 5.61), 0.2613			
Across Treatment Arm [c]	0.63 (0.36 - 1.11), 0.1096					
Treatment Interaction [d]	1.44 (0.33 - 6.26), 0.6230					
Chest X-ray Finding of ARDS						
No	72	50 (69.4%)	88	51 (58.0%)	0.61 (0.31 - 1.17)	0.1340
Yes	43	34 (79.1%)	25	19 (76.0%)	0.84 (0.26 - 2.72)	0.7685
Within Treatment Arm [b]	1.66 (0.68 - 4.05), 0.2604		2.30 (0.84 - 6.31), 0.1010			
Across Treatment Arm [c]	0.66 (0.37 - 1.16), 0.1460					
Treatment Interaction [d]	1.38 (0.36 - 5.31), 0.6376					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.3

Treatment-Emergent Serious Adverse Events Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with SAEs (%)	Number of Patients	Number with SAEs (%)		
History of Sepsis						
No	15	11 (73.3%)	17	7 (41.2%)	0.25 (0.06 - 1.14)	0.0673
Yes	100	73 (73.0%)	97	64 (66.0%)	0.72 (0.39 - 1.32)	0.2844
Within Treatment Arm [b]	0.98 (0.29 - 3.35), 0.9784		2.77 (0.97 - 7.94), 0.0516			
Across Treatment Arm [c]	0.61 (0.35 - 1.08), 0.0884					
Treatment Interaction [d]	2.82 (0.56 - 14.2), 0.2091					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	55 (71.4%)	81	46 (56.8%)	0.53 (0.27 - 1.02)	0.0555
>=0.5 ug/kg/min	38	29 (76.3%)	33	25 (75.8%)	0.97 (0.33 - 2.89)	0.9562
Within Treatment Arm [b]	1.29 (0.53 - 3.16), 0.5785		2.38 (0.96 - 5.90), 0.0581			
Across Treatment Arm [c]	0.62 (0.35 - 1.09), 0.0952					
Treatment Interaction [d]	1.85 (0.51 - 6.62), 0.3472					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	1 (100%)	73	40 (54.8%)		0.3664
>=20 ng/kg/min	114	83 (72.8%)	41	31 (75.6%)	1.16 (0.51 - 2.64)	0.7271
Within Treatment Arm [b]	, 0.5418		2.56 (1.09 - 5.98), 0.0278			
Across Treatment Arm [c]	1.07 (0.48 - 2.37), 0.8718					
Treatment Interaction [d]	31E3 (0.00 - 2.45E157), 0.9541					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.3

Treatment-Emergent Serious Adverse Events Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with SAEs (%)	Number of Patients	Number with SAEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	15 (65.2%)	27	15 (55.6%)	0.67 (0.21 - 2.10)	0.4870
72.3 - <253 pg/mL	26	21 (80.8%)	22	13 (59.1%)	0.34 (0.09 - 1.25)	0.0997
253 - <676 pg/mL	25	19 (76.0%)	27	20 (74.1%)	0.90 (0.26 - 3.18)	0.8727
>=676 pg/mL	27	21 (77.8%)	26	17 (65.4%)	0.54 (0.16 - 1.82)	0.3167
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	40 (76.9%)	53	37 (69.8%)	0.69 (0.29 - 1.66)	0.4100
<253 pg/mL	49	36 (73.5%)	49	28 (57.1%)	0.48 (0.21 - 1.13)	0.0896
Within Treatment Arm [b]	0.83 (0.34 - 2.05), 0.6877		0.58 (0.26 - 1.30), 0.1837			
Across Treatment Arm [c]	0.57 (0.31 - 1.06), 0.0741					
Treatment Interaction [d]	0.69 (0.21 - 2.34), 0.5562					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	23 (79.3%)	28	16 (57.1%)	0.35 (0.11 - 1.12)	0.0719
23.85 - <83.75 pg/mL	28	20 (71.4%)	25	15 (60.0%)	0.60 (0.19 - 1.89)	0.3805
83.75 - <299.5 pg/mL	12	8 (66.7%)	28	19 (67.9%)	1.06 (0.25 - 4.45)	0.9413
>=299.5 pg/mL	31	24 (77.4%)	20	13 (65.0%)	0.54 (0.16 - 1.88)	0.3319
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	32 (74.4%)	48	32 (66.7%)	0.69 (0.28 - 1.71)	0.4190
<83.75 pg/mL	57	43 (75.4%)	53	31 (58.5%)	0.46 (0.20 - 1.04)	0.0584
Within Treatment Arm [b]	1.06 (0.42 - 2.63), 0.9072		0.70 (0.31 - 1.59), 0.3970			
Across Treatment Arm [c]	0.55 (0.30 - 1.01), 0.0521					
Treatment Interaction [d]	0.67 (0.20 - 2.26), 0.5162					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.3
Treatment-Emergent Serious Adverse Events Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with SAEs (%)	Number of Patients	Number with SAEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	45 (86.5%)	53	36 (67.9%)	0.33 (0.12 - 0.88)	0.0231
< 1.63	47	30 (63.8%)	46	27 (58.7%)	0.81 (0.35 - 1.86)	0.6113
Within Treatment Arm [b]	0.27 (0.10 - 0.74), 0.0085		0.67 (0.29 - 1.53), 0.3411			
Across Treatment Arm [c]	0.55 (0.29 - 1.02), 0.0577					
Treatment Interaction [d]	2.44 (0.67 - 8.88), 0.1746					
Vasopressin Use at Baseline						
No	11	5 (45.5%)	6	4 (66.7%)	2.40 (0.30 - 19.0)	0.4024
Yes	104	79 (76.0%)	108	67 (62.0%)	0.52 (0.29 - 0.94)	0.0286
Within Treatment Arm [b]	3.79 (1.07 - 13.5), 0.0301		0.82 (0.14 - 4.66), 0.8199			
Across Treatment Arm [c]	0.58 (0.33 - 1.03), 0.0631					
Treatment Interaction [d]	0.22 (0.02 - 1.86), 0.1627					
Baseline AKI (Acute Kidney Injury)						
No	63	40 (63.5%)	82	48 (58.5%)	0.81 (0.41 - 1.59)	0.5448
Yes	52	44 (84.6%)	32	23 (71.9%)	0.46 (0.16 - 1.37)	0.1581
Within Treatment Arm [b]	3.16 (1.27 - 7.87), 0.0111		1.81 (0.75 - 4.40), 0.1867			
Across Treatment Arm [c]	0.69 (0.39 - 1.23), 0.2107					
Treatment Interaction [d]	0.57 (0.16 - 2.04), 0.3899					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.4

TEAEs Regardless of Relationship to Study Drug Resulting in Discontinuation: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Discon AEs (%)	Number of Patients	Number with Discon AEs (%)		
Age (years)						
< 65	54	13 (24.1%)	62	10 (16.1%)	0.61 (0.24 - 1.52)	0.2844
>=65	61	19 (31.1%)	52	8 (15.4%)	0.40 (0.16 - 1.02)	0.0502
Within Treatment Arm [b]	1.43 (0.62 - 3.26), 0.3982		0.95 (0.34 - 2.60), 0.9135			
Across Treatment Arm [c]	0.49 (0.26 - 0.94), 0.0327					
Treatment Interaction [d]	0.66 (0.18 - 2.45), 0.5372					
Gender						
Female	39	12 (30.8%)	49	10 (20.4%)	0.58 (0.22 - 1.53)	0.2648
Male	76	20 (26.3%)	65	8 (12.3%)	0.39 (0.16 - 0.97)	0.0377
Within Treatment Arm [b]	0.80 (0.34 - 1.88), 0.6139		0.55 (0.20 - 1.51), 0.2403			
Across Treatment Arm [c]	0.47 (0.24 - 0.90), 0.0228					
Treatment Interaction [d]	0.68 (0.18 - 2.56), 0.5698					
Race						
Other	29	8 (27.6%)	17	3 (17.6%)	0.56 (0.13 - 2.49)	0.4456
White	86	24 (27.9%)	97	15 (15.5%)	0.47 (0.23 - 0.98)	0.0402
Within Treatment Arm [b]	1.02 (0.40 - 2.60), 0.9734		0.85 (0.22 - 3.34), 0.8199			
Across Treatment Arm [c]	0.49 (0.25 - 0.94), 0.0314					
Treatment Interaction [d]	0.84 (0.16 - 4.40), 0.8366					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	11 (18.3%)	60	9 (15.0%)	0.79 (0.30 - 2.06)	0.6242
>=30 kg/m2	54	21 (38.9%)	52	8 (15.4%)	0.29 (0.11 - 0.72)	0.0067
Within Treatment Arm [b]	2.83 (1.21 - 6.65), 0.0147		1.03 (0.37 - 2.90), 0.9549			
Across Treatment Arm [c]	0.46 (0.23 - 0.88), 0.0202					
Treatment Interaction [d]	0.36 (0.10 - 1.39), 0.1389					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.4

TEAEs Regardless of Relationship to Study Drug Resulting in Discontinuation: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Discon AEs (%)	Number of Patients	Number with Discon AEs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	11 (23.4%)	27	2 (7.4%)	0.26 (0.05 - 1.28)	0.0817
< 2.5 g/dL	67	21 (31.3%)	82	15 (18.3%)	0.49 (0.23 - 1.05)	0.0641
Within Treatment Arm [b]	1.49 (0.64 - 3.50), 0.3531		2.80 (0.60 - 13.1), 0.1763			
Across Treatment Arm [c]	0.43 (0.22 - 0.84), 0.0142					
Treatment Interaction [d]	1.87 (0.32 - 10.9), 0.4855					
Geographic Region						
Rest of World	17	4 (23.5%)	17	4 (23.5%)	1.00 (0.20 - 4.88)	1.0000
US/Canada	98	28 (28.6%)	97	14 (14.4%)	0.42 (0.21 - 0.86)	0.0163
Within Treatment Arm [b]	1.30 (0.39 - 4.33), 0.6685		0.55 (0.16 - 1.92), 0.3427			
Across Treatment Arm [c]	0.49 (0.25 - 0.93), 0.0291					
Treatment Interaction [d]	0.42 (0.07 - 2.40), 0.3305					
Baseline MAP						
>=65 mmHg	70	16 (22.9%)	74	6 (8.1%)	0.30 (0.11 - 0.81)	0.0139
< 65 mmHg	45	16 (35.6%)	40	12 (30.0%)	0.78 (0.31 - 1.93)	0.5865
Within Treatment Arm [b]	1.86 (0.81 - 4.26), 0.1381		4.86 (1.66 - 14.2), 0.0022			
Across Treatment Arm [c]	0.49 (0.25 - 0.95), 0.0357					
Treatment Interaction [d]	2.61 (0.67 - 10.1), 0.1657					
Baseline APACHE II Score						
<=30	63	12 (19.0%)	74	12 (16.2%)	0.82 (0.34 - 1.99)	0.6639
> 30	52	20 (38.5%)	40	6 (15.0%)	0.28 (0.10 - 0.79)	0.0132
Within Treatment Arm [b]	2.66 (1.15 - 6.16), 0.0208		0.91 (0.31 - 2.65), 0.8650			
Across Treatment Arm [c]	0.51 (0.27 - 0.98), 0.0439					
Treatment Interaction [d]	0.34 (0.09 - 1.33), 0.1226					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.4

TEAEs Regardless of Relationship to Study Drug Resulting in Discontinuation: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Discon AEs (%)	Number of Patients	Number with Discon AEs (%)		
Exposure to ACEi						
No	102	29 (28.4%)	106	17 (16.0%)	0.48 (0.25 - 0.94)	0.0313
Yes	13	3 (23.1%)	8	1 (12.5%)	0.48 (0.04 - 5.58)	0.5489
Within Treatment Arm [b]	0.76 (0.19 - 2.94), 0.6850		0.75 (0.09 - 6.48), 0.7913			
Across Treatment Arm [c]	0.48 (0.25 - 0.92), 0.0271					
Treatment Interaction [d]	0.99 (0.08 - 12.7), 0.9941					
Exposure to ARBs						
No	108	31 (28.7%)	106	14 (13.2%)	0.38 (0.19 - 0.76)	0.0054
Yes	7	1 (14.3%)	8	4 (50.0%)	6.00 (0.48 - 75.3)	0.1432
Within Treatment Arm [b]	0.41 (0.05 - 3.58), 0.4094		6.57 (1.47 - 29.3), 0.0059			
Across Treatment Arm [c]	0.48 (0.25 - 0.92), 0.0273					
Treatment Interaction [d]	15.9 (1.15 - 219), 0.0390					
Medical History of ARDS						
No	85	23 (27.1%)	95	15 (15.8%)	0.51 (0.24 - 1.05)	0.0644
Yes	30	9 (30.0%)	19	3 (15.8%)	0.44 (0.10 - 1.88)	0.2597
Within Treatment Arm [b]	1.16 (0.46 - 2.89), 0.7573		1.00 (0.26 - 3.86), 1.0000			
Across Treatment Arm [c]	0.49 (0.26 - 0.94), 0.0323					
Treatment Interaction [d]	0.87 (0.17 - 4.43), 0.8624					
Chest X-ray Finding of ARDS						
No	72	20 (27.8%)	88	13 (14.8%)	0.45 (0.21 - 0.99)	0.0431
Yes	43	12 (27.9%)	25	5 (20.0%)	0.65 (0.20 - 2.11)	0.4678
Within Treatment Arm [b]	1.01 (0.43 - 2.34), 0.9881		1.44 (0.46 - 4.52), 0.5285			
Across Treatment Arm [c]	0.50 (0.26 - 0.97), 0.0392					
Treatment Interaction [d]	1.43 (0.35 - 5.93), 0.6195					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.4

TEAEs Regardless of Relationship to Study Drug Resulting in Discontinuation: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Discon AEs (%)	Number of Patients	Number with Discon AEs (%)		
History of Sepsis						
No	15	7 (46.7%)	17	1 (5.9%)	0.07 (0.01 - 0.68)	0.0078
Yes	100	25 (25.0%)	97	17 (17.5%)	0.64 (0.32 - 1.27)	0.2004
Within Treatment Arm [b]	0.38 (0.13 - 1.16), 0.0808		3.40 (0.42 - 27.4), 0.2246			
Across Treatment Arm [c]	0.48 (0.25 - 0.93), 0.0282					
Treatment Interaction [d]	8.92 (0.84 - 94.9), 0.0696					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	14 (18.2%)	81	8 (9.9%)	0.49 (0.19 - 1.25)	0.1317
>=0.5 ug/kg/min	38	18 (47.4%)	33	10 (30.3%)	0.48 (0.18 - 1.28)	0.1422
Within Treatment Arm [b]	4.05 (1.71 - 9.58), 0.0010		3.97 (1.40 - 11.2), 0.0067			
Across Treatment Arm [c]	0.49 (0.25 - 0.96), 0.0374					
Treatment Interaction [d]	0.98 (0.25 - 3.78), 0.9760					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	73	6 (8.2%)		0.7649
>=20 ng/kg/min	114	32 (28.1%)	41	12 (29.3%)	1.06 (0.48 - 2.33)	0.8840
Within Treatment Arm [b]	, 0.5329		4.62 (1.58 - 13.5), 0.0031			
Across Treatment Arm [c]	1.07 (0.49 - 2.35), 0.8590					
Treatment Interaction [d]	0.00 (0.00 - 2.38E173), 0.9685					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.4

TEAEs Regardless of Relationship to Study Drug Resulting in Discontinuation: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Discon AEs (%)	Number of Patients	Number with Discon AEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	4 (17.4%)	27	1 (3.7%)	0.18 (0.02 - 1.77)	0.1079
72.3 - <253 pg/mL	26	7 (26.9%)	22	4 (18.2%)	0.60 (0.15 - 2.42)	0.4728
253 - <676 pg/mL	25	9 (36.0%)	27	5 (18.5%)	0.40 (0.11 - 1.44)	0.1556
>=676 pg/mL	27	7 (25.9%)	26	5 (19.2%)	0.68 (0.19 - 2.50)	0.5604
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	16 (30.8%)	53	10 (18.9%)	0.52 (0.21 - 1.29)	0.1578
<253 pg/mL	49	11 (22.4%)	49	5 (10.2%)	0.39 (0.13 - 1.23)	0.1010
Within Treatment Arm [b]	0.65 (0.27 - 1.59), 0.3450		0.49 (0.15 - 1.55), 0.2171			
Across Treatment Arm [c]	0.47 (0.23 - 0.95), 0.0351					
Treatment Interaction [d]	0.75 (0.17 - 3.22), 0.6994					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	10 (34.5%)	28	1 (3.6%)	0.07 (0.01 - 0.60)	0.0031
23.85 - <83.75 pg/mL	28	9 (32.1%)	25	4 (16.0%)	0.40 (0.11 - 1.52)	0.1727
83.75 - <299.5 pg/mL	12	2 (16.7%)	28	6 (21.4%)	1.36 (0.23 - 7.98)	0.7301
>=299.5 pg/mL	31	6 (19.4%)	20	4 (20.0%)	1.04 (0.25 - 4.28)	0.9548
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	8 (18.6%)	48	10 (20.8%)	1.15 (0.41 - 3.25)	0.7899
<83.75 pg/mL	57	19 (33.3%)	53	5 (9.4%)	0.21 (0.07 - 0.61)	0.0024
Within Treatment Arm [b]	2.19 (0.85 - 5.63), 0.1005		0.40 (0.12 - 1.26), 0.1077			
Across Treatment Arm [c]	0.47 (0.23 - 0.96), 0.0375					
Treatment Interaction [d]	0.18 (0.04 - 0.80), 0.0248					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.4

TEAEs Regardless of Relationship to Study Drug Resulting in Discontinuation: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Discon AEs (%)	Number of Patients	Number with Discon AEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	21 (40.4%)	53	8 (15.1%)	0.26 (0.10 - 0.67)	0.0038
< 1.63	47	6 (12.8%)	46	7 (15.2%)	1.23 (0.38 - 3.97)	0.7332
Within Treatment Arm [b]	0.22 (0.08 - 0.60), 0.0021		1.01 (0.34 - 3.04), 0.9864			
Across Treatment Arm [c]	0.46 (0.23 - 0.95), 0.0345					
Treatment Interaction [d]	4.67 (1.04 - 21.0), 0.0441					
Vasopressin Use at Baseline						
No	11	2 (18.2%)	6	1 (16.7%)	0.90 (0.06 - 12.6)	0.9376
Yes	104	30 (28.8%)	108	17 (15.7%)	0.46 (0.24 - 0.90)	0.0217
Within Treatment Arm [b]	1.82 (0.37 - 8.94), 0.4529		0.93 (0.10 - 8.50), 0.9517			
Across Treatment Arm [c]	0.48 (0.25 - 0.92), 0.0262					
Treatment Interaction [d]	0.51 (0.03 - 7.78), 0.6297					
Baseline AKI (Acute Kidney Injury)						
No	63	8 (12.7%)	82	12 (14.6%)	1.18 (0.45 - 3.08)	0.7376
Yes	52	24 (46.2%)	32	6 (18.8%)	0.27 (0.09 - 0.76)	0.0109
Within Treatment Arm [b]	5.89 (2.35 - 14.8), <.0001		1.35 (0.46 - 3.96), 0.5881			
Across Treatment Arm [c]	0.58 (0.30 - 1.14), 0.1120					
Treatment Interaction [d]	0.23 (0.06 - 0.94), 0.0412					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.5
Fatal TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Fatal AEs (%)	Number of Patients	Number with Fatal AEs (%)		
Age (years)						
< 65	54	32 (59.3%)	62	24 (38.7%)	0.43 (0.21 - 0.92)	0.0272
>=65	61	38 (62.3%)	52	32 (61.5%)	0.97 (0.45 - 2.07)	0.9342
Within Treatment Arm [b]	1.14 (0.54 - 2.41), 0.7392		2.53 (1.19 - 5.40), 0.0152			
Across Treatment Arm [c]	0.64 (0.38 - 1.09), 0.0992					
Treatment Interaction [d]	2.23 (0.77 - 6.48), 0.1402					
Gender						
Female	39	22 (56.4%)	49	26 (53.1%)	0.87 (0.37 - 2.04)	0.7540
Male	76	48 (63.2%)	65	30 (46.2%)	0.50 (0.25 - 0.98)	0.0429
Within Treatment Arm [b]	1.32 (0.60 - 2.91), 0.4827		0.76 (0.36 - 1.59), 0.4652			
Across Treatment Arm [c]	0.62 (0.37 - 1.05), 0.0752					
Treatment Interaction [d]	0.57 (0.19 - 1.69), 0.3121					
Race						
Other	29	19 (65.5%)	17	10 (58.8%)	0.75 (0.22 - 2.58)	0.6498
White	86	51 (59.3%)	97	46 (47.4%)	0.62 (0.34 - 1.11)	0.1080
Within Treatment Arm [b]	0.77 (0.32 - 1.85), 0.5532		0.63 (0.22 - 1.80), 0.3858			
Across Treatment Arm [c]	0.64 (0.38 - 1.09), 0.1002					
Treatment Interaction [d]	0.82 (0.21 - 3.22), 0.7800					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	34 (56.7%)	60	26 (43.3%)	0.58 (0.28 - 1.20)	0.1441
>=30 kg/m2	54	35 (64.8%)	52	28 (53.8%)	0.63 (0.29 - 1.38)	0.2502
Within Treatment Arm [b]	1.41 (0.66 - 3.00), 0.3742		1.53 (0.72 - 3.22), 0.2668			
Across Treatment Arm [c]	0.61 (0.36 - 1.03), 0.0646					
Treatment Interaction [d]	1.08 (0.37 - 3.14), 0.8831					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.5
Fatal TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Fatal AEs (%)	Number of Patients	Number with Fatal AEs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	22 (46.8%)	27	11 (40.7%)	0.78 (0.30 - 2.04)	0.6132
< 2.5 g/dL	67	47 (70.1%)	82	43 (52.4%)	0.47 (0.24 - 0.93)	0.0279
Within Treatment Arm [b]	2.67 (1.23 - 5.80), 0.0121		1.60 (0.66 - 3.87), 0.2917			
Across Treatment Arm [c]	0.55 (0.32 - 0.97), 0.0370					
Treatment Interaction [d]	0.60 (0.19 - 1.94), 0.3948					
Geographic Region						
Rest of World	17	8 (47.1%)	17	5 (29.4%)	0.47 (0.11 - 1.92)	0.2897
US/Canada	98	62 (63.3%)	97	51 (52.6%)	0.64 (0.36 - 1.14)	0.1306
Within Treatment Arm [b]	1.94 (0.69 - 5.47), 0.2063		2.66 (0.87 - 8.13), 0.0780			
Across Treatment Arm [c]	0.62 (0.36 - 1.05), 0.0725					
Treatment Interaction [d]	1.37 (0.30 - 6.30), 0.6836					
Baseline MAP						
>=65 mmHg	70	36 (51.4%)	74	33 (44.6%)	0.76 (0.39 - 1.46)	0.4119
< 65 mmHg	45	34 (75.6%)	40	23 (57.5%)	0.44 (0.17 - 1.10)	0.0771
Within Treatment Arm [b]	2.92 (1.28 - 6.67), 0.0097		1.68 (0.77 - 3.65), 0.1884			
Across Treatment Arm [c]	0.63 (0.37 - 1.07), 0.0900					
Treatment Interaction [d]	0.58 (0.19 - 1.79), 0.3399					
Baseline APACHE II Score						
<=30	63	30 (47.6%)	74	35 (47.3%)	0.99 (0.50 - 1.93)	0.9700
> 30	52	40 (76.9%)	40	21 (52.5%)	0.33 (0.14 - 0.81)	0.0140
Within Treatment Arm [b]	3.67 (1.63 - 8.27), 0.0014		1.23 (0.57 - 2.66), 0.5959			
Across Treatment Arm [c]	0.66 (0.39 - 1.13), 0.1267					
Treatment Interaction [d]	0.34 (0.11 - 1.03), 0.0562					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.5
Fatal TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Fatal AEs (%)	Number of Patients	Number with Fatal AEs (%)		
Exposure to ACEi						
No	102	64 (62.7%)	106	54 (50.9%)	0.62 (0.35 - 1.07)	0.0859
Yes	13	6 (46.2%)	8	2 (25.0%)	0.39 (0.06 - 2.70)	0.3324
Within Treatment Arm [b]	0.51 (0.16 - 1.63), 0.2483		0.32 (0.06 - 1.66), 0.1570			
Across Treatment Arm [c]	0.59 (0.35 - 1.01), 0.0550					
Treatment Interaction [d]	0.63 (0.08 - 4.73), 0.6538					
Exposure to ARBs						
No	108	67 (62.0%)	106	51 (48.1%)	0.57 (0.33 - 0.98)	0.0406
Yes	7	3 (42.9%)	8	5 (62.5%)	2.22 (0.28 - 17.6)	0.4468
Within Treatment Arm [b]	0.46 (0.10 - 2.15), 0.3136		1.80 (0.41 - 7.91), 0.4325			
Across Treatment Arm [c]	0.62 (0.37 - 1.05), 0.0751					
Treatment Interaction [d]	3.92 (0.46 - 33.3), 0.2115					
Medical History of ARDS						
No	85	50 (58.8%)	95	45 (47.4%)	0.63 (0.35 - 1.14)	0.1243
Yes	30	20 (66.7%)	19	11 (57.9%)	0.69 (0.21 - 2.25)	0.5349
Within Treatment Arm [b]	1.40 (0.58 - 3.35), 0.4492		1.53 (0.56 - 4.14), 0.4021			
Across Treatment Arm [c]	0.64 (0.38 - 1.09), 0.0991					
Treatment Interaction [d]	1.09 (0.29 - 4.10), 0.8971					
Chest X-ray Finding of ARDS						
No	72	40 (55.6%)	88	39 (44.3%)	0.64 (0.34 - 1.19)	0.1572
Yes	43	30 (69.8%)	25	17 (68.0%)	0.92 (0.32 - 2.67)	0.8791
Within Treatment Arm [b]	1.85 (0.83 - 4.11), 0.1308		2.67 (1.04 - 6.83), 0.0366			
Across Treatment Arm [c]	0.70 (0.41 - 1.20), 0.1950					
Treatment Interaction [d]	1.45 (0.42 - 4.97), 0.5577					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.5
Fatal TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Fatal AEs (%)	Number of Patients	Number with Fatal AEs (%)		
History of Sepsis						
No	15	8 (53.3%)	17	4 (23.5%)	0.27 (0.06 - 1.22)	0.0822
Yes	100	62 (62.0%)	97	52 (53.6%)	0.71 (0.40 - 1.25)	0.2330
Within Treatment Arm [b]	1.43 (0.48 - 4.25), 0.5213		3.76 (1.14 - 12.3), 0.0221			
Across Treatment Arm [c]	0.62 (0.37 - 1.06), 0.0814					
Treatment Interaction [d]	2.63 (0.52 - 13.2), 0.2404					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	44 (57.1%)	81	35 (43.2%)	0.57 (0.30 - 1.07)	0.0800
>=0.5 ug/kg/min	38	26 (68.4%)	33	21 (63.6%)	0.81 (0.30 - 2.16)	0.6708
Within Treatment Arm [b]	1.63 (0.72 - 3.69), 0.2438		2.30 (1.00 - 5.30), 0.0479			
Across Treatment Arm [c]	0.63 (0.37 - 1.07), 0.0887					
Treatment Interaction [d]	1.42 (0.44 - 4.56), 0.5603					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	1 (100%)	73	32 (43.8%)		0.2618
>=20 ng/kg/min	114	69 (60.5%)	41	24 (58.5%)	0.92 (0.45 - 1.90)	0.8235
Within Treatment Arm [b]	, 0.4207		1.81 (0.83 - 3.92), 0.1319			
Across Treatment Arm [c]	0.86 (0.42 - 1.75), 0.6732					
Treatment Interaction [d]	32E3 (0.00 - 2.56E145), 0.9500					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.5
Fatal TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Fatal AEs (%)	Number of Patients	Number with Fatal AEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	12 (52.2%)	27	13 (48.1%)	0.85 (0.28 - 2.59)	0.7766
72.3 - <253 pg/mL	26	17 (65.4%)	22	11 (50.0%)	0.53 (0.17 - 1.69)	0.2814
253 - <676 pg/mL	25	15 (60.0%)	27	13 (48.1%)	0.62 (0.21 - 1.86)	0.3917
>=676 pg/mL	27	19 (70.4%)	26	14 (53.8%)	0.49 (0.16 - 1.52)	0.2147
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	34 (65.4%)	53	27 (50.9%)	0.55 (0.25 - 1.21)	0.1337
<253 pg/mL	49	29 (59.2%)	49	24 (49.0%)	0.66 (0.30 - 1.47)	0.3108
Within Treatment Arm [b]	0.77 (0.34 - 1.72), 0.5203		0.92 (0.43 - 2.01), 0.8429			
Across Treatment Arm [c]	0.60 (0.34 - 1.05), 0.0757					
Treatment Interaction [d]	1.20 (0.39 - 3.69), 0.7451					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	17 (58.6%)	28	13 (46.4%)	0.61 (0.21 - 1.74)	0.3567
23.85 - <83.75 pg/mL	28	18 (64.3%)	25	11 (44.0%)	0.44 (0.14 - 1.32)	0.1386
83.75 - <299.5 pg/mL	12	5 (41.7%)	28	16 (57.1%)	1.87 (0.47 - 7.35)	0.3691
>=299.5 pg/mL	31	22 (71.0%)	20	10 (50.0%)	0.41 (0.13 - 1.32)	0.1305
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	27 (62.8%)	48	26 (54.2%)	0.70 (0.30 - 1.62)	0.4049
<83.75 pg/mL	57	35 (61.4%)	53	24 (45.3%)	0.52 (0.24 - 1.11)	0.0902
Within Treatment Arm [b]	0.94 (0.42 - 2.13), 0.8875		0.70 (0.32 - 1.53), 0.3725			
Across Treatment Arm [c]	0.59 (0.34 - 1.04), 0.0701					
Treatment Interaction [d]	0.74 (0.24 - 2.30), 0.6067					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.5
Fatal TEAEs Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Fatal AEs (%)	Number of Patients	Number with Fatal AEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	37 (71.2%)	53	27 (50.9%)	0.42 (0.19 - 0.94)	0.0338
< 1.63	47	25 (53.2%)	46	23 (50.0%)	0.88 (0.39 - 1.99)	0.7581
Within Treatment Arm [b]	0.46 (0.20 - 1.06), 0.0651		0.96 (0.44 - 2.12), 0.9254			
Across Treatment Arm [c]	0.60 (0.34 - 1.07), 0.0824					
Treatment Interaction [d]	2.09 (0.66 - 6.57), 0.2071					
Vasopressin Use at Baseline						
No	11	4 (36.4%)	6	3 (50.0%)	1.75 (0.23 - 13.2)	0.5851
Yes	104	66 (63.5%)	108	53 (49.1%)	0.55 (0.32 - 0.96)	0.0348
Within Treatment Arm [b]	3.04 (0.84 - 11.1), 0.0799		0.96 (0.19 - 4.99), 0.9648			
Across Treatment Arm [c]	0.60 (0.35 - 1.02), 0.0586					
Treatment Interaction [d]	0.32 (0.04 - 2.57), 0.2816					
Baseline AKI (Acute Kidney Injury)						
No	63	31 (49.2%)	82	41 (50.0%)	1.03 (0.54 - 1.99)	0.9245
Yes	52	39 (75.0%)	32	15 (46.9%)	0.29 (0.12 - 0.75)	0.0090
Within Treatment Arm [b]	3.10 (1.39 - 6.88), 0.0048		0.88 (0.39 - 2.00), 0.7643			
Across Treatment Arm [c]	0.68 (0.40 - 1.15), 0.1501					
Treatment Interaction [d]	0.28 (0.09 - 0.89), 0.0314					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.6
Significant SOC Cardiac Disorders Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Age (years)						
< 65	54	23 (42.6%)	62	19 (30.6%)	0.60 (0.28 - 1.28)	0.1817
>=65	61	33 (54.1%)	52	18 (34.6%)	0.45 (0.21 - 0.96)	0.0380
Within Treatment Arm [b]	1.59 (0.76 - 3.32), 0.2180		1.20 (0.55 - 2.63), 0.6520			
Across Treatment Arm [c]	0.52 (0.30 - 0.89), 0.0162					
Treatment Interaction [d]	0.75 (0.26 - 2.22), 0.6081					
Gender						
Female	39	16 (41.0%)	49	15 (30.6%)	0.63 (0.26 - 1.53)	0.3097
Male	76	40 (52.6%)	65	22 (33.8%)	0.46 (0.23 - 0.91)	0.0251
Within Treatment Arm [b]	1.60 (0.73 - 3.49), 0.2385		1.16 (0.52 - 2.57), 0.7151			
Across Treatment Arm [c]	0.52 (0.30 - 0.89), 0.0170					
Treatment Interaction [d]	0.73 (0.24 - 2.21), 0.5735					
Race						
Other	29	13 (44.8%)	17	7 (41.2%)	0.86 (0.26 - 2.89)	0.8095
White	86	43 (50.0%)	97	30 (30.9%)	0.45 (0.24 - 0.82)	0.0085
Within Treatment Arm [b]	1.23 (0.53 - 2.87), 0.6299		0.64 (0.22 - 1.84), 0.4051			
Across Treatment Arm [c]	0.51 (0.30 - 0.87), 0.0142					
Treatment Interaction [d]	0.52 (0.13 - 2.01), 0.3434					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	33 (55.0%)	60	16 (26.7%)	0.30 (0.14 - 0.64)	0.0016
>=30 kg/m2	54	22 (40.7%)	52	19 (36.5%)	0.84 (0.38 - 1.83)	0.6570
Within Treatment Arm [b]	0.56 (0.27 - 1.18), 0.1282		1.58 (0.71 - 3.54), 0.2610			
Across Treatment Arm [c]	0.49 (0.28 - 0.84), 0.0094					
Treatment Interaction [d]	2.81 (0.94 - 8.42), 0.0640					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.6
Significant SOC Cardiac Disorders Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	25 (53.2%)	27	10 (37.0%)	0.52 (0.20 - 1.36)	0.1803
< 2.5 g/dL	67	30 (44.8%)	82	24 (29.3%)	0.51 (0.26 - 1.00)	0.0501
Within Treatment Arm [b]	0.71 (0.34 - 1.51), 0.3761		0.70 (0.28 - 1.76), 0.4498			
Across Treatment Arm [c]	0.51 (0.29 - 0.89), 0.0183					
Treatment Interaction [d]	0.99 (0.30 - 3.21), 0.9814					
Geographic Region						
Rest of World	17	10 (58.8%)	17	4 (23.5%)	0.22 (0.05 - 0.95)	0.0365
US/Canada	98	46 (46.9%)	97	33 (34.0%)	0.58 (0.33 - 1.04)	0.0662
Within Treatment Arm [b]	0.62 (0.22 - 1.76), 0.3655		1.68 (0.51 - 5.55), 0.3941			
Across Treatment Arm [c]	0.51 (0.30 - 0.87), 0.0128					
Treatment Interaction [d]	2.71 (0.55 - 13.2), 0.2192					
Baseline MAP						
>=65 mmHg	70	29 (41.4%)	74	26 (35.1%)	0.77 (0.39 - 1.50)	0.4372
< 65 mmHg	45	27 (60.0%)	40	11 (27.5%)	0.25 (0.10 - 0.63)	0.0026
Within Treatment Arm [b]	2.12 (0.99 - 4.55), 0.0518		0.70 (0.30 - 1.63), 0.4060			
Across Treatment Arm [c]	0.51 (0.30 - 0.87), 0.0141					
Treatment Interaction [d]	0.33 (0.11 - 1.03), 0.0560					
Baseline APACHE II Score						
<=30	63	32 (50.8%)	74	22 (29.7%)	0.41 (0.20 - 0.83)	0.0119
> 30	52	24 (46.2%)	40	15 (37.5%)	0.70 (0.30 - 1.62)	0.4050
Within Treatment Arm [b]	0.83 (0.40 - 1.73), 0.6203		1.42 (0.63 - 3.19), 0.3978			
Across Treatment Arm [c]	0.51 (0.30 - 0.87), 0.0140					
Treatment Interaction [d]	1.71 (0.57 - 5.11), 0.3382					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.6
Significant SOC Cardiac Disorders Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Exposure to ACEi						
No	102	51 (50.0%)	106	35 (33.0%)	0.49 (0.28 - 0.86)	0.0129
Yes	13	5 (38.5%)	8	2 (25.0%)	0.53 (0.08 - 3.76)	0.5251
Within Treatment Arm [b]	0.63 (0.19 - 2.04), 0.4331		0.68 (0.13 - 3.52), 0.6404			
Across Treatment Arm [c]	0.50 (0.29 - 0.85), 0.0108					
Treatment Interaction [d]	1.08 (0.14 - 8.24), 0.9394					
Exposure to ARBs						
No	108	53 (49.1%)	106	34 (32.1%)	0.49 (0.28 - 0.85)	0.0114
Yes	7	3 (42.9%)	8	3 (37.5%)	0.80 (0.10 - 6.35)	0.8327
Within Treatment Arm [b]	0.78 (0.17 - 3.64), 0.7498		1.27 (0.29 - 5.63), 0.7520			
Across Treatment Arm [c]	0.51 (0.30 - 0.87), 0.0128					
Treatment Interaction [d]	1.63 (0.19 - 13.9), 0.6542					
Medical History of ARDS						
No	85	45 (52.9%)	95	31 (32.6%)	0.43 (0.24 - 0.79)	0.0059
Yes	30	11 (36.7%)	19	6 (31.6%)	0.80 (0.24 - 2.70)	0.7154
Within Treatment Arm [b]	0.51 (0.22 - 1.21), 0.1252		0.95 (0.33 - 2.75), 0.9287			
Across Treatment Arm [c]	0.48 (0.28 - 0.83), 0.0089					
Treatment Interaction [d]	1.85 (0.47 - 7.22), 0.3750					
Chest X-ray Finding of ARDS						
No	72	33 (45.8%)	88	29 (33.0%)	0.58 (0.31 - 1.10)	0.0962
Yes	43	23 (53.5%)	25	8 (32.0%)	0.41 (0.15 - 1.15)	0.0863
Within Treatment Arm [b]	1.36 (0.64 - 2.90), 0.4268		0.96 (0.37 - 2.48), 0.9285			
Across Treatment Arm [c]	0.53 (0.31 - 0.91), 0.0205					
Treatment Interaction [d]	0.70 (0.21 - 2.38), 0.5722					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.6
Significant SOC Cardiac Disorders Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
History of Sepsis						
No	15	8 (53.3%)	17	6 (35.3%)	0.48 (0.12 - 1.98)	0.3047
Yes	100	48 (48.0%)	97	31 (32.0%)	0.51 (0.28 - 0.91)	0.0216
Within Treatment Arm [b]	0.81 (0.27 - 2.40), 0.7000		0.86 (0.29 - 2.54), 0.7864			
Across Treatment Arm [c]	0.50 (0.29 - 0.86), 0.0124					
Treatment Interaction [d]	1.07 (0.23 - 4.95), 0.9348					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	35 (45.5%)	81	27 (33.3%)	0.60 (0.32 - 1.14)	0.1188
>=0.5 ug/kg/min	38	21 (55.3%)	33	10 (30.3%)	0.35 (0.13 - 0.94)	0.0344
Within Treatment Arm [b]	1.48 (0.68 - 3.24), 0.3222		0.87 (0.36 - 2.08), 0.7540			
Across Treatment Arm [c]	0.51 (0.30 - 0.87), 0.0137					
Treatment Interaction [d]	0.59 (0.18 - 1.89), 0.3727					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	1 (100%)	73	26 (35.6%)		0.1841
>=20 ng/kg/min	114	55 (48.2%)	41	11 (26.8%)	0.39 (0.18 - 0.86)	0.0174
Within Treatment Arm [b]	, 0.3026		0.66 (0.29 - 1.54), 0.3362			
Across Treatment Arm [c]	0.37 (0.17 - 0.80), 0.0117					
Treatment Interaction [d]	21E3 (0.00 - 7.88E148), 0.9534					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.6

Significant SOC Cardiac Disorders Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	14 (60.9%)	27	9 (33.3%)	0.32 (0.10 - 1.02)	0.0515
72.3 - <253 pg/mL	26	15 (57.7%)	22	10 (45.5%)	0.61 (0.19 - 1.92)	0.3978
253 - <676 pg/mL	25	13 (52.0%)	27	11 (40.7%)	0.63 (0.21 - 1.90)	0.4158
>=676 pg/mL	27	10 (37.0%)	26	4 (15.4%)	0.31 (0.08 - 1.16)	0.0739
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	23 (44.2%)	53	15 (28.3%)	0.50 (0.22 - 1.12)	0.0895
<253 pg/mL	49	29 (59.2%)	49	19 (38.8%)	0.44 (0.19 - 0.98)	0.0433
Within Treatment Arm [b]	1.83 (0.83 - 4.03), 0.1329		1.60 (0.70 - 3.68), 0.2623			
Across Treatment Arm [c]	0.47 (0.26 - 0.83), 0.0090					
Treatment Interaction [d]	0.88 (0.28 - 2.76), 0.8231					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	17 (58.6%)	28	10 (35.7%)	0.39 (0.13 - 1.14)	0.0834
23.85 - <83.75 pg/mL	28	16 (57.1%)	25	10 (40.0%)	0.50 (0.17 - 1.50)	0.2127
83.75 - <299.5 pg/mL	12	7 (58.3%)	28	8 (28.6%)	0.29 (0.07 - 1.17)	0.0748
>=299.5 pg/mL	31	12 (38.7%)	20	5 (25.0%)	0.53 (0.15 - 1.83)	0.3106
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	19 (44.2%)	48	13 (27.1%)	0.47 (0.20 - 1.13)	0.0880
<83.75 pg/mL	57	33 (57.9%)	53	20 (37.7%)	0.44 (0.21 - 0.95)	0.0345
Within Treatment Arm [b]	1.74 (0.78 - 3.86), 0.1743		1.63 (0.70 - 3.80), 0.2543			
Across Treatment Arm [c]	0.45 (0.25 - 0.81), 0.0070					
Treatment Interaction [d]	0.94 (0.29 - 3.01), 0.9162					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.6
Significant SOC Cardiac Disorders Regardless of Relationship to Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	28 (53.8%)	53	22 (41.5%)	0.61 (0.28 - 1.32)	0.2057
< 1.63	47	24 (51.1%)	46	10 (21.7%)	0.27 (0.11 - 0.66)	0.0033
Within Treatment Arm [b]	0.89 (0.41 - 1.97), 0.7819		0.39 (0.16 - 0.95), 0.0359			
Across Treatment Arm [c]	0.42 (0.24 - 0.76), 0.0039					
Treatment Interaction [d]	0.44 (0.13 - 1.44), 0.1731					
Vasopressin Use at Baseline						
No	11	5 (45.5%)	6	1 (16.7%)	0.24 (0.02 - 2.79)	0.2352
Yes	104	51 (49.0%)	108	36 (33.3%)	0.52 (0.30 - 0.90)	0.0201
Within Treatment Arm [b]	1.15 (0.33 - 4.02), 0.8211		2.50 (0.28 - 22.2), 0.3961			
Across Treatment Arm [c]	0.50 (0.29 - 0.85), 0.0113					
Treatment Interaction [d]	2.16 (0.18 - 26.8), 0.5473					
Baseline AKI (Acute Kidney Injury)						
No	63	32 (50.8%)	82	26 (31.7%)	0.45 (0.23 - 0.89)	0.0200
Yes	52	24 (46.2%)	32	11 (34.4%)	0.61 (0.25 - 1.52)	0.2876
Within Treatment Arm [b]	0.83 (0.40 - 1.73), 0.6203		1.13 (0.47 - 2.68), 0.7846			
Across Treatment Arm [c]	0.50 (0.29 - 0.86), 0.0130					
Treatment Interaction [d]	1.36 (0.44 - 4.23), 0.5969					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.7
Significant SOC Cardiac Disorders Resulting in Discontinuation of Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Age (years)						
< 65	54	6 (11.1%)	62	1 (1.6%)	0.13 (0.02 - 1.13)	0.0321
>=65	61	7 (11.5%)	52	1 (1.9%)	0.15 (0.02 - 1.27)	0.0485
Within Treatment Arm [b]	1.04 (0.33 - 3.30), 0.9509		1.20 (0.07 - 19.6), 0.9000			
Across Treatment Arm [c]	0.14 (0.03 - 0.64), 0.0112					
Treatment Interaction [d]	1.15 (0.06 - 23.8), 0.9264					
Gender						
Female	39	3 (7.7%)	49	1 (2.0%)	0.25 (0.02 - 2.50)	0.2061
Male	76	10 (13.2%)	65	1 (1.5%)	0.10 (0.01 - 0.83)	0.0103
Within Treatment Arm [b]	1.82 (0.47 - 7.03), 0.3809		0.75 (0.05 - 12.3), 0.8397			
Across Treatment Arm [c]	0.14 (0.03 - 0.66), 0.0125					
Treatment Interaction [d]	0.41 (0.02 - 9.22), 0.5764					
Race						
Other	29	3 (10.3%)	17	0 (0.0%)		0.1702
White	86	10 (11.6%)	97	2 (2.1%)	0.16 (0.03 - 0.75)	0.0091
Within Treatment Arm [b]	1.14 (0.29 - 4.46), 0.8503		, 0.5503			
Across Treatment Arm [c]	0.14 (0.03 - 0.62), 0.0102					
Treatment Interaction [d]	6461 (0.00 - 8.86E125), 0.9512					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	5 (8.3%)	60	0 (0.0%)		0.0224
>=30 kg/m2	54	8 (14.8%)	52	2 (3.8%)	0.23 (0.05 - 1.14)	0.0534
Within Treatment Arm [b]	1.91 (0.59 - 6.25), 0.2770		, 0.1253			
Across Treatment Arm [c]	0.14 (0.03 - 0.64), 0.0111					
Treatment Interaction [d]	53E3 (0.00 - 2.16E180), 0.9579					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.7
Significant SOC Cardiac Disorders Resulting in Discontinuation of Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	5 (10.6%)	27	0 (0.0%)		0.0792
< 2.5 g/dL	67	8 (11.9%)	82	1 (1.2%)	0.09 (0.01 - 0.75)	0.0063
Within Treatment Arm [b]	1.14 (0.35 - 3.73), 0.8295		, 0.5643			
Across Treatment Arm [c]	0.07 (0.01 - 0.55), 0.0112					
Treatment Interaction [d]	11E3 (0.00 - 1.26E167), 0.9614					
Geographic Region						
Rest of World	17	1 (5.9%)	17	1 (5.9%)	1.00 (0.06 - 17.4)	1.0000
US/Canada	98	12 (12.2%)	97	1 (1.0%)	0.07 (0.01 - 0.59)	0.0017
Within Treatment Arm [b]	2.23 (0.27 - 18.4), 0.4444		0.17 (0.01 - 2.80), 0.1599			
Across Treatment Arm [c]	0.14 (0.03 - 0.64), 0.0109					
Treatment Interaction [d]	0.07 (0.00 - 2.53), 0.1488					
Baseline MAP						
>=65 mmHg	70	6 (8.6%)	74	1 (1.4%)	0.15 (0.02 - 1.25)	0.0440
< 65 mmHg	45	7 (15.6%)	40	1 (2.5%)	0.14 (0.02 - 1.19)	0.0396
Within Treatment Arm [b]	1.96 (0.61 - 6.28), 0.2483		1.87 (0.11 - 30.7), 0.6557			
Across Treatment Arm [c]	0.14 (0.03 - 0.65), 0.0118					
Treatment Interaction [d]	0.95 (0.05 - 19.7), 0.9748					
Baseline APACHE II Score						
<=30	63	6 (9.5%)	74	1 (1.4%)	0.13 (0.02 - 1.11)	0.0304
> 30	52	7 (13.5%)	40	1 (2.5%)	0.16 (0.02 - 1.40)	0.0643
Within Treatment Arm [b]	1.48 (0.46 - 4.71), 0.5069		1.87 (0.11 - 30.7), 0.6557			
Across Treatment Arm [c]	0.15 (0.03 - 0.66), 0.0128					
Treatment Interaction [d]	1.27 (0.06 - 26.2), 0.8786					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.7
Significant SOC Cardiac Disorders Resulting in Discontinuation of Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Exposure to ACEi						
No	102	12 (11.8%)	106	2 (1.9%)	0.14 (0.03 - 0.66)	0.0045
Yes	13	1 (7.7%)	8	0 (0.0%)		0.4215
Within Treatment Arm [b]	0.63 (0.07 - 5.24), 0.6623		, 0.6951			
Across Treatment Arm [c]	0.14 (0.03 - 0.62), 0.0101					
Treatment Interaction [d]	0.00 (0.00 - I), 0.9855					
Exposure to ARBs						
No	108	13 (12.0%)	106	1 (0.9%)	0.07 (0.01 - 0.54)	0.0010
Yes	7	0 (0.0%)	8	1 (12.5%)		0.3329
Within Treatment Arm [b]	, 0.3297		15.0 (0.85 - 266), 0.0164			
Across Treatment Arm [c]	0.14 (0.03 - 0.64), 0.0109					
Treatment Interaction [d]	2E6 (0.00 - I), 0.9687					
Medical History of ARDS						
No	85	12 (14.1%)	95	2 (2.1%)	0.13 (0.03 - 0.60)	0.0027
Yes	30	1 (3.3%)	19	0 (0.0%)		0.4214
Within Treatment Arm [b]	0.21 (0.03 - 1.69), 0.1088		, 0.5234			
Across Treatment Arm [c]	0.12 (0.03 - 0.57), 0.0073					
Treatment Interaction [d]	0.00 (0.00 - I), 0.9797					
Chest X-ray Finding of ARDS						
No	72	8 (11.1%)	88	1 (1.1%)	0.09 (0.01 - 0.75)	0.0064
Yes	43	5 (11.6%)	25	1 (4.0%)	0.32 (0.03 - 2.88)	0.2849
Within Treatment Arm [b]	1.05 (0.32 - 3.45), 0.9325		3.63 (0.22 - 60.1), 0.3379			
Across Treatment Arm [c]	0.15 (0.03 - 0.67), 0.0134					
Treatment Interaction [d]	3.44 (0.16 - 72.6), 0.4267					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.7
Significant SOC Cardiac Disorders Resulting in Discontinuation of Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
History of Sepsis						
No	15	2 (13.3%)	17	1 (5.9%)	0.41 (0.03 - 5.00)	0.4705
Yes	100	11 (11.0%)	97	1 (1.0%)	0.08 (0.01 - 0.67)	0.0034
Within Treatment Arm [b]	0.80 (0.16 - 4.04), 0.7901		0.17 (0.01 - 2.80), 0.1599			
Across Treatment Arm [c]	0.14 (0.03 - 0.63), 0.0103					
Treatment Interaction [d]	0.21 (0.01 - 5.36), 0.3431					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	6 (7.8%)	81	1 (1.2%)	0.15 (0.02 - 1.26)	0.0453
>=0.5 ug/kg/min	38	7 (18.4%)	33	1 (3.0%)	0.14 (0.02 - 1.19)	0.0408
Within Treatment Arm [b]	2.67 (0.83 - 8.60), 0.0904		2.50 (0.15 - 41.2), 0.5078			
Across Treatment Arm [c]	0.14 (0.03 - 0.65), 0.0121					
Treatment Interaction [d]	0.94 (0.04 - 19.5), 0.9655					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	73	1 (1.4%)		0.9062
>=20 ng/kg/min	114	13 (11.4%)	41	1 (2.4%)	0.19 (0.02 - 1.53)	0.0859
Within Treatment Arm [b]	, 0.7199		1.80 (0.11 - 29.6), 0.6765			
Across Treatment Arm [c]	0.21 (0.03 - 1.47), 0.1155					
Treatment Interaction [d]	0.00 (0.00 - 5.36E181), 0.9702					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.7
Significant SOC Cardiac Disorders Resulting in Discontinuation of Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	3 (13.0%)	27	0 (0.0%)		0.0529
72.3 - <253 pg/mL	26	3 (11.5%)	22	1 (4.5%)	0.37 (0.04 - 3.79)	0.3824
253 - <676 pg/mL	25	3 (12.0%)	27	0 (0.0%)		0.0637
>=676 pg/mL	27	3 (11.1%)	26	0 (0.0%)		0.0801
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	6 (11.5%)	53	0 (0.0%)		0.0109
<253 pg/mL	49	6 (12.2%)	49	1 (2.0%)	0.15 (0.02 - 1.29)	0.0499
Within Treatment Arm [b]	1.07 (0.32 - 3.57), 0.9127		, 0.2960			
Across Treatment Arm [c]	0.07 (0.01 - 0.58), 0.0130					
Treatment Interaction [d]	51E3 (0.00 - 6.12E194), 0.9613					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	5 (17.2%)	28	0 (0.0%)		0.0214
23.85 - <83.75 pg/mL	28	5 (17.9%)	25	1 (4.0%)	0.19 (0.02 - 1.77)	0.1120
83.75 - <299.5 pg/mL	12	1 (8.3%)	28	0 (0.0%)		0.1219
>=299.5 pg/mL	31	1 (3.2%)	20	0 (0.0%)		0.4172
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	2 (4.7%)	48	0 (0.0%)		0.1308
<83.75 pg/mL	57	10 (17.5%)	53	1 (1.9%)	0.09 (0.01 - 0.73)	0.0062
Within Treatment Arm [b]	4.36 (0.90 - 21.1), 0.0495		, 0.3389			
Across Treatment Arm [c]	0.07 (0.01 - 0.59), 0.0138					
Treatment Interaction [d]	4246 (0.00 - 1.58E124), 0.9530					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.7
Significant SOC Cardiac Disorders Resulting in Discontinuation of Study Drug: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac SOC AEs (%)	Number of Patients	Number with Cardiac SOC AEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	10 (19.2%)	53	1 (1.9%)	0.08 (0.01 - 0.66)	0.0037
< 1.63	47	2 (4.3%)	46	0 (0.0%)		0.1573
Within Treatment Arm [b]	0.19 (0.04 - 0.90), 0.0226		, 0.3491			
Across Treatment Arm [c]	0.07 (0.01 - 0.55), 0.0114					
Treatment Interaction [d]	0.00 (0.00 - 4.32E197), 0.9692					
Vasopressin Use at Baseline						
No	11	1 (9.1%)	6	1 (16.7%)	2.00 (0.10 - 39.1)	0.6431
Yes	104	12 (11.5%)	108	1 (0.9%)	0.07 (0.01 - 0.56)	0.0013
Within Treatment Arm [b]	1.30 (0.15 - 11.1), 0.8074		0.05 (0.00 - 0.86), 0.0043			
Across Treatment Arm [c]	0.14 (0.03 - 0.65), 0.0120					
Treatment Interaction [d]	0.04 (0.00 - 1.33), 0.0712					
Baseline AKI (Acute Kidney Injury)						
No	63	2 (3.2%)	82	1 (1.2%)	0.38 (0.03 - 4.25)	0.4123
Yes	52	11 (21.2%)	32	1 (3.1%)	0.12 (0.01 - 0.98)	0.0218
Within Treatment Arm [b]	8.18 (1.72 - 38.9), 0.0024		2.61 (0.16 - 43.1), 0.4862			
Across Treatment Arm [c]	0.18 (0.04 - 0.84), 0.0290					
Treatment Interaction [d]	0.32 (0.01 - 7.88), 0.4850					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.8
Summary of Treatment Emergent Thromboembolic Events: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Thrombo AEs (%)	Number of Patients	Number with Thrombo AEs (%)		
Age (years)						
< 65	54	50 (92.6%)	62	53 (85.5%)	0.47 (0.14 - 1.63)	0.2260
>=65	61	60 (98.4%)	52	48 (92.3%)	0.20 (0.02 - 1.85)	0.1189
Within Treatment Arm [b]	4.80 (0.52 - 44.3), 0.1301		2.04 (0.59 - 7.05), 0.2536			
Across Treatment Arm [c]	0.37 (0.13 - 1.09), 0.0713					
Treatment Interaction [d]	0.42 (0.03 - 5.42), 0.5096					
Gender						
Female	39	38 (97.4%)	49	44 (89.8%)	0.23 (0.03 - 2.07)	0.1578
Male	76	72 (94.7%)	65	57 (87.7%)	0.40 (0.11 - 1.38)	0.1351
Within Treatment Arm [b]	0.47 (0.05 - 4.39), 0.5016		0.81 (0.25 - 2.65), 0.7265			
Across Treatment Arm [c]	0.34 (0.12 - 1.00), 0.0498					
Treatment Interaction [d]	1.71 (0.14 - 21.3), 0.6769					
Race						
Other	29	27 (93.1%)	17	16 (94.1%)	1.19 (0.10 - 14.1)	0.8930
White	86	83 (96.5%)	97	85 (87.6%)	0.26 (0.07 - 0.94)	0.0288
Within Treatment Arm [b]	2.05 (0.33 - 12.9), 0.4364		0.44 (0.05 - 3.65), 0.4375			
Across Treatment Arm [c]	0.36 (0.12 - 1.04), 0.0595					
Treatment Interaction [d]	0.22 (0.01 - 3.55), 0.2834					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	57 (95.0%)	60	52 (86.7%)	0.34 (0.09 - 1.36)	0.1137
>=30 kg/m2	54	52 (96.3%)	52	47 (90.4%)	0.36 (0.07 - 1.95)	0.2205
Within Treatment Arm [b]	1.37 (0.22 - 8.52), 0.7358		1.45 (0.44 - 4.73), 0.5401			
Across Treatment Arm [c]	0.35 (0.12 - 1.02), 0.0538					
Treatment Interaction [d]	1.06 (0.12 - 9.34), 0.9602					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.8
Summary of Treatment Emergent Thromboembolic Events: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Thrombo AEs (%)	Number of Patients	Number with Thrombo AEs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	45 (95.7%)	27	23 (85.2%)	0.26 (0.04 - 1.50)	0.1092
< 2.5 g/dL	67	64 (95.5%)	82	73 (89.0%)	0.38 (0.10 - 1.47)	0.1471
Within Treatment Arm [b]	0.95 (0.15 - 5.91), 0.9545		1.41 (0.40 - 5.01), 0.5934			
Across Treatment Arm [c]	0.33 (0.11 - 0.97), 0.0431					
Treatment Interaction [d]	1.49 (0.16 - 13.8), 0.7264					
Geographic Region						
Rest of World	17	16 (94.1%)	17	12 (70.6%)	0.15 (0.02 - 1.46)	0.0719
US/Canada	98	94 (95.9%)	97	89 (91.8%)	0.47 (0.14 - 1.63)	0.2262
Within Treatment Arm [b]	1.47 (0.15 - 14.0), 0.7368		4.64 (1.30 - 16.5), 0.0113			
Across Treatment Arm [c]	0.35 (0.12 - 1.02), 0.0533					
Treatment Interaction [d]	3.16 (0.24 - 42.0), 0.3839					
Baseline MAP						
>=65 mmHg	70	66 (94.3%)	74	63 (85.1%)	0.35 (0.11 - 1.15)	0.0724
< 65 mmHg	45	44 (97.8%)	40	38 (95.0%)	0.43 (0.04 - 4.95)	0.4885
Within Treatment Arm [b]	2.67 (0.29 - 24.7), 0.3701		3.32 (0.70 - 15.8), 0.1138			
Across Treatment Arm [c]	0.36 (0.12 - 1.06), 0.0631					
Treatment Interaction [d]	1.24 (0.08 - 18.8), 0.8748					
Baseline APACHE II Score						
<=30	63	59 (93.7%)	74	63 (85.1%)	0.39 (0.12 - 1.29)	0.1116
> 30	52	51 (98.1%)	40	38 (95.0%)	0.37 (0.03 - 4.26)	0.4101
Within Treatment Arm [b]	3.46 (0.37 - 31.9), 0.2467		3.32 (0.70 - 15.8), 0.1138			
Across Treatment Arm [c]	0.39 (0.13 - 1.13), 0.0821					
Treatment Interaction [d]	0.96 (0.06 - 14.5), 0.9762					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.8
Summary of Treatment Emergent Thromboembolic Events: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Thrombo AEs (%)	Number of Patients	Number with Thrombo AEs (%)		
Exposure to ACEi						
No	102	98 (96.1%)	106	95 (89.6%)	0.35 (0.11 - 1.15)	0.0720
Yes	13	12 (92.3%)	8	6 (75.0%)	0.25 (0.02 - 3.34)	0.2710
Within Treatment Arm [b]	0.49 (0.05 - 4.75), 0.5301		0.35 (0.06 - 1.94), 0.2096			
Across Treatment Arm [c]	0.33 (0.11 - 0.98), 0.0450					
Treatment Interaction [d]	0.71 (0.04 - 12.2), 0.8131					
Exposure to ARBs						
No	108	103 (95.4%)	106	94 (88.7%)	0.38 (0.13 - 1.12)	0.0703
Yes	7	7 (100%)	8	7 (87.5%)		0.3329
Within Treatment Arm [b]	, 0.5605		0.89 (0.10 - 7.90), 0.9194			
Across Treatment Arm [c]	0.35 (0.12 - 1.02), 0.0553					
Treatment Interaction [d]	0.00 (0.00 - 1.11E283), 0.9748					
Medical History of ARDS						
No	85	80 (94.1%)	95	84 (88.4%)	0.48 (0.16 - 1.43)	0.1800
Yes	30	30 (100%)	19	17 (89.5%)		0.0696
Within Treatment Arm [b]	, 0.1744		1.11 (0.23 - 5.48), 0.8952			
Across Treatment Arm [c]	0.37 (0.13 - 1.08), 0.0702					
Treatment Interaction [d]	0.00 (0.00 - 1.06E224), 0.9653					
Chest X-ray Finding of ARDS						
No	72	67 (93.1%)	88	79 (89.8%)	0.66 (0.21 - 2.05)	0.4647
Yes	43	43 (100%)	25	21 (84.0%)		0.0069
Within Treatment Arm [b]	, 0.0772		0.60 (0.17 - 2.13), 0.4247			
Across Treatment Arm [c]	0.36 (0.12 - 1.07), 0.0650					
Treatment Interaction [d]	0.00 (0.00 - 3.49E185), 0.9555					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.8
Summary of Treatment Emergent Thromboembolic Events: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Thrombo AEs (%)	Number of Patients	Number with Thrombo AEs (%)		
History of Sepsis						
No	15	15 (100%)	17	14 (82.4%)		0.0874
Yes	100	95 (95.0%)	97	87 (89.7%)	0.46 (0.15 - 1.39)	0.1601
Within Treatment Arm [b]	, 0.3759		1.86 (0.46 - 7.62), 0.3799			
Across Treatment Arm [c]	0.35 (0.12 - 1.03), 0.0566					
Treatment Interaction [d]	78E3 (0.00 - 2.63E201), 0.9611					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	73 (94.8%)	81	70 (86.4%)	0.35 (0.11 - 1.15)	0.0723
>=0.5 ug/kg/min	38	37 (97.4%)	33	31 (93.9%)	0.42 (0.04 - 4.84)	0.4738
Within Treatment Arm [b]	2.03 (0.22 - 18.8), 0.5261		2.44 (0.51 - 11.6), 0.2520			
Across Treatment Arm [c]	0.36 (0.12 - 1.05), 0.0618					
Treatment Interaction [d]	1.20 (0.08 - 18.3), 0.8949					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	1 (100%)	73	65 (89.0%)		0.7259
>=20 ng/kg/min	114	109 (95.6%)	41	36 (87.8%)	0.33 (0.09 - 1.21)	0.0809
Within Treatment Arm [b]	, 0.8304		0.89 (0.27 - 2.91), 0.8420			
Across Treatment Arm [c]	0.32 (0.09 - 1.17), 0.0864					
Treatment Interaction [d]	1618 (0.00 - 1.1E173), 0.9705					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.8
Summary of Treatment Emergent Thromboembolic Events: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Thrombo AEs (%)	Number of Patients	Number with Thrombo AEs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	21 (91.3%)	27	25 (92.6%)	1.19 (0.15 - 9.19)	0.8671
72.3 - <253 pg/mL	26	25 (96.2%)	22	18 (81.8%)	0.18 (0.02 - 1.75)	0.1052
253 - <676 pg/mL	25	25 (100%)	27	26 (96.3%)		0.3312
>=676 pg/mL	27	26 (96.3%)	26	22 (84.6%)	0.21 (0.02 - 2.03)	0.1458
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	51 (98.1%)	53	48 (90.6%)	0.19 (0.02 - 1.67)	0.0974
<253 pg/mL	49	46 (93.9%)	49	43 (87.8%)	0.47 (0.11 - 1.99)	0.2940
Within Treatment Arm [b]	0.30 (0.03 - 2.99), 0.2795		0.75 (0.21 - 2.62), 0.6475			
Across Treatment Arm [c]	0.34 (0.10 - 1.10), 0.0727					
Treatment Interaction [d]	2.48 (0.18 - 34.1), 0.4961					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	27 (93.1%)	28	26 (92.9%)	0.96 (0.13 - 7.35)	0.9710
23.85 - <83.75 pg/mL	28	28 (100%)	25	21 (84.0%)		0.0277
83.75 - <299.5 pg/mL	12	10 (83.3%)	28	25 (89.3%)	1.67 (0.24 - 11.5)	0.6019
>=299.5 pg/mL	31	31 (100%)	20	18 (90.0%)		0.0725
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	41 (95.3%)	48	43 (89.6%)	0.42 (0.08 - 2.28)	0.3028
<83.75 pg/mL	57	55 (96.5%)	53	47 (88.7%)	0.28 (0.05 - 1.48)	0.1149
Within Treatment Arm [b]	1.34 (0.18 - 9.92), 0.7729		0.91 (0.26 - 3.20), 0.8842			
Across Treatment Arm [c]	0.34 (0.10 - 1.11), 0.0743					
Treatment Interaction [d]	0.68 (0.06 - 7.21), 0.7483					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.8
Summary of Treatment Emergent Thromboembolic Events: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Thrombo AEs (%)	Number of Patients	Number with Thrombo AEs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	51 (98.1%)	53	46 (86.8%)	0.13 (0.02 - 1.09)	0.0293
< 1.63	47	44 (93.6%)	46	42 (91.3%)	0.72 (0.15 - 3.39)	0.6725
Within Treatment Arm [b]	0.29 (0.03 - 2.87), 0.2604		1.60 (0.44 - 5.85), 0.4762			
Across Treatment Arm [c]	0.34 (0.10 - 1.10), 0.0709					
Treatment Interaction [d]	5.56 (0.40 - 77.8), 0.2029					
Vasopressin Use at Baseline						
No	11	10 (90.9%)	6	6 (100%)		0.4465
Yes	104	100 (96.2%)	108	95 (88.0%)	0.29 (0.09 - 0.93)	0.0281
Within Treatment Arm [b]	2.50 (0.25 - 24.6), 0.4173		, 0.3666			
Across Treatment Arm [c]	0.36 (0.12 - 1.04), 0.0580					
Treatment Interaction [d]	0.00 (0.00 - 2.94E183), 0.9585					
Baseline AKI (Acute Kidney Injury)						
No	63	59 (93.7%)	82	73 (89.0%)	0.55 (0.16 - 1.88)	0.3337
Yes	52	51 (98.1%)	32	28 (87.5%)	0.14 (0.01 - 1.29)	0.0466
Within Treatment Arm [b]	3.46 (0.37 - 31.9), 0.2467		0.86 (0.25 - 3.03), 0.8180			
Across Treatment Arm [c]	0.37 (0.13 - 1.09), 0.0702					
Treatment Interaction [d]	0.25 (0.02 - 3.21), 0.2867					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.9
TEAEs of Special Interest: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with AESIs (%)	Number of Patients	Number with AESIs (%)		
Age (years)						
< 65	54	17 (31.5%)	62	17 (27.4%)	0.82 (0.37 - 1.83)	0.6316
>=65	61	26 (42.6%)	52	18 (34.6%)	0.71 (0.33 - 1.53)	0.3843
Within Treatment Arm [b]	1.62 (0.75 - 3.48), 0.2178		1.40 (0.63 - 3.11), 0.4067			
Across Treatment Arm [c]	0.76 (0.44 - 1.33), 0.3368					
Treatment Interaction [d]	0.87 (0.29 - 2.62), 0.8000					
Gender						
Female	39	16 (41.0%)	49	14 (28.6%)	0.58 (0.24 - 1.40)	0.2208
Male	76	27 (35.5%)	65	21 (32.3%)	0.87 (0.43 - 1.75)	0.6876
Within Treatment Arm [b]	0.79 (0.36 - 1.75), 0.5639		1.19 (0.53 - 2.68), 0.6685			
Across Treatment Arm [c]	0.74 (0.43 - 1.28), 0.2837					
Treatment Interaction [d]	1.51 (0.49 - 4.67), 0.4782					
Race						
Other	29	7 (24.1%)	17	6 (35.3%)	1.71 (0.46 - 6.35)	0.4173
White	86	36 (41.9%)	97	29 (29.9%)	0.59 (0.32 - 1.09)	0.0914
Within Treatment Arm [b]	2.26 (0.87 - 5.86), 0.0880		0.78 (0.26 - 2.32), 0.6563			
Across Treatment Arm [c]	0.71 (0.41 - 1.24), 0.2313					
Treatment Interaction [d]	0.35 (0.08 - 1.46), 0.1494					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	26 (43.3%)	60	15 (25.0%)	0.44 (0.20 - 0.95)	0.0342
>=30 kg/m2	54	17 (31.5%)	52	18 (34.6%)	1.15 (0.51 - 2.59)	0.7316
Within Treatment Arm [b]	0.60 (0.28 - 1.30), 0.1924		1.59 (0.70 - 3.60), 0.2656			
Across Treatment Arm [c]	0.69 (0.40 - 1.20), 0.1893					
Treatment Interaction [d]	2.64 (0.86 - 8.11), 0.0895					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.9
TEAEs of Special Interest: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with AESIs (%)	Number of Patients	Number with AESIs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	16 (34.0%)	27	8 (29.6%)	0.82 (0.29 - 2.27)	0.6963
< 2.5 g/dL	67	26 (38.8%)	82	25 (30.5%)	0.69 (0.35 - 1.37)	0.2871
Within Treatment Arm [b]	1.23 (0.56 - 2.68), 0.6038		1.04 (0.40 - 2.69), 0.9329			
Across Treatment Arm [c]	0.73 (0.41 - 1.28), 0.2715					
Treatment Interaction [d]	0.85 (0.25 - 2.90), 0.7922					
Geographic Region						
Rest of World	17	6 (35.3%)	17	5 (29.4%)	0.76 (0.18 - 3.23)	0.7139
US/Canada	98	37 (37.8%)	97	30 (30.9%)	0.74 (0.41 - 1.34)	0.3155
Within Treatment Arm [b]	1.11 (0.38 - 3.26), 0.8465		1.07 (0.35 - 3.32), 0.9005			
Across Treatment Arm [c]	0.74 (0.43 - 1.28), 0.2862					
Treatment Interaction [d]	0.97 (0.20 - 4.59), 0.9657					
Baseline MAP						
>=65 mmHg	70	28 (40.0%)	74	24 (32.4%)	0.72 (0.36 - 1.42)	0.3447
< 65 mmHg	45	15 (33.3%)	40	11 (27.5%)	0.76 (0.30 - 1.92)	0.5602
Within Treatment Arm [b]	0.75 (0.34 - 1.64), 0.4708		0.79 (0.34 - 1.84), 0.5858			
Across Treatment Arm [c]	0.73 (0.42 - 1.27), 0.2692					
Treatment Interaction [d]	1.05 (0.33 - 3.34), 0.9292					
Baseline APACHE II Score						
<=30	63	21 (33.3%)	74	20 (27.0%)	0.74 (0.36 - 1.54)	0.4218
> 30	52	22 (42.3%)	40	15 (37.5%)	0.82 (0.35 - 1.90)	0.6411
Within Treatment Arm [b]	1.47 (0.69 - 3.14), 0.3222		1.62 (0.71 - 3.68), 0.2473			
Across Treatment Arm [c]	0.77 (0.44 - 1.35), 0.3624					
Treatment Interaction [d]	1.10 (0.36 - 3.38), 0.8618					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.9
TEAEs of Special Interest: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with AESIs (%)	Number of Patients	Number with AESIs (%)		
Exposure to ACEi						
No	102	39 (38.2%)	106	33 (31.1%)	0.73 (0.41 - 1.30)	0.2817
Yes	13	4 (30.8%)	8	2 (25.0%)	0.75 (0.10 - 5.47)	0.7763
Within Treatment Arm [b]	0.72 (0.21 - 2.49), 0.6003		0.74 (0.14 - 3.85), 0.7169			
Across Treatment Arm [c]	0.73 (0.42 - 1.27), 0.2664					
Treatment Interaction [d]	1.03 (0.13 - 8.12), 0.9796					
Exposure to ARBs						
No	108	41 (38.0%)	106	33 (31.1%)	0.74 (0.42 - 1.30)	0.2935
Yes	7	2 (28.6%)	8	2 (25.0%)	0.83 (0.08 - 8.24)	0.8760
Within Treatment Arm [b]	0.65 (0.12 - 3.53), 0.6187		0.74 (0.14 - 3.85), 0.7169			
Across Treatment Arm [c]	0.74 (0.43 - 1.29), 0.2909					
Treatment Interaction [d]	1.13 (0.11 - 12.0), 0.9201					
Medical History of ARDS						
No	85	32 (37.6%)	95	29 (30.5%)	0.73 (0.39 - 1.35)	0.3136
Yes	30	11 (36.7%)	19	6 (31.6%)	0.80 (0.24 - 2.70)	0.7154
Within Treatment Arm [b]	0.96 (0.40 - 2.27), 0.9240		1.05 (0.36 - 3.04), 0.9276			
Across Treatment Arm [c]	0.74 (0.43 - 1.29), 0.2884					
Treatment Interaction [d]	1.10 (0.28 - 4.30), 0.8961					
Chest X-ray Finding of ARDS						
No	72	26 (36.1%)	88	27 (30.7%)	0.78 (0.40 - 1.52)	0.4679
Yes	43	17 (39.5%)	25	8 (32.0%)	0.72 (0.25 - 2.03)	0.5344
Within Treatment Arm [b]	1.16 (0.53 - 2.52), 0.7135		1.06 (0.41 - 2.76), 0.8999			
Across Treatment Arm [c]	0.76 (0.44 - 1.33), 0.3441					
Treatment Interaction [d]	0.92 (0.27 - 3.15), 0.8931					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.9
TEAEs of Special Interest: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with AESIs (%)	Number of Patients	Number with AESIs (%)		
History of Sepsis						
No	15	4 (26.7%)	17	6 (35.3%)	1.50 (0.33 - 6.83)	0.5993
Yes	100	39 (39.0%)	97	29 (29.9%)	0.67 (0.37 - 1.21)	0.1791
Within Treatment Arm [b]	1.76 (0.52 - 5.91), 0.3573		0.78 (0.26 - 2.32), 0.6563			
Across Treatment Arm [c]	0.74 (0.43 - 1.29), 0.2902					
Treatment Interaction [d]	0.44 (0.09 - 2.26), 0.3292					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	30 (39.0%)	81	25 (30.9%)	0.70 (0.36 - 1.35)	0.2856
>=0.5 ug/kg/min	38	13 (34.2%)	33	10 (30.3%)	0.84 (0.31 - 2.27)	0.7257
Within Treatment Arm [b]	0.81 (0.36 - 1.83), 0.6204		0.97 (0.40 - 2.35), 0.9530			
Across Treatment Arm [c]	0.74 (0.43 - 1.28), 0.2785					
Treatment Interaction [d]	1.20 (0.36 - 3.96), 0.7700					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	73	24 (32.9%)		0.4855
>=20 ng/kg/min	114	43 (37.7%)	41	11 (26.8%)	0.61 (0.28 - 1.33)	0.2094
Within Treatment Arm [b]	, 0.4376		0.75 (0.32 - 1.74), 0.5017			
Across Treatment Arm [c]	0.65 (0.30 - 1.39), 0.2673					
Treatment Interaction [d]	0.00 (0.00 - 9.45E145), 0.9542					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.9
TEAEs of Special Interest: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with AESIs (%)	Number of Patients	Number with AESIs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	7 (30.4%)	27	8 (29.6%)	0.96 (0.29 - 3.24)	0.9506
72.3 - <253 pg/mL	26	13 (50.0%)	22	8 (36.4%)	0.57 (0.18 - 1.82)	0.3427
253 - <676 pg/mL	25	11 (44.0%)	27	13 (48.1%)	1.18 (0.40 - 3.52)	0.7643
>=676 pg/mL	27	11 (40.7%)	26	4 (15.4%)	0.26 (0.07 - 0.98)	0.0405
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	22 (42.3%)	53	17 (32.1%)	0.64 (0.29 - 1.43)	0.2780
<253 pg/mL	49	20 (40.8%)	49	16 (32.7%)	0.70 (0.31 - 1.60)	0.4019
Within Treatment Arm [b]	0.94 (0.43 - 2.08), 0.8792		1.03 (0.45 - 2.36), 0.9503			
Across Treatment Arm [c]	0.67 (0.38 - 1.19), 0.1738					
Treatment Interaction [d]	1.09 (0.35 - 3.44), 0.8808					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	12 (41.4%)	28	10 (35.7%)	0.79 (0.27 - 2.29)	0.6605
23.85 - <83.75 pg/mL	28	10 (35.7%)	25	8 (32.0%)	0.85 (0.27 - 2.65)	0.7756
83.75 - <299.5 pg/mL	12	9 (75.0%)	28	9 (32.1%)	0.16 (0.03 - 0.73)	0.0125
>=299.5 pg/mL	31	11 (35.5%)	20	6 (30.0%)	0.78 (0.23 - 2.60)	0.6850
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	20 (46.5%)	48	15 (31.3%)	0.52 (0.22 - 1.23)	0.1352
<83.75 pg/mL	57	22 (38.6%)	53	18 (34.0%)	0.82 (0.38 - 1.78)	0.6137
Within Treatment Arm [b]	0.72 (0.32 - 1.61), 0.4272		1.13 (0.49 - 2.61), 0.7716			
Across Treatment Arm [c]	0.67 (0.37 - 1.19), 0.1676					
Treatment Interaction [d]	1.57 (0.49 - 4.98), 0.4480					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.9
TEAEs of Special Interest: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with AESIs (%)	Number of Patients	Number with AESIs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	25 (48.1%)	53	21 (39.6%)	0.71 (0.33 - 1.54)	0.3827
< 1.63	47	17 (36.2%)	46	11 (23.9%)	0.55 (0.23 - 1.37)	0.1976
Within Treatment Arm [b]	0.61 (0.27 - 1.37), 0.2313		0.48 (0.20 - 1.15), 0.0956			
Across Treatment Arm [c]	0.64 (0.36 - 1.15), 0.1336					
Treatment Interaction [d]	0.78 (0.24 - 2.57), 0.6859					
Vasopressin Use at Baseline						
No	11	2 (18.2%)	6	1 (16.7%)	0.90 (0.06 - 12.6)	0.9376
Yes	104	41 (39.4%)	108	34 (31.5%)	0.71 (0.40 - 1.24)	0.2267
Within Treatment Arm [b]	2.93 (0.60 - 14.2), 0.1662		2.30 (0.26 - 20.4), 0.4438			
Across Treatment Arm [c]	0.71 (0.41 - 1.24), 0.2315					
Treatment Interaction [d]	0.78 (0.05 - 11.6), 0.8600					
Baseline AKI (Acute Kidney Injury)						
No	63	23 (36.5%)	82	23 (28.0%)	0.68 (0.34 - 1.37)	0.2780
Yes	52	20 (38.5%)	32	12 (37.5%)	0.96 (0.39 - 2.38)	0.9298
Within Treatment Arm [b]	1.09 (0.51 - 2.32), 0.8294		1.54 (0.65 - 3.65), 0.3256			
Across Treatment Arm [c]	0.77 (0.44 - 1.35), 0.3631					
Treatment Interaction [d]	1.42 (0.45 - 4.47), 0.5529					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.10
TEAEs of Special Interest - Cardiac: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac AESIs (%)	Number of Patients	Number with Cardiac AESIs (%)		
Age (years)						
< 65	54	13 (24.1%)	62	14 (22.6%)	0.92 (0.39 - 2.18)	0.8494
>=65	61	22 (36.1%)	52	14 (26.9%)	0.65 (0.29 - 1.46)	0.2985
Within Treatment Arm [b]	1.78 (0.79 - 4.01), 0.1631		1.26 (0.54 - 2.97), 0.5916			
Across Treatment Arm [c]	0.77 (0.43 - 1.38), 0.3721					
Treatment Interaction [d]	0.71 (0.22 - 2.31), 0.5692					
Gender						
Female	39	13 (33.3%)	49	11 (22.4%)	0.58 (0.22 - 1.49)	0.2548
Male	76	22 (28.9%)	65	17 (26.2%)	0.87 (0.41 - 1.83)	0.7116
Within Treatment Arm [b]	0.81 (0.36 - 1.87), 0.6284		1.22 (0.51 - 2.92), 0.6492			
Across Treatment Arm [c]	0.74 (0.41 - 1.34), 0.3212					
Treatment Interaction [d]	1.50 (0.45 - 5.00), 0.5075					
Race						
Other	29	6 (20.7%)	17	5 (29.4%)	1.60 (0.40 - 6.33)	0.5032
White	86	29 (33.7%)	97	23 (23.7%)	0.61 (0.32 - 1.17)	0.1340
Within Treatment Arm [b]	1.95 (0.71 - 5.32), 0.1872		0.75 (0.24 - 2.34), 0.6145			
Across Treatment Arm [c]	0.72 (0.40 - 1.30), 0.2797					
Treatment Interaction [d]	0.38 (0.08 - 1.75), 0.2158					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	22 (36.7%)	60	10 (16.7%)	0.35 (0.15 - 0.81)	0.0132
>=30 kg/m2	54	13 (24.1%)	52	16 (30.8%)	1.40 (0.59 - 3.31)	0.4395
Within Treatment Arm [b]	0.55 (0.24 - 1.24), 0.1455		2.22 (0.90 - 5.46), 0.0779			
Across Treatment Arm [c]	0.68 (0.38 - 1.23), 0.2064					
Treatment Interaction [d]	4.06 (1.21 - 13.7), 0.0237					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.10
TEAEs of Special Interest - Cardiac: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac AESIs (%)	Number of Patients	Number with Cardiac AESIs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	15 (31.9%)	27	7 (25.9%)	0.75 (0.26 - 2.15)	0.5874
< 2.5 g/dL	67	19 (28.4%)	82	20 (24.4%)	0.81 (0.39 - 1.69)	0.5836
Within Treatment Arm [b]	0.84 (0.38 - 1.90), 0.6828		0.92 (0.34 - 2.50), 0.8726			
Across Treatment Arm [c]	0.79 (0.43 - 1.44), 0.4471					
Treatment Interaction [d]	1.09 (0.30 - 3.95), 0.8939					
Geographic Region						
Rest of World	17	6 (35.3%)	17	3 (17.6%)	0.39 (0.08 - 1.94)	0.2435
US/Canada	98	29 (29.6%)	97	25 (25.8%)	0.83 (0.44 - 1.55)	0.5513
Within Treatment Arm [b]	0.77 (0.26 - 2.28), 0.6371		1.62 (0.43 - 6.11), 0.4728			
Across Treatment Arm [c]	0.74 (0.42 - 1.33), 0.3205					
Treatment Interaction [d]	2.10 (0.38 - 11.7), 0.3955					
Baseline MAP						
>=65 mmHg	70	23 (32.9%)	74	21 (28.4%)	0.81 (0.40 - 1.65)	0.5598
< 65 mmHg	45	12 (26.7%)	40	7 (17.5%)	0.58 (0.20 - 1.67)	0.3113
Within Treatment Arm [b]	0.74 (0.32 - 1.70), 0.4814		0.54 (0.21 - 1.40), 0.1978			
Across Treatment Arm [c]	0.73 (0.41 - 1.31), 0.2917					
Treatment Interaction [d]	0.72 (0.20 - 2.56), 0.6121					
Baseline APACHE II Score						
<=30	63	18 (28.6%)	74	16 (21.6%)	0.69 (0.32 - 1.50)	0.3480
> 30	52	17 (32.7%)	40	12 (30.0%)	0.88 (0.36 - 2.15)	0.7829
Within Treatment Arm [b]	1.21 (0.55 - 2.69), 0.6326		1.55 (0.65 - 3.72), 0.3213			
Across Treatment Arm [c]	0.77 (0.43 - 1.38), 0.3755					
Treatment Interaction [d]	1.28 (0.39 - 4.17), 0.6832					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.10
TEAEs of Special Interest - Cardiac: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac AESIs (%)	Number of Patients	Number with Cardiac AESIs (%)		
Exposure to ACEi						
No	102	33 (32.4%)	106	26 (24.5%)	0.68 (0.37 - 1.25)	0.2108
Yes	13	2 (15.4%)	8	2 (25.0%)	1.83 (0.20 - 16.5)	0.5858
Within Treatment Arm [b]	0.38 (0.08 - 1.81), 0.2105		1.03 (0.19 - 5.40), 0.9762			
Across Treatment Arm [c]	0.73 (0.41 - 1.31), 0.2867					
Treatment Interaction [d]	2.70 (0.28 - 26.4), 0.3936					
Exposure to ARBs						
No	108	34 (31.5%)	106	26 (24.5%)	0.71 (0.39 - 1.29)	0.2576
Yes	7	1 (14.3%)	8	2 (25.0%)	2.00 (0.14 - 28.4)	0.6048
Within Treatment Arm [b]	0.36 (0.04 - 3.13), 0.3380		1.03 (0.19 - 5.40), 0.9762			
Across Treatment Arm [c]	0.75 (0.42 - 1.34), 0.3260					
Treatment Interaction [d]	2.83 (0.19 - 43.0), 0.4540					
Medical History of ARDS						
No	85	29 (34.1%)	95	23 (24.2%)	0.62 (0.32 - 1.18)	0.1432
Yes	30	6 (20.0%)	19	5 (26.3%)	1.43 (0.37 - 5.55)	0.6057
Within Treatment Arm [b]	0.48 (0.18 - 1.31), 0.1485		1.12 (0.36 - 3.44), 0.8457			
Across Treatment Arm [c]	0.72 (0.40 - 1.29), 0.2694					
Treatment Interaction [d]	2.31 (0.51 - 10.4), 0.2743					
Chest X-ray Finding of ARDS						
No	72	21 (29.2%)	88	23 (26.1%)	0.86 (0.43 - 1.72)	0.6693
Yes	43	14 (32.6%)	25	5 (20.0%)	0.52 (0.16 - 1.67)	0.2658
Within Treatment Arm [b]	1.17 (0.52 - 2.65), 0.7021		0.71 (0.24 - 2.10), 0.5306			
Across Treatment Arm [c]	0.75 (0.41 - 1.35), 0.3392					
Treatment Interaction [d]	0.60 (0.15 - 2.35), 0.4661					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.10
TEAEs of Special Interest - Cardiac: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac AESIs (%)	Number of Patients	Number with Cardiac AESIs (%)		
History of Sepsis						
No	15	4 (26.7%)	17	4 (23.5%)	0.85 (0.17 - 4.20)	0.8379
Yes	100	31 (31.0%)	97	24 (24.7%)	0.73 (0.39 - 1.37)	0.3277
Within Treatment Arm [b]	1.24 (0.36 - 4.19), 0.7338		1.07 (0.32 - 3.59), 0.9147			
Across Treatment Arm [c]	0.75 (0.42 - 1.34), 0.3246					
Treatment Interaction [d]	0.86 (0.15 - 4.83), 0.8685					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	25 (32.5%)	81	22 (27.2%)	0.78 (0.39 - 1.54)	0.4658
>=0.5 ug/kg/min	38	10 (26.3%)	33	6 (18.2%)	0.62 (0.20 - 1.95)	0.4133
Within Treatment Arm [b]	0.74 (0.31 - 1.76), 0.5001		0.60 (0.22 - 1.64), 0.3125			
Across Treatment Arm [c]	0.73 (0.41 - 1.31), 0.2950					
Treatment Interaction [d]	0.80 (0.21 - 3.04), 0.7456					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	73	19 (26.0%)		0.5540
>=20 ng/kg/min	114	35 (30.7%)	41	9 (22.0%)	0.63 (0.27 - 1.47)	0.2865
Within Treatment Arm [b]	, 0.5065		0.80 (0.32 - 1.98), 0.6275			
Across Treatment Arm [c]	0.68 (0.30 - 1.53), 0.3450					
Treatment Interaction [d]	0.00 (0.00 - 2.54E157), 0.9584					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.10
TEAEs of Special Interest - Cardiac: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac AESIs (%)	Number of Patients	Number with Cardiac AESIs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	7 (30.4%)	27	6 (22.2%)	0.65 (0.18 - 2.32)	0.5094
72.3 - <253 pg/mL	26	12 (46.2%)	22	7 (31.8%)	0.54 (0.17 - 1.78)	0.3116
253 - <676 pg/mL	25	9 (36.0%)	27	11 (40.7%)	1.22 (0.40 - 3.75)	0.7255
>=676 pg/mL	27	6 (22.2%)	26	2 (7.7%)	0.29 (0.05 - 1.60)	0.1396
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	15 (28.8%)	53	13 (24.5%)	0.80 (0.34 - 1.91)	0.6169
<253 pg/mL	49	19 (38.8%)	49	13 (26.5%)	0.57 (0.24 - 1.34)	0.1962
Within Treatment Arm [b]	1.56 (0.68 - 3.59), 0.2913		1.11 (0.46 - 2.71), 0.8167			
Across Treatment Arm [c]	0.67 (0.37 - 1.24), 0.2037					
Treatment Interaction [d]	0.71 (0.21 - 2.40), 0.5834					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	10 (34.5%)	28	8 (28.6%)	0.76 (0.25 - 2.33)	0.6312
23.85 - <83.75 pg/mL	28	9 (32.1%)	25	7 (28.0%)	0.82 (0.25 - 2.67)	0.7429
83.75 - <299.5 pg/mL	12	7 (58.3%)	28	6 (21.4%)	0.19 (0.05 - 0.84)	0.0224
>=299.5 pg/mL	31	8 (25.8%)	20	5 (25.0%)	0.96 (0.26 - 3.49)	0.9486
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	15 (34.9%)	48	11 (22.9%)	0.55 (0.22 - 1.39)	0.2071
<83.75 pg/mL	57	19 (33.3%)	53	15 (28.3%)	0.79 (0.35 - 1.78)	0.5683
Within Treatment Arm [b]	0.93 (0.41 - 2.15), 0.8713		1.33 (0.54 - 3.27), 0.5365			
Across Treatment Arm [c]	0.68 (0.37 - 1.24), 0.2072					
Treatment Interaction [d]	1.42 (0.42 - 4.85), 0.5738					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.10
TEAEs of Special Interest - Cardiac: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Cardiac AESIs (%)	Number of Patients	Number with Cardiac AESIs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	18 (34.6%)	53	17 (32.1%)	0.89 (0.40 - 2.01)	0.7825
< 1.63	47	16 (34.0%)	46	8 (17.4%)	0.41 (0.15 - 1.08)	0.0665
Within Treatment Arm [b]	0.97 (0.42 - 2.24), 0.9522		0.45 (0.17 - 1.16), 0.0935			
Across Treatment Arm [c]	0.64 (0.35 - 1.19), 0.1584					
Treatment Interaction [d]	0.46 (0.13 - 1.62), 0.2260					
Vasopressin Use at Baseline						
No	11	2 (18.2%)	6	1 (16.7%)	0.90 (0.06 - 12.6)	0.9376
Yes	104	33 (31.7%)	108	27 (25.0%)	0.72 (0.39 - 1.31)	0.2768
Within Treatment Arm [b]	2.09 (0.43 - 10.2), 0.3530		1.67 (0.19 - 14.9), 0.6444			
Across Treatment Arm [c]	0.73 (0.40 - 1.30), 0.2820					
Treatment Interaction [d]	0.80 (0.05 - 11.9), 0.8693					
Baseline AKI (Acute Kidney Injury)						
No	63	22 (34.9%)	82	18 (22.0%)	0.52 (0.25 - 1.09)	0.0833
Yes	52	13 (25.0%)	32	10 (31.3%)	1.36 (0.51 - 3.62)	0.5327
Within Treatment Arm [b]	0.62 (0.28 - 1.40), 0.2498		1.62 (0.65 - 4.02), 0.3000			
Across Treatment Arm [c]	0.74 (0.41 - 1.33), 0.3098					
Treatment Interaction [d]	2.60 (0.77 - 8.83), 0.1253					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.11
TEAEs of Special Interest - Ischemic: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Ischemic AESIs (%)	Number of Patients	Number with Ischemic AESIs (%)		
Age (years)						
< 65	54	5 (9.3%)	62	5 (8.1%)	0.86 (0.23 - 3.15)	0.8191
>=65	61	5 (8.2%)	52	5 (9.6%)	1.19 (0.33 - 4.37)	0.7913
Within Treatment Arm [b]	0.88 (0.24 - 3.20), 0.8401		1.21 (0.33 - 4.44), 0.7706			
Across Treatment Arm [c]	1.01 (0.40 - 2.54), 0.9800					
Treatment Interaction [d]	1.39 (0.22 - 8.69), 0.7274					
Gender						
Female	39	4 (10.3%)	49	6 (12.2%)	1.22 (0.32 - 4.67)	0.7703
Male	76	6 (7.9%)	65	4 (6.2%)	0.77 (0.21 - 2.84)	0.6881
Within Treatment Arm [b]	0.75 (0.20 - 2.83), 0.6705		0.47 (0.13 - 1.77), 0.2551			
Across Treatment Arm [c]	0.96 (0.38 - 2.42), 0.9331					
Treatment Interaction [d]	0.63 (0.10 - 4.09), 0.6252					
Race						
Other	29	2 (6.9%)	17	1 (5.9%)	0.84 (0.07 - 10.1)	0.8930
White	86	8 (9.3%)	97	9 (9.3%)	1.00 (0.37 - 2.71)	0.9956
Within Treatment Arm [b]	1.38 (0.28 - 6.93), 0.6909		1.64 (0.19 - 13.8), 0.6480			
Across Treatment Arm [c]	0.97 (0.39 - 2.45), 0.9550					
Treatment Interaction [d]	1.18 (0.08 - 17.1), 0.9025					
Body Mass Index (kg/m^2)						
< 30 kg/m2	60	6 (10.0%)	60	7 (11.7%)	1.19 (0.37 - 3.77)	0.7690
>=30 kg/m2	54	4 (7.4%)	52	3 (5.8%)	0.77 (0.16 - 3.60)	0.7342
Within Treatment Arm [b]	0.72 (0.19 - 2.70), 0.6251		0.46 (0.11 - 1.89), 0.2750			
Across Treatment Arm [c]	1.01 (0.40 - 2.55), 0.9753					
Treatment Interaction [d]	0.64 (0.09 - 4.44), 0.6549					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.11
TEAEs of Special Interest - Ischemic: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Ischemic AESIs (%)	Number of Patients	Number with Ischemic AESIs (%)		
Baseline Albumin (g/dL)						
>=2.5 g/dL	47	2 (4.3%)	27	1 (3.7%)	0.87 (0.07 - 10.0)	0.9078
< 2.5 g/dL	67	8 (11.9%)	82	8 (9.8%)	0.80 (0.28 - 2.25)	0.6684
Within Treatment Arm [b]	3.05 (0.62 - 15.1), 0.1534		2.81 (0.34 - 23.6), 0.3216			
Across Treatment Arm [c]	0.81 (0.31 - 2.10), 0.6610					
Treatment Interaction [d]	0.92 (0.06 - 13.2), 0.9517					
Geographic Region						
Rest of World	17	1 (5.9%)	17	3 (17.6%)	3.43 (0.32 - 36.8)	0.2871
US/Canada	98	9 (9.2%)	97	7 (7.2%)	0.77 (0.27 - 2.15)	0.6167
Within Treatment Arm [b]	1.62 (0.19 - 13.7), 0.6556		0.36 (0.08 - 1.57), 0.1608			
Across Treatment Arm [c]	1.01 (0.40 - 2.53), 0.9847					
Treatment Interaction [d]	0.22 (0.02 - 2.98), 0.2576					
Baseline MAP						
>=65 mmHg	70	6 (8.6%)	74	5 (6.8%)	0.77 (0.22 - 2.66)	0.6820
< 65 mmHg	45	4 (8.9%)	40	5 (12.5%)	1.46 (0.36 - 5.88)	0.5891
Within Treatment Arm [b]	1.04 (0.28 - 3.91), 0.9530		1.97 (0.53 - 7.27), 0.3009			
Across Treatment Arm [c]	1.02 (0.41 - 2.57), 0.9581					
Treatment Interaction [d]	1.89 (0.30 - 12.2), 0.5006					
Baseline APACHE II Score						
<=30	63	5 (7.9%)	74	6 (8.1%)	1.02 (0.30 - 3.53)	0.9706
> 30	52	5 (9.6%)	40	4 (10.0%)	1.04 (0.26 - 4.17)	0.9509
Within Treatment Arm [b]	1.23 (0.34 - 4.52), 0.7505		1.26 (0.33 - 4.75), 0.7333			
Across Treatment Arm [c]	1.03 (0.41 - 2.60), 0.9454					
Treatment Interaction [d]	1.02 (0.16 - 6.54), 0.9829					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.11
TEAEs of Special Interest - Ischemic: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Ischemic AESIs (%)	Number of Patients	Number with Ischemic AESIs (%)		
Exposure to ACEi						
No	102	8 (7.8%)	106	10 (9.4%)	1.22 (0.46 - 3.24)	0.6833
Yes	13	2 (15.4%)	8	0 (0.0%)		0.2435
Within Treatment Arm [b]	2.14 (0.40 - 11.4), 0.3634		, 0.3631			
Across Treatment Arm [c]	1.01 (0.40 - 2.55), 0.9756					
Treatment Interaction [d]	0.00 (0.00 - I), 0.9791					
Exposure to ARBs						
No	108	9 (8.3%)	106	10 (9.4%)	1.15 (0.45 - 2.94)	0.7772
Yes	7	1 (14.3%)	8	0 (0.0%)		0.2685
Within Treatment Arm [b]	1.83 (0.20 - 17.0), 0.5881		, 0.3631			
Across Treatment Arm [c]	1.01 (0.40 - 2.53), 0.9793					
Treatment Interaction [d]	0.00 (0.00 - I), 0.9793					
Medical History of ARDS						
No	85	4 (4.7%)	95	9 (9.5%)	2.12 (0.63 - 7.15)	0.2173
Yes	30	6 (20.0%)	19	1 (5.3%)	0.22 (0.02 - 2.01)	0.1509
Within Treatment Arm [b]	5.06 (1.32 - 19.4), 0.0106		0.53 (0.06 - 4.46), 0.5537			
Across Treatment Arm [c]	1.10 (0.43 - 2.79), 0.8402					
Treatment Interaction [d]	0.10 (0.01 - 1.30), 0.0791					
Chest X-ray Finding of ARDS						
No	72	5 (6.9%)	88	7 (8.0%)	1.16 (0.35 - 3.82)	0.8093
Yes	43	5 (11.6%)	25	3 (12.0%)	1.04 (0.23 - 4.76)	0.9634
Within Treatment Arm [b]	1.76 (0.48 - 6.48), 0.3885		1.58 (0.38 - 6.61), 0.5297			
Across Treatment Arm [c]	1.11 (0.44 - 2.83), 0.8267					
Treatment Interaction [d]	0.89 (0.13 - 6.20), 0.9105					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.11
TEAEs of Special Interest - Ischemic: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Ischemic AESIs (%)	Number of Patients	Number with Ischemic AESIs (%)		
History of Sepsis						
No	15	0 (0.0%)	17	2 (11.8%)		0.1701
Yes	100	10 (10.0%)	97	8 (8.2%)	0.81 (0.31 - 2.14)	0.6695
Within Treatment Arm [b]	, 0.1999		0.67 (0.13 - 3.49), 0.6363			
Across Treatment Arm [c]	1.02 (0.41 - 2.55), 0.9721					
Treatment Interaction [d]	0.00 (0.00 - 7.98E181), 0.9576					
Baseline Norep Eq Dose						
< 0.5 ug/kg/min	77	6 (7.8%)	81	5 (6.2%)	0.78 (0.23 - 2.66)	0.6893
>=0.5 ug/kg/min	38	4 (10.5%)	33	5 (15.2%)	1.52 (0.37 - 6.20)	0.5591
Within Treatment Arm [b]	1.39 (0.37 - 5.26), 0.6245		2.71 (0.73 - 10.1), 0.1243			
Across Treatment Arm [c]	1.04 (0.41 - 2.62), 0.9333					
Treatment Interaction [d]	1.95 (0.30 - 12.6), 0.4837					
Sensitivity to Therapy at 30 Minutes						
< 20 ng/kg/min	1	0 (0.0%)	73	6 (8.2%)		0.7649
>=20 ng/kg/min	114	10 (8.8%)	41	4 (9.8%)	1.12 (0.33 - 3.80)	0.8505
Within Treatment Arm [b]	, 0.7566		1.21 (0.32 - 4.55), 0.7807			
Across Treatment Arm [c]	1.16 (0.35 - 3.83), 0.8131					
Treatment Interaction [d]	0.00 (0.00 - 1.34E158), 0.9665					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.11
TEAEs of Special Interest - Ischemic: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Ischemic AESIs (%)	Number of Patients	Number with Ischemic AESIs (%)		
Baseline Angiotensin I (pg/mL)						
<72.3 pg/mL	23	1 (4.3%)	27	3 (11.1%)	2.75 (0.27 - 28.4)	0.3796
72.3 - <253 pg/mL	26	1 (3.8%)	22	2 (9.1%)	2.50 (0.21 - 29.6)	0.4545
253 - <676 pg/mL	25	2 (8.0%)	27	3 (11.1%)	1.44 (0.22 - 9.41)	0.7038
>=676 pg/mL	27	6 (22.2%)	26	2 (7.7%)	0.29 (0.05 - 1.60)	0.1396
Baseline Angiotensin I (pg/mL)						
>=253 pg/mL	52	8 (15.4%)	53	5 (9.4%)	0.57 (0.17 - 1.88)	0.3546
<253 pg/mL	49	2 (4.1%)	49	5 (10.2%)	2.67 (0.49 - 14.5)	0.2393
Within Treatment Arm [b]	0.23 (0.05 - 1.16), 0.0573		1.09 (0.30 - 4.02), 0.8960			
Across Treatment Arm [c]	0.99 (0.39 - 2.49), 0.9766					
Treatment Interaction [d]	4.66 (0.59 - 36.8), 0.1445					
Baseline Angiotensin II (pg/mL)						
<23.85 pg/mL	29	3 (10.3%)	28	3 (10.7%)	1.04 (0.19 - 5.65)	0.9638
23.85 - <83.75 pg/mL	28	1 (3.6%)	25	2 (8.0%)	2.35 (0.20 - 27.6)	0.4861
83.75 - <299.5 pg/mL	12	2 (16.7%)	28	4 (14.3%)	0.83 (0.13 - 5.30)	0.8468
>=299.5 pg/mL	31	4 (12.9%)	20	1 (5.0%)	0.36 (0.04 - 3.43)	0.3541
Baseline Angiotensin II (pg/mL)						
>=83.75 pg/mL	43	6 (14.0%)	48	5 (10.4%)	0.72 (0.20 - 2.54)	0.6054
<83.75 pg/mL	57	4 (7.0%)	53	5 (9.4%)	1.38 (0.35 - 5.44)	0.6441
Within Treatment Arm [b]	0.47 (0.12 - 1.77), 0.2524		0.90 (0.24 - 3.31), 0.8688			
Across Treatment Arm [c]	0.97 (0.38 - 2.45), 0.9478					
Treatment Interaction [d]	1.92 (0.30 - 12.4), 0.4916					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3

Table 14.3.20.1.6.11
TEAEs of Special Interest - Ischemic: Univariate (mITT Population with >=2 Vasopressors)

Characteristic	Placebo		LJPC-501		Odds Ratio (95% CI) [a]	Chi-sq. P-value [a]
	Number of Patients	Number with Ischemic AESIs (%)	Number of Patients	Number with Ischemic AESIs (%)		
Baseline Angiotensin I/II Ratio						
>=1.63	52	7 (13.5%)	53	6 (11.3%)	0.82 (0.26 - 2.63)	0.7391
< 1.63	47	3 (6.4%)	46	4 (8.7%)	1.40 (0.29 - 6.62)	0.6725
Within Treatment Arm [b]	0.44 (0.11 - 1.80), 0.2432		0.75 (0.20 - 2.83), 0.6655			
Across Treatment Arm [c]	0.99 (0.39 - 2.51), 0.9908					
Treatment Interaction [d]	1.70 (0.24 - 11.9), 0.5917					
Vasopressin Use at Baseline						
No	11	0 (0.0%)	6	0 (0.0%)		
Yes	104	10 (9.6%)	108	10 (9.3%)	0.96 (0.38 - 2.41)	0.9293
Within Treatment Arm [b]	, 0.2818		, 0.4352			
Across Treatment Arm [c]	0.96 (0.38 - 2.41), 0.9293					
Treatment Interaction [d]	0.96 (0.00 - 1.54E135), 0.9998					
Baseline AKI (Acute Kidney Injury)						
No	63	3 (4.8%)	82	7 (8.5%)	1.87 (0.46 - 7.53)	0.3739
Yes	52	7 (13.5%)	32	3 (9.4%)	0.67 (0.16 - 2.78)	0.5744
Within Treatment Arm [b]	3.11 (0.76 - 12.7), 0.0994		1.11 (0.27 - 4.58), 0.8869			
Across Treatment Arm [c]	1.13 (0.44 - 2.89), 0.7979					
Treatment Interaction [d]	0.36 (0.05 - 2.63), 0.3113					

Note: Odds ratio compares the first characteristic to second characteristic.
[a] Odds Ratio and Chi-square test of treatment effect within subgroup.
[b] Odds Ratio, Chi-square test of subgroup effect of first characteristic versus second characteristic within treatment arm
[c] Odds Ratio, Chi-square test of treatment stratified by characteristic
[d] Odds Ratio, Chi-square test of treatment-subgroup interaction
Listing: 16.2.6.1.1, 16.2.4.1, 16.2.4.2, 16.2.4.3, 16.2.4.4, 16.2.4.5, 16.2.5.1, 16.2.5.2, 16.2.6.2, 16.2.6.3.1, 16.2.6.8, 16.2.8.2.3